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Nicotine, the psychoactive component of tobacco smoke, binds to neuronal nicotinic 
acetylcholine receptors (nAChR) through which it mediates pharmacological effects. The present 
study demonstrates that [125I]-a-bungarotoxin ([125I]-a-bgt) binding sites are upregulated in 
primary hippocampal neurones and SH-SY5Y cells after chronic treatment with nicotine, 3, 4- 
dimethylaminocinnamylidene anabaseine (DMAC) and KC1. KCl-evoked upregulation is 
prevented in the presence of the calcium channel blocker, verapamil or the specific Ca2+- 
calmodulin-dependent protein kinase II (CaM-kinase II) inhibitor l-[7V,0-bis-(5- 
isoquinolinesulfonyl)-ALmethyl-L-tyrosyl]-4-phenylpiperazine, (KN-62). Upregulation elicited by 
nicotinic agonists is unaffected by these drugs. These data suggest that upregulation evoked by 
nicotinic agonists and KC1 depolarisation is mediated by different cellular mechanisms. [3H]- 
Epibatidine binding to SH-SY5Y cells identified that nicotine and DMAC upregulated a3- 
containing (a3*) nAChR. Mechanisms governing upregulation of a3* nAChR, investigated by 
co-application of verapamil or KN-62 or 3-[l-[3(amidinothio)propyl-lH-indol-3-(l-methyl-lH-indol- 
3-yl)maleimide methane sulfonate (RO 31-8220) with either nicotine or DMAC, did not prevent 
upregulation of [3H]-epibatidine binding. In contrast to its action on [125I]-a-bgt binding, KC1 did 
not upregulate a3* nAChR in SH-SY5Y cells.
An investigation into the quantitation of a3 and a7 subunit RNA after chronic nicotine, 
DMAC or KC1 treatment to SH-SY5Y cells shows that these treatments differentially effect 
subunit expression. Nicotinic agonist treatment does not alter the total RNA expression for either 
a3 or a7 subunits, whereas KC1 is without effect on the expression of a3 subunit RNA but 
dramatically increases the expression of the a7 transcript. A preliminary confocal analysis 
identifies that chronic nicotinic agonist treatment upregulates intracellular a3 and a l  nAChR 
subunits in SH-SY5Y cells. Together these findings support the concept that nicotinic agonists 
and KC1 depolarisation modulate nAChR binding sites by different cellular mechanisms and that 
KC1 increases the expression of a l  subunit RNA by a mechanism involving transcription.
Functional assays using fiira-2 loaded SH-SY5Y cells were used to construct concentration- 
response curves for nicotine and KC1 showing increases in intracellular calcium ([Ca2+]i) in a 
Ca2+-dependent manner. The nicotine-evoked increase in [Ca2+]i is mediated in part by L-type 
Ca2+ channels, a3* and a7* nAChR. The data reveal that chronic drug treated SH-SY5Y cells 
with drug regimes that produce upregulation of nAChR, produce a variety of changes in the 
functioning of upregulated nAChR present on the surface of SH-SY5Y cells.
Continued study of neuronal nAChR will help to elucidate physiological functional roles for 
these receptors. The demonstration that both a3* and a7* nAChR are upregulated after different 
drug treatments may provide an insight for relevant roles for nicotine and KC1 depolarisation in 
neuronal development, in terms of neurite retraction and neurite outgrowth and also in the 
therapeutic application of nicotinic agonists not only in tobacco use but in smoking cessation 
strategies and in neuroprotection in the treatment of Alzheimer’s and Parkinson’s disease.
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NE Norepinephrine
NEAA Non-essential amino-acids
NGF Nerve growth factor
nH Hill number
NMDA N-methyl -D -aspartic acid
6-OHDA 6-hydroxydopamine
O.D Optical density
P2 Pellet from medium speed centrifugation
PBS Phosphate buffered saline
PC 12 cells Pheochromocytoma cells
PCR Polymerase chain reaction
PEI Polyethyleneimine
xxii
PKA Protein kinase A






Rmax The fluorescence of Ca2+-saturated dye
Rmin The fluorescence signal quenching of the dye
RNA Ribose nucleic acid
RO 31-8220 3-[l-[3(amidinothio)propyl-lH-indol-3-(l-methyl-lH-indol-3-yl)maleimide
methane sulfonate
RT-PCR Reverse transcriptase -  polymerase chain reaction
SI and S2 Supernatant fraction from low speed centrifugation
s.c. Subcutaneous
SCG Superior cervical ganglion
SDS-PAGE Sodium dodecyl sulphate polyaciylamide gel electrophoresis











VOCC Voltage operated calcium channel
VTA Ventral tegmental area
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1.1. Nicotine:
Nicotine was first isolated in a pure form from the tobacco plant, nicotiana tabacum 
by two students Wilhelm Heinrich Posselt and Ludwig Reimann in 1828 (see Ashton 
and Stepney, 1982). It then took a further 110 years to elucidate that this alkaloid, 
nicotine, when biochemically isolated and extracted from the hundreds of other different 
chemicals present within tobacco, was the pharmacologically active agent (Johnston, 
1942). Nicotine is a weak base composed of carbon, hydrogen and nitrogen (empirical 
formula C 10H 14N2) which assemble together to form a dibasic, tertiary amine 
incorporating a weakly basic pyridine and strongly basic pyrrolidine ring in its structure 
(Barlow and Hamilton, 1962; Benowitz, 1996). Once nicotine is within the body, it is in 
the form of its free base. Nicotine in this form is readily absorbed and extensively 
distributed throughout the body. The structure of nicotine and the nicotinium ion (free 




Figure 1.1 The structures o f nicotine and the nicotinium ion.
1.2. An introduction to the Torpedo nAChR:
At physiological pH nicotine is predominantly in its ionised state in the form of the 
univalent nicotinium ion (Benowitz and Jacob, 1998). This is the active form of nicotine 
and in this state the alkaloid is capable of acting at neuromuscular junctions, at
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autonomic ganglia and on many neurones in the central nervous system (CNS) via 
ligand-gated ion channel (LGIC) cholinoceptors. In order to provide a thorough and 
comprehensive study on the biochemical and pharmacological properties of nicotine and 
to characterise the LGIC where it binds, large quantities of this LGIC are essential and 
necessary in a highly purified form.
Initial characterisation of the nAChR, as reviewed by Changeux (1981), used nAChR 
obtained from the electric organs of the electric eel (Electrophorus) and the electric ray 
(Torpedo califomica). Within the electric organs from these fish, large quantities of 
highly enriched nicotinic synapses derived from embryonic muscle-type cells can be 
found and purified for biochemical analysis. Muscle nAChR are considered as the 
‘prototype’ of all other members of the LGIC superfamily. Molecular, immunological 
and electrophysiological studies have greatly expanded the knowledge and biochemical 
insight into functional nAChR present in vast abundance as a rich homogeneous source 
on postsynaptic membranes of the electric organs of Torpedo (hundreds of mg nAChR 
per kg of fresh Torpedo electric organ). a-Bgt, a 8 kDa polypeptide from the venom 
isolated from the East Asian banded krait, Bungarus multicinctus (Loring and Zigmond, 
1988), with high affinity for nAChR at the neuromuscular synapse present in Torpedo, 
has facilitated the initial purification and characterisation of this nAChR.
After initial isolation and affinity purification, the muscle receptor protein was found 
to be a large, transmembrane, oligomeric glycoprotein complex with an apparent 
molecular mass in the region of 290 kDa. Due to the receptor being a membrane bound 
glycoprotein multimer complex, it has been difficult to use conventional techniques of 
crystallisation and X-ray diffraction to determine and solve the quaternary structure of 
nAChR. This has led to the three-dimensional (3-D) receptor structure image being 
analysed by using the electron microscope (EM) to view isolated postsynaptic
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membrane-bound molecules that are readily converted to form helical, tubular vesicles 
and when rapidly frozen retain much structural information of the receptor complex. 
Kubalek et al (1987) were able to locate the binding sites and determine the 
arrangement of the subunits around the channel pore of the nAChR using electron 
image analysis of tubular crystals of receptors grown from postsynaptic membranes of 
Torpedo marmorata electric organ preserving its structure within its native 
environment. Unwin (1993a, 1995) has since used electron image reconstruction of two- 
dimensional ly-ordered arrays of the Torpedo receptor in electric postsynaptic tissue 
membrane fragments that were embedded in amorphous ice to determine the 3-D 
structure of the Torpedo ray nAChR. Images obtained have been at a higher resolution 
of 9A in both the resting closed channel configuration and also in the activated open 
channel formation after acetylcholine- (ACh) induced changes (Unwin, 1993a, 1995). 
More recently the receptor complex has been resolved to a resolution of 4.6 A in the 
closed conformation which has also aided the identification of prominent structural 
features of these receptors and build upon the picture that is already forming on the 
functional architecture of these receptors (Miyazawa, 1999) (Figure 1.2).
The use of molecular weight estimates has helped to identify the number of subunits 
present within nAChR. It is now agreed that these LGIC receptor complexes are 
assembled from five transmembrane spanning polypeptide subunits with high sequence 
homology and are arranged in a pentameric ring fashion (Cartaud etal., 1973: Cooper et 
al., 1991; Decker et a l, 1995). The subunits are arrayed to form a barrel-like structure 
that is toroidal in shape with a pseudosymmetric 5-fold axis, delineating a central, 
cation conducting pore through the membrane (Karlin, 1993; Unwin, 1993a). Sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), analysis have shown
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Figure 1.2 The Torpedo nAChR in 
axial section through the ion channel at 9A  
resolution by electron microscopy (taken 
from Unwin, 1993a).
The subunits are designated as a  (often termed as a l ;  40 kDa), P (50 kDa), y (60 kDa) 
and 5 (66 kDa) (Schmidt and Raftery, 1973; Claudio et al., 1983), with the 
stoichiometry of a 2, p, y, 5 (Raftery et al., 1980; Clarke, 1992; as reviewed by, Stroud 
et al., 1990). Analysis has shown that the clockwise arrangement of this five subunit 
assembly, around the receptor complex, when viewed from the synaptic cleft could be
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a, p, a , y and 5 or a , y, a , p and 5 or a , y, a , 5, and P within the lipid bilayer (Kubalek 
et al., 1987; Pedersen and Cohen, 1990; as reviewed by Arias, 2000).
Comparisons of the amino acid sequences of cloned nAChR subunit cDNA show 
that the subunits of this gene family display similar structural compositions and 
homology in vertebrate, invertebrate species and also within the peripheral nervous 
system. This strongly suggests that the subunits are evolutionarily related proteins that 
have evolved by the process of gene duplication from a single common genetic ancestor 
(Noda et al., 1983 a, b). Partial or complete cDNA sequences have revealed that each of 
the nAChR subunits (and members of their super gene family) share similar 
characteristic regions and certain motifs within their tertiary structure. Sequence 
alignment analysis of the a  subunit (Noda et al., 1982) shows that the p and 5 subunits 
share 19% (Noda et al., 1983 a), and the y subunit share 54% homology (Noda et al., 
1983b). Some of the shared motifs include the following (Stroud et al., 1990; as 
reviewed by Arias, 2000 and Paterson and Norberg, 2000) (Figure 1.3);
1). the nAChR subunits have a large, extracellular hydrophilic amino-terminal 
domain of approximately 200 conserved amino acids which aids in the formation 
of the cholinergic agonist binding site,
2). a 15-residue cysteine loop, and A-glycosylation sites are contained within the 





Figure 1.3 Proposed transmembrane topology o f nAChR 
superfamily subunits. Each subunit contains a large extracellular N- 
terminus (location o f the agonist binding sites), followed by four highly 
hydrophobic transmembrane regions (Ml to M4) which have strong sequence 
homology. The M2-domain is thought to be exposed to the lumen of the pore 
throughout the length of the receptor and therefore contributes to the lining o) 
the receptor ion-channel pore. There is also a long intracellular M3-M4 loop 
with a small extracellular C-terminal domain contained within nAChR 
subunits.
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3). a transmembrane spanning domain which is comprised of four short hydrophobic 
membrane spanning regions. These segments, designated as M1-M4 contain a 
stretch of 27, 20, 20 and 19 uncharged amino acid residues respectively (Claudio 
et al., 1983; Noda et al., 1983b); the domains M1-M3 are connected by short 
intra- and extra-cellular loops. The a-helical M2 transmembrane segment 
contributes to the formation of the lining of the receptor ion channel complex and 
also aids in the gating of ion flow through the channel due to conserved residues 
contained in this domain (Akabas et al., 1994; Ortells and Lunt, 1995; Unwin, 
1995),
4). a large, variable, hydrophilic intracellular, cytoplasmic loop located between M3 
and M4 (about 100-200 amino acids in length) containing consensus 
serine/threonine and tyrosine phosphorylation sites,
5). a short, extracellular C-terminus of 20 amino acids that is highly variable and 
hydrophilic.
The nAChR can be reconstituted into lipid bilayers; the resulting receptor can be 
identified by the binding of specific ligands and is capable of desensitising. The ion 
channel pore permits the flux of monovalent and divalent cations and non-electrolytes 
and is capable of discriminating against anions (Dani and Eisenman, 1987; as reviewed 
in Galzi et al., 1991). This property of the receptor channel having a high conductance 
for cations may be explained in part to the negatively charged amino acids located in the 
channel vestibule which would serve to repel anions and therefore attract and contribute 
to the concentration of positively charged ions (Dani and Eisenman, 1987; Stroud et al.,
1990). The pore is a narrow-membrane spanning water-filled portion of the receptor
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complex approximately 30 A in length (Toyoshima and Unwin, 1988), the lining of 
which is made up of the five a-helical M2 segments from each of the polypeptide 
chains (Herz et al., 1989). Within the middle of each of the pore lining M2 domains, 
there is a leucine residue that is highly conserved across most subunits (Filatov and 
White, 1995; Labarca et al., 1995). The role of this conserved amino-acid, is thought to 
be involved in the setting of the mean opening time of the receptor channel once 
activated by ligand binding (Filatov and White, 1995). The M2 segments come together 
in close proximity near the middle of the membrane to produce the gate of the receptor 
in the absence of ACh or binding ligand (Unwin, 1993a, b) (Figure 1.4).
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Figure 1.4 Diagram o f an axial section through 
the structure o f the nAChR possible locations fo r  
agonist binding are shown. The receptor traverses the 
membrane with the majority o f the receptor complex on the 
synaptic side o f the cell membrane. Shown are the two 
putative agonist binding sites at the ar and a§ subunit 
interfaces. Each receptor is a heteromer composed o f a, y 
and S subunits.
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nAChR ion channels are activated after the binding of agonist molecules to regions 
located on the two a  subunits at a-y and a-5 interfaces and mediates the opening of the 
ion permeation pathway of the LGIC gate. The two molecules of, for example, ACh 
bind in a non-cooperative fashion to the a  subunits resulting in the opening of the 
nAChR channel. Both of the a  subunits contained in muscle and Torpedo nAChR have 
identical amino acid sequences (Changeux, 1990), but differ in their affinities for 
agonists and competitive antagonists. Differences between the two non-equivalent a  
subunits arise due to contributions from the neighbouring y and 5 subunits which are in 
contact with the a  subunits leading to the formation of ligand binding sites at the a-y 
and a-5 interfaces (Stroud et al., 1990; Sine et al., 1995). nAChR contain a readily 
reducible disulphide bond, following reduction, the conserved ACh binding sites on a-y 
and a-5 subunit interfaces in native nAChR are susceptible to, and uniquely identified 
by, affinity labelling with electrophilic reagents containing quaternary ammonium 
moieties, for example, the inhibitory affinity label 4-[7V-maleimido] benzyltrimethyl- 
ammonium iodide (MBTA), A-[4-maleimido] phenyltrimethyl-ammonium iodide 
(MPTA) and p-(trimethylammonium) benzenediazonium fluoroborate (TDF) (Kao et 
al., 1984). These affinity labelling agents covalently react with two bridged cysteines 
positions 192 and 193 associated near the ACh or ligand binding site in the A-terminal 
extracellular portion of the receptor and are therefore incorporated solely to the a  
subunits (Kao et al., 1984; Ortells and Lunt, 1995). The South American arrow tip 
poison, d-tubocurarine (d-TC) is a potent competitive neuromuscular nicotinic 
antagonist that binds non-equivalently with markedly different affinities to the two ACh 
agonist binding sites in nAChR present in Torpedo (Pedersen and Cohen, 1990; Chiara 
and Cohen, 1997). This natural aromatic alkaloid ligand, when irradiated with 254 nm 
UV light, is covalently photoincorporated in a concentration dependent and
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pharmacologically specific, agonist inhibitable fashion into the a , y and 8 nAChR 
subunits in Torpedo (Pedersen and Cohen, 1990; Chiara and Cohen, 1997). This further 
demonstrates, and is consistent with previous reports, that the neighbouring y and 8 
subunits contribute direct effects to the high- and low-affinity d-TC binding sites in 
addition to the a  subunit (Pedersen and Cohen, 1990; Sine and Claudio, 1991). The 
binding of agonist molecules to the nAChR activates the receptor, by triggering distinct 
localised changes at the binding sites (Figure 1.5). These disturbances produce rapid, 
transient allosteric changes of the cation channel (Lena and Changeux, 1993; Unwin, 
1995).
+ACh
Figure 1.5: Views from the synaptic cleft o f the mouth o f a 
Torpedo nAChR embedded in the membrane (a) before and 
(b) after activation by ACh. Images determined by electron 
microscopy, scale bars, 10 A (taken from Unwin, 1995).
Small clockwise rotations of the a  subunits can be considered as a trigger for channel 
opening after ACh binds to extracellular surface sites located on the membrane. This 
signal is transmitted to the channel gate within the nAChR, on the cytoplasmic surface 
of the membrane, producing a global conformational twist resulting in the opening of 
the nAChR ion channel. The cations Na+, K+ and Ca2+ flux through the channel
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vestibule along their electrochemical concentration gradients (Galzi and Changeaux, 
1995; Akabas et al., 1994). This depolarisation leads to an increase in the concentration 
of intracellular calcium ([Ca2+]i) and mediates other calcium dependent intracellular 
processes. The activation of the nAChR is terminated and the gate of the channel closes 
after ACh is unbound from the receptor and removed from the synaptic cleft by 
diffusion or hydrolysed by acetylcholinesterase. On longer or continual exposure to 
ACh, the nAChR proceeds from the closed resting state, to a transient open state and 
then to a transient desensitised state before reaching a stable inactivated desensitised 
state (Karlin, 1991; see Marks, 1998 for review). During this phenomenon of 
desensitisation, ACh is bound tighter to the nAChR than in the resting state and the ion 
channel is closed (Figure 1.6), this state will last until ACh is removed and the initial 
resting state of the receptor complex is resumed.
R e s t i n g A c t i v e
A g o n i s t
I n t e r m  e d i a t e
D e s e n s i t i s e d
Figure 1.6 Different states o f allosteric 
modulation o f nAChR function.
Adaptedfrom Galzi and Changeux (1995).
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1.3. Cloning of neuronal nAChR subunits:
After the discovery, characterisation, isolation and cloning of the amino acid 
sequences of the subunits comprising the nAChR from Torpedo electroplax, the search 
for nAChR in both the mammalian peripheral and central nervous system followed. 
nAChR located at the neuromuscular junction have the subunit composition of 
(al)2P15y or (al)2pl5s (Karlin, 1991; Ortells and Lunt, 1995). The y subunit is 
expressed in embryonic muscle and during muscle development the homologous 8 
subunit replaces the y-subunit and is expressed in adult muscle with the a, P and 5 
subunits to form functional receptor complexes (Takai et al., 1985; Mishina et al.,
1986). Differences identified between fetal and adult muscle nAChR channel gating 
properties and conductance are a result of the contribution of either the y or 8 subunits 
respectively (Mishina et al., 1986). These mammalian muscle nAChR are analogous to 
the muscle-type Torpedo spp. receptors due to similarities in their 7V-terminus sequences 
and the four types of subunits they are composed from (Devillers-Thiery et al., 1979, 
Raftery et al., 1980). This discovery led to the identification (De Bias and Mahler, 
1978), purification and characterisation (Whiting and Lindstrom, 1988) of a family of 
genes coding for homologous subunits expressed in neurones that also bind ACh.
The Torpedo muscle-type nAChR is the best-characterised neurotransmitter-gated 
ion-channel involved in fast synaptic transmission. Diversity within the nAChR family 
results from the expression of genes that code for one or more of the nAChR subunit 
subtypes which, when combined together, form a plethora of functional receptors. These 
excitatory nAChR, although diverse, share a homologous conserved primary subunit 
structure (see Figure 1.3). Each nAChR subunit gene is a member of the same gene 
family and also to the larger supergene family of LGIC. This supergene family includes
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the excitatory LGIC sensitive to the neurotransmitter serotonin (5-HT which binds to 
the 5 -HT3 receptor; Marciq et al., 1991) and the inhibitory ligand-gated receptors for 
glycine (Grenningloh et al., 1987a, b; Langosch et al., 1988; Betz, 1990) and y- 
aminobutyric acid A (GABAa; Wisden and Seeburg, 1992) which are selective for 
anions (Barnard, 1992; Deneris et al., 1991; Lindstrom et al., 1990; Sargent, 1993; 
Orteils and Lunt, 1995; as reviewed by Changeux and Edelstein, 1998).
Amino acid alignments of the receptor subunit sequences contained within this gene 
family identify that there is a high degree of sequence conservation between the 
subunits present in nAChR, 5 -HT3 and GABAa receptors. The close functional 
similarity of this gene family of receptors may be reflected in them all sharing a 
common protein architectural structure. This includes similar distributions of the highly 
hydrophobic sequence segments (designated M1-M4), also interpreted as membrane- 
spanning domains (as reviewed by Popot and Changeux, 1984; and Arias, 2000) and the 
possession of two conserved cysteine residues (128 and 142, Torpedo califomica a  
subunit numbering) separated by 13 other residues to form the analogous cys-loop 
(reviewed in Orteils and Lunt, 1995).
The principal excitatory receptors in the CNS are glutamate gated ion channels 
(Nakaniski, 1992; Cully et al., 1994), these receptors are not included in the same gene 
family of receptors as nAChR. Glutamate receptors, although permitting the flux of 
cations, have a different membrane topology for their subunits and hence a different 3-D 
structure. They are composed of three membrane spanning segments (Ml, M3 and M4) 
and a membrane embedded loop that is thought to be the M2 domain (Figure 1.7) 












Figure 1.7. The membrane topologies o f (a) cys-loop receptors and 
(b) glutamate receptors, (a) Proposed transmembrcme topology of nAChR 
subunits, showing an external N-terminus containing the agonist binding 
sites, four transmembrane segments (M1-M4), a long intracellular M3-M4 
loop and a small extracellular C-terminus. (b) Proposed transmembrane 
topology of the glutamatergic subfamily of subunits which have a more 
extensive N-terminal extracellular region, that combines with the 
extracellular M3-M4 loop forming the glutamate-binding site. This leads to 
an intracellular C-terminus. The 'M2' hydrophobic sequence is a re-entrant 
loop that is situated within the membrane leaflet.
The structural transmembrane topology of muscle receptor subunits (Figure 1.3) and 
the high degree of amino acid sequence identity between neuronal-type nAChR subunits 
(Figure 1.7a) suggests that this transmembrane topology is present in all nAChR 
subunits and other receptors contained in this supergene family (Stroud et al., 1990; 
Karlin, 1991). It is now widely accepted that the main psychopharmacological effects 
associated with tobacco usage and therefore ‘nicotine addiction’, are mediated via 
interactions with one or more of these nAChR located on neuronal membranes
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(Wonnacott, 1987, 1990). Since the first cloning of a neuronal nAChR subunit gene in 
1986, molecular cloning has identified many of the putative neuronal nAChR subunit 
isoforms within the CNS by means of probes based on previous oligonucleotide 
sequences for muscle receptor subunits (not expressed in neurones), which express 
considerable sequence homology to neuronal nAChR.
Classically, several lines of evidence including immunoaffinity purification using 
monoclonal antibodies (mAbs) and the development of cDNA probes (Whiting and 
Lindstrom, 1988; Whiting et al., 1991a, b) established that neuronal nAChR can be 
broadly divided into two main subtypes of subunits which is in contrast to the four types 
found in muscle-type receptors (Karlin, 1991) (see sections 1.5.1). Pioneering affinity 
labelling studies identified that any receptor subunit cDNA containing homologues of 
the vicinal cysteine residues homologous to positions 192 and 193 of muscle a  subunits 
are characteristic of and were termed as a  subunits (Karlin and Akabas, 1995). 
Homologous neuronal subunits designated as P subunits lack the cysteine pair and 
distinguishes them from a  subunits (Karlin and Akabas, 1995). This neuronal family of 
receptor subunits is assumed to assemble in a pentameric fashion similar to the 
membrane topology of Torpedo spp. receptors and those receptors at the neuromuscular 
junction (Anand et al., 1991). The subunits are therefore arranged in a narrow waisted 
barrel style formation, perpendicular to the membrane, and delineating a central water- 
filled pathway that permits the flux of specific cations namely Na+, Ca+ and K+, to and 
from the ion-channel.
The neuronal subunit cDNAs that have been cloned, sequenced and expressed to date 
in the vertebrate CNS are the eight a  subunits a2-a9  (containing the two conserved 
cysteine residues in the A-terminus domain; for review see Orteils and Lunt, 1995), and
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the three p subunits, P2-p4 which lack the pair of cysteines (as reviewed by Sargent, 
1993; McGehee and Role, 1995). Therefore neuronal nAChR consist of several 
subtypes with various functional characteristics, compared to only two muscle-type 
nAChR consisting of either fetal (a ip iyb) or adult (ocipieb) nAChR.
Molecular and immunological techniques indicate that these subunits are capable of 
assembling to produce a diverse spectrum of receptor ion-channel complexes in vitro 
(Whiting et al., 1987; Sargent, 1993; Decker et al., 1995; McGehee and Role, 1995; 
Wang et al., 1996; Fenster et al., 1997). Diversity in nAChR lies partially with the 
nAChR genes that code the various nAChR subunits and differences in receptor 
composition and therefore stoichiometry. The association of differential combinations 
of a  and P subunits reflects the vast number of putative functional neuronal receptor 
oligomers that could potentially be expressed within the CNS. Different receptor 
stoichiometries produce nAChR that display different pharmacological, physiological 
and biochemical profiles in relation to agonist binding, antagonist affinities (Galzi and 
Changeaux, 1995; Luetje and Patrick, 1991), ion permeability, conductance kinetics and 
the degree to which the receptors desensitise (Cachelin and Jaggi, 1991).
1.4. Characterisation of neuronal nicotinic binding sites:
The ability of nicotine to mediate central psychopharmacological effects is now 
widely accepted as a result of this alkaloid binding to receptors located on neuronal 
membranes. Progress in this field has allowed for the identification and localisation of 
populations of subtype specific nAChR in neuronal membranes to be detected by the 
binding of specific radiolabelled ligands. Radioligands have made it possible to identify 
and distinguish between the main pharmacological classes of putative native neuronal
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nAChR present within the mammalian nervous system. Classically neuronal nAChR 
can be subdivided into at least two broad categories. They comprise of 1). the 
predominant high affinity nicotine sites that bind nicotine, ACh and cytisine with high 
affinity and bind the neurotoxin a-bgt with low affinity and 2). those nAChR that are 
sensitive to a-bgt, a-conotoxin IMI (a-CTX-IMI; see section 1.7.2.1) and low 
nanomolar concentrations of methyllycaconitine (MLA; see section 1.7.1) with low 
affinity for the nicotinic agonists nicotine, ACh, epibatidine and cytisine (Clarke et al., 
1985; Marks et al., 1986; Pabreza et al., 1990; Marks et al., 1998; Whiteaker et al., 
1999, 2000; Perry et al., 1995, 2000).
1.4.1. High affinity [3H]-nicotinic agonist binding sites:
nAChR, as their name suggests, all bind nicotine but with different affinities. nAChR 
that have high affinity for [3H]-nicotine bind this tritiated radioligand with a Kd 
measurable in the nanomolar region or lower (Wonnacott, 1987). Initial binding 
experiments designed to elucidate [3H]-nicotine binding to subfractions of mouse brain 
were performed in the mid-seventies (Schleiffer and Eldefrawi, 1974). Romano and 
Goldstein (1980) later demonstrated that there was a saturable, high affinity site and a 
multitude of low affinity binding sites detected in rat brain membranes using racemic 
(±)-[3H]-nicotine. These sites were hypothesised to correspond to the high affinity 
nAChR and a-bgt-sensitive sites respectively. In these binding studies tritiated nicotinic 
agonists are used to label and distinguish the appropriate high affinity nicotinic binding 
sites as the classical nicotinic antagonists, for example hexamethonium, mecamlyamine 
and a-bgt (with dihydro-P-ethroidine (DHPE) being the exception) have lower affinity 
and are poor, ineffective competitive inhibitors of high affinity nicotine and ACh
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binding sites (Romano and Goldstein, 1980; Schwartz et al., 1982; Marks and Collins, 
1982). The naturally occurring (-)-enantiomer of nicotine binds to brain nicotinic sites 
70 times more potently than the (+)-isoform, showing the strong stereospecific nature of 
nicotine binding (Romano and Goldstein, 1980; Wonnacott, 1987). This led to the 
production of enantiomerically pure (-)-[3H]-nicotine, which is now commercially 
available as a tool for pharmacological characterisation studies.
In vitro binding techniques have characterised nAChR binding sites in the 
mammalian CNS that saturably bind [3H]-nicotine with high affinity (Lippiello et a l,
1987). The ganglionic agonist (-)-cytisine, an alkaloid found in the seed of Laburnum 
anagyroides (Pabreza et al., 1990), ACh (Schwartz et al., 1982), N- 
methylcarbamylcholine (Anderson and Americ, 1994) and epibatidine (Houghtling et 
al., 1995; Perry et al., 1995), are other nicotinic agonists, which when tritiated, detect 
high affinity neuronal nAChR binding site populations with similar regional 
distributions (Schwartz et al., 1982; Schwartz and Kellar, 1985; Martino-Barrows and 
Kellar, 1987; Pabreza et al., 1990; Houghtling et al., 1995). The population of binding 
sites identified and densely labelled by the snake toxin, a-bgt have a distinct 
distribution within the brain and display different pharmacological properties compared 
to the binding sites labelled by classical nicotinic agonists (Clarke et al., 1985, 1992; 
Marks and Collins, 1982; Marks et al., 1986).
Marks et al. (1986) compared the binding of radiolabelled acetylcholine, nicotine and 
a-bgt to rat and mouse brain. This study found that the [3H]-nicotine and [3H]-ACh bind 
with high affinity in a saturable and reversible manner to receptor sites located on 
neuronal membranes. These tritiated agonists compete for high affinity neuronal 
nAChR binding sites, have low non-specific binding and similar apparent affinities for 
the receptor and the maximum number of sites identified by these tritiated agonists are
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similar. All of these merits make them useful tools for further biochemical analyses on 
nAChR (Marks et al., 1986). The two binding sites for nicotinic agonists on a nAChR 
respond identically when challenged with the following treatments; nicotinic agents, 
thermal denaturation and dithiothreitol (DTT) treatment and reversal of this effect with 
5, 5’-dithiobis-(2-nitrobenzoic acid) (DTNB).
These data are consistent with the hypothesis that proposes a specific class of 
cholinoceptor is labelled by [3H]-nicotinic agonists in both mouse and rat brain. There 
does appear to be interspecies differences in the regional distribution of these two 
radiolabelled binding sites and is supported by extensive autoradiographical analysis 
performed using various rat and mouse brain regions. These analyses reveal the 
widespread distribution of high affinity nAChR throughout the nervous system labelled 
with [3H]-acetylcholine and have a similar if not identical distribution and 
pharmacological profile of neuroanatomical binding to populations of nAChR 
recognition sites labelled by [3H]-nicotine (Clarke et al., 1985; Marks et al., 1986).
The identity of the receptor complex binding site that exhibits high affinity for [3H]- 
nicotinic agonists was revealed by immunoprecipitation analysis performed with avian 
and mammalian brain. Initial immunoprecipitation attempts used the monoclonal 
antibody (mAb) mAb 35, raised against receptors from Electrophorus electric organ, to 
immunopurify a high affinity [3H]-nicotine binding site from chick brain (Whiting and 
Lindstrom, 1986). Analysis revealed the nAChR as an integral membrane glycoprotein 
comprised of two subunit populations, identified as two bands of 49 and 59 kDa 
apparent mass on a SDS-Page gel. The smaller polypeptide subunit also binds antisera 
to a  subunits and mAb 210, clearly suggesting that this subunit is homologous to the a  
subunit found in muscle nAChR.
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A second antibody, mAb 270, capable of precipitating all high affinity nicotinic 
binding sites from extracts of rat brain was used to purify and further characterise the 
neuronal nAChR found in chick brain. mAb 270 is made to receptors immunoaffinity 
purified from chick brain using mAb 35 which has low affinity for receptors in rat brain 
but high affinity for receptors in chick brain (Whiting and Lindstrom, 1987a). This 
chicken brain derived mAb 270 cross-reacts with rat brain and identifies the presence of 
two subunits 51 kDa (homologous to the subunit found as a 49 lcDa band from chick 
brain) and 79 kDa (homologous to the 75 kDa subunit identified by mAb 286 found in 
chicken brain (Whiting and Lindstrom, 1987a)). Further analysis identifies that there are 
at least two populations of nAChR contained within chick brain that bind [3H]-nicotine 
with high affinity; those containing the 49 and 59 kDa subunits and those containing 49 
and 75 kDa subunits (Whiting and Lindstrom, 1987a).
Immunopurification using mAb 270 identifies the a4  and 02 subunits as the principal 
high affinity neuronal [3H]-nicotine binding sites in rat brain. Flores et al. (1992) 
generated antisera against a4  and 02 subunits, these specifically immunoprecipitate 
receptors labelled by [3H]-cytisine. Few radiolabelled receptors were left in the 
solubilised rat brain supernatant, further emphasising that greater than 90% of high 
affinity nicotinic cholinergic recognition sites are a402 nAChR. Other antisera 
generated against a2, a3, a5, 03 and 04 subunits did not decrease the amount of 
precipitable a4  or 02 subunits (Flores et al., 1992).
As mentioned above, [3H]-epibatidine (also see section 1.6.3) has been used to 
explore and characterise the diversity of nAChR binding sites in rat and human brain 
due to its ability to interact with various nAChR subtypes with high affinity (Houghtling 
et al., 1995; Perry et al., 1995). Epibatidine displays its highest affinity at the a402
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nAChR with an affinity value (Kd) of 43 pM in rat brain by competition against [3H]- 
cytisine (Sullivan et al., 1994). In human post-mortem brain tissue the presence of two 
high affinity nAChR were identified in the cortex, with Kd values of 0.3 and 28.4 pM. 
The first is thought to represent the cc4p2 nAChR while the second site was thought to 
be representative of an a3-containing (a3*; Lukas et al., 1999) nAChR (Houghtling et 
al., 1995). The use of [3H]-epibatidine for autoradiography revealed a binding pattern 
similar to [3H]-cytisine but with greater intensity in the optic nerve, optic chiasm and 
optic tract. [3H]-epibatidine is therefore labelling an additional nAChR binding site, 
thought to contain the a3 nAChR subunit (Perry and Kellar, 1995). Zoli et al. (1998) 
performed autoradiography with [3H]-epibatidine in mouse brain and identified that this 
tritiated nicotinic agonist produced a greater density of binding when compared with 
[3H]-nicotine, [3H]-cytisine, [3H]-ACh and [3H]-methylcarbamylcholine in a variety of 
brain regions including the medial habenula and interpenducular nucleus. The 
concentrations of tritiated radioligands used in this study are such that they are not 
expected to interact with a3* nAChR except for [3H]-epibatidine, which further 
confirms it reliably labels a3* nAChR with high affinity (Zoli et al., 1998).
A recent study by Wang et al. (1996) showed that [3H]-epibatidine binds to two a3* 
nAChR sites in the SH-SY5Y cell line with Kd values of 0.15 and 7.4 nM, representing 
the a3p2 and a3P4 nAChR respectively. Sullivan et al. (1994) demonstrated that 
epibatidine has lower affinity at a-bgt-sensitive nAChR with an affinity of 230 nM in 
rat brain by competition binding studies performed against [125I]-a-bgt. Epibatidine has 
shown little or no affinity for other receptors including opioid, 5 -HT3 , AMP A, kainate, 
NMDA and GABAa (Bonhaus et al., 1995). [3H]-epibatidine is therefore a radioligand
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that can be used in the present study to reliably identify numbers of a3* nAChR binding 
sites in SH-SY5Y cells.
1.4.2. High affinity [125I]-a-bgt binding sites:
The a-neurotoxin a-bgt is a toxin isolated from Bungarus multicinctus venom, 
initially used in the characterisation of the prototypical Torpedo and neuromuscular type 
nAChR and has also been utilised, when iodinated, to study the binding sites labelled in 
brain sections and also in cell culture. a-Bgt binds competitively and with high affinity 
to neuronal membranes (De Bias and Mahler, 1978; Clarke et al., 1985). As mentioned 
in the section above, a-bgt is poor at displacing [3H]-nicotine from high affinity nAChR 
binding sites, as it possesses low affinity for these sites. In comparison to the substantial 
number of studies performed to map [3H]-nicotinic agonist binding sites, essentially no 
radioligand binding studies with [125I]-a-bgt have been performed in human post­
mortem brain, probably due to post-mortem deterioration. Autoradiographical analysis 
in mouse (Marks and Collins, 1982; Marks et al., 1986), rat (Clarke et al., 1985) and in 
human brain (Rubboli et al., 1994; Spurden et al., 1997) show neuronal labelling with
125  •  • •[ I]-a-bgt. These binding sites reveal a single high affinity site with a different and 
distinct distribution to that of [3H]-nicotinic agonist. This signifies that these 
radiolabelled ligands are not tagging the same populations of neuronal receptors (Clarke 
et al., 1985). The a-bgt-sensitive receptor can be found densely populating the 
hippocampal formation and other neuronal populations of rat brain (Seguela et a l,
1993). The nAChR proteins that bind [125I]-a-bgt with high affinity also selectively bind 
[3H]-MLA (Ward et al., 1990; Davies et al., 1999) and displays strikingly similar 
distributions as detected by autoradiography (Whiteaker et al., 1999). MLA is a
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norditerpenoid alkaloid isolated from the seeds from the Delphinium plant that has 
selective competitive antagonistic actions at a7* nAChR (Ward et al., 1990; Davies et 
al., 1999) (see section 1.7.1).
The development and availability of mAbs against and different cDNA probes for 
nAChR subunits has aided in the affinity purification of nAChR and enhanced the 
ability to locate a-bgt binding proteins within neuronal tissue. The a-bgt binding 
protein was isolated from chick brain using a mAb raised against the muscle nAChR of 
chicken (Conti-Tronconi et al., 1985). Purification using a-bgt affinity columns 
produced bands with apparent molecular masses between 45 and 70 kDa upon SDS- 
Page analysis. A 54-55 kDa band was alkylated by MBTA and the acetylcholine 
analogue, bromoacetylcholine, are two cholinergic affinity labels shown to abolish a - 
bgt binding, indicative that the a-bgt binding protein contains a pair of cysteines like 
those also located on the a  subunits of muscle-type nAChR (Kemp et al., 1985; Kao 
and Karlin, 1986; see section 1.2 and Figure 1.3).
Initial chick brain cDNA clones (based on a-bgt binding peptide sequences purified 
from chick brain) were used to discover two nicotinic a  subunits that encode a-bgt- 
sensitive binding proteins in chick brain (Schoepfer et al., 1990). These a-bgt binding 
subunits were originally designated as a l  and a2 (Schoepfer et al., 1990) are now 
referred to as a7  and a8 subunits respectively (Britto et al., 1992). These a-bgt binding 
proteins have had subunit specific mAbs raised bacterially and identify that there are at 
least two different populations of such a-bgt binding proteins in embryonic day 18 
(E l8) chick brains. Evidence has revealed that embryonic chick sympathetic neurones 
express at least three subtypes of native a7* nAChR (Yu and Role, 1998a, b). The 
predominant subunit in E l8 chick brain was the a l*  receptor (approximately 75%) and
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the minor a-bgt-sensitive receptor population consisted of both a7  and a8 subunits 
(approximately 15%) (Schoepfer et al., 1990; Keyser et al., 1993). The stoichiometry of 
these a7a8* nAChR complexes has yet to be elucidated. In addition to these two 
receptor subtypes, there appeared to be a major receptor complex expressed in chick 
retina as a homooligomer composed of only a8 subunits. The a8 subunit thus far 
appears to be uniquely expressed in avians. Based on electrophysiological responses 
and sensitivity to agonists and antagonists, the a5 subunit has been shown as a 
candidate subunit expressed with a l  subunits to form heteromeric receptors in chick 
sympathetic ganglia (Yu and Role, 1998b).
Couturier et al. (1990) cloned and sequenced cDNA and genomic clones encoding 
the a l  nAChR subunit around the same time as Schoepfer et al. (1990). The injection 
into Xenopus oocytes of either a l-  (Couturier et al., 1990) or a8-cRNAs, allow for the 
assembly of homomeric complexes (Gerzanich et al., 1994). These subunits efficiently 
assemble as robust homomeric ACh-gated cation channels that are capable of producing 
functional nAChR with electrophysiological responses and properties similar to those of 
certain native a-bgt-sensitive nAChR (Peng et al., 1994a). The responses shown by the 
a-bgt-sensitive homomeric a7* and a8* receptors when expressed in oocytes are 
characterised by their high permeability to Ca2+, which triggers the activation of a Ca2+- 
dependent chloride current, rapid desensitisation, exhibit strong inward rectification 
(Couturier et al., 1990; Bertrand et al., 1992; Amar et al., 1993; Seguela et al., 1993; 
Gerzanich et al., 1994; Castro and Albuquerque, 1995). These studies conclude that 
native a l  nAChR are homomeric because of the remarkable similarities in kinetic 
profiles and pharmacological properties of reconstituted homomeric a l  subunits as 
nAChR when compared to nAChR found in native neuronal tissue preparations (Anand
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etal., 1993a). Chen and Patrick (1997) provided further evidence using affinity-purified 
polyclonal antibodies in Western blot analyses of immunoisolated a-bgt binding 
proteins purified from rat brain. The data produced was in agreement with the previous 
hypothesis that the functional al* nAChR (57 kDa band) is homomeric in nature as this 
study found no evidence that the a l  subunit was associated with other subunits in the a- 
bgt sensitive nAChR (Chen and Patrick, 1997).
Another subunit, a9, has been identified, isolated and functionally characterised 
from the nAChR gene family that binds a-bgt with high affinity (Elgoyhen, et al.,
1994). The cloned a9  subunit can be localised in vertebrate cochlear hair cells and 
assembles as a homomeric receptor after a9-cDNA injection into Xenopus oocytes 
(Elgoyhen, et a l,  1994); there was no evidence of expression of the a9  gene in rat brain 
after in situ hybridisation on rat brain sections (Elgoyhen, et al., 1994). Section 1.5.1 
will discuss in more detail the functional expression of these homomeric and 
heteromeric nAChR complexes.
The snake venom from the protected species of the Taiwanese banded krait 
Bungarus multicinctus contains a mixture of a-toxins, one being a-bgt and another 
minor component called neuronal-bgt (n-bgt; K-bgt) (Loring and Zigmond, 1988). When 
iodinated, this minor component [125I]-neuronal-bgt ([125I]-n-bgt) showed initial promise 
as it recognised and labelled two sites with high affinity, and has also been shown to 
antagonise cholinergic transmission in the chick ciliary ganglion (Chiappinelli, 1983). 
Extensive blockade of a3p2 and partial blockade of a4p2 neuronal receptors was 
achieved with 10 nM and 1 |xM n-bgt respectively (Luetje et al., 1990). Problems arise 
with availability of the protected B. multicinctus species and in the purification process 
of n-bgt from the venom. There are high concentrations of other contaminating a-toxins
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that must be removed to obtain pure n-bgt. This has restricted the usefulness of this 
ligand for a pharmacological tool in laboratory practice.
1.5. Heterologous expression using Xenopus oocytes as a functional 
expression system:
A profusion of cDNAs for neuronal nAChR subunit subtypes have been identified by 
molecular cloning techniques (ot2-a9, P2-04; Boulter et al., 1987; Deneris et al., 1989; 
Nef et al., 1988; Boulter et al., 1990; Couturier et al., 1990) (as mentioned in section 
1.3). The use of heterologous expression systems led to the confirmation that nAChR 
subunit genes encode nAChR subunits by their ability to form functional channels that 
are responsive to ACh or nicotine (Boulter, 1987; Ballivet et al., 1988). By injecting the 
synthetic RNAs encoding different a  or P neuronal nAChR subunits from rat, chick or 
human into oocytes of the clawed toad Xenopus laevis, provides a transient model of 
expression to study the electrophysiology and pharmacology of nAChR subtypes 
(Boulter et al., 1987; Cooper et al., 1991; Luetje and Patrick, 1991; Gerzanich et al., 
1994; Peng et al., 1994a). By way of pentameric co-assembly (Anand et al., 1991), the 
injected subunit RNAs combine to create viable robust in vitro heteromeric or 
homomeric receptor combinations with various stoichiometries, herein lies the diversity 
of nAChR subtypes (Luetje and Patrick, 1991). nAChR complexes will have different 
channel properties depending on the particular a  and P subunits expressed and 
contained within their pentameric structure.
Further analysis can distinguish if there are differences between the pharmacological 
properties of receptors expressed endogenously in their native environment in vivo and 
those of receptor complexes expressed either in Xenopus oocytes or in transfected cell
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lines in vitro. These expression systems are useful to aid in the pharmacological 
determination of individual nAChR with known stoichiometries and consequently 
deducing nAChR subtypes that assemble in vivo. Different subunit combinations form a 
plethora of functional receptors in the brain with significant pharmacological diversity 
from receptor to receptor (Luetje et al., 1990).
1.5.1. Neuronal nAChR subunits expressed in vitro as functional receptors:
1.5.1.1. Heteromeric nAChR expression:
Xenopus oocytes were found to express functional nAChR channels after co­
injection of pairwise combinations of either 02 or 04 subunit mRNAs with a2, a3 or a4 
receptor subunit mRNAs (Deneris e ta l., 1991; Sargent, 1993; McGhee and Role, 1995). 
Boulter et al. (1987) demonstrated that functional neuronal receptors could be 
reconstituted from as few as one or two types of subunit gene product, described as 
homomeric and heteromeric nAChR respectively. Boulter et al. (1987) concluded that 
heterodiomeric receptors in their study were derived from combinations of a specific a  
RNA (either a3 or a4) and the other from 02 RNA. When expressed on its own, the 02 
transcript produced no response to ACh. The presence of either a3 or a4  subunit RNA 
was necessary for the formation of a fully functional nAChR, as identified by testing for 
depolarisation in response to perfused ACh (Boulter et al., 1987). This is also true for 
the a3 transcript when expressed alone, no response is observed and requires the 
presence of the synthetic RNA corresponding to the 02 subunit to produce a functional 
cationic channel. Similar ACh induced currents, that were reversibly blocked by 
hexamethonium and showed little sensitivity to or were resistant to functional blockade
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by a-bgt, were recorded from oocytes co-injected with full-length cDNAs for a4  and a 
“structural” (3 subunit of avian brain nAChR (Boulter et al., 1987; Ballivet et al., 1988).
Most of the neuronal a  and P subunit transcripts (a2-a4 and P2 and P4 respectively) 
when expressed individually in oocytes are not capable of forming functional nicotinic 
ionophores, indicating that they exist as heteromeric complexes. One study established a 
cholinergic response in a third of all oocytes injected and expressed with the a4  subunit 
alone (Boulter et al., 1987). Homomeric nAChR constituted from a4  clones assemble as 
unstable, weakly functional LGIC capable of producing a small depolarisation and 
opening of the ion-channel only in the presence of high concentrations of ACh (Boulter 
e ta l,  1987).
The sensitivity of the six putative functional neuronal nAChR assembling after co- 
injecting synthetic RNA encoding one of two different p subunits (P2 or p4) and one of 
three different a  subunits (a2, a3 or a4) expressed in Xenopus oocytes were 
investigated with respect to their rank order of potency for nicotinic agonists, ACh, 
nicotine, cytisine and 1, l-dimethyl-4-phenylpiperazinium (DMPP) (Luetje and Patrick, 
1991). These observations indicate that heteromeric nAChR assemble from a  and p 
subunits with both subunits contributing to the pharmacological and functional profile 
of the nAChR LGIC (Luetje and Patrick, 1991). The P subunit has a profound affect on 
the rate at which agonist binds to receptors to evoke opening and also in agonist and 
antagonist dissociation rates from nAChR (Papke and Heinemann, 1991; Papke et al., 
1993; Luetje et al., 1993; Harvey and Luetje, 1996; Harvey et al., 1996). The resulting 
nAChR complexes display unique patterns of sensitivity to basic pharmacological 
agents and display distinct physiological properties. nAChR composed of a l,  a3 or a4  
with P2 were generally less sensitive to cytisine than the corresponding p4* receptors.
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This led to the conclusion that the P subunit contributes, most noticeable, to the 
sensitivity of the receptor to cytisine the most potent of the nicotinic agonists studied. 
Cytisine acts as a partial agonist at receptors assembling with the P2 subunit, while 
being a full agonist and therefore more sensitive at p4* nAChR (Luetje and Patrick, 
1991).
The a  subunits are also important in the determination o f the rank order of potency 
in either p2* or P4* nAChR complexes (Luetje and Patrick, 1991). Oocytes injected 
with either chick neuronal a3 or a4  cDNA expression vectors constituted with a P2 
subunit cDNA displayed functional receptors readily distinguished by their sensitivity 
and desensitisation to ACh (Gross et al., 1991). As the P2 subunit was conserved in 
both subunit subtypes, it denotes the a  subunits as responsible for the observed 
functional differences. a3 Subunit cDNA expressed a nAChR in oocytes with a lower 
agonist sensitivity and a stronger desensitisation profile than a4/p2 receptors (Gross et 
al., 1991). Sensitivity depends on the affinity of agonist binding to a receptor and the 
efficiency of the agonist once bound to mediate channel opening of a receptor and is a 
measure of the dose of agonist required to evoke the desired effect. Desensitisation is 
defined as when a receptor loses the ability to evoke a response as a consequence of a 
prolonged stimulus. As well as the a  subunit playing a role in desensitisation in chick 
neuronal nAChR, there is also evidence for the importance of the “structural” P subunit 
being important in the time course of desensitisation in both Torpedo and neuronal rat 
a3* nAChR (Unwin et al., 1988; Cachelin and Jaggi, 1991 respectively). The latter 
study discovered that in a3P2 nAChR desensitisation occurred faster and was more 
extensive than that observed with a3p4 nAChR and complements previous results from 
other groups.
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Native receptors have been suggested to be composed of more than two subunit 
subtypes, due to the difference in pharmacological and physiological properties of 
expressed receptors in heterologous expression systems with only two subunit types 
(Sivilotti et al., 1997). This has been extrapolated from immunoprecipitation studies 
that show neurones can express more than two subunit subtypes (Conroy and Berg,
1995). Oocytes can indeed form functional heterotrimeric nAChR from three nAChR 
subunits. Expression of cDNA coding for (a3, (32 and (34) rat subunits and (oc3, a5, and 
P4) and (a5, a4  and (32) subunits of chick have been demonstrated to form functional 
heterotrimeric nAChR (Colquhoun and Patrick, 1997, Vemallis et al., 1993; Ramirez- 
Latorre et al., 1996; Conroy and Berg, 1995). The a3p2p4 nAChR possessed mixed 
characteristics of the a3p2 and a3p4 nAChR when expressed in oocytes. The 
heterotrimeric a3p2p4 nAChR was therefore activated by cytisine and blocked by n-bgt 
(Colquhoun and Patrick, 1997). The functional response evoked by cytisine and the n- 
bgt inhibition of the a3p2p4 nAChR is donated by the a3p4 and a3p2 subunits pairs 
respectively.
The a5 subunit did not form functional receptors when expressed as a 
homopentameric complex or when co-injected with any one subtype of P subunit alone 
(Boulter et al., 1990; Ramirez-Latorre et al., 1996), nor did they assemble as pairs with 
a3 subunits (Wang et al., 1996). Functional nAChR assembled on the cell surface of 
oocytes when either the human a3 and p2 or oc3 and P4 subunit RNAs were co-injected 
with the a5 receptor subunit RNA into Xenopus oocytes (Wang et al., 1996). The a5 
subunit also forms functional receptors when co-expressed with a3 and p4 subunit 
cDNAs in the human BOSC-23 cell line (Fucile et al., 1997). The presence of the a5 
subunit incorporated into a heterotrimeric receptor appears to increase the rate of
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desensitisation of the nAChR, produce a receptor with a greater probability of opening 
and a greater chance of being activated by nicotinic agonists (Ramirez-Latorre et al., 
1996; Wang etal., 1996).
The a 6  nAChR subunit was termed as an “orphan” receptor subunit until recently, as 
it had not been shown to form a functional LGIC. cDNA encoding the chick a 6  subunit 
forms a heteromeric functional nicotinic LGIC in oocytes when expressed with P4 
subunit cDNA(Gerzanich etal., 1997). The rat (33 nicotinic subunit does not participate 
in the formation of functional nAChR activated by nicotine or ACh when co-injected in 
the form of mRNA with wild-type al, a 3 , a 4  or a l  genes into oocytes (Deneris et al., 
1989; McGehee and Role, 1995; Palma et al., 1999). A reason may be that although the 
(33 subunit is nicotinic and may be able to assemble with cloned nAChR subunits, they 
are perhaps just not able to form functional nicotinic channels with these nAChR 
subunits that have been identified to date. Failure of the p3 subunit to form functional 
channels with other wild-type nAChR subunits in Xenopus oocytes may be simply that 
the gene products do not assemble correctly together in this expression system or they 
may require a specific post-translational modification process not made by the oocytes 
in order for them to function. Forsayeth and Kobrin (1997) transfected COS cells with 
cDNAs for a 4 , P2, P3 and p4 subunits which coassembled to form a functional LGIC. 
By omitting a single subunit cDNA from the transfection it was possible to establish the 
role of each subunit in the a 4 p 2 p 3 p 4  receptor subtype. The p3 subunit appears to 
function as a structural component that links the a4p2 heterodimer to the more stable 
a 4 p 4  receptor subtype. It has also been demonstrated that the P3 subunit gene can form 
functional channels in oocytes with a mutant al  nAChR subunit (L247Ta7) (Palma et a l, 
1999). The P3 subunit, when inserted with a reporter mutation (V273T) to produce
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V273Tp3, can also be expressed in oocytes with a3 and p4 subunits to form functional 
channels; the mutation converts the hydrophobic residue in the middle of the 
transmembrane domain M2 into a hydrophilic residue and would be expected to 
increase the channels sensitivity to agonists (Groot-Kormelink et al., 1998).
To demonstrate the reliability and accuracy of Xenopus oocytes as a heterologous 
expression system, the expression of a known subunit composition of mouse muscle 
nAChR in oocytes displayed similar single-channel currents that were characteristic of 
those reported for the same receptors expressed in BC3H-1 cells (Luetje and Patrick
1991). This study therefore suggests that oocytes are capable of accurately expressing 
LGIC with similar properties to those expressed in their native environment. The 
ultimate goal of using heterologous expressions systems is to elucidate the function and 
stoichiometry of nAChR found in vivo in their native environment which to date is still 
poorly understood.
I.5 .I.2 . Homomeric nAChR expression:
Reports involving heterologous in vitro expression studies revealed that most of the 
a  and P subunits co-assemble to form functional nAChR channels. The mRNA for a l-  
a9 nAChR subunits can efficiently be expressed to give subunits that assemble in 
Xenopus oocytes, resulting in the formation of robust fully functional homomeric cation 
LGIC (Couturier et al., 1990; Seguela et al., 1993; Gerzanich et al., 1994; Elgoyhen et 
al., 1994; Chen and Patrick 1997). These homomeric channels are activated by ACh and 
channel responses are potently blocked in the presence of nanomolar concentrations of 
a-bgt (IC50 = 0.7 nM).
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As members of a family of LGIC, the nAChR family has an apparently simple 
functional repertoire: they bind a specific ligand, open the channel pore, conduct 
specific ions across the membrane and can result in receptor desensitisation. The entry 
of positively charged cations through nAChR leads to depolarisation and is a classical 
example of how these receptors can influence the biology of the cell. Homomeric 
receptors share the characteristics of desensitising rapidly and have a high permeability 
to Ca2+ when compared to heteromeric pairwise combinations of neuronal a  and p 
subunits. Homomeric a l  subunits expressed in oocytes have a Ca2+: Na2+ permeability 
ratio close to 20 compared to receptors composed of various a/p  stoichiometries which 
have a ratio of 1:1.5 (McGehee and Role, 1995; Role and Berg, 1996). The recognition 
that these homomeric nAChR have a high Ca2+ permeability has opened the possibility 
that they are capable of directly mediating several Ca2+-dependant intracellular 
processes and demonstrate a relevant role for nAChR in Ca2+ signalling (Seguela et al., 
1993; Chan and Quik, 1993; Pugh and Berg, 1994; Role and Berg, 1996; Pugh and 
Margiotta, 2000).
The pharmacological characteristics of homomeric a l  subunits expressed in oocytes 
(Anand et al., 1993a; Peng et al., 1994a; Castro and Albuquerque, 1995; Alkondon et 
al., 1998) or in cells stably transfected with human or rat nAChR subunit al  cDNA 
(Gopalakrishnan etal., 1995; Quik et al., 1996) show an excellent correlation to and are 
similar to native a-bgt-sensitive nAChR (as reviewed by McGehee and Role, 1995). 
When ligand binding studies are compared there was found to be a 50 fold discrepancy 
with regard to the binding affinity of cytisine for this receptor, which brought about 
debate on whether the native al  receptor is homomeric in nature (Anand et al., 1993a). 
Co-injections o f a mixture of any of the muscle subunits a, p, y, or the neuronal a3, a5, 
p2, P3 and p4 nAChR subunits with the a l  subunit gene, do not modify the sensitivity
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or physiological characteristics of the a l  subunit when expressed alone. This indicates 
that in oocytes at least, a l  subunits do not combine with other known neuronal nAChR 
subunits and therefore assemble as homomers (Couturier et al., 1990; Seguela et al., 
1993; McGehee and Role, 1995). As mentioned in section 1.4.2, there are cases where 
the a l  subunit is thought to form receptors in situ by combining with the a8 subunit to 
create functional receptor channels containing both the a l  and a8 subunits in chicken 
brain (Keyser et al., 1993).
In the avian and mammalian CNS, the a l  homomeric nAChR is the predominant a- 
bgt-sensitive binding site (Anand et al., 1991b). Homomeric a8 nAChR are 
predominantly expressed in chick retina and when reconstituted in oocytes share many 
of the functional channel properties and elicit time course responses that are 
indistinguishable from homomeric a l  channels (Couturier et al., 1990; Seguela et al., 
1993; Gerzanich et al., 1994). a8 Homomers exhibit lower affinity for a-bgt but higher 
affinity for other nicotinic agonists (Gotti et al., 1994; Gerzanich et al., 1994). The 
affinities and efficacies of ligands for chick a l  and a8 homomers expressed in oocytes 
have also been shown to reflect the ligand-binding characteristics of natively expressed 
a l  and a8 nAChR (Gerzanich et al., 1994).
Homomeric a9  nAChR have distinctive pharmacology and electrophysiological 
properties when compared to a l  and a8 homo-oligomers (Elgoyhen et al., 1994). These 
receptors have a mix of nicotinic and muscarinic properties, in that the nicotinic 
agonists ACh, DMPP, and the muscarinic agonist oxotremonine activate the receptor. 
a9 nAChR are also functionally blocked in the presence of moderate concentrations of 
a-bgt and n-bgt (100 nM), nicotine, muscarine, d-TC and atropine. These 
pharmacological characteristics of the homomeric a9  nAChR expressed in oocytes,
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reveals remarkably similar properties to the cholinergic receptor present at the synapse 
between cochlear efferent neuronal terminals and hair cells in the chick and guinea pig 
cochlea. It remains to be elucidated whether this homomeric a9  receptor is 
representative of the native a9  receptors obtained from rat cochlear hair cells (Elgoyhen 
e ta l., 1994).
The production of functional nAChR channels after artificially expressing neuronal 
nAChR subunits in non-neuronal cell systems has helped to demonstrate that different 
subunit combinations display similar pharmacological properties to those receptors 
found in situ. Stable transfection of subunit cDNAs into neuronal/non-neuronal cell 
lines provide a means of expression to characterise pharmacological, physiological and 
biochemical properties of the various combinations of both homomeric and heteromeric 
receptors in a cellular environment, for example, a7, a4p2, a3p2* and a3p4* nAChR. 
Comparisons then can be drawn from the responses evoked by receptors stably 
transfected in vitro and compared to responses elicited by native neuronal receptors 
expressed in vivo (Gopalakrishnan et al., 1996; Quik et al., 1996). It still remains to be 
elucidated whether many of the artificial nAChR subtype combinations generated in 
vitro are representative of, and occur within their natural neuronal membrane 
environment in vivo. It is becoming apparent that the stoichiometry of neuronal nAChR 
is more complex than was first thought and therefore the diversity of nAChR may have 
been underestimated. The expression of multiple nAChR subtypes within the same 
neuron may be explained by the diverse functional and regulatory features associated 
with individual receptors providing them with their unique pharmacological profiles for 
ion permeability, channel opening duration, agonist and antagonist affinities and various 
physiological functions in vivo.
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1.6. Introduction to some nicotinic agonists of interest to this thesis:
1.6.1. Anabaseine:
Anabaseine, 2-(3-pyridyl)-3,4,5,6-tetrahydropyridine, is a pyridine nicotinoid 
alkaloid neurotoxin found in some marine worms, nemertines e.g. the hoplonemertine 
Paranemertes peregrina, and isolated from venom glands of some terrestrial insects, 
ants (Wheeler et al., 1981; for review, see Kem, 1985). These naturally occurring toxins 
are thought to have offensive and defensive functional roles, perhaps against predators 
or to capture prey after prolonged topical administration. The chemical structure of 
anabaseine (Figure 1.8) resembles nicotine and anabasine, the homolgue of nomicotine, 
which are two of the major naturally occurring alkaloids found in the tobacco plant (see 
Holladay etal., 1998).
Figure 1.8. The structure o f (a) nicotine, (b) anabasine and (c) anabaseine.
CH
Anabaseine is pharmacologically appealing and has been useful as a molecular 
model for nicotinic drug design, due to its potency as an agonist at both peripheral and 
central nicotinic receptors (Kem et al., 1971, Meyer et al., 1994). This compound was 
found to have pharmacological activity at all of the nicotinic subtypes tested in muscle 
and neuronal preparations in a variety of systems investigated, including Xenopus
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oocytes, cultured cells, and contractility assays using muscle strips (Kem et al., 1997). 
Anabaseine was selective for activity at nAChR and this compound did not possess 
activity at rat brain muscarinic receptors, except at high concentrations >100 (iM (Kem 
et al., 1997). Anabaseine has also been demonstrated to cause upregulation of central 
nicotinic binding sites (Collins etal., 1990).
Anabaseine exhibits a twenty-fold weaker affinity than nicotine at high affinity 
nicotine binding sites in rat brain and in contrast is highly efficacious at stimulating a7- 
homomeric channels in oocytes displaying high affinity for neuronal a-bgt binding sites 
in the high nanomolar range (De Fiebre et al., 1995; Kem et al., 1997). In terms of 
affinity, the rank order of potency of anabaseine was compared to the tobacco alkaloid 
compounds at rat brain membrane a-bgt binding sites was anabaseine > anabasine > 
nicotine (Kem et al., 1997). At the a402 nAChR subtype the apparent affinities and 
efficacies of anabaseine and anabasine were less than observed with nicotine, showing 
their weak partial agonist activity (Kem et al., 1997). When these compounds were 
tested on different autonomic nAChR differences in potency resulted. This may be 
attributed to the expression of different nAChR subtypes.
Several novel anabaseine-derived compounds have been synthesised after reactions 
with aldehydes to produce 3-substituted derivatives (Zoltewicz et al., 1993). Some of 
these derivatives are thought to possess cytoprotective and also memory-enhancing 
properties (see section 1.6.2.1). It has been proposed that these actions of novel 
anabaseine derivatives may arise due to their interaction with brain nAChR and have 
been subject to pharmacological evaluation. This was the impetus for Meyer et al. 
(1994) to test the ability of anabaseine derived compounds to displace the binding of 
[3H]-cytisine from rat brain membranes, [125I]-a-bgt binding from neuronal nicotinic
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binding sites, and to alter the function of a4p2 and a7* nAChR expressed in Xenopus 
oocytes (De Fiebre et al., 1995). Results suggest that these anabaseine 3-substituted 
derivatives do not diminish peripheral nervous system nAChR activity and a4p2 
activity and thus these compounds may be candidates as partial a l  agonists and 
antagonists at a3p4 and other nAChR (De Fiebre et al., 1995). Advances in this field 
will be advantageous, to identify compounds with selective activities at specific nAChR 
subtypes. In view of the narrow therapeutic window for nicotine and its undesirable 
peripheral actions (tachycardia, increased blood pressure, nausea and abdominal pain), 
these anabaseine-related compounds may be of physiological value and have clinical 
potential as candidate neurological tools, employed as therapies for the possible 
treatment of neurological disorders and dementia (Shimohama, 1996).
1.6.2. Novel Anabaseine derivatives:
I.6.2.I. 3-(2, 4)-dimethoxybenzylidene anabaseine (GTS-21; DMXB):
An anabaseine derivative, 2, 4-dimethoxybenzilidene, (GTS-21; DMXB, Figure 1.9) 
has been evaluated for its neuroprotective properties as a therapeutic drug for the 
treatment of Alzheimer’s disease (AD) (Kem et al., 1996; Meyer et al., 1997). GTS-21 
has been characterised with respect to activity at nAChR subtypes and has been shown 
to displace high affinity [125I]-a-bgt and [3H]-acetylcholine binding (Hunter et al.,
1994). [3H]-cytisine binding was displaced by GTS-21 in both rat brain preparations and 
in the K177 cell line (Meyer et al., 1994; Briggs et al., 1997). Studies using Xenopus 
oocyte preparations indicate that GTS-21 possesses partial agonist activity at human and 
rat a7* homomers and not at the human or rat a4p2 nAChR subtype (or other 
combinations including, a2p2, a3p2, a2p4,a3p4 and a4p4) expressed in oocytes,
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indicating its apparent specificity as a novel a7-selective agonist (Hunter et al., 1994; 
De Fiebre et al., 1995; Meyer et al., 1997).
och3
Figure 1.9, The structure o f DMXB.
In vivo microdialysis analysis of cortical extracellular ACh, dopamine (DA), 
norepinephrine (NE) and 5-HT levels has been investigated after the administration of 
either anabaseine or GTS-21 (Summers et al., 1997). Anabaseine was found to increase 
cortical levels of ACh and NE above baseline controls (in a mecamylamine sensitive 
manner) without having significant effects on DA or 5-HT. Contrasting results were 
obtained with GTS-21 in that it increased NE and DA without affecting ACh and 5-HT 
levels. Mecamylamine applied before the administration of GTS-21 led to an increase in 
ACh and 5-HT levels, with a slight decrease in the release of cortical NE and DA when 
compared to GTS-21 applied alone (Summers et al., 1997). nAChR present may 
normally have a tonic inhibitory effect on ACh release. If this effect is blocked by 
mecamylamine, this could be a possible explanation of the increase in ACh evoked by 
GTS-21 after a pre-administration of mecamylamine, thus permitting the stimulatory
Chapter 1. 41
effect of GTS-21 at a7  receptors to be revealed. Further in vivo analysis will be 
essential to characterise the effects of GTS-21 and the other anabaseine derivatives. 
GTS-21 can also release [3H]-DA from rat striatal slices that can be blocked by the 
nicotinic antagonist DH|3E (Briggs et al., 1997).
This compound has been used in animal models o f cognition, has potential learning 
and memory-enhancing actions as it was found to facilitate the induction of LTP in rat 
hippocampus (Hunter et a l, 1994; Briggs et a l, 1997; Meyer et a l,  1997). When GTS- 
21 was administered to mice it appeared not to have adverse effects and displayed low 
toxicity in comparison to nicotine. A dose of 185 |ig/mol/kg administered i.p. to mice 
was lethal. GTS-21 also has neuroprotective actions against (3-amyloid neurotoxicity, 
and protects against neocortical neuronal cell loss induced by lesions of the nucleus 
basalis magnocellularis in rats (Meyer et a l, 1994; Arendash et a l,  1995; Shimohama, 
1996, 1998; Nanri et a l, 1997). This compound may therefore be a putative therapy 
capable of treating dementia and is currently undergoing clinical trials. This identifies 
other neuronal nAChR subtypes other than a4|32 as targets for putative therapy for 
dementia and a new class of agent as a target for drug discovery in the treatment of 
these neurological disorders.
I.6.2.2. 3-[(4-Dimethylamino) cinnamylidene] anabaseine maleate (DM AC).
Another synthetic analogue of anabaseine is DMAC (see Figure 1.10 for structure). 
DM AC has been reported to displace high affinity [3H]-cytisine binding from rat brain 
membranes (Meyer et a l, 1994); its relative potency for displacement of 1 nM [3H]- 
cytisine binding, compared to the parent compound and other novel anabaseine 
derivatives, is: anabaseine > 3-(4)-dimethylaminobenzylidine anabaseine (DMAB) =
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DMXB >anabasine > DMAC (Meyer et al., 1994; De Fiebre et al., 1995). This 
demonstrates that DMAC is the least potent at displacing [3H]-cytisine from rat brain 
membranes, therefore exhibiting low binding potency for the a4p2 nAChR subtype.
CKH,C.
Figure 1.10. The structure o f DMAC.
When DMAC was examined for potency at the a7* nAChR it was found to be more 
potent than nicotine, ACh, anabaseine and the other 3-substituted anabaseine derivatives 
at displacing [125I]-a-bgt sensitive binding from rat brain membranes (De Fiebre et al., 
1995). The relative Kt values for DMAC at displacing [I25I]-a-bgt, when compared to 
the parent compound and other novel substituted derivatives, is: anabaseine < DMXB < 
DMAB < DMAC. Hunter et al. (1994) also demonstrated that DMAC was a a l-  
selective agonist and the most potent compound compared to anabaseine and its series 
of novel derivatives at activating the a l  subtype. All of the anabaseine derivatives 
displayed significant agonist activity at the a l  nAChR, unlike agonist activity at the 
a4J32 subtype, with DMAC being the most potent at displacing [125I]-a-bgt binding and 
activating a7* nAChR (De Fiebre et al., 1995). The response evoked by DMAC was
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assessed at other nAChR subtypes in oocytes expressing either a4p2, a4|34, a2p2, 
a3p2 or a lp ly b  cRNA. This DMAC evoked response was compared to the response 
elicited by ACh. Maximal responses were obtained with DMAC using concentrations 
ranging from 1-500 |uM and these responses were approximately 1% of the ACh control 
response (De Fiebre et al., 1995) showing little agonist activity at other nAChR 
subtypes.
In summary, previous data indicate that the 3-substituted anabaseine derivatives 
characterised to date selectively activate a l  nAChR over a4p2 subtypes, indicating 
some degree of selectivity. DMAC, when compared with anabaseine and other novel 
anabaseine-derived compounds, is the most potent at displacing [125I]-a-bgt binding 
from its putative a l  receptor binding site and is least potent when displacing [3H]- 
cytisine binding from the putative a4p2 nicotinic receptor subtype found in rat brain 
membranes. The selectivity of these anabaseine-derived compounds for a l * nAChR 
will be useful to elucidate the physiological function and decipher putative roles for 
neuronal a l  nAChR in normal CNS functioning and in human CNS pathologies, for 
example AD and their putative roles as cytoprotective and memory enhancing agents.
DMAC was synthesised by Organon (Newhouse) for analyses documented in this 
thesis (Chapter 2 and 3). Initial experiments were conducted to draw comparisons the 
potency of DMAC at different nAChR binding sites by using [3H]-nicotine, [3H]- 
epibatidine, [125I]-a-bgt and [3H]-MLA in competitive binding assays initially using rat 
brain membranes with DMAC (see section 2.7.2.1). This compound will also be 
examined with nicotine and KC1 with respect to chronic drug treatment and 
investigating its ability to produce upregulation of a3* and a7* nAChR in primary 
hippocampal and also SH-SY5Y cell cultures (Chapter 2 and 3).
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1.6.3. Epibatidine:
Epibatidine is a potent nicotinic ligand that was first isolated from skin extracts of an 
Ecuadorian poison frog Epipedobates tricolor (Figure 1.11), by Daly and co-workers 
who also elucidated its structure (Spande et al., 1992), shown below in Figure 1.12.
Figure 1.11. Epipedobates tricolor.
Figure 1.12. The structure o f (+)-epibatidine, 
the natural enantiomer.
After the structure of epibatidine was established, epibatidine was readily 
synthesised. Both enantiomers are pharmacologically equipotent in most cases and 
display high affinity for nAChR sites in whole rat brain studies (Badio and Daly, 1994; 
Damaj et al., 1994; Bonhaus et al., 1995; Badio et al., 1995). A Kt value of between 20- 
60 pM for epibatidine at a4p2 receptors was found in rat brain by competition against 
[ H]-nicotine and [ H]-cytisine demonstrating that this is the highest affinity ligand 
known at these receptors (Badio and Daly, 1994; Damaj et al., 1994; Sullivan et al.,
1994).
This azabicycloheptane alkaloid displays potent analgesic-like effects in vivo that are 
not reversed by naloxone, an opiate receptor antagonist (Spande et al., 1992; Damaj et 
al., 1994). These effects were blocked by the neuronal nAChR channel blocker 
mecamylamine, which crosses the blood brain barrier, and DHJ3E, but not blocked by
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hexamethonium, a compound that does not cross the blood brain barrier (Qian et al., 
1993; Badio and Daly, 1994; Damaj et al., 1994; Rupniak et al., 1994; Badio et al., 
1995; Bonhaus et al., 1995). These findings identify epibatidine as an analgesic agent 
that acts highly selectively and potently via a neuronal nicotinic mechanism (Qian et al., 
1993; Rupniak et al., 1994). Epibatidine exerts other effects consistent with potent 
actions at nAChR. When injected into mice there is a mecamylamine-sensitive 
reduction in body temperature and a decrease in the observed locomotor activity at 
doses more potent than nicotine in evoking similar behavioural responses (Damaj et al., 
1994; Sullivan et al., 1994). Epibatidine when administered in high doses also displays 
toxic effects of laboured respiration, reduced activity and convulsions resembling those 
toxic effects produced by nicotine.
Epibatidine has in fact got high affinity for both neuronal and neuromuscular nAChR 
with little or no significant affinity for other (non-nicotinic) receptors. This was shown 
by the lack of effect of epibatidine (10 (iM) when used in a range of radioligand-binding 
assays for opioid, muscarinic, adrenergic, DA, 5-HT, AMP A, kainate, NMD A and 
GABAa receptors (Qian et al., 1993; Badio and Daly, 1994; Rupniak et al., 1994; 
Bonhaus et al., 1995). This potent ligand therefore has been used to pharmacologically 
explore the diversity of nAChR subtypes. Epibatidine is available as a tritiated ligand 
which can be used reliably to label a variety of nAChR complexes with extraordinarily 
high affinity, which is in contrast to other nicotinic ligands and in particular [3H]- 
nicotine which only reliably labels the a4p2 site and displays a large proportion of non­
specific in vivo binding (London et al., 1995) (see section 1.4.1). Both enantiomers of 
epibatidine displace the binding of [3H]-nicotine to rat brain membranes (Damaj et al., 
1994; Rupniak et al., 1994). Both of the enantiomers of epibatidine behaved as full 
agonists when examined in Xenopus oocytes using a variety of species neuronal nAChR
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subtypes including chicken (a302, a304, a402, a l  and a8) and human (a302, a3p4 
and a l)  (Gerzanich et al., 1995).
[3H]-epibatidine can be used in radiolabelled binding assays to detect oc3* nAChR 
with high affinity (Perry and Kellar, 1995; Lukas et al., 1999). Hence the utility of this 
tritiated agonist to label a3* nAChR endogenously expressed in the human 
neuroblastoma SH-SY5Y cells or ganglionic-type nAChR present in rat 
pheochromocytoma PC 12 cells used in this thesis. [ H]-Epibatidine saturably binds at 
an a3* nAChR expressed in PC 12 cells with a Kd of 83 pM and to two sites, a3p2 and 
a3p4 nAChR in SH-SY5Y with Kd values of 0.15 and 7.4 nM respectively (Wang et 
al., 1996). In rat forebrain homogenates, where a heterogeneous population of nAChR 
are expressed, [3H]-epibatidine was found to saturably bind to two distinct sites with 
low non-specific binding. [3H]-epibatidine bound with Kd values of 15 pM and 360 pM 
putatively representing the a4P2 and a3* nAChR binding sites respectively 
(Houghtling et al., 1995). Each site was found to represent 50% of [3H]-epibatidine 
binding as each site appeared to be present in equal densities within the rat forebrain 
homogenates. Autoradiographical analysis comparing the binding of [3H]-epibatidine to 
that found with [3H]-nicotine and [3H]-cytisine identifies differential maps for these 
radioligands in rat and mouse brain slices (Perry and Kellar, 1995; Marks et al., 1998; 
Zoli etal., 1998).
Zoli et al. (1998) combined data relating to the pharmacological properties of 
nAChR, their location and functional responses evoked from defined brain regions and 
compared responses in wild-type mice and those lacking the 02 subunit. In mice lacking 
the 02 subunit four distinct subtypes of nAChR were identified after autoradiography 
and patch-clamp recordings in thin murine brain slices (Zoli et al., 1998). Type 1
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nAChR are a-bgt-sensitive and the pattern of [125I]-a-bgt binding obtained from 
autoradiography did not change significantly in (32 mutant mice, but was abolished in 
a l  mutant mice (Orr-Utreger et al., 1997) identifying the presence of a l  and not (32 
subunits. Type 2 nAChR represent the vast majority of high affinity [3H]-epibatidine 
binding sites in mouse brain and contain the (32 subunit as high affinity [3H]-nicotine 
binding was abolished in (32 mutant mice. a-Bgt did not bind to these receptors, in 
contrast all nicotinic agonists bound to these nAChR with high affinity and are therefore 
thought to be a4|32 nAChR. Type 3 nAChR bind [3H]-epibatidine with high affinity, 
their persistence in P2 mutant mice strongly suggests they lack the p2 subunit and are 
probably composed of a3p4 subunits. Type 4 nAChR bind both [3H]-epibatidine and
3  • •  • •  •  • » » »  • •[ H]-cytisine with high affinity, this binding is maintained in P2 mutant mice indicating 
that these nAChR do not contain the p2 subunit. The putative composition of these 
receptors could either be a l  and/or a4  with P2 subunits or a3 and/or a4 with p4 
subunits. The binding differences observed with [3H]-epibatidine therefore reflect 
nAChR heterogeneity and the ability of [3H]-epibatidine to label more than one nAChR 
subtype with high affinity, revealing an a3 * component.
Epibatidine has lower affinity for the displacement of [125I]-a-bgt from the neuronal 
a l  a-bgt-sensitive nAChR subtype present in rat brain (X, = 230 nM) but is more potent 
when competing for the receptor present in Torpedo electroplax (X, = 2.7 nM) (Sullivan 
et al., 1994). [3H]-Epibatidine opens new avenues to characterise and deduce 
pharmacological properties of nAChR due to its exceptionally high affinity for these 
receptor sites in brain, periphery, ganglia and in cell lines. The high potency of 
epibatidine provides a structural basis to model new compounds as selective probes 
with high affinity for specific nAChR subtypes within the brain and to help in the study
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of central nicotinic cholinergic systems. Such compounds may be useful in clinical trials 
as safe and efficacious non-opioid analgesic therapies that would overcome unwanted 
side effects of narcotic analgestics, which include respiratory depression, emesis, 
sedation and dependence, or as potential tools in the treatment of pathological 
conditions involving central neuronal nAChR function.
1.7. Some nicotinic antagonists of interest to this thesis:
1.7.1. M ethyllycaconitine (MLA):
MLA is a tertiary norditerpenoid alkaloid isolated from the seeds of Delphinium 
brownii, and found to have a markedly greater affinity for the [125I]-a-bgt binding site 
(MacAllan et al., 1988; Ward et al., 1990) in brain compared to the muscle type nAChR 
(Ward et al., 1990), with approximate Kt values of 1 nM and 1 |iM respectively. The 
reversible concentration-dependent inhibition by MLA was also observed on ACh and 
anatoxin-a evoked currents in cultured fetal rat hippocampal neurones (Alkondon et al., 
1992). The action of MLA was specific to nAChR, no blockade of the responses to 
NMDA, quisqualate, kainate or GABA receptor agonists were observed in neurones 
(Alkondon et al., 1992).
MLA is a potentially useful probe to dissect nAChR subtypes and to characterise the 
pharmacological and physiological functions of a7* a-bgt-sensitive nAChR from their 
a-bgt-insensitive counterparts in the mammalian nervous system. MLA is a small, 
reversible, potent, competitive antagonist compared to the large, pseudo-irreversible 
nature of the snake neurotoxin a-bgt. In the tritiated form, [3H]-MLA is a relatively 
novel radioligand that binds to a single class of binding site in rat brain membrane 
preparations (Davies et al., 1999). Autoradiographic analysis with [3H]-MLA in mouse
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brain sections reveals binding that closely parallels that obtained with [125I]-a-bgt 
(Whiteaker et al., 1999). [3H]-MLA may therefore help to quantitate and unveil 
characteristics of the neuronal a-bgt sensitive nAChR binding site as it displays rapid 
association and dissociation kinetics (Davies etal., 1999).
1.7.2. a-Conotoxins:
a-Conotoxins (a-CTX) are members of a family of small, paralytic peptides 
characterised from the venom produced from the carnivorous Conus vermivorous, 
piscivorous or mollusc hunting marine snails (for reviews, see Gray et al., 1988; Olivera 
et al., 1990; Arias, 2000; McIntosh et al., 2000). The venom contains a complex 
mixture of disulfide-rich peptides, each of which is capable of targeting specific 
macromolecular receptors (Olivera et al., 1984, review, 1990). One large class of these 
hypervariable toxins is the a-CTX that target muscle or neuronal subtypes of nAChR. 
In contrast to snake a-neurotoxins (60-80 amino acids), the a-conotoxins are about 12- 
25 amino acids in length. They are the smallest of the major paralytic conotoxins and 
are the smallest peptidergic selective, competitive antagonists that show promise in 
targeting and characterising both native and heterologously expressed subtype specific 
nAChR and are capable of inhibiting neuromuscular transmission (Myers et al., 1991; 
Johnson et al., 1995). Three different fish-hunting Conus species, Conus geographus, 
Conus striatus, and Conus magus produce venom containing a-CTX peptides that 
inhibit muscle-nAChR located at the vertebrate neuromuscular junction e.g. a-CTX-MI 
and a-CTX-GI with IC50 values of 12 and 20 nM respectively (Myers et al., 1991; 
Johnson etal., 1995; McIntosh etal., 1999; Arias, 2000).
Chapter 1. 50
Due to their size being between that of smaller nicotinic ligands and the larger a - 
neurotoxin snake venom polypeptides (a-bgt, a-cobratoxin), the a-conotoxins are 
useful novel chemical probes for receptors and ion-channels, in particular nAChR. The 
small size of the a-conotoxins enables them to be synthesised by chemical techniques in 
biologically active forms. To date there are approximately 500 different species of 
Conus predatory gastropods, each having its own set of venom, many containing a- 
CTXs that can be purified and sequenced (Olivera et al., 1990). These disulfide-rich 
peptides all have high structural homology in their conserved cysteine sequence motifs, 
which provides a means to identify specific target receptors, but are hypervariable in 
their intercysteine disulfide bonding patterning. The consensus sequence 
ACC(H/N)PACGXX(Y/F)XC is shared by most of the a-CTXs purified from 
piscivorous-hunting cone snails (not a-CTX-MII; Cartier et al., 1996) (Hopkins et al., 
1995) (see Table 1.1).
Table 1.1. Peptide sequences o f some o f the a-contoxins. The fish-hunting Conus species from 
which each toxin was isolated is indicated (reviewed by Arias, 2000).
Conotoxin Sequence Source Reference
a-GI ECCNPACGRHYSC-NH2 C. geographus Gray et al. (1984, 1988)
a-GIA e c c n pa c g r h y sc g k -n h 2 C. geographus Gray etal. (1981)
a-GII e c c h p a c g k h f s c -n h 2 C. geographus Gray et al. (1988)
a-SI ic c n p a c g k n f d c -n h 2 C. striatus Zafaralla etal. (1988)
a-MI g r c c h pa c g k n y s c -n h 2 C. magnus McIntosh et al. (1982)
a-MII g c c s n pv c h l e h sn l c -n h 2 C. magus Cartier et al. (1996)
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a-CTXs purified from the non-fish hunting Conus have sequences that retain a cysteine 
residue framework XnCCXnCX„CXn (Hopkins et al., 1995). Differences in the primary 
structure of these peptides probably accounts for the specificity attributed to each toxin 
for nAChR subtypes.
1.7.2.1. a-Conotoxin-IM I:
a-Conotoxin-Iml (a-CTX-Iml) is a 12 amino acid peptide neurotoxin, 
GCCSDPRCAWRC-NH2, isolated from the vermivorous marine snail C. imperialis 
(McIntosh et al., 1994; Johnson et al., 1995). This a-neurotoxin has been found to 
selectively target specific subtypes of nAChR when expressed in Xenopus oocytes, a - 
CTX-Iml selectively blocks a7-homomeric nAChR with an apparent affinity (IC50) of 
0.2 pM and a9  homomers with 8-fold less potency (IC50 = 1.8 pM) (Johnson et a l, 
1995). a-CTX-Iml had negligible effects on mammalian neuromuscular transmission 
and other combinations of neuronal nAChR subunits a202, a3p2, a4|32, a2P4, a3p4, 
a4p4 (Johnson et al., 1995; Pereira et al., 1996). Patch-clamp analysis applied to 
hippocampal neurones in culture was also used to study the effect of a-CTX-Iml on 
native a-bgt-sensitive neuronal nAChR (Pereira et a l, 1996). If hippocampal neurones 
were pre-exposed for 5 min with a-CTX-Iml, there was a competitive, reversible 
concentration-dependent decrease in the peak amplitude of native a l*  a-bgt-sensitive 
currents (Pereira et al., 1996). The action of a-CTX-Iml was specific for a-bgt- 




A relatively novel 16 amino acid peptide has been sequenced from the venom of the 
marine snail Conus magus (Cartier et al., 1996). This a-CTX is thought to selectively 
target a3p2* nAChR subtypes with subnanomolar affinity (IC50 = 0.5 nM) expressed in 
Xenopus oocytes (Cartier et al., 1996). a-CTX-MII selectively blocks the slowly 
decaying current in avian ciliary ganglion (Ullian et al., 1997) and blocks 
approximately 93% of the ACh-induced response in a3P2-expressing oocytes 
(McIntosh et al., 2000). The peptide sequence of a-CTX-MII is shown in Table 1.1. Its 
sequence identifies both structural and functional differences from the previously 
isolated, cloned and sequenced a-neurotoxins. Most of the previously identified a- 
CTXs target muscle-type receptors, subsequently the identification of a-CTX-Iml 
(Pereira et al., 1996) and a-CTX-AUIB (Luo et al., 1998) were selectively found to 
target a7  and a3P4 nAChR respectively. a-CTX-MII has been demonstrated to act as a 
competitive antagonist that targets a3P2* nAChR (Cartier et al., 1996; Ullian et al., 
1997; McIntosh et al., 2000), partially blocks nicotine-stimulated DA release (Kulak et 
al., 1997; Kaiser et al., 1998) and when iodinated as [125I]-a-CTX-MII, identifies a 
novel population of nAChR in mouse brain (Whiteaker et al., 2000).
The a-CTXs represent a group of potent and selective ligands capable of 
discriminating functional responses evoked by various nAChR subtypes and provide 
support for the vast diversity of nAChR targeted toxins present in the Conus species’. 
Further analysis of these peptide neurotoxins may help to locate amino acid residues 
that determine specific nAChR selectivity. The ability of these conotoxins to be 
synthesised means that they are free from any potential venom contaminants and can be
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chemically modified to covalently incorporate radioactive or fluorescent moieties used 
to identify structure-fimction relationships and in imaging analysis studies.
1.8. Nicotine and the tobacco smoking habit in man:
A major stimulus of research into nAChR has been the desire to understand the 
molecular and cellular basis of nicotine dependence. The chronic use of tobacco in man 
leads to tolerance, physical and psychological dependence along with the subjective 
euphoric effects (Johnston, 1942; Perkins et a l, 1993). Tolerance develops rapidly to 
the initial aversive effects of nicotine to the human body including the feelings of 
nausea and vomiting, mediated in part by the peripheral nervous system. It is now 
widely accepted that nicotine causes predominantly psychological dependence in 
habitual smokers (Balfour, 1990). This results in a combination of objective and 
subjective states, euphoria, cognitive enhancement, changed adaptation to stress, which 
together support the maintenance of drug seeking behaviour (Stolerman and Jarvis, 
1995). After inhaling tobacco smoke nicotine is readily absorbed via the buccal cavity, 
nasopharengeal tract and the lungs before entering the arterial circulation for 
distribution around the body (Benowitz, 1996). Chronic smokers tend to maintain an 
elevated plasma nicotinic level which is further increased after each tobacco smoke 
inhalation, persisting over the course of a day. The resultant accumulation of nicotine 
causes the development of neuroadaptation as the tobacco smoker’s day progresses 
(Ashton and Stepney, 1982; Benowitz, 1991).
The absorption of inhaled nicotine from a bolus of tobacco smoke is extremely rapid 
with the onset of central effects within 10 seconds of inhalation (Russell, 1991; 
Benowitz, 1996). This rapid delivery is an effective rewarding process as reinforcement
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is almost immediate and plays an essential role in reward learning mechanisms and 
maintaining the addiction of cigarette smoking. The rapid delivery of nicotine from 
inhaled tobacco smoke allows the smoker to carefully adjust their smoking pattern and 
to titrate their plasma nicotine levels accordingly, hence alleviating their mood 
(Benowitz, 1991). It is advantageous to analyse the pharmacological profile of nicotine 
after inhalation and the rate at which nicotine is absorbed into the body when trying to 
achieve a successful therapeutic smoking cessation treatment (Sutherland et al., 1992). 
The pharmacological profile of dosing with nicotine gums or patches produce a gradual 
dosing of nicotine which does not mimic the efficient and rapid dosing via the 
pulmonary route observed with inhalation of tobacco smoke (Rose et al, 1985; Russell, 
1991). Smoking cessation aids with a slower entry time o f nicotine to the brain have a 
longer delay elapsing before the desired subjective effects are produced (for review see, 
Leischow and Cook, 1998). Consequently, the positive reinforcing effects of nicotine 
within the CNS will be weaker compared to those perceived after smoking a cigarette 
(Benowitz, 1991). This different pharmacological profile of the drug response may alter 
the degree of desensitisation of the nAChR and will in turn reflect the degree of 
reinforcement experienced. To ensure that rapid reinforcement develops it is important 
that the association between drug-taking behaviour and its pharmacological 
consequences occurs rapidly without a substantial delay.
The craving for the rewarding properties of an addictive drug and the avoidance of 
the unpleasant symptoms on drug withdrawal are both likely to contribute to the 
maintenance of drug-taking behaviour (Balfour, 1991; Wilner and Jones, 1996). 
Nicotine is considered to act both as a positive and as a negative reinforcer (Stolerman 
and Jarvis, 1995). The concept of positive reinforcement correlates with the pleasurable 
experiences associated with smoking. If a person smokes to escape the ‘psychological
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discomfort’ related to withdrawal and thus relieve anxiety, depression, psychosis and 
the unpleasant consequences whenever they are deprived from nicotine, under these 
circumstances nicotine acts as a negative reinforcer (Di Chiara, 1992). This 
demonstrates the importance of the aversive withdrawal phenomena in situations 
concerning the maintenance of the tobacco smoking habit and perhaps in the initiation 
of smoking after cessation. Negative reinforcement contributes to the tobacco smoking 
habit but by no means is the principal driving force to continue nicotine abuse (West 
and Schneider, 1987; Wilner and Jones, 1996). Dependence on nicotine can be 
considered as when abstinent smokers relapse due to the craving for nicotine and to 
obtain the rewarding, euphoric effects of the drug.
Each inhaled puff of cigarette smoke contains nicotine in suspension on tiny droplets 
of tar and will evoke a series of intermittent boli of the alkaloid. Individual 
characteristic styles of smoking have developed and has split the smoking population 
into either ‘peak seekers’ or ‘trough maintainers’ (Russell, 1990) depending on their 
daily cigarette consumption. The former can also be termed indulgent smokers as they 
smoke in a fashion as to create peak plasma nicotine levels after a cigarette. In contrast, 
trough maintainers are perhaps smoking on a more frequent basis and are considered as 
heavy smokers, who will regulate their smoking consumption to establish a relatively 
constant body nicotine level which remains higher than a baseline level. Habitual 
smokers will dose themselves with enough nicotine to produce the desired effects that 
are most rewarding on both their brain and behaviour. The actual intake of nicotine can 
be considered as lying within a rewarding window, avoiding nicotine toxicity from over 
smoking and withdrawal from under smoking (Rose et al., 1993).
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1.9. Beneficial roles for nicotine and nAChR subtypes involved:
It has been shown that nicotine, when in a pure state, free from tobacco carcinogens 
including carbon monoxide, polycyclic aromatic hydrocarbons and tar (Benowitz, 1991; 
Jarvik, 1991), is able to alleviate the symptoms of withdrawal from tobacco smoking 
and may prove to be a therapeutically active and a valuable pharmaceutical agent for 
treating other conditions (see Decker and Americ, 1998). Different nAChR subtypes 
have been implicated in cognitive processes, including short-term memory and 
vigilance and in pathological conditions. nAChR subtypes have also been implicated 
with exerting changes within the CNS on various neurotransmitter systems (Balfour, 
1982, 1989, 1994; Soliakov and Wonnacott, 1996; Kaiser et al., 1998). These 
principally include the catecholaminergic, serotonergic and cholinergic neural 
pathways. Tobacco smokers therefore benefit from nicotine in the smoke, as it helps to 
alleviate some of the symptoms of such pathological disorders eg. schizophrenia and 
Alzheimer disease deficits. The identification of the specific subtypes of nAChR 
involved in particular medical conditions, using nAChR subtype specific ligands, offers 
the prospect that these receptors can be targeted with selective drugs to evoke beneficial 
effects or alleviate symptoms of a particular condition. The continued development of 
selective nAChR ligands will help to elucidate and unravel the physiological roles of 
nAChR in both normal neuronal functioning and in diseased conditions.
1.9.1. Neuronal development and neuroprotective-related actions:
The role of nAChR in the CNS, other than their involvement in the mediation of 
synaptic transmission, is well documented and recognised. It has been suggested that a 
possible role for transmission via nAChR is the determination of the fate of specific
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neuronal populations. The oc7* nAChR is highly permeable to Ca2+ and may regulate 
target cell function via Ca2+-dependent processes, such as second messenger systems 
(Vijayaraghavan et al., 1992) and the induction of immediate-early gene expression, a- 
Bgt-sensitive receptors have also been implicated in development and synapse 
formation (Mandelzys et al., 1994), neuronal development and in the context of 
neuroprotection after toxic insults to cells (Semba et al., 1996; Minana et al., 1998). It 
has been demonstrated that activation of a7* nAChR promotes survival o f spinal cord 
motoneurones (Messi et al., 1997) and nicotine, by activation of a7* nAChR, prevents 
NMDA and glutamate neurotoxicity in primary cultures of cerebellar neurones (Minana 
et al., 1998) and is neuroprotective against excitotoxic insults applied to striatal, 
cortical, and hippocampal neurons (Marin eta l., 1994; Semba e ta l ., 1996; Kihara et a l, 
1997).
1.9.2. A lzheim er’s Disease and memory-related actions:
The ageing process of the human brain is associated with reductions in various 
nAChR subtypes; in the case of Alzheimer’s and Parkinson’s disease (AD and PD 
respectively) these changes are selective (see Gotti et al., 1997 for an overview). AD is 
a progressive neurodegenerative disorder affecting individuals over the age of 65 years. 
Intracellular neurofibrillary tangles and senile plaques in combination with extensive 
cellular atrophy and cell loss are all distinct neuropathological features of this disease 
displayed in AD brains on post-mortem examination (see Selkoe, 1999 for review). The 
cholinergic innervation to the cerebral cortex and hippocampus is degenerated in AD 
brains, and results in the progressive deterioration of higher cognitive function and the 
loss of memory. This has led to studies characterising the changes in choline
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acetyltransferase levels and nAChR density in AD brains. The level of cortical 
acetyltransferase and [3H]-nicotine binding sites are significantly decreased in AD 
patient (Perry et al., 1982, 1995; Aubert etal., 1992; Sihver et al., 1999). The reduction 
in nicotinic binding sites has also been confirmed in the temporal cortex, frontal cortex, 
substantia nigra and the hippocampus using n C-nicotine in in vivo PET studies 
(Nordberg et al., 1995). It has been demonstrated that in the cortex there is a selective
• • •  •  •  ♦ 3loss of a4  subunits detected by subunit immunoreactivity and a reduction in [ H]- 
nicotine and [3H]-epibatidine binding. The a3 and a l  nAChR subunits were not 
affected likewise the binding of [125I]-cc-bgt was unaltered in AD brain compared to 
control (Perry et al., 2000). These findings indicate that AD is associated with a loss of 
nicotinic binding sites that incorporate the a4  nAChR subunit.
The a7-selective agonists DMXB (see section 1.6.2.1) and DMAC (see section 
1.6.2.2) enhance performance in several spatial and non-spatial memory-related 
paradigms in rats (Meyer et al., 1994, 1997; Bjugstad et al., 1996) and may be of 
therapeutic value to treat age-associated memory impairment and AD. An injection of 
ibotenic acid, an excitotoxin, into the nucleus basalis magnocellularis significantly 
decreases the number of neuronal cells in the cerebral cortex, providing an animal 
model similar to AD (Nanri et al., 1997). The protective action of DMXB was observed 
after treatment to lesioned rats when compared to control untreated animals (Nanri et 
al., 1997), due to the a l  selective nature of DMXB, it can be speculated that a l* 
nAChR may be implicated in memory-related behaviours and play a role in this 
cytoprotctive action and neuronal survival. In this thesis, the related drug DMAC will 




PD is characterised by muscle rigidity, tremor and bradykinesia, postural deficits, 
impaired gait and dementia in a minority of patients (for review see, Dunnett and 
Bjorklund, 1999). The main pathological features of this neurological disease are the 
detection of Lewy bodies, hyaline inclusions in the cytoplasm of neurones and the 
substantial loss of forebrain dopaminergic neurones predominantly from the substantia 
nigra. There are reports of a negative correlation between the development of PD and 
smoking (Morens et al., 1996) and that changes in the symptomatology were observed 
after PD patients were treated with nicotine gum and patches (Fagerstrom et al., 1994). 
Nicotinic agonists may therefore have therapeutic potential to compensate and alleviate 
the cognitive deficits associated with AD and PD patients and help to slow the 
progression of neurodegeneration (Decker and Americ, 1998).
1.9.4. Schizophrenia:
The incidence of tobacco smoking amongst the population who suffer from mental 
illness is higher than the general population. A high incidence of smoking (50%-84%) 
has also been found in schizophrenic patients (Hughes et al., 1986). Schizophrenia is 
characterised by symptoms of delusions, hallucinations (auditory), disorganised 
thinking and speech and a deficit in their auditory processing (for review see, Leonard 
et al., 1998). Nicotine normalises the processing of this sensory deficit in schizophrenic 
patients and on post-mortem examination, schizophrenic brain contains aberrant 
expression and regulation of nAChR (Leonard et al., 1998, 2000). In this disorder the 
intake of nicotine proves beneficial and indeed neuroprotective. nAChR are therefore 
implicated in the sensory deficit in schizophrenics and this has been mapped to a
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chromosomal region that contains the a7  nAChR subunit gene (Freedman et al., 1997), 
revealing another importance of this nAChR subtype in normal neuronal functioning. 
Much research still needs to be completed in this field to elucidate the functional 
implications of nicotine and nAChR subtypes in neuropsychiatric and neurological 
disorders, in relation to long term exposure without creating long term side effects or 
dependence on the drug.
1.10. Neuronal receptor changes relating to tolerance:
Chronic drug exposure leads to the development of adaptive changes within neural 
networks leading to the production of tolerance to the acute peripheral effects of 
nicotine and also to drug dependency (Marks et al., 1983, 1985; Schwartz and Kellar, 
1985). This is the case with the psychoactive drug nicotine, which is sufficient to create 
an addictive state after chronic nicotine exposure in rodents or in dependent tobacco 
smokers (Marks et al., 1983; as reviewed by Balfour, 1991). The adaptations produced 
within the CNS after long term exposure to nicotine correspond to changes in the 
number of neuronal nAChR where nicotine exerts its effects within the brain. In 
neurophysiological terms this adaptation is also known as receptor desensitisation (see 
Marks, 1998). Conventionally, chronic stimulation of receptors by repeated agonist 
treatment is expected to lead to down-regulation of neurotransmitter receptors (for 
review, see Creese and Sibley, 1980). The action of chronic nicotine is now well 
documented in that it exerts a paradoxical increase, or upregulation, of the high affinity 
tritiated agonist and a-bgt-sensitive binding site densities within the CNS, attributed to 
a protracted functional blockade of these nAChR complexes (as reviewed by 
Wonnacott, 1990).
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1.10.1. Chronic nicotine treatment upregulates high affinity [ H]-agonist and [ I]- 
a-bgt binding sites:
The ability of chronic nicotine treatment to produce upregulation and elicit 
adaptation of neuronal tissue must be due to the prolonged nicotine enriched 
environment. Binding assays have shown that chronic exposure to nicotine differentially 
affects [3H]-nicotine, [3H]-cytisine, [125I]-a-bgt and [3H]-quinuclidinyl benzilate ([3H]- 
QNB) binding in different brain regions after similar chronic drug treatment regimes 
(Marks et al., 1983, 1985; Schwartz and Kellar, 1983, 1985; Pauly et al., 1991; 
Sanderson et al., 1993). Chronic nicotine increases the density of the high affinity [3H]- 
nicotine and [125I]-a-bgt-sensitive nAChR binding sites with no change in binding of 
[3H]-QNB binding (Marks et al., 1983, 1985). [3H]-QNB identifies muscarinic binding 
sites within the brain and this study reveals that the upregulatory action of nicotine is 
specific to nAChR.
Marks et al. (1983) investigated the effects of constantly infusing nicotine at 
different rates (0.2, 1.0, 5.0 mg/kg/h) into female mice for a period of 8-10 days. 
Nicotine binding was assessed in several brain regions with [3H]-nicotine. Results 
confirmed a significant dose-dependent increase in nAChR binding sites in the 
following 5 brain regions: the cortex, midbrain, hindbrain, hypothalamus and the 
hippocampus. Upregulation was evoked with doses of nicotine lower than those 
required to elicit changes in the number of [125I]-a-bgt binding sites. Populations of 
neuronal nAChR identified by a-bgt binding were also significantly increased in both 
the midbrain and hippocampal regions after chronic infusion with a high dose of 
nicotine (5 mg/kg/h). This is consistent with the ability of nicotine to bind to [3H]- 
nicotinic agonist sites with greater affinity than to [125I]-a-bgt binding sites.
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Quantitative autoradiographic analysis of mouse brains, previously subjected to 
chronic infusions of nicotine ranging from 0.25-2.0 mg/kg/h for 10 days, revealed that 
[3H]-nicotine binding sites were increased in a dose-dependent manner within most of 
the brain regions studied, compared to saline infused control animals (Pauly et al., 
1991). [125I]-a-Bgt binding observed in cryostat sections was increased after chronic 
nicotine treatment but in a less robust fashion compared to those sites labelled with 
[3H]-nicotine. Muscarinic binding sites were not affected by chronic nicotine treatment. 
These data support and compliment the previously reported homogenate binding assays 
used to measure the magnitude of upregulation of receptor ligand binding in dissected 
brain regions. This study provides more detailed maps of the regional specificity and 
distribution of upregulated nAChR binding sites in mouse brain (Pauly et al., 1991). 
Upregulation of putative nAChR binding sites by the administration of chronic nicotine 
to experimental animals is now a well-documented phenomenon (as reviewed by 
Wonnacott, 1990).
These results are also supported by the increase observed in [3H]-ACh binding sites 
in the cerebral cortex of rats administered with chronic nicotine for 10 days with no 
significant effect on [3H]-QNB sites (Schwartz and Kellar, 1983). Schwartz and Kellar 
(1983) measured the effect of chronic administration of diisopropyl fluorophosphate 
(DFP), a cholinesterase inhibitor capable of increasing the concentration of ACh at 
synapses by retarding its hydrolysis and thereby prolonging cholinergic receptor 
stimulation. DFP produces an opposite effect compared to that of nicotine. Chronic DFP 
treatment decreases [3H]-ACh binding by 20-38%, which is proposed to be an 
adaptative response to the increased synaptic levels of ACh (Schwartz and Kellar, 1983, 
1985). This down-regulation of brain nicotinic cholinergic sites labelled with [3H]-ACh 
is similar to the decrease in both nicotinic and muscarinic binding sites observed after
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chronic administration of another acetylcholinesterase inhibitor, disulfoton (2 
mg/kg/day for 10 days) to rats (Costa and Murphy, 1983).
Schatchard analysis of the changes in radioligand binding in all o f these studies 
demonstrates an increase in the number, and therefore density, of receptor binding sites 
Bmax with no change in the apparent affinity (Kd) of nicotine binding for its receptors 
(Marks et al., 1983, 1985; Schwartz and Kellar, 1983; Rowell and Wonnacott, 1990; 
Sanderson e ta l ., 1993; Bhat etal., 1994; Yates etal., 1995). This change in Bmax is also 
extrapolated to the decrease in [ H]-ACh binding sites observed after chronic DFP 
treatment to rats, which was due to a decrease in the apparent density of these tritiated 
agonist binding sites in the various regions analysed (Schwartz and Kellar, 1985).
Marks et al. (1985) performed a range of experiments investigating the time course 
relating to the onset and loss of tolerance to nicotine in mice when chronically 
administered a continuous i.v. infusion of nicotine. The results reported that maximum 
tolerance was observed after 4 days of chronic drug infusion with a parallel increase in 
the number of [3H]-nicotine and [125I]-a-bgt binding sites and no change in the 
muscarinic sites labelled with [3H]-QNB in any of the brain regions examined at any 
time point during the study. More prolonged treatments did not evoke more extensive 
changes, this implies that at a given dose nicotine will increase the number of nAChR 
binding sites until a steady state is achieved. Brain nicotinic binding sites returned to 
control binding values after 4 and 8 days after withdrawal of nicotine treatment (relating 
to a-bgt and nicotine binding sites respectively) indicating that nicotine-induced 
increases in nAChR binding sites are reversible in mice (Marks et al., 1985) and also in 
rats (Schwartz and Kellar, 1985). This can be related to the number of nAChR binding 
sites in former smokers which are not significantly different from numbers documented 
for non-smokers (Breese et al., 1997).
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The time course for the development of increases in Bmax evoked by chronic i.v. 
nicotine infusion reported by Marks et al. (1985) is similar to the observed time course 
of increases in [3H]-ACh binding after repeated injections of nicotinic agonists. Either 
nicotine or the nicotinic agonist cytisine administered to rats for 5-21 days, or a one 
week treatment with the nicotinic agonist (+)-anatoxin-a, administered via osmotic 
minipumps, elicited similar time courses for the development of upregulation of 
functional [3H]-nicotine binding sites (Schwartz and Kellar, 1985; Rowell and 
Wonnacott, 1990, respectively). Similarly nicotine administered to rats (4 mg/kg/day) 
via minipumps increased [3H]-nicotine binding sites by 59% and 48% in the cortex and 
the hippocampus respectively in a time-dependent manner (Sanderson et al., 1993). 
Schwartz and Kellar (1985 ) showed an increase of 20% in [3H]-ACh binding sites after 
5 days of chronic nicotine treatment, with the maximum increase of 28-30% being 
found in the cortex, thalamus, striatum and hypothalamus after 10 days. Upregulation 
was not evoked with cotinine the major metabolite of nicotine. When animals were 
sacrificed after 7 days following the 10 day chronic nicotine treatment, nAChR binding 
site numbers had returned to values comparable to those in control untreated conditions 
which is also consistent with the observations noted by Marks et al. 1985. To 
investigate whether the upregulation of nAChR binding sites could be mediated by mere 
occupancy of the receptor, centrally active nicotinic antagonists were administered to 
rats. Neither mecamylamine nor DH0E significantly altered [3H]-ACh binding 
following 10-14 days of their administration to rats, signifying that occupancy and 
activation of the [3H]-agonist recognition site is a requirement for upregulation (Marks 
et al., 1985). Collectively these studies demonstrate that nAChR are differentially 
upregulated by chronic treatment with nAChR agonists and antagonists when analysing 
and comparing data generated ex vivo from rodent brain.
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Not all chronic nicotine treatment regimes have resulted in an increase in nicotinic 
binding sites (Benwell and Balfour, 1984; Pauly et al., 1992). This can be explained if 
considerably lower doses of nicotine are administered less frequently, for example a s.c. 
injection of 0.4 mg/kg/day nicotine on a once daily basis (Benwell and Balfour, 1984). 
Under these conditions [3H]-nicotine binding sites in nicotine-treated rats were found 
not to be significantly different from those in drug-naive animals, even after 39 days of 
chronic drug treatment (Benwell and Balfour, 1984). However, in another study low 
doses of nicotine treatment ranging from 0.1-0.4 mg/kg did produce an increase of 
between 18-26% in cortical nAChR (Ksir et al., 1985). Concentration and injection 
schedules of nicotine previously used in rat protocols to evoke upregulation of nAChR, 
may not elicit upregulation of [3H]-nicotine or [125I]-a-bgt sites after daily nicotine 
injections administered to mice (Pauly et al., 1992). This could be due to species 
differences between rats and mice, and can be explained in terms of the half-life of 
nicotine being shorter and perhaps receptor turnover occurring more rapidly in the 
neuronal tissue of mice.
The majority of results produced from animal studies using rodents, different drug 
regimes and also different routes of chronic drug administration, show that nicotinic 
agonist treatment produces upregulation of high affinity neuronal [3H]-agonist binding 
sites correlating with the predominant a4p2 receptor subtype (Flores et al., 1992). The 
effect of cigarette smoking on alterations of the binding site densities of high affinity 
nAChR within brain tissue taken from prolonged cigarette smokers was compared to the 
brain tissue of age-matched non-smoking controls at post-mortem examination 
(Benwell et al., 1988; Breese et al., 1997; Perry et al., 1999). Studies using human post­
mortem tissue produced evidence of an increase in the density of nAChR in both the 
hippocampal formation and the hippocampal neocortex along with significant increases
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in the gyrus rectus and the median raphe nuclei of the midbrain (Benwell et al., 1988). 
This phenomenon of upregulation of nAChR exhibited in human brains of smokers has 
been demonstrated to be due to an increase in receptor density measured by high affinity 
nicotinic binding rather than a change in the apparent affinity of the receptor for 
nicotine.
It therefore seems likely that upregulation of neuronal nAChR in various brain 
regions in human smokers’ can be attributed to chronic exposure of nicotine present in 
tobacco smoke (Benwell et al., 1988; Breese et al., 1997). This relationship between 
upregulation of nAChR following cigarette smoking being similar to those effects 
observed in vitro is strengthened by the results of a study involving rats exposed to 
mainstream cigarette smoke 1 h/day for 5 days over a period of 13 weeks (Yates et al.,
1995). Smoke-exposed rats had significant increases in [3H]-nicotine binding to sites 
within the cortex, striatum and cerebellum when compared to sham-exposed control 
animals. This reinforces the proposal that nicotine contained in tobacco smoke evokes 
upregulation of nAChR in vivo and probably by a mechanism similar to that underlying 
chronic exposure to cigarette smoke in animals (Yates et al., 1995). Breese et al. (1997) 
also reported that individuals who had ceased to smoke two months before their death 
had nAChR levels the same or below that of control non-smoker autopsy brain tissue. 
This reveals that in humans the nicotine-induced upregulation of neuronal nAChR is 
reversible after smoking cessation (Breese et al., 1997) as is observed in rats after 
chronic nicotine administration (Marks etal., 1985).
As demonstrated ex vivo, the chronic administration of nicotine to animals produces 
upregulation of both [3H]-agonist and also the [125I]-a-bgt binding sites identifying 
a4p2* and a l * nAChR respectively. Similar changes in [3H]-agonist binding sites 
binding and nicotinic receptor density following chronic nicotinic drug treatment have
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been reproduced in primary cultures of fetal rat cortical neurones (Bencherif et al.,
1995), clonal cell lines expressing endogenous nAChR (Peng et al., 1997; Warpman et 
al., 1998) and in cells transfected with specific nAChR subtypes in vitro (Peng et al., 
1994a, b; Bencherif et al., 1995; Gopalakrishnan et al., 1996; Warpman et al., 1998; 
Whiteaker et al., 1998). The mouse fibroblast M10 and the human embryonic kidney, 
HEK 293 cell lines have been stably transfected with a4 and 02 nAChR subunits under 
the control of a dexamethasone-inducible promoter (Peng et al., 1994b; Bencherif et al., 
1995; Gopalikrishnan et al., 1995; Whiteaker et al., 1998). Peng et al. (1994b) found 
that mecamylamine upregulated nAChR in M10 cells thus showing that upegulation 
does not require ion flow through the channel. Gopalakrishnan et al. (1997) reported 
that d-TC, DH0E and MLA all upregulated [3H]-cytisine binding sites in HEK 293 
cells. The M10 and HEK 293 cell lines do not contain endogenous nAChR subunit gene 
promoter elements, yet are still capable of producing an analogous upregulation in 
nAChR densities with no change in affinity of [3H]-agonist for its sites (Peng et al., 
1994b; Bencherif et al., 1995; Gopalakrishnan etal., 1997; Whiteaker et al., 1998). This 
suggests that upregulation is not an adaptive response dependent on neuronal factors 
unique to neurones where these receptor subtypes are normally endogenously 
expressed, but must be the result of an intrinsic attribute of the receptor complex itself 
(Peng etal., 1994b; Bencherif et al., 1995; Zhang et al., 1995; Rothhut etal., 1996).
This phenomenon of upregulation of [125I]-a-bgt binding sites is also displayed and 
preserved after chronic nicotine treatment to primary cultures of rat hippocampal 
neurones (Barrantes et al., 1995a), human SH-SY5Y neuroblastoma cells (Peng et al., 
1997) and human embryonic kidney cells (HEK) stably transfected with a l  subunits 
(Molinari etal., 1998). Concentration-dependent increases were observed in [125I]-a-bgt 
binding sites in HEK 293 cells stably transfected with the a l  neuronal nAChR subunit,
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after long-term treatment with (±)-epibatidine, GTS-21, DMPP and MLA (Molinari et 
al., 1998). Upregulation is evoked after exposure to activator or antagonist ligands and 
indicates that the mere occupancy of the receptor binding site may be adequate to 
prompt receptor upregulation.
De Koninck and Cooper (1995) observed that upregulation of a7* nAChR could be 
elicited by KC1 depolarisation in sympathetic neurones. KC1 depolarisation provoked a 
corresponding increase in the level of a l  mRNA when compared to control. This 
upregulation was proposed to be a result of Ca2+ influx through L-type Ca2+ channels 
and also through a CaM-kinase II pathway (see sections 2.1.4, 2.7 and 3.18.1). KC1 is 
thought to be physiologically important in neurite outgrowth during development and 
also neural sprouting after injury (Pugh and Berg, 1994; Solem etal., 1995; Soler et al., 
1998; Egea et al., 1999; also see Chapter 5).
In addition to a7* nAChR-evoked upregulation, Peng et al. (1997) reported 
upregulation of a3* nAChR, using [3H]-epibatidine binding to the SH-SY5Y cell line 
and in transfected tsA201 cells (a derivative of the HEK 293 cell line) after chronic 
nicotine treatment (1 mM for 4 days, Peng et al., 1997; Wang et al., 1998). Wang et al. 
(1998) have shown that chronic nicotine treatment stimulates upregulation of the a3|32 
but not the a3J34 nAChR complexes in SH-SY5Y cells.
1.10.2. M echanisms underlying upregulation o f the high affinity [3H]-agonist and 
[125I]-a-bgt binding sites:
The underlying cellular mechanism of nAChR upregulation still remains to be fully 
elucidated despite all of these investigations undertaken to date. Collectively, the 
previously mentioned studies in section 1.10.1 generate data suggesting that
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upregulation of a4(32, a3* and a7* nAChR evoked by chronic treatment with nicotinic 
ligands is independent of increased transcription levels or stabilisation of the subunit 
mRNA (Marks et al., 1992; Flores et al., 1992; Peng et al., 1994b, 1997; Bencherif et 
al., 1995; Rothhut et al., 1996). Although upregulation was demonstrated, there was 
little effect on the intensity of signal for the nicotinic subunit mRNAs encoding either 
a2, a3, a4, a5 or the p2 nAChR subunits of mice chronically treated with nicotine, 
compared to saline treated controls (Marks et al, 1992). The failure of chronic nicotine 
treatment to elevate corresponding subunit mRNA levels encoding the upregulated 
nAChR subunit subtypes strongly implicates that upregulation is not a result of 
increased protein synthesis but mediated via a post-transcriptional mechanism (Marks et 
al., 1992; Flores et al., 1992; Peng et al., 1994b, 1997; Bencherif et al., 1995; Rothhut 
et al., 1996; Warpman et al., 1998). The precise mechanism is controversial and 
putative mechanisms proposed to account for nAChR upregulation include the 
following (see section 3.18);
1). a decrease in the rate of receptor turnover due to nicotine evoked metabolic 
stabilisation either by a decrease in the rate of degradation of the receptor complex 
(Peng et al., 1994b; Wang et al., 1998), or an increase in the rate of assembly and 
enhanced recruitment of pre-existing receptor complexes present in a finite 
reserve pool (Bencherif e ta l ,  1995; Wang etal., 1998),
2). altered rates of translation (Gopalakrisnan et al., 1997),
3). enhanced subunit maturation, transport or assembly, leading to an improved 
ability of the receptors to form receptor complexes (Rothhut et al., 1996).
An obvious question is, are these upregulated receptor complexes functional? 
Functional properties of receptors can be measured using either [3H]-neurotansmitter
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release, 86Rb+ efflux assays (Marks et al., 1993a) or Ca2+-evoked responses in oocytes 
or using fluorescently labelled cells in suspension. Chronic exposure of mice to nicotine 
(0.25-4.0 mg/kg/h) for 10 days resulted in a dose-dependent increase in [3H]-nicotine 
binding. This was accompanied by a decrease in the tolerance of mice to nicotine- 
induced decreases in body temperature and locomotor activity. Biochemically in 
functional assays, chronic nicotine decreased the maximal effect of nicotine. A 20% 
decrease in nicotine-induced [3H]-DA release from the striatum and a 50% decrease in 
86Rb+ efflux per nicotine binding site was observed for nicotine-evoked efflux in 
synaptosomes from chronically treated mice (Marks et al., 1993b). A decrease in 86Rb+ 
efflux also indicated the loss of nAChR function from PC 12 cells and the TE671/RD 
human clonal cell line (Lukas, 1991). Lapchack et al. (1989) noted that a schedule of 
chronic nicotine administered to rats for 10 days, known to yield maximal increases in 
nAChR density (Bmax), was accompanied by a decrease in nicotine-induced 
acetylcholine release from brain tissue. An analogous result, consistent with functional 
data from native brain analyses, was obtained from HEK 293 cells expressing ot4p2* 
nAChR, a consistent decline in the maximal ACh-evoked ion flux was displayed after 
cells were chronically treated with nicotine (>1 mM) (Gopalakrishnan et al., 1997). 
When the relative functional response for control cells is compared to chronic drug- 
treated cells there is an observed reduction of 75% (Peng et al., 1994b) and 65% 
(Gopalakrishnan et al., 1996, 1997) in the functional response per unit binding site 
when upregulation of a4p2 nAChR numbers are at a maximum.
These results illustrate an uncoupling of receptor density and their functional status 
in different species and cell lines in relation to either an attenuation of hormone, 
neurotransmitter release, or behavioural tolerance (Lapchack et al., 1989; 
Gopalakrishnan et al., 1997). This down-regulation of receptor function after chronic
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nicotine exposure could either be explained as a consequence of a treatment that evokes 
an increase in receptor density or as the cause that evokes receptor upregulation 
(Lapchack et al., 1989; Hulihan-Giblin et al., 1990; Marks et al., 1993b). Hsu et al. 
(1996) investigated the effects of prolonged exposure to varying concentrations of 
nicotine, comparing the responsiveness of both the a 3 p 2  and the <*402 nAChR when 
co-injected and expressed in oocytes. Results indicated that both receptor combinations 
elicited a diminished responsiveness to an acute challenge of nicotine after prior chronic 
exposure to nicotine. a 3 p 2  nAChR recovered quicker than the a 4 p 2  subtype after 
removal of nicotine. This proposed decrease in responsiveness can be attributed to a 
receptor-inactivated state, which may explain the paradoxical increase in nAChR 
density after chronic nicotine exposure to compensate for these sub-maximally 
functioning upregulated receptors.
Together these data support the hypothesis that chronic nicotine administration 
evokes behavioural tolerance to the physiological effects mediated by nicotine and is a 
consequence of down-regulation of function that leads to upregulation of neuronal 
nAChR in most brain regions. This is perhaps an adaptive process as a result of 
accumulation of chronically desensitised receptors and recovery of receptor function in 
vivo may require several days (Schwartz and Kellar, 1983; Lapchack et al., 1989; Marks 
et al., 1993a, b; Fenster et al., 1999). Studies performed on the functionality of 
receptors obtained from chronically treated animals or dissected neuronal tissue will 
usually have had a rigorous wash procedure in the protocol which will lead to the 
removal of the nicotine enriched environment. This should return the upregulated 
receptors to a state in which they are no longer in a functionally “inactive” desensitised 
conformation due to removal of residual nicotine. The presence of residual nicotine 
therefore does not seem to be a plausible explanation for the decrease in receptor
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function in the study by Marks et al. (1993b). The cellular mechanisms relating to 
functional down-regulation of nAChR function are unknown, likewise it remains to be 
elucidated whether this loss of nAChR function is a uniform decrease in the function of 
each nAChR subtype, or the presence of functionally active populations of nAChR and 
a pool of inactive nAChR.
1.11. Aims of this thesis:
The work described in this thesis aims to explore the upregulation of nAChR after 
chronic exposure to nicotinic agonists and KC1 depolarisation and has been the impetus 
for investigating the cellular mechanisms underlying the process of nAChR 
upregulation. The study focuses on nAChR in primary hippocampal neurones and in the 
SH-SY5Y human neuroblastoma cell line.
The areas of focus for this thesis are summarised below:
1). To establish drug treatments that reliably lead to the phenomenon of receptor 
upregulation of a3* and a7* nAChR. [125I]-a-bgt is a high affinity antagonist 
used for the detection of ot7* nAChR in intact E l8 primary hippocampal cultures 
in situ and in SH-SY5Y cells. The a7* nAChR is predominantly expressed in the 
hippocampus and has been proposed to be involved in neuronal development, 
neuronal plasticity and also in neuroprotection and is therefore of interest to the 
present study. [ H]-epibatidine is used to detect changes in the level of expression 
of ot3* nAChR in intact SH-SY5Y cells after chronic drug treatments. These data
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can then be compared to changes in the level of expression of a l*  nAChR in SH- 
SY5Y cells after [125I]-a-bgt binding.
2). To compare the cellular mechanisms underlying the process of nAChR 
upregulation evoked by nicotinic agonists and KC1. Both nicotine and KC1 have 
been reported to be involved in neurite retraction and neuronal survival which 
may be mediated via activation of a l*  nAChR. It is of interest to determine 
whether these drug treatments differentially upregulate a3* and a l*  nAChR and 
if a common or different cellular mechanism is involved. The effects of KC1 and 
nicotinic agonist treatment on the level of expression of a3 and a l  nAChR 
subunit RNA after chronic drug treatment to SH-SY5Y cells will also be 
investigated to determine if transcription is involved as a possible mechanism 
resulting in nAChR upregulation.
3). Chronic drug treatments that have been shown to upregulate nAChR in the SH- 
SY5Y cell line will be applied to examine the functional status of upregulated 
nAChR in response to acute challenges with either nicotine or KC1. Fluorescence 
changes in fura-2 loaded SH-SY5Y cells will be used to determine nAChR- 
evoked changes in [Ca2+]i responses to acute challenges with either nicotine or 
KC1. These experiments will provide an insight into the functional properties of 
responses to both acute and chronic application of nicotinic agonists and KC1 
depolarisation.
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Previous studies have shown that human brain tissue contains nAChR that are 
defined by [3H]-nicotine binding. It has been observed that the density of these high 
affinity [3H]-nicotine binding sites is increased in brain tissue taken from prolonged 
tobacco smokers examined post-mortem, compared with age-matched non-smoking 
controls (Benwell et al., 1988; Breese et al., 1997; Perry et al., 1999). Upregulation of 
nAChR has been attributed to chronic exposure of the alkaloid nicotine present in 
tobacco smoke. This is due to comparable changes observed in nAChR density from 
specific regions of rodent brain tissue after chronic nicotine treatment in vivo (for 
review, see Wonnacott, 1990; Flores et al., 1992; Rowell and Li, 1997). High affinity 
binding of [3H]-nicotine (and [3H]-cytisine) has been correlated with nAChR comprised 
of a4  and p2 subunits (Whiting et al., 1987; Flores et al., 1992). More recently, 
upregulation of this nAChR subtype has been demonstrated in vitro, after chronic 
exposure to nicotine, in stably transfected cell lines (Peng et al., 1994b, Gopalakrishnan 
et al., 1996) and also in the human neuroblastoma SH-SY5Y cell line (Peng et al., 
1997). M10 cells transfected with chick a4  and p2 subunits and HEK 293 cells 
transfected with human a4  and P2 subunits, treated with nicotine for a few days results 
in a dramatic increase in the number of a4p2 nAChR measured by the binding of [3H]- 
nicotine (Peng et al., 1994b; Bencherif et al., 1995; Zhang et al., 1995), [3H]-cytisine 
(Gopalakrishnan et al., 1996) or [3H]-epibatidine (Whiteaker et al., 1998).
Other subtypes of nAChR are also upregulated by chronic nicotine treatment. [125I]- 
a-bgt labels a nicotinic site correlated with a7* nAChR in rat brain (Seguela et al., 
1993; Barrantes et al., 1995a). Chronic nicotine regimes in vivo upregulate [125I]-a-bgt 
binding sites in some brain regions (as reviewed by Wonnacott, 1990; Collins et al,
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• •  * 31990), although this response is less robust than that observed with high affinity [ H]- 
nicotine binding sites and requires higher nicotine doses (Pauly et al., 1991; Peng et al.,
1997). More recently hippocampal (Barrantes et al., 1995a) and cortical (Bencherif et 
al., 1995) cultures have both been used as model in vitro systems for the study of 
chronic nicotine treatment. [125I]-a-Bgt bound to hippocampal cultures with a Bmax of 
128 fmoles/mg protein and a Kd of 0.6 nM. Barrantes et al. (1995a) showed that one 
day of nicotine (10 pM) treatment produced a minimum upregulation of putative a l*  
nAChR in rat hippocampal cultures. However, significant upregulation was not detected 
until either 4 or 7 days of chronic exposure to nicotine, detected by an increase in the
125  125number of cell surface [ I]-a-bgt binding sites. Upregulation of cell surface [ I]-a- 
bgt binding sites has also been reproduced in cell lines transfected with the rat a l  
subunit (Quik et a l, 1996; Molinari et al., 1998). This Chapter describes experiments 
using primary cultures of hippocampal neurones that have previously been dissected 
from the brains of E l 8 rat fetuses. At this stage of gestation the generation of pyramidal 
cells is essentially complete. One pregnant rat will yield 7 x 106 neurones from 
approximately 15 E l8 hippocampi and these can be plated into 24 well plates to provide 
a high density hippocampal neuronal culture with only 5% glial cells if grown in serum- 
free medium (Banker and Waxman, 1988).
2.1.1 Dissociated cell cultures:
When tissue is dissected and prepared directly from an animal to form suspensions of 
individual cells for plating into sterile flasks or culture dishes, these cultures are referred 
to as primary cultures. Neurones in dissociated cultures have the advantage of providing 
an accessible means of studying living cells following transplantation into culture plates
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and also the ability to investigate receptor complexes and cellular processes occurring in 
intact cells within their native environment. Primary neurones grown in culture maintain 
their individual identities. After a few days in culture medium, primary dissociated 
neuronal cell tissue cultures lay down an extensive dense neural network composed of 
axons and dendritic arbours after neuronal maturation. Morphological and physiological 
properties of the neurones ex vivo closely correspond to the characteristics of the cell 
populations found in vivo in their original tissue location (Banker and Waxman, 1988). 
This resemblance is probably attributable to the neurones being of a postmitotic nature 
and are hence committed in the process of their cellular differentiation.
Accomplishing optimum growth conditions for primary cells in culture can often be 
a laborious procedure to ensure that cultures are viable, permit maturation and are 
growing reproducibly over time. Once these criteria have been met, it is possible to 
perform biochemical analysis and to detect and pharmacologically characterise specific 
populations of cells and the receptors that they express, for example by the binding of 
specific radiolabelled ligands. Such embryonic neuronal cultures although amenable to 
study, have the disadvantage of not being capable of dividing once plated in culture. 
This limits the quantity of material obtainable for these cultures and therefore limits the 
number of experiments capable of being performed. In contrast, cell lines grown in 
culture will divide, can be passaged and further subcultured into sterile flasks to 
generate many cells for biochemical analysis, although these cells may express receptor 
complexes differing in composition to those found natively in primary cultures.
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2.1.2 The hippocampus:
When using primary neuronal cultures the heterogeneity of cell types contained 
within the tissue of choice may complicate biochemical analysis if specific cell 
populations are to be targeted and analysed. Therefore, for successful primary neuronal 
cultures the choice of tissue is of main importance. There are a few regions within the 
CNS that contain a single principal cell type. These include the cerebellar cortex and the 
hippocampus, which predominantly contain granule cells and pyramidal cells, 
respectively, within their structures (Banker and Goslin, 1991).
The hippocampal formation is composed of two layers of interconnected neurones. 
The first layer consists of three neighbouring cortical areas termed as CA fields (cornu 
Ammonis or Ammons’ horn) also known as the hippocampus proper, comprised of the 






Figure 2.1. Schematic representation o f the rat 
hippocampal formation, (a) Schematic diagram of the 
rat brain showing the location o f the hippocampal 
formation (Hip), (b) Schematic representation o f a 
horizontal section through the hippocampal formation 
and the overlying neocortex (N). The dashed lines and 
shaded portions represent layers o f neuronal bodies. The 
CA1 and CA3 areas o f the hippocampus, the entorhinal 
cortex (E) and the subiculum (S) are shown.
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The CA fields are comprised of pyramidal neurones with their cell bodies packed into 
narrow layers, tucked under the edge of the neocortex. The axons from these neocortical 
pyramidal neurones project to the entorhinal cortex (as shown in Figure 2.1) and 
through to the subiculum and into the dentate gyrus by a fan of axons known as the 
perforant pathway (Figure 2.2). The second layer of the hippocampal formation is the 
dentate gyrus, which contains tightly packed granule cells.
Figure 2.2. Schematic diagram o f the trisynaptic 
circuit in a hippocampal slice. The dashed lines depict 
the outlines of tightly packed layers o f cell bodies. The 
areas lying outside the dashed lines contain axons, 
dendrites and numerous synaptic contacts. Additional 
axons project to the hippocampus through the fimbria (f), 
or through the subicular complex (S) and entorhinal 
cortex, (s.c.p. is the Schaffer collateral pathway; p.p. is the 
perforant pathway and D is the dentate gyrus).
A major part of the hippocampal network is the trisynaptic circuit which is preserved 
when thin coronal slices of the hippocampus are sectioned (Figs 2.1b and 2.2). Axons 
from the perforant pathway synapse onto dentate granule cells, the axons of these cells
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(also known as mossy fibres) project to synapse on dendrites of pyramidal cells in the 
CA3 field within the hippocampus proper. The CA3 area contains pyramidal cells with 
highly branched axons that either leave the hippocampus or loop around to form 
synapses in the CA1 field with dendrites of pyramidal cells in this area, also known as 
the Schaffer collateral pathway. CA1 neurones project axons to dendrites of neurones 
contained in the subicular complex which in turn project axons to the entorhinal cortex, 
thus completing the circuit.
Within the brain the hippocampus is a structure involved in learning, memory and 
cognitive processes (for reviews, see Squire and Zola-Morgan, 1988; Eichenbaum et al., 
1996; Bear, 1996). The neurodegenerative condition of Alzheimer’s disease (AD) is 
characterised behaviourally by a progressive impairment in memory and cognitive 
function, and neuropathologically by the appearance of neuritic plaques and 
neurofibrillary tangles, implicating a cholinergic dysfunction (for review, see Selkoe, 
1999; see section 1.9.2). Within the cerebral cortex and the hippocampi of AD patients 
there is a reduction of the neurotransmitter ACh, choline acetyltransferase and high 
affinity choline uptake and a substantial (> 70%) and selective degeneration of the 
cholinergic pathways that innervate these target regions (Whitehouse et al., 1982). 
These patients also have reduced numbers of neurones in the nucleus basalis of Meynert 
and decreased numbers of nAChR (Aubert et al., 1992). The ability of nicotine to 
enhance cognition in some animal models, in humans and also its neuroprotective 
properties, suggests a possible role for nAChR agonists as potential treatments to 
reverse the effects of these deficits in some neurological disorders and dementia (see 
Holladay et al., 1995; James and Norberg, 1995). These cholinomimetic drugs may be 
able to restore some of the proposed physiological functions of nAChR contained 
within the circuitry of the hippocampal formation.
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The development of subtype specific ligands has enabled the neuroanatomical 
distribution and pharmacological characterisation of nAChR to be recognised. Ospina et 
al. (1998) performed quantitative autoradiography to compare the binding of a7-type 
nAChR, detected by [125I]-a-bgt, in fetal and adult rat hippocampus. Results showed 
that throughout the fetal CA1 field, high levels of [I25I]-a-bgt were observed with a 
significant reduction of [125I]-a-bgt binding density in adult hippocampus (Ospina et al.,
1998). Seguela et al. (1993) used the technique of in situ hybridisation to localise the 
oc7-transcript, high levels were expressed in the hippocampus, hypothalamus, the 
amygdala and the cerebral cortex. Alkondon and Albuquerque (1991) initially 
characterised the nAChR in E l7-18 rat hippocampal neurones by whole-cell patch 
clamp analysis. Results demonstrated that 83% of the fetal hippocampal neurones tested 
exhibited the presence of a functional nAChR subtype that displayed inward 
rectification with currents reversibly blocked by micromolar concentrations of d-TC and 
DHpE and irreversibly blocked by nanomolar concentrations of n-bgt, a-bgt and ct- 
cobratoxin (Alkondon and Albuquerque, 1991, 1993). These data are consistent with an 
a7* nAChR (Amar et al., 1993).
The hippocampus is of interest for this project as it is a source of a relatively 
homogeneous population of neurones containing a high preponderance of a7* nAChR. 
The hippocampus is composed primarily of pyramidal neurones that account for 
approximately 85-90% of the total neuronal population (reviewed by Goslin and 
Banker, 1991). This cell type is also the principal primary hippocampal neurone grown 
in culture in serum free medium. Pyramidal neurones have a characteristic, well-defined 
shape with a single axon and projections of several highly branched dendrites (typically 
shorter basilar dendrites branching from a long apical dendrite). These dendrites make 
direct contact and extensive synaptic connections with one another in culture wells
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through the continual process of development and neuronal maturation. Therefore fetal 
(E l8) hippocampal material is a good candidate tissue to study the effect of chronic 
drug treatment on the numbers of a7* nAChR binding sites in vitro, and to try to 
elucidate the underlying cellular mechanisms of upregulation. The detection, disruption 
or exploitation of these underlying physiological processes may be beneficial in the 
treatment of neurological disorders including cognitive dysfunction, perhaps clarifying 
the role of specific nAChR subtypes in different brain regions.
2.1.3. Cultures of hippocampal neurones:
When using primary hippocampal cultures, the hippocampi are typically obtained 
from E l8 fetuses (Goslin and Banker, 1991; Barrantes et al.y 1995a). At this stage of 
gestation, the generation of pyramidal neurones is essentially complete and a relatively 
low percentage of glial cells is present. The hippocampi at this stage are also easily 
dissociated into small pieces and fragmented by passage though a Pasteur pipette: this 
prevents reaggregation of the neuronal tissue and the formation of clumps. The cells can 
then be plated onto polyethyleneimmine (PEI) (see Goslin and Banker, 1991; Barrantes 
et al., 1995a) to enhance cell adhesion and simply left to attach to the lower surface of 
these culture well plates. In these protocols, the embryonic neuronal cells are plated and 
initially grown in a serum rich medium containing fetal calf serum (FCS) to aid in the 
process of cell attachment. Glial cell growth is minimised by maintaining the neurones 
in a serum-free medium, as serum-containing media will allow for the rapid 
proliferation and survival of endogenous glial cells (see Goslin and Banker, 1991). The 
discovery in 1979, that neuroblastoma cells could be grown and proliferate rapidly in 
the absence of serum in a synthetic supplemented medium with insulin, transferrin,
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progesterone, selenium and putrescine was an important advance in cell culture 
(Bottenstein and Sato, 1979). Supplemented medium is used in the cell culture of 
primary hippocampal cultures described in this Chapter (see section 2.4.1) to support 
the growth and maintain the survival of these neurones. After a few days, the 
hippocampal neurones begin to extend processes from their cell bodies and form 
contacts synapsing with one another. Immunocytochemical markers are widely 
available to stain and therefore visualise the morphology and development of axons, 
neurite outgrowth of dendrites or the presence of glial cells in neuronal cultures.
As with all ex vivo neuronal studies, caution has to be taken when interpreting 
results. The primary hippocampal cultures will resemble their native tissue in vivo 
however, due to the dissection there will be a less complex neural network due to loss of 
extrinsic afferents innervating this region and target cells due to removal of the 
hippocampi from their native environment. In all, the results obtained indicate that 
primary neuronal rat cultures are a useful system to study a snapshot of a7* nAChR 
during development (Barrantes et al., 1995a; Samuel et al., 1997; Davila-Garcia et al.,
1999).
2.1.4. Physiological significance of a l*  nAChR and KC1 treatment:
The expression, upregulation and roles of neuronal nAChR in vivo are complex, and 
are still poorly understood. Primary hippocampal neurones grown in culture provide a 
system that is considerably less complex than whole animal studies in vivo, making 
neuronal cultures more amenable to experimental manipulation and facilitating the 
interpretation of experimental results. For this reason, the experimental work performed 
in this Chapter was carried out using in vitro primary rat hippocampal cultures as a
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system to model, probe and elucidate the mechanisms underlying the cellular processes 
of upregulation of [125I]-a-bgt binding sites representative of a7* nAChR. The 
extrasynaptic location of a-bgt binding sites in embryonic and mature chick ciliary 
neurones and synaptic location in the hippocampus raises questions about the functional 
physiological relevance of a7* nAChR complexes (Horch and Sargent, 1995).
The a7  nAChR mRNA and [125I]-a-bgt binding peaks in the developing rat 
somatosensory cortex (SI), a region of the neocortex, approximately 1 week postnatal 
before declining to adult levels (Broide et al., 1996). The transient increased expression 
of a l  mRNA and its corresponding increase in binding-site density expression during 
the early postnatal period, identify a possible role for a-bgt-sensitive nAChR in critical 
stages of synaptogenesis during the course of CNS development (Fiedler et al., 1987; 
for review, see Role and Berg, 1996). Earlier studies have also demonstrated that the a l  
nAChR subunit protein is developmentally regulated at the transcriptional level 
(Couturier et al., 1990) and that activation of this receptor induces the elevation of 
intracellular free Ca2+ ([Ca2+]i) in neurones by influx through the receptor cation 
channel pore (Vijayaraghavan et al., 1992; Seguela et al., 1993; Zhang et al., 1994). 
The marked permeability to Ca2+ ions and the resulting increase in [Ca2+]i mediated by 
activation of a7* nAChR, suggests a possible role for these receptors in influencing or 
triggering a variety of intracellular Ca2+-dependent cytoplasmic events in specific 
cholinoceptive neuronal populations to modulate target cell function. This provides the 
possibility of interesting functional roles of the a7-gene product in early neuronal 
development. These roles include neuronal survival and the termination of axonal 
neurite outgrowth during development and also an involvement in neural sprouting after
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injury due to sufficient Ca2+ entry into the neurite after activation of a-bgt binding sites 
(Pugh and Berg, 1994; Messi et al., 1997; Pugh and Margiotta, 2000).
Previously KC1 has been shown to produce an increase in a-bgt binding sites in 
cultured ciliary ganglion neurones in culture (Smith et al., 1983). A range of 
concentrations of KC1 (2-50 mM; 3 days) have been used to determine whether 
changing the K+ concentration could influence the number of a-bgt binding sites 
located on chromaffin cells grown in culture (Geertsen et al., 1988). Geertsen et al. 
(1988) demonstrated that KC1 upregulated a-bgt binding sites in chromaffin cells in a 
concentration-dependent manner with a maximum effect at 20 mM KC1. De Koninck 
and Cooper (1995) observed that upregulation of surface a7* nAChR in cultured 
neonatal rat sympathetic neurones was evoked by chronic KC1 depolarisation (40 mM; 
1-2 days). Upregulation of a-bgt-sensitive nAChR was accompanied by a 
corresponding increase in the level of a l  mRNA, compared to control cultures. This 
KCl-evoked upregulation was proposed to result from Ca2+ influx through L-type Ca2+ 
channels and activation of a Ca2+-CaM-kinase II pathway. In the present study, the 
effect of chronic treatment with nicotinic ligands and KC1 depolarisation on [125I]-a-bgt 
binding sites in E l8 primary rat hippocampal cultures were compared. The binding data 
described in this Chapter reveal that nicotine and KC1 upregulate a7* nAChR via 
distinct mechanisms.
2.2. Aims:
The aim of this Chapter is to examine the effect of KC1 on upregulation of [125I]-a- 
bgt binding sites in primary rat hippocampal neurones and to evaluate if the same 
mechanisms operate, as reported by De Koninck and Cooper (1995). The effect of
Chapter 2. 86
chronic treatment with the nicotinic agonists, nicotine and DMAC will also be 
investigated on [125I]-a-bgt-sensitive nAChR sites. The cellular mechanisms underlying 
KC1- and nicotine-evoked upregulation will be compared.
2.3. Materials and methods.
2.3.1. Drugs and reagents:
Tissue culture media, serum and plasticware were from Gibco BRL (Paisley, 
Renfrewshire, Scotland). Media supplements, biochemicals, (-)-nicotine, (±)-verapamil 
hydrochloride and a-bgt were purchased from Sigma Co. (Poole, Dorset, U.K.). KN-62 
was purchased from Calbiochem-Novabiochem Corporation; KN-04 from AMS 
Biotechnology. DMAC, was provided by Organon Laboratories Ltd., Newhouse, 
Lanarkshire. GFAP (NCL-GFAP-GA5) was from Novocastra Laboratories Ltd. 
(Newcastle upon Tyne, U.K.), the secondary anti-mouse IgG fluorescein linked whole 
antibody from sheep was purchased from Life Sciences, Amersham. Optiphase Safe 
scintillant was purchased from Fisons Chemicals, Loughborough, U.K. All other 
chemicals used were of analytical grade and obtained from standard commercial 
sources.
[ HJ-MLA (specific radioactivity, 25 Ci/mmol) was from Tocris Cookson Ltd. 
(Bristol, U.K.). [3H]-epibatidine (specific radioactivity, 33.8 Ci/mmol) was obtained 
from Dupont-NEN Ltd., (Boston, MA). (-)-Ar-methyl-[3H]-nicotine (specific 
radioactivity 75 Ci/mmol) and [125I]-Nal were obtained from Amersham International 
(Aylesbury, U.K.). The a-bgt was iodinated by the chloramine-T method to a specific
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activity of approximately 700 Ci/mmol and stored in 10 mM phosphate, pH 7.5 at 4°C 
for up to 4 weeks (see section 2.6.1 and 2.6.2).
2.3.2. Preparation of rat brain P2 membranes:
Crude rat brain membranes were prepared as previously described (MacAllan et al., 
1988). In brief, fresh brain tissue (minus cerebellum) from adult male Sprague-Dawley 
rats were homogenised (10% weight/volume (w/v)) in ice-cold 0.32 M sucrose 
containing 1 mMEDTA, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 0.01 % (w/v) 
sodium azide, pH 7.4), before centrifugation (1,000 x g, 4°C, 10 min). The supernatant 
fraction (SI) was decanted and retained on ice. The pellet (PI) was resuspended in ice- 
cold 0.32 M sucrose (5 ml/g original wet weight) and re-centrifuged. The supernatant 
was combined with SI and centrifuged at 12,000 x g (4°C, 30 min). The pellet (P2) was 
resuspended (2.5 ml/g original wet weight) in ice cold phosphate buffer (50 mM 
potassium phosphate buffer containing 1 mM EDTA, 0.1 mM PMSF, 0.01% (w/v) 
sodium azide, pH 7.4), and washed twice by centrifugation (12,000 x g, 4°C, 30 min). 
The washed pellet was resuspended in phosphate buffer (2.5 ml/g original wet weight) 
and restored in 5 ml aliquots at -20°C. The protein content was determined using the 
method of Markwell et al. (1978), using bovine serum albumen (BSA) as the standard.
2.3.3. Competition binding assays with DMAC:
The nicotinic agonist DMAC, was assessed for its ability to displace the binding of a 
number of nicotinic radioligands by means of competition binding assays. Competition 
binding assays were performed against [125I]-a-bgt (1 nM) and [3H]-MLA (1 nM) or
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against [3H]-epibatidine (200 pM) and [3H]-nicotine (10 nM) binding to rat brain P2 
membranes to identify the potency of DMAC against a7* or a4p2* nAChR 
respectively, as described by (Davies et al., 1999). In brief, for [125I]-a-bgt binding, P2 
membranes were diluted in assay buffer (phosphate buffer supplemented with 0.1 % 
(w/v) BSA, 1 mg/ml (Davies et al., 1999). Membranes were incubated with [125I]-a-bgt 
(final concentration of 1 nM) and a range of dilutions of the competing drug, DMAC or 
unlabelled a-bgt at 37°C for 3 h. Following incubation, samples were diluted with 0.5 
ml of ice cold phosphate buffered saline (PBS; 20 mM Na2HPC>4, 5 mM KH2PO4, 150 
mM NaCl, pH 7.4) at 4°C. Membranes were pelleted at 12,000 x g (2 min) in a 
microcentrifuge and resuspended in 1.25 ml of ice cold PBS before centrifuging (12,000 
x g for 2 min). The supernatant was removed and the radioactivity contained in the 
pellets was determined using a Packard Cobra II gamma-counter to detect bound [125I]- 
a-bgt.
Competition binding assays were also performed with [3H]-MLA, [3H]-epibatidine 
and [3H]-epibatidine as follows: P2 membranes were diluted in assay buffer (Krebs 
Ringer-Tris Hepes buffer composed of 118 mM NaCl, 4.8 mM KC1, 2.5 mM CaCl2, 20 
mM Hepes, 200 mM Tris, 0.1 mM PMSF, 0.01% sodium azide, pH 7.4) to give the 
desired protein content (typically 0.5 mg protein for [3H]-MLA competition binding 
assays and 1-2 mg protein/ml for the [3H]-epibatidine and [3H]-nicotine binding assays, 
all in final assay volumes of 250 pi) supplemented with 0.1% (w/v) BSA. P2 
membranes were incubated with [3H]-MLA (final concentration 1 nM) and a suitable 
range of dilutions of the competing drug, DMAC. Assay tubes were incubated at 37°C 
for 2 h. Non-specific binding was detected in the presence of 10 pi of cold ML A (final 
concentration 1 pM) and in the absence of DMAC. P2 membranes were also incubated
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with either [3H]-epibatidine or [3H]-nicotine (final concentration 200 pM and 10 nM 
respectively) and a suitable range of dilutions of DMAC. Assay tubes were incubated at 
room temperature for 2.5 h or 3o min at room temperature followed by 1 h at 4°C. Non­
specific binding was detected in the presence of 10 pi of cold nicotine (final 
concentration 1 mM) and in the absence of DMAC. Incubations were terminated by 
dilution with 4 ml of ice cold PBS at 4°C and rapid filtration through Whatman GFA/E 
glass filters (Gelman Sciences), pre-soaked in 0.3% (v/v) PEI for 3 h to reduce non­
specific binding, using a Brandel Cell Harvester. Filters were washed twice with 4 ml of 
ice cold PBS at 4°C and bound radioactivity determined by liquid scintillation 
spectrometry in a Packard Tri-Carb liquid scintillation counter 1600 spectrometer 
(counting efficiency 45%)
2.3.3.1 . Determination of IC50 and Kd:
The data from the competition binding assays were calculated as percentages of total 
radioligand binding minus non-specific binding in the absence of competing cold 
ligand. The IC50 values were calculated by fitting plots to the Hill equation, using the 
non-linear least squares curve fitting facility of Sigma Plot version 2.0 for Windows:
% Bound = 100% / 1 + ([Ligand]/IC5o)”"
where nn is the Hill number, [Ligand] is the concentration of the competing ligand, and 
IC50 is the concentration of ligand that displaces 50% of specific radioligand binding. 
The affinity constant (Ki) values were derived from IC50 values for DMAC against each 
of the radiolabelled nicotinic ligands according to the method of Cheng and Prusoff 
(1973):
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Ki = IC50/ (1 + [Ligand]/^)
Where [Ligand] is the concentration of the labelled radioligand, and Kd is the 
equilibrium displacement binding constant. Displacement binding Kd values of 10.2 pM 
and 10 nM for [3H]-epibatidine and [3H]-nicotine respectively and 1 nM for [125I]-a-bgt 
and [3H]-MLA were assumed (Whiteaker et al., 1998; Davies et al., 1999; Sharpies et 
al., 2000).
2.4. Cell culture: £18 primary rat hippocampal cultures:
2.4.1. Dissociation and maintenance o f hippocampal neurones:
High density hippocampal neuronal cultures were prepared from E l8 rat fetuses by 
microdissection as previously described (Goslin and Banker 1991; Barrantes et al., 
1995a). In summary, rats were killed by cervical dislocation and the entire uterus 
containing the fetuses was removed; each fetus was separated one at a time by cutting 
the umbilical cord. The fetuses were decapitated, and the cerebral hemispheres were 
separated from the diencephalon and brainstem using fine spring mounted scissors and 
style forceps under 20 x magnification. The thalamus and meninges were removed in 
one piece. At this stage, the hippocampi are visible on the posterior half of the 
hemisphere and were then dissected by cutting the boundaries between the hippocampus 
and the adjoining cortex (see Figure 2.3).
The dissected hippocampi were placed into a 35 mm Petri dish containing 
Dulbecco’s modified Eagle medium (DMEM), cut into pieces and transferred into a 12 
ml test tube to enable further cell dissociation. The tissue pieces were washed twice 
with 10 ml of phosphate buffered saline (PBS; 150 mM NaCl, 8 mM K2HPO4, 2 mM 





Figure 2.3. Dissection o f E18 hippocampi (a) Ventral aspect o f E18 rat brain 
(olfactory bulbs are identified as o.b.). The dashed line represents the position o f the 
right hippocampus projected unto the ventral surface o f the hemisphere, (b) Shows the 
left hemisphere when viewed from the midline after removal of the meninges. 
Arrowheads denote boundary between hippocampus and the adjoining cortex, (c) A 
hippocampus after dissection. Magnification is indicated
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The washed hippocampal tissue was incubated at 37° in 2 ml of PBS, in the presence of 
trypsin (100 pi) and D-glucose 20%. The enzyme reaction was terminated by the 
addition of 8 ml of serum supplemented chemically defined medium. The tissue 
suspension was centrifuged and resuspended by triturating the hippocampal tissue with 
a Pasteur pipette. Once a cloudy suspension was obtained the cells were ready to be 
plated into a sterile, PEI-coated 24 x 16 mm well Falcon plate at a high plating density 
(1.5 x 105 cells/cm2).
Cell density was determined using a haemocytometer. This is a thickened 
microscope slide ruled with a grid pattern and a counting chamber of 0.1 mm in depth. 
To count viable cells, the dye trypan blue was used to exclude the proportion of cells 
that were damaged by the dissociation process. Viable cells have intact membranes and 
do not incorporate the dye, thus appearing as white cells with bright halos. Damaged 
cells appear blue in colour as they will take up the dye. The standard protocol used was 
to take an equal volume of cell suspension to 0.08% trypan blue solution, pipette into 
the haemocytomoeter chamber and examine the viable to damaged cells by taking the 
mean value of viable cells counted within 3 different 16 square ruled grids (the mean (n) 
is equivalent to n x 104 cell per ml). A simple calculation allows for the dilution factor 
so that a final plating concentration of 1.5 x 105 cells/cm2 is achieved.
Initially cells were plated in serum supplemented (10%, FCS chemically defined 
DMEM (1 ml for each well; DMEM; (glucose 4.5 g/1): Nutrient Mixture F12 (Ham) 
(3:1), supplemented with L-glutamine (2 mM), penicillin (50 IU/ml), streptomycin (50 
pg/ml), human transferrin (100 pg/ml), putrescine (100 pM), insulin 5 pg/ml), 
progesterone (20 nM) and sodium selenite (30 nM)) for 2 h, to ensure attachment of 
neuronal cells. After 2 h the medium was replaced with serum-free chemically defined 
medium and the neurones were allowed to mature for three days (Barrantes et al,
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1995a). This procedure resulted in viable cultures of robust neurones with less than 5% 
contamination with glial cells (see Figure 2.5b). For long-term survival, cultures were 
fed every 3-4 days by replacing half of the medium in the wells with fresh chemically 
defined serum-free medium. Drug dilutions were prepared in ‘conditioned’ medium and 
were applied to mature cultures for either 4 or 7 days.
2.4.2. Drug treatment:
Initial experiments used confluent hippocampal neurones cultured in 24 well Falcon 
plates. Cultures were chronically treated with a number of drugs, alone or in 
combination, for 7 days. Subsequently a 4 day drug exposure was employed. Nicotine, 
KC1 and (±)-verapamil hydrochloride were made up freshly in ‘conditioned’ chemically 
defined medium on day 1 of drug treatment (equates to day 3 in culture). KN-62 and 
DMAC were made up in dimethylsulfoxide (DMSO) in stock solutions of 10 mM so 
that the final concentration of DMSO on cultures did not exceed 0.1%. Chronic 
exposure to this concentration of DMSO had no effect on subsequent ligand binding 
assays. All drugs were applied to confluent cultures and after 4 or 7 days of drug 
treatment, a binding assay with [125I]-a-bgt was performed (see section 2.6.3).
2.5. Detection of glial cells in hippocampal cultures by fluorescence 
cytochemistry:
Seven day old E l 8 hippocampal cultures were grown in x 6 well plates, in the 
absence of drugs, were washed x 3 with 1 ml warm PBS before being fixed and 
permeabilised by the drop-wise addition of 2 0 0  jliI cold acid ethanol solution (5 %  acetic
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acid in 70% ethanol). After 15 min, the cultures were washed x 3 with 500 pi of PBS. 
Blocking solution (sheep serum in PBS; 1 ml of 1%) was applied to hippocampal 
cultures for 1 h at room temperature before applying the glial fibrillary acidic protein 
(GFAP) (1:400 dilution) monoclonal antibody (mAb). Negative controls for non­
specific fluorescence omitted the primary antibody from the procedure and were 
incubated in the presence of the sheep serum blocking solution thus determining non- 
specific binding. After 1 h incubation the cultures were washed x 3 with 1 ml of the 
sheep serum blocking solution before the addition of 250 pi of the secondary anti­
mouse IgG fluorescein-linked whole antibody from sheep (1:100) dilution. After 1 h 
incubation in the dark, the neurones were washed x 3 with 1 ml PBS and mounted with 
Vectashield (Vector Labs.) before being viewed in a Nikon inverted microscope 
equipped for epifluorescence.
2.6. Radioligand binding with [ I]-a -bgt on cultured cells in situ:
2.6.1. Procedure for iodination o f a-bgt to high specific activity:
Sephadex G25 beads (25 g) were allowed to swell and washed in reaction buffer 
before being poured into a Pharmacia column (0.9 x 12 cm). The column was packed 
with Sephadex to within 5 cm from the top, and then washed with 30 ml o f elution 
buffer. The iodination was performed in a fume hood with suitable protection and 
shielding from the radiolabelled compound.
A reaction tube (LP3 tube) was clamped over a magnetic stirrer and the following 
were added, a magnetic flea to constantly stir the reaction mixture, a-bgt (20 pi, 2.5 
nmol), reaction buffer (10 pi; 0.05 M potassium phosphate, pH 7.5) and [125I]-NaI (20 
pi, 2 mCi). The reaction was started by the addition of chloramine T (10 pi; 5 mg/ml in
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reaction buffer). The reaction was terminated after 1 min by the addition of 0.75 ml 
sodium metabisulphite (0.16 mg/ml in reaction buffer) and 0.2 ml potassium iodide (10 
mg/ml in reaction buffer). The column was drained of any elution buffer that was 
covering the G25 Sephadex before transferring the reaction mixture by Pasteur pipette 
to the top of the G25 Sephadex column. The reaction tube was rinsed by the addition of 
0.5 ml elution buffer (0.01 M potassium phosphate, pH 7.5 containing 1% BSA) which 
was then transferred to the column. When the sample had drained into the Sephadex, the 
column was washed with elution buffer and approximately 20 fractions (1 ml) were 
collected. From each fraction, 5 pi was counted for radioactivity (Packard Cobra II Auto 












Figure 2.4. Typical elution profiles fo r the iodination o f a-bgt. In both traces a and 
b, there are two radioactive peaks. The first predominant peak (sample 6 or 7) corresponds to 
[,25I]-a-bgt (mono-iodinated or di-iodinatedproduct) and the second, lower peak (samples 16-18) 
corresponds to the free [l25IJ.
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2.6.2. Calculation o f specific activity of [125I]-a-bgt:
Typical values obtained from a successful iodination of a-bgt are: a concentration of 
>0.5 pmol a-bgt/ml, 0.4 pCi 125I/ml, > 90% incorporation of 125I into a-bgt and specific 
activity o f 700 Ci/mmol for the resulting [125I]-a-bgt. Typical results obtained for the 
iodination procedure are shown in Table 2.1.
Table 2.1. Typical values obtainedfrom two separate iodination experiments.




% incorporation  
of 125I into a -b gt
Specific activity 
of [125I]-a-bgt
Elution profile A 0.54 0.42 95.6 766 Ci/mmol
Elution profile B 0.71 0.5 88.0 700 Ci/mmol
2.6.3. Assay for [125I]-a-bgt binding to hippocampal cultures:
[125I]-a-Bgt binding assays were performed on primary rat hippocampal cultures 
grown in the presence of drugs for either 4 or 7 days in 24 x 16 mm culture well plates. 
The binding assays were performed essentially as described by Barrantes et a l  (1995a). 
In brief, on the day of assay, cultures were washed four times with warm medium over a 
3 h period prior to the assay, to remove all traces of drugs from the cultures that could 
interfere with specific binding whilst being a long enough period not to have significant 
changes on receptor numbers due to nAChR turnover (Dr Rogers personal 
communication). After 3 h, non-specific binding was defined by pre-incubation of 
cultures (in triplicate) with 2 jliM  a-bgt (made in chemically defined medium containing 
0.01% BSA (200 pi; 1 h; 25°C)). Total binding was defined in parallel cultures with
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200 |iil of 0.01% BSA containing medium (1 h; 25°C). After this incubation period, 
[125I]-a-bgt (final concentration 10 nM) was applied to all culture wells and further 
incubated for 2 h at 25°C. The cultures were subsequently washed three times with 1 ml 
warm PBS, solubilised in 0.1 M NaOH (200 pi; 16 h at 4°C), counted for radioactivity 
(Packard Cobra II Auto Ultra y counter) and then assayed for protein (Markwell et al., 
1978). Radioactivity bound was then directly related to protein values.
All raw data (fmol/mg protein) generated in this thesis were analysed statistically 
using an analysis of variance (ANOVA). Quoted significance values obtained (p<0.05) 
relate to values obtained using the Tukey test which was used as a multiple range test 
when the ANOVA gave significance of p<0.05. The raw data are presented as 
normalised data throughout the thesis unless otherwise stated, with control conditions 
being represented as 100% and the S.E.M. being normalised from the S.E.M. obtained 
for the fmoles of radioligand bound/mg protein.
2.7. Results.
2.7.1. Fluorescence cytochemistry:
The panels shown in Figure 2.5 were obtained from high density E l8 primary rat 
hippocampal cultures that had been growing in culture for 7 days. The top panel (a) 
shows the normal field of vision when cultures were viewed by ordinary bright phase 
contrast (tungsten) under a light microscope. The lower panel (b) shows the same field 
of view immunolabelled with mAb-GFAP to identify glial cells in the hippocampal 
cultures when viewed under a u.v. filter. Glial cells contribute to approximately 5% of 
the mature hippocampal neuronal population that has developed an extensive network 
of neurites (Figure 2.5). Chronic treatment with nicotinic drugs or KC1 depolarisation 
does not alter this proportion of glial cells within hippocampal neuronal populations.
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Figure 2.5. mAb-GFAP immunostaining o f E l8 rat hippocampal neuronal cultures. Seven 
day old E18 rat hippocampal cultures were fixed/permeabilised with 5% acetic-acid - 70% ethanol 
solution. Preparations were blocked with 1% normal sheep serum in PBS to reduce non-specific 
immunostaining. Cells were incubated with mAb-GFAP to determine total immunostaining. Anti­
mouse Ig, fluorescin linked whole antibody was applied to the preparations as a secondary antibody. 
The fields viewed correspond to the same preparation and the same field o f view observed either 
under (a) ordinary bright phase contrast (tungsten) or (b) u.v. filter using x 20 objective.
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2.7.2. Upregulation of [125I]-a-bgt binding sites in hippocampal 
cultures:
2.7.2.1 Pharmacological characterisation: effects o f nicotinic agonists and KC1:
Upregulation of [125I]-a-bgt binding sites in response to exposure to nicotine has 
previously been shown to be concentration-dependent when applied to primary 
hippocampal cultures for 7 days (Barrantes et al., 1995a); 1 pM nicotine had no 
influence on binding site density, 10 pM nicotine produced an increase of 30 ± 3% 
(n=27) and high concentrations of nicotine (100 pM) proved toxic to the neurones 
within 7 days (Rogers and Wonnacott, 1997). It was therefore decided to use nicotine at 
a dose of 10 pM which was not toxic to the neurones in culture and which would 
establish detectable levels of upregulation of [125I]-a-bgt binding sites.
In the present study control hippocampal cultures expressed 92 ± 5 fmol of [125I]-a- 
bgt binding/mg protein. Hippocampal cultures grown in the presence of nicotine for 7 
days displayed an increase in the number of surface [125I]-a-bgt binding sites to 28 ± 
3% (n=4) above control levels of binding (100%) (Table 2.2). The values obtained for 
upregulation of [125I]-a-bgt binding sites represent a real increase in numbers of a7* 
nAChR subtypes, rather than reflecting a change in cell density, as the [125I]-a-bgt 
binding site density was calculated in terms of protein, determined for each assay well 
(see methods 2.6.3).
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Table 2.2. Upregulation of [12SI]-a-bgt binding sites in E18 hippocampal cultures following 
chronic exposure to nicotine (10 pM) or KCl (20 mM) for either 4 or 7 days. Control values are 
expressed as Jmoles [125I]-a-bgt bound/mg protein; the upregulation mediated by nicotine and KCl is 






10 pM  Nicotine 
(% control)
20 mM  KCl 
(% control)
4 92 ± 14 (n=14) 125 ± 3% (n=6)* 159 ± 13% (n=12)*
7 92 ± 5 (n=24) 128 ± 3% (n=4)* 157 ± 14% (n=6)*
To determine if general depolarisation had any influence on the numbers of surface
125[ I]-a-bgt binding sites, cultures were exposed for 7 days to medium in which the KCl 
concentration was increased from 5 to 20 mM. This produced a 57 + 14% (n=6) 
increase in the number of binding sites (Table 2.2).
The effect of shorter drug exposure times was examined by treatment of 
hippocampal cultures for 4 days with the nicotinic agonists, nicotine and DMAC or KCl 
depolarisation. Nicotine and KCl produced similar increases in the numbers of [125I]-a- 
bgt binding sites after 4 days compared to those seen after 7 days (Table 2.2, Figure 
2.6). Therefore subsequent experiments used a 4 day drug exposure protocol, which also 
reduced the risk of contamination to the primary cultures.
DMAC, a novel nicotinic agonist with putative a7-selectivity (see section 1.6.2.2; 
De Fiebre et al., 1995), evoked a concentration-dependent upregulation of [125I]-a-bgt 
binding sites when applied to hippocampal cultures for 4 days: 1 pM DMAC did not 
upregulate numbers of [125I]-a-bgt binding sites compared to control, whereas 10 pM
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DMAC increased [125I]-a-bgt binding by 26 ± 1% above control levels (n=3; 
significantly different from control *p<0.05, one way ANOVA) (Figure 2.6). This is 
similar to the degree of upregulation produced by 10 pM nicotine compared to untreated 
control cells, 25 ± 3% (n=6) (Table 2.2).
200
5 100
Figure 2.6. Upregulation o f [I25I]-a-bgt binding sites in 
hippocampal cultures. Hippocampal cultures were exposed to 
chronic drug treatment with either nicotinic agonists DMAC (1 pM, 
10 juM), nicotine (nic; 10 pM) or KCl depolarisation (20 mM) for 4 
days before the binding assays were performed. Values are the mean 
± S.E.M. from at least 3 independent cultures. * Significantly 
different from control at p<0.05; one way ANOVA.
The putative reported a7-selectivity of DMAC compared to other nAChR subtypes 
led to an investigation to examine the ability of DMAC to displace the binding of [125I]- 
a-bgt, [3H]-MLA, [3H]-nicotine and [3H]-epibatidine from rat brain membranes was 
assessed in competition binding assays (Figure 2.7; Table 2.3). DMAC was 4-5 fold
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more potent at displacing [3H]-epibatidine and [3H]-nicotine binding than at displacing 
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Figure 2.7. Competition binding assays fo r  [I25I]-a-bgt, [3H]-MLA, [3H]-nicotine and 
f HJ-epibatidine performed on rat brain membranes. A range of concentrations of DMAC or 
cold a-bgt were used as competing ligands to displace (a) f 251]-a-bgt (10 nM), or DMAC was used 
to displace (b) f  HJ-MLA binding, (c) f  H]-nicotine binding and (d) f  H]-epibatidine binding, from 
rat brain membranes. Points are the mean o f at least 3 independent experiments performed in 
triplicate ±  S.E.M.
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Table 2.3. Kt values obtained for DMAC against the binding of [125I]-a-bgt, fH]-MLA, fH]- 
nicotine and f  H]-epibatidine to rat brain membranes. Each value represents the mean ±  S.E.M. 
of at least three separate binding experiments.
Radioligand Ki values (nM )




2.1.2.2. M echanisms o f nicotine- and KCl-evoked upregulation o f [125I]-a-  
bgt binding sites in hippocampal cultures:
To investigate whether the upregulation induced by nicotine (10 pM) and a 
depolarising concentration of KC1 (20 mM) might arise through a common cellular 
pathway, further experiments were performed in the presence of inhibitors of putative 
intermediate steps. The effect of verapamil, an L-type Ca2+ channel blocker, was 
examined to determine whether alterations in Ca2+ entry into hippocampal cells might 
play a role in the upregulation of hippocampal [125I]-a-bgt binding sites. Exposure of 
hippocampal cultures to 5 pM verapamil for 4 days had no significant effect on 
numbers of binding sites when applied alone but prevented the upregulation elicited by 
KC1 (Figure 2.8a).
To determine whether upregulation involves a CaM-kinase II pathway, cultures were 
incubated with either 10 pM nicotine or 20 mM KC1 in the absence or presence of KN- 
62, a selective CaM-kinase II inhibitor (Tokumisto et al., 1990). Upregulation elicited 
by KC1 was totally abolished by co-incubation with KN-62, which itself had no effect
Chapter 2. 104
on the level of [125I]-a-bgt binding to these cultures (Figure 2.8b). In contrast, nicotine- 
induced upregulation was not blocked in the presence o f 5 pM KN-62; the number of 
[I25I]-a-bgt binding sites remained at 29 ± 9% above control after treatment with KN-62 
and nicotine, compared with a 25 ± 3% increase produced by nicotine alone (Figure
1 c
2.8c). These results suggest that the process of upregulation of [ I]-a-bgt binding sites 
in hippocampal neurones evoked by nicotine and by KC1 occur through different 
cellular mechanisms.
I  100os
200 Figure 2.8. Inhibition o f upregulation of 
[,2SI]-a-bgt binding sites in hippocampal 
cultures. Hippocampal cultures were exposed to 
chronic drug treatments for 4 days to investigate 
the effects of (a) 5 pM verapamil (verap) on KCl 
mediated upregulation; the effect of 5 pM KN-62 
on (b) KCl-induced and (c) nicotine (nic)-evoked 
upregulation o f [I25I]-a-bgt binding sites. Values 
are the mean ± S.E.M. from at least 3 
independent cultures. * Significantly different 




This Chapter has demonstrated that chronic exposure to the nicotinic agonists 
nicotine and DMAC or after KC1 depolarisation, evoke an upregulation of the numbers 
of [125I]-a-bgt binding sites in primary hippocampal neurones. However, the underlying 
cellular mechanisms of upregulation differ between nicotine- and KCl-evoked 
upregulation: only the upregulation evoked by the latter chronic treatment is blocked by 
the CaM-kinase II inhibitor, KN-62.
2.8.1. Upregulation o f [125l]-a -bgt binding sites in hippocampal cultures -  
pharmacological characterisation:
These data confirm that primary hippocampal neurones can be dissociated and grown 
in high density cultures containing low expression of glial cells and detect reproducible 
binding of [125I]-a-bgt (Goslin and Banker, 1991; Barrantes et al., 1995a). The data 
described in this Chapter confirm and extend previous observations that chronic 
exposure of cell cultures in vitro, to nicotine, the prototypical agonist for neuronal 
nAChR, produces an upregulation of [125I]-a-bgt binding sites after 4 or 7 days of 
chronic drug treatment (Barrantes et a l 1995a; Peng et al., 1997; Molinari et al., 1998). 
Radiolabelled binding assays with this large polypeptide snake toxin ([125I]-a-bgt) were 
performed on cells in situ, therefore only the surface a7* nAChR population of 
receptors was labelled. Therefore the upregulation of [125I]-a-bgt binding sites observed 
in these assays reflects an increase in the number of surface binding sites. Furthermore, 
the fact that a-bgt binds to all conformations of a7* nAChR makes the increased 
density of binding sites with an increase receptor number unambiguous.
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Previous experiments have demonstrated that primary hippocampal cultures provide 
an in vitro system that can be used to explore the concentration- and time-dependent 
upregulation of [125I]-a-bgt binding to surface sites after chronic nicotine treatment 
(Barrantes et al., 1995a). Initial experiments performed in this study indicate that 
detectable increases of a7* nAChR result after 7 days of chronic drug treatment with 
nicotine or 20 mM KC1. Previously, upregulation of [125I]-a-bgt binding sites evoked by 
KC1 has been demonstrated not to be mediated by an increase in the ionic strength by 
changing the osmolarity. This was concluded by increasing NaCl, rather than KC1: 
increased NaCl did not effect [125I]-a-bgt binding sites in chromaffin cells or in 
hippocampal cultures (Geertsen et al., 1988; Rogers and Wonnacott, 1997). Previous 
data indicate that increasing the concentration of KC1 ( >3 0  mM) is toxic to cultures 
(Rogers and Wonnacott, 1997).
After 4 days, in the presence of either nicotine or KC1, significant upregulation of 
[125I]-a-bgt binding sites was observed in the same range as that produced after 7 days. 
This can be related to the work performed by Marks et al. (1985) who chronically 
administered nicotine to mice and investigated the time course relating to the onset and 
loss of tolerance. Results identified that maximum tolerance was observed after 4 days 
of continuous nicotine infusion and was paralleled by increases in the number of [3H]- 
nicotine and [125I]-a-bgt binding sites. Prolonging the nicotine treatment did not 
significantly evoke more extensive changes. Therefore in subsequent experiments in 
this study a drug regime of 4 instead of 7 days of chronic treatment was used to reduce 
the risk of contamination of the primary cultures. The level of upregulation observed by 
nicotine (approximately 30%) is consistent with previous data for a7* nAChR 
upregulation (Barrantes et al., 1995a; Quik et al., 1996; Peng et al., 1997). The 
magnitude of upregulation reported in vitro is reminiscent of the magnitude of
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upregulation of [125I]-a-bgt binding sites (between 33 and 40%) reported after in vivo 
administration of nicotine (Marks et al., 1985; Conroy and Berg, 1995). However, 
nicotine-evoked upregulation of a7* nAChR is low compared to the enormous 
increases in upregulation of a4P2 nAChR in transfected cell lines (e.g. 1500% in HEK 
293 cells, Gopalakrishnan et a l, 1996). The presence of expression vectors may 
contribute to this huge response.
The ability of chronic nicotine treatment to upregulate the number of [125I]-a-bgt 
nAChR binding sites has previously been documented (Barrantes et al., 1995a; Peng et 
al., 1997; Molinari et al., 1998). These studies demonstrate that upregulation reflects an 
increase in B max of [125I]-a-bgt binding sites without a change in Kd in cells transfected 
with a l  cDNA or in cells endogenously expressing the a l  subunit gene (Quik et a l, 
1996; Peng etal., 1997).
In addition to nicotine, chronic exposure of cultures to the putative a7-selective 
agonist DMAC yielded increases in [I25I]-a-bgt binding sites comparable to those 
observed after nicotine treatment. DMAC, an anabaseine derivative, was first described 
by De Fiebre et a l  (1995). In competition binding assays these authors found DMAC to 
be 10-fold more potent at displacing [125I]-a-bgt binding than [3H]-nicotine binding 
from rat brain membranes. The competition binding assays of DMAC described in this 
Chapter indicate that DMAC is 10 times less potent at a l  binding sites than previously 
reported (Table 2.3). This might reflect the different salt of the anabaseine derivative. 
Nevertheless, this compound was only 4-fold less potent at a l  sites (identified by 
displacing [125I]-a-bgt and [3H]-MLA binding) than at high affinity agonist binding sites 
(predominantly a4P2 nAChR subtype). At a7* nAChR expressed in Xenopus oocytes,
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DMAC is a potent agonist, whilst it behaves as a weak partial agonist with little efficacy 
at other subtypes (De Fiebre et al., 1995).
Rogers and Wonnacott (1997) also showed upregulation of [125I]-a-bgt binding sites 
in PC 12 cells in response to nicotine and also cytisine. Both of these nicotinic agonists 
are tertiary amines which enables them to cross the cell membrane efficiently. This 
would not exclude a putative intracellular mechanism underlying the upregulation of 
nAChR. This could be a mechanism which promotes conformational maturation of the 
a l  subunits, an increase in the efficiency of assembling a l  subunits as homomeric 
nAChR (modified from a4P2 in Peng et al., 1994b) or nicotinic agonists could increase 
a7* nAChR levels by enhancing receptor stabilisation. The quaternary nitrogen 
containing amine, DMPP acts as a partial agonist with very low efficacy on chick a l * 
nAChR expressed in Xenopus oocytes (Amar et a l, 1993), and is capable of evoking 
comparable concentration-dependent increases of [125I]-a-bgt binding sites in primary 
hippocampal cultures (Rogers and Wonnacott, 1997) and in HEK-293 cells transfected 
with human a l  subunits (Molinari et al., 1998). DMPP is membrane impermeant in 
nature, providing suggestive evidence that upregulation of a l * nAChR is mediated by 
this agonist acting outside the cell at ot7* nAChR present on the surface of the cell 
membrane, therefore dismissing an intracellular mechanism. A similar conclusion for 
the upregulation of a7* nAChR in SH-SY5Y cells has been obtained using 
carbamylcholine (Peng et al., 1997). Peng et al. (1997) conclude that the process of 
nicotine-evoked upregulation is achieved without an increase in transcription of the a l * 
nAChR subunit gene, due to unaltered levels of a l  subunit mRNA compared to control. 
This presumes that a post-transcriptional mechanism may underlie the process of 
upregulation. Such a mechanism could be one already proposed to account for the
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upregulation of the high affinity a402 nAChR, including a decrease in nAChR turnover 
(Peng et al., 1994b; Rothhut et a l, 1996), increase in the rate of receptor assembly 
(Wang et al., 1998), or an increase in receptor recruitment from a pre-existing 
intracellular receptor pool (Bencherif et al., 1995).
The al  nAChR subunit mRNA is expressed and [125I]-a-bgt binding peaks early 
during development in the postnatal period of rat in the SI neuronal region (Broide et 
al., 1996). The transient increase in expression of a l  mRNA and the corresponding 
increase in [ I]-a-bgt binding site density expression during the early postnatal period, 
identify a possible role for a-bgt-sensitive nAChR being important in critical stages of 
CNS development (Broide et al., 1996; Role and Berg, 1996), may have a role in the 
termination of axonal neurite outgrowth during development and also an involvement in 
neural sprouting after injury by high Ca2+ influx after a l* nAChR activation (see 
Chapter 5; Pugh and Berg, 1994). a-Bgt-sensitive nAChR have also been shown to play 
an important role as modulators of synaptic strength in the CNS (McGhee et al., 1995; 
Gray et al., 1996), and roles in neuroprotection (see section 1.9.1; Semba et al., 1996; 
Minana et al., 1998), and in the pathophysiology of disorders including schizophrenia 
(see section 1.9.4; Freedman etal., 1997).
The major objective of this Chapter was to compare the mechanisms of nicotine- 
evoked and depolarisation-induced upregulation of a7* nAChR, based on previous 
findings reported by De Koninck and Cooper (1995) on KCl-induced changes in al 
nAChR in rat sympathetic neurones. In agreement with De Koninck and Cooper (1995), 
a modest depolarising concentration of KC1 was found to increase the number of [125I]- 
a-bgt binding sites on the surface of hippocampal neurones, and this upregulation was 
sensitive to both the L-type voltage-operated calcium channel (VOCC) blocker
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verapamil and the CaM-kinase II inhibitor KN-62 (Figure 2.8) Membrane 
depolarisation is a survival factor for some developing neurones, and physiologically 
may contribute to synapse formation and strengthening. In rat sympathetic neurones, 
KCl-induced increases of surface [125I]-a-bgt binding were correlated with increased 
levels of a l  mRNA gene expression, suggesting a mechanism involving enhanced 
transcription (De Koninck and Cooper, 1995). The key observation in this Chapter that 
KN-62 did not prevent the nicotine-induced upregulation of [125I]-a-bgt binding sites in 
these primary rat hippocampal cultures suggests that nicotine-evoked upregulation 
occurs by a different mechanism (see discussion Chapter 3).
Primary cultures are potentially very useful in experimental analysis as they provide 
information on the native receptors obtained ex vivo after dissection from a living 
system, but these cultures introduce a few inconveniences. Studies on primary 
hippocampal cultures are severely limited by the paucity of material available from 
dissection and the labour intensive techniques involved in the preparation of cultures to 
provide sufficient material for these experiments. The inability of primary cultures of 
neurones to divide encouraged us to seek an alternative system to circumvent this 
problem, namely the use of cell lines derived from neuronal tumours. Chapter 3 
describes initial experiments performed with the rat pheochromocytoma PC 12 cell line 
and then progression on to the SH-SY5Y human neuroblastoma cell line for further 
studies to investigate the effects of chronic drug treatment and the cellular mechanisms 
underlying nAChR upregulation.
Chapter 3. Upregulation and localisation 
o f nAChR in SH-SY5Y cells.
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3.1. Introduction.
As described in Chapter 2, primary hippocampal cultures were grown and exposed to 
chronic drug treatments before determining the number of [125I]-a-bgt binding sites. 
Using primary hippocampal tissue has several drawbacks; first the paucity of 
hippocampal material which yields low numbers of cells with a limited life span. The 
labour intensive preparation of hippocampal material and the low tolerance of these 
neurones to chronic drug treatment regimes, provide criteria and considerable 
advantages for the search of a suitable cell line over primary neuronal cultures. A cell 
line used as an alternative model system would help to circumvent these problems, 
enabling us to extend the investigation of the mechanisms underlying upregulation of 
nAChR and the level of expression of the a3 and a l  nAChR subunits in vitro. 
Preliminary data was generated using the rat pheochromocytoma PC 12 cell line before 
advancing to the SH-SY5Y cell line.
The relative ease and inexpensive nature of using cell lines compared to using 
primary cultures is immediate and has helped to expand and compare the cellular 
mechanisms underlying upregulation already obtained with primary hippocampal cell 
cultures. Using cell lines is typically a matter of defrosting a vial of cells of low passage 
number, plating the cells into a sterile flask with chemically defined medium and 
leaving them to grow to confluency. Once confluent cells can either be subcultured into 
tissue culture plates or flasks, or frozen to maintain cell stocks. Some additional 
advantages of robust cell lines are that they consist of a homogeneous population of 
cells, identical to each other that should produce reliable results within the same culture 
and also between cultures over a period of time (see Lukas, 1998). This is in contrast to 
in vivo studies that can be expensive with respect to the quantity of animals often 
needed to overcome individual experimental variation and of course, is subject to
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ethical considerations. Despite the many advantages of using cell lines, a disadvantage 
is that the functioning of cells in culture does not represent the full complexity of an 
intact, native neural network laid down in the CNS, with the many biochemical and 
biophysical interactions occurring between different neural regions as observed with in 
vivo techniques. Cell culture techniques have the additional advantage that an exact 
drug concentration can be applied to cells without the hindrance of the blood brain 
barrier. Drug treatment can be directly correlated to receptor numbers by the use of 
specific radiolabelled ligands. As far as binding data is concerned, cell lines have 
proved to be invaluable as model systems, producing results that closely parallel 
receptor changes observed in vivo.
This Chapter is divided into four main sections:
1). Section 1 investigates the cellular mechanisms underlying upregulation of a3* 
and ot7* nAChR in SH-SY5Y cells.
2). Section 2 introduces molecular biological techniques used to detect and 
quantitate the level of expression of a3 and a7 subunit RNA after chronic drug 
treatment to SH-SY5Y cells compared to control.
3). Section 3 is a preliminary investigation into the visualisation of upregulated a3 
and a l  nAChR subunits after chronic nicotinic agonist and KC1 treatment 
compared to control untreated SH-SY5Y cells.
4). Section 4 discusses the results obtained in this Chapter.
Sections 1-3 will contain a brief introduction, methods and materials with a results 
section to follow. A final overall discussion is presented in Section 4 to incorporate and 
discuss the results obtained from all sections on the SH-SY5Y cell line experimental 
data.
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Section 1: Upregulation of nAChR in SH-SY5Y cells.
3.1.1. The rat pheochromocytoma (PC12) cell line:
PC 12 cells are a clonal cell line initially established from a transplantable rat adrenal 
pheochromocytoma tumour (Greene and Tischler, 1976). This cell line displays 
phenotypic properties associated with pheochromocytomas and they resemble their neo­
plastic counterparts, noradrenergic adrenal medulla (chromaffin) cells. PC 12 cells are 
therefore capable of synthesising and storing catecholamines (DA and NE) (Greene and 
Tischler, 1976; Inoue and Kenimer, 1988) and express a3, a5, a7, 02, (33 and 04 
nAChR subunits (Boulter et al., 1990; Rogers et al., 1992; Ishiguro et al., 1997). When 
growing PC 12 cells in culture, one important feature is that upon the addition of nerve 
growth factor (NGF) the cells will be prevented from further division and hence 
proliferation (Greene, 1978; Henderson et al., 1994). This differentiation ofPC12 cells 
causes a dramatic change in the cellular phenotype by the development of long 
branching neuronal processes from the cell bodies, the cells become electrically 
excitable to ACh (Greene, 1978; see Greene et al., 1991) and there is a change in the 
expression of nAChR genes encoding a3, a5, a l ,  02 and 04 subunits (Rogers et al., 
1992; Henderson et al., 1994; Hu et al., 1994). In contrast, NGF deprivation promotes 
PC 12 cell death (Batisatou and Greene, 1991), and this process could be subsequently 
reversed by the application of nicotine (1-100 pM), revealing neuroprotective effects 
mediated through nAChR (Yamashita and Nakamura, 1996).
Long-term nicotine treatment has previously been shown to produce a concentration- 
dependent increase in [3H]-nicotine binding to PC 12 cells without altering the levels of 
a3, a5, a l  or the 04 nAChR subunit genes, but increasing the mRNA level of the 02 
nAChR subunit gene (Madhok et al., 1995). The former nAChR subunit mRNAs were
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down regulated by treatment with forskolin, indicating the possible involvement of a 
protein kinase A (PKA) pathway (Ishiguro et a l, 1997). Nicotine treatment failed to 
enhance [3H]-nicotine binding to PC 12 cell mutants deficient in PKA, suggesting that 
this protein kinase may be required for upregulation of nAChR in response to nicotine 
(Madhok et a l, 1994, 1995). Long-term treatment with the nicotinic agonist, 
carbamoylchoiine, produced a decrease in the responsiveness, also termed “functional 
down-regulation”, of wild-type PC 12 cells (Robinson and McGee, 1985). In contrast to 
nicotine, KC1 depolarisation (50 mM) for 4 days was found not to have an effect on the 
subsequent responsiveness of PC 12 cells to nicotinic cholinergic stimulation, or regulate 
neuronal nAChR on PC 12 cells (De Lorme and McGee, 1988) or to affect [3H]- 
epibatidine binding after chronic KC1 treatment for 7 days (Rogers and Wonnacott, 
1997). PC 12 cells were therefore employed as a useful model cell line system, as a 
starting point to further the data generated from primary hippocampal neuronal cultures.
3.1.2. The SH-SY5Y cell line:
The SH-SY5Y neuroblastoma clonal cell line was initially established through 
sequential subcloning from the SHSY line and the parental epithelial cell-like subclone 
of the SK-N-SH human neuroblastoma-derived cell line established from a biopsied, 
metastatic tumour diagnosed as a peripheral neuroblastoma (Lukas et a l,  1993). This 
cell line, of sympathetic adrenergic ganglion origin, expresses two types of nAChR: 1) 
ganglionic AChR that are normally post-synaptic and are tentatively composed of the 
a3, a5, 02 and 04 nAChR subunits, and 2) neuronal a-bgt-sensitive nAChR, which are 
probably extrasynaptic and contain a7  subunits. The SH-SY5Y cell line offers 
advantages over primary hippocampal cultures and transfected cell lines due to these
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cells endogenously expressing a3, a5, a l,  P2 and P4 nAChR subunit subtypes (Lukas 
et al., 1993). Due to more than one defined receptor subtype being expressed in the SH- 
SY5Y cell line, these subunits will combine in a variety of homomeric and heteromeric 
combinations, that can be elucidated by using specific antagonists for specific nAChR 
subtypes. Thus in addition to expressing native [125I]-a-bgt binding sites representative 
of putative a l * nAChR, the SH-SY5Y cell line has enabled this study to encompass 
a3* nAChR. These nAChR are heterogeneous, comprising combinations of oc3 with a5, 
p2 and/or P4 subunits. These a-bgt-insensitive nAChR are labelled with the novel, 
potent, high affinity nicotinic agonist [3H]-epibatidine. [3H]-Epibatidine is a 
radiolabelled pharmacological tool introduced in section 1.6.3. It has been demonstrated 
that approximately half of the ot3* nAChR in SH-SY5Y cells also contain the P2 
subunit (Wang et al., 1996). Other studies have shown that SH-SY5Y cells resemble 
human fetal sympathetic neurones grown in primary culture, express noradrenergic 
biosynthetic enzymes and functional muscarinic and opioid receptors (Adem et al., 
1987; Kazmi and Mishra, 1987).
3.1.3. Previous studies performed with SH-SY5Y cells:
Lukas et al. (1993) demonstrated an agonist-sensitive cation flux mediated by a3* 
post-synaptic-type nAChR present in SH-SY5Y cells. Radioligand binding studies with 
SH-SY5Y cells have identified the expression of a single class of nicotinic [125I]-a-bgt 
binding site, that binds [I25I]-a-bgt with high affinity (K d  = 4 nM) and binds other 
nicotinic ligands with lower affinity (in the pM range) (Lukas et al., 1993). Previous 
experiments with this human neuroblastoma cell line have shown that chronic nicotine 
exposure upregulates both a3* and a l * nAChR subtypes (Peng et al., 1997). Wang et
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al. (1998) indicated that chronic nicotine or carbamylcholine treatment upregulates 
a302 and oc3p2a5 nAChR subtypes, with no effect on P4* nAChR combinations. This 
demonstrates that upregulation of a3* nAChR depends upon the presence of P2 but not 
P4 subunits (Wang et al., 1998).
Upregulation of either a3* or a7* nAChR was evoked at concentrations of nicotine 
greater than those required to elicit upregulation of the a4p2 nAChR expressed in 
fibroblasts (Peng et al., 1994b, 1997; Warpman et al., 1998). These higher levels of 
nicotine may not be physiologically relevant to the plasma nicotine concentrations found 
in smokers. However, the underlying mechanism of nicotine-evoked upregulation of 
a3* and a7* nAChR has been proposed to be the same as that for a4p2 nAChR, with 
regard to the lack of increased gene transcription (Peng et al., 1997). This was indicated 
by the failure of nicotine to increase a3 or a7  subunit mRNA, suggesting that these 
nAChR subunits are upregulated via a post-transcriptional mechanism (Peng et al., 
1997). This section shows that nicotinic agonists, nicotine and DMAC, and KC1 
depolarisation upregulate a7* nAChR via distinct mechanisms whereas a3* nAChR are 
not responsive to KC1 treatment.
3.2. Aims:
This section aims to compare the effects of chronic drug treatments applied to SH- 
SY5Y cells in culture, drug treatments that have previously been shown to produce 
upregulation of [125I]-a-bgt binding sites in rat primary hippocampal cultures after 4 
days of treatment (see section 2.7.2). Detection of a3* nAChR expressed in the SH- 
SY5Y cell line will be investigated in terms of upregulation and the underlying cellular
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mechanisms of this phenomenon and will be compared to a7* nAChR evoked 
upregulation.
3.3. Materials and methods.
3.3.1. Drugs, reagents and cell lines:
Tissue culture media, serum and plasticware were from Gibco BRL (Paisley, 
Renfrewshire, Scotland). Media supplements, biochemicals, cycloheximide and poly-L- 
lysine (hydrobromide) were purchased from Sigma Co. (Poole, Dorset, U.K.). A-[1-[A- 
methyl-/?-(5-isoquinolinesulfonyl)-benzyl]-2-(4-phenylpiperazine)ethyl]-5-isoquinoline 
sulfonamide (KN-04) was from AMS Biotechnology and 3-[ 1 -[3(amidinothio)propy 1-1H- 
indol-3-(l-methyl-lH-indol-3-yl)maleimide methane sulfonate (Ro 31-8220) was purchased 
from Calbiochem. Cell culture equipment was supplied by Beckton Dickinson (Oxford, 
U.K.) or Sterilin (Stone, Staffs., U.K.). PC 12 and SH-SY5Y cells were from the European 
Collection of Cell Cultures (ECACC), Porton Down (Salisbury, Wilts., U.K.).
3.3.2. Maintenance of PC 12 cells and the SH-SY5Y cell line:
PC 12 cells adhere poorly to tissue culture plastic, therefore stock cultures and sub­
cultures were routinely maintained in tissue culture vessels to which poly-L-lysine 
(PLL) (1 mg/ml prepared in 150 mM sodium borate buffer (pH 8.4)), an adhesive 
coating, had been previously applied for at least 4 h and rinsed with sterile water to 
remove remaining traces of the PLL. PC 12 cells were maintained in RPMI 1640
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medium supplemented with horse serum (10%), FCS (5%), penicillin (25 IU/ml) and 
streptomycin (25 |ng/ml).
SH-SY5Y human neuroblastoma stock cultures were routinely maintained in a 
DMEM:Ham’s F12 (1:1) modified medium containing 1% non-essential aminoacids 
(NEAA) and supplemented with FCS (15%), glutamine (2 mM), penicillin (50 IU/ml) 
and streptomycin (50 pg/ml).
Cultures of both cell lines were seeded into 75 cm2 flasks containing 20 ml of 
supplemented medium and maintained at 37°C in a humid atmosphere containing 5% 
CCVhumidified air. Stock cultures were passaged 1:4 weekly at approximately 80% 
confluency. Optimum proliferation of PC12 cells was obtained by feeding cultures 
every 3 to 4 days, with approximately 65% of the medium in the culture being 
exchanged so as to leave a portion of RPMI “conditioned” medium in the culture to 
facilitate growth. SH-SY5Y cultures were fed twice weekly with modified DMEM: 
Ham’s F12 medium. Cultures for binding assays were subcultured in 24 well plates at a 
seeding density of 5 x 105 cells/ml or 10 x 105 cells/ml for PC 12 and SH-SY5Y cells 
respectively (adapted from Vaughan et al., 1993). Once confluent, cultures were treated 
chronically with drugs.
3.3.3. Drug treatment:
In initial experiments, PC 12 cells were incubated with varying concentrations of 
NGF (0-200 ng/ml) for 7 days. Confluent SH-SY5Y cultures in 24 well plates were 
chronically treated with a number of drugs, either alone or in combination, for 4 days. 
All drug solutions were made up as described previously in section 2.4.2. KN-04 and 
Ro 31-8220 were made up in DMSO stock solutions of 10 mM so that the final
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concentration of DMSO on cultures did not exceed 0.1%. Binding assays were 
performed with [3H]-epibatidine binding after 7 or 4 days (PC 12 or SH-SY5Y cells 
respectively), or with [125I]-a-bgt binding after 4 days of chronic drug treatment to SH- 
S Y5 Y cells.
3.3.4. Radioligand binding assays on Cultured Cells in situ.
3.3.4.I. [3H]-Epibatidine binding to PC12 cells and SH-SY5Y cultures:
Cultures were washed x 4 with warm medium over 3 h prior to the assay, to remove 
all traces of drugs from the cultures. After 3 h the cultures were incubated with 1 ml 
PC 12 or SH-SY5Y medium containing [3H]-epibatidine (500 pM; specific activity 33.8 
Ci/mmol) for 2 h at 25°C. Non-specific binding was defined in parallel cultures in the 
presence of 1 mM nicotine. The cultures were subsequently washed x 3 with warm PBS 
and solubilised in 800 pi 0.1 M NaOH (16 h at 4°C). An aliquot (500 pi) was added to 5 
ml Optiphase Safe scintillant (Fisons Chemicals, Loughborough, U.K.) and counted for 
radioactivity in a Packard Tri-Carb liquid scintillation counter 1600 spectrometer 
(counting efficiency 45-50%) to give total bound and non specific bound cpm, and a 
200 pi aliquot was assayed for protein using the method of Markwell et al. (1978). 
Radioactivity counts and protein assay data were combined to give total and non­
specific binding (and hence specific = total binding -  non-specific binidng) in terms of 
fmol [3H]-epibatidine bound/mg protein.
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3.3.4.2. [125I]-a-bgt binding to SH-SY5Y cultures:
[125I]-a-Bgt binding assays were performed on intact SH-SY5Y cells as described for 
hippocampal cultures (see section 2.6.3) to measure surface [125I]-a-bgt binding sites 
representative of putative oc7* nAChR.
3.3.5. Radioligand binding to SH-SY5Y membrane preparations:
3.3.5.1. SH-SY5Y membrane preparation protocol:
Confluent 7 day old SH-SY5Y cells in 175 cm2 flasks were scraped into 10 ml o f ice 
cold PBS pH 7.5 containing 10 mM EDTA, 1 mM PMSF and centrifuged at 500 x g for 
3 min. The pellet was resusupended in 10 ml of PBS per flask of cells and sonicated for 
3 x 10 s at an amplitude of 9 microns, resuspensions were kept on ice. The homogenate 
was centrifuged at 35,000 x g for 30 min and the pellet washed by an identical 
centrifugation step. Finally, the pellet was resuspended in 1 ml ice cold Tris Ringer (N- 
(2-hydroxyethyl)piperazine-N’-2-ethane) sulphonic acid (HEPES) buffer (118 mM 
NaCl, 4.8 mM KC1, 2.5 mM CaCl2, 2 mM M gS04, 20 mM HEPES, 200 mM Tris, 0.1 
mM PMSF and 0.01% sodium azide, pH 7.4) per original flask and stored in 2 ml 
aliquots at -20°C until required for assay.
3.3.5.2. Optimisation o f tissue quantity used in membrane [3H]-M LA  
binding assays:
Protein assays were performed on the SH-SY5Y cell membrane batches by the 
method of Bradford (1976), as the Markwell assay is incompatible with a Tris based 
buffer. SH-SY5Y cell membranes (200, 100, 50, 25, 10 jug) were diluted in a final
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volume of 250 pi in Tris-Ringer HEPES buffer containing 1 mg/ml BSA and 20 nM 
[3H]-MLA. Non-specific binding was determined in the presence of 1 mM nicotine and 
non-specific/total binding were determined in triplicate. Samples were incubated for 2 h 
at 37°C. Following this, samples were washed x 3 with ice cold PBS and filtered using a 
Brandel cell harvester through Gelman GFA/C filters presoaked in 0.3% PEI in PBS, 
pH 7.4. The filters were transferred into tubes and 5ml Optiphase Safe scintillation 
cocktail added and the contents mixed before counting for 5 min in a Packard 1600 
Tricarb counter (counting efficiency 45-50%). Radioactivity counts and protein assay 
data were combined to give total and non-specific binding in terms of fmol [3H]-MLA 
bound/mg protein.
3.3.5.3. [3H]-M LA saturation binding to SH-SY5Y membranes:
For total binding 10 pi of Tris-Ringer HEPES buffer (containing 1 mg/ml BSA) and 
10 pi of [3H]-MLA were incubated with 230 pi of SH-SY5Y membranes (final protein 
concentration of 200 pg per sample tube). Non-specific binding was determined in the 
presence of 1 mM nicotine. Assays were performed in triplicate with a range of 
concentrations of [3H]-MLA ranging from 2.5 nM to 20 nM and incubated for 2 h at 
37°C to measure total [3H]-MLA binding sites (i.e. surface and intracellular located a7* 
nAChR). The reaction was terminated, and assay tube contents filtered and counted as 
described above in section 3.3.5.2.
3.3.5.4. Data analysis:
Data obtained from the [3H]-MLA saturation binding assays were fitted to the 
hyperbolic curve equation [5war*[L]]/^D + [L] using Sigma Plot V2.0 for windows
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(Jandel Scientific, Corte Madera, CA, USA). KD and Bmax were directly calculated from 
the saturation binding curves. Each saturation binding isotherm was transformed to 
linearity by using the Scatchard equation in order to characterise the number of binding 
sites.
3.4. Results.
3.4.1. NGF treatment on PC 12 cells:
The high affinity of epibatidine for neuronal nAChR (Sullivan et al., 1994; 
Houghtling et al., 1995; Gerzanich et al., 1995) suggests that these receptors in PC 12 
will be labelled by [3H]-epibatidine. Preliminary data described in this section is from 
binding assays performed on the PC 12 cell line in situ using 500 pM [3H]-epibatidine. 
Initial assays using PC 12 cells were performed after exposure to varying concentrations 
of NGF for 7 days before being assayed for [3H]-epibatidine binding. Results produced 
a profile of increasing specific binding with increased NGF concentration showing that 
NGF produces a concentration-dependent increase in the number of [3H]-epibatidine 
binding sites. Results are shown in Figure 3.1.
A concentration of approximately 100 ng/ml NGF produces maximum increases and 
a steady state binding of [3H]-epibatidine to PC 12 cells which is 5-6 fold greater than 
[3H]-epibatidine binding found in PC 12 cells grown in the absence of NGF. However, 
due to persistent problems experienced with this cell line in this laboratory, for example 
contamination from source, it was decided to investigate the cellular mechanisms 
mediating upregulation of nAChR in another cell line, SH-SY5Y cells, and abandon 
further investigations with the PC 12 cell line.
Chapter 3. 124
140
0 10 25 50 100 200
C oncen tration  o f NGF (ng/m l)
Figure 3.1. [SH]-Epibatidine binding sites after 
NGF treatment to PC12 cells. PC12 cell cultures 
were exposed to various concentrations o f NGF ranging 
from 0-200 ng/ml for 7 days before performing f3HJ- 
epibatidine binding assays. Values are the mean ± 
S.E.M. from at least 3 independent cultures performed in 
duplicate. * Significantly different from control at 
p<0.05; one way ANOVA.
3.4 .2 . U pregulation  o f  [,25I]-a -b g t b inding sites in SH -SY 5Y  cultures:
Initial experiments were performed to examine the upregulation of a-bgt binding 
sites in SH-SY5Y cell cultures, for comparison with the findings obtained from primary 
rat hippocampal cultures as described in section 2.7.2. In the absence of drugs, SH- 
SY5Y cells expressed 25 ± 2 fmol [125I]-a-bgt binding/mg protein (Table 3.1). Nicotine 
(10 jliM), DMAC (10 pM) and KC1 (20 mM), applied for 4 days, increased the number 
of putative [125I]-a-bgt binding sites by 37 ± 5 % (n=13), 20 ± 6% (n=4), and 51 ± 10% 
(n=9; Table 3.1, Figure 3.2) respectively. These values closely parallel the changes in 
[123I]-a-bgt binding sites produced in hippocampal cultures (Table 2.2) and represent a
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real increase in numbers of a l*  nAChR subtypes as the [125I]-a-bgt binding site density 
was calculated in terms of protein, determined for each assay well (see methods 2.6.3).
Table 3.1. Upregulation of [12SI]-a-bgt and f  H]-epibatidine binding sites in SH-SY5Y 
cultures treated for 4 days with either nicotine (10 pM), DMAC (10 pM), or KCl (20 mM).
Control values o f [125l]-a-bgt and [3H]-epibatidine binding sites are expressed as Jmoles radioligand 
bound/mg protein (expressed as 100%) and the upregulation elicited by nicotine, DMAC and KCl are 







25 ±2 (n=14) 69 + 4 (n=43)
Nicotine (10 pM)
(% control)
137 ± 5% (n=13)* 136 ± 6% (n=15)*
DMAC (10 pM)
(% control)
120 ± 6% (n=4)* 143 ± 8% (n=13)*
KCl (20 mM)
(% control)
151 ± 10% (n=9)* 107 ± 5% (n=13)
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Figure 3.2. Upregulation o f [I25I]-a-bgt binding sites 
in SH-SY5Y cultures. SH-SY5Y cultures were exposed to 
chronic drug treatment with either nicotinic agonists DMAC 
(10 pM), nicotine (nic; 10 pM) or KCl depolarisation (20 
mM) for 4 days before the binding assays were performed. 
Values are the mean ± S.E.M. from at least 4 independent 
cultures. * Significantly different from control at p<0.05; 
one way AN OVA.
3 .4 .3 . [3H )-M L A  binding to S H -S Y 5Y  m em branes:
3.4.3.I. Optimisation of |3H]-MLA binding to SH-SY5Y membranes:
In order to minimise amounts of SH-SY5Y cells used it was decided to prepare SH- 
SY5Y cell membranes using aliquots of a known protein concentration in each assay 
tube. The binding of [3H]-MLA to SH-SY5Y cell membranes increased in a linear 
manner as the quantity of SH-SY5Y membranes was increased. Based on these results, 
200 pg protein of SH-SY5Y cell membranes was chosen to use for further
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experimentation in saturation binding assays for [3H]-MLA as this quantity of protein 
gave a satisfactory specific binding signal without using too many SH-SY5Y cells.
3.4.3.2. Saturation o f [3H]-M LA binding to SH-SY5Y membranes:
Saturation binding of [3H]-MLA to 7 day confluent SH-SY5Y cell membranes 
treated with nicotine, KCl or no drugs for 4 days were compared. A range of 
concentrations of the novel a7-selective ligand [3H]-MLA (2.5-20 nM) was used 
(Figure 3.3). Data reveal that [3H]- MLA bound in a saturable manner to this cell line. 
These binding assays allowed for the determination of Bmax (surface and intracellular 
[3H]-MLA binding) and Kd values to be calculated from drug treated cells for 
comparison with values for membranes from control untreated SH-SY5Y cells. 
Scatchard analysis is consistent with one population of receptor binding site in the SH- 
SY5Y cell line, as previously suggested by Davies et al. (1999) for rat brain 
membranes. In control SH-SY5Y cells binding was saturable with observed Bmax values 
of 28.02 fmoles [3H]-MLA bound/mg protein with a Kd value of 3.02 nM (Table 3.2). 
Chronic treatment with either nicotine or KCl significantly increased Bmax values but did 
not significantly alter Kd values after upregulation. These values suggest that nicotine 
and KCl depolarisation upregulate [3H]-MLA binding sites in terms of fmoles [3H]- 
MLA bound/mg of protein. Upregulation mediated by nicotine resulted from an 
increase in the amount of nAChR rather than from an increase in the affinity of a7* 
nAChR for nicotine, a similar result found after nicotine treatment and detection of a7* 
(Molinari et al., 1998) and a4p2 nAChR (Schwartz and Kellar, 1983; Bencherif et al., 
1995). The large increases observed with Bmax after nicotine and KCl treatment is
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probably representative of [3H]-MLA binding to intracellular populations of a7* 
nAChR.
Table 3.2. and KD values for fH]-MLA saturation binding to SH-SY5Y cells. *
Significantly different from control at p<0.05; one way ANOVA.
Treatment Bmax (ftnol /mg) KD (nM)
Control 28.0 ±2.2 3.0 ±0.56
Nicotine (10 pM) 92.2 ±3.4* 2.1 ±0.47
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Figure 3.3. Saturation binding o f [3H]-MLA to SH-SY5Y cells in situ. Saturation 
binding was performed on 7 day confluent SH-SY5Y membrane preparations treated for 4 days 
with (a) no drugs, control, (b) nicotine or (c) KCI. The panels on the left show total, non-specific 
and specific binding (cpm), with the panels on the right showing the concentration o f [3H]-MLA 
bound against specific binding expressed in fmol [3H]-MLA bound'mg protein. Values are the 
mean ± S.E.M. from at least 3 independent cultures. Saturation data was fitted to a hyperbolic 
curve equation ([Bmax* [LJJ/KD + [L]).
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Figure 3.4. Scatchard analyses o f [SH]-MLA saturation binding. Saturation binding data was 
transformed to linearity by using the Scatchard equation for (a) control, (b) nicotine or (c) KCI treated 
SH-SY5Y cells.
3.4.4. Mechanisms of nicotine- and KCl-evoked upregulation of 
putative a7* nAChR in SH-SY5Y cultures:
Experiments were performed to investigate the cellular mechanisms underlying 
nicotinic agonist- and KCl-evoked upregulation of a7* nAChR in SH-SY5Y cells. To 
identify if the phenomenon of upregulation evoked by these compounds arise from 
different cellular pathways as indicated by the data in hippocampal cultures. Further 
experiments were performed on SH-SY5Y cultures in the presence of specific 
inhibitors. Exposure of cultures to the L-type Ca2+ channel blocker, verapamil (5 pM) or 
the CaM-kinase II inhibitor, KN-62 for 4 days had no significant effect on numbers of 
[125I]-a-bgt binding sites when applied alone and did not abolish nicotine-evoked 
upregulation (Figure 3.5a, b) Upregulation mediated by nicotine was maintained at 44 ± 
16% (n=4) and 40 ± 16% (n=4) in the presence of verapamil and KN-62 respectively. In 
contrast, verapamil and KN-62 were found to prevent the upregulation elicited by KCI 
depolarisation (Figure 3.5a). Results obtained with SH-SY5Y cell cultures are in close
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accordance with and extend the [ I]-a-bgt binding data generated from the primary 
hippocampal cultures described in section 2.7.2.2. These results suggest that the process 
of upregulation of [12:>I]-a-bgt binding sites in hippocampal neurones and the SH-SY5Y 
human neuroblastoma cell line evoked by nicotine and KCI depolarisation arise through 
the mediation of different cellular mechanisms.
a b
200 - r -
Figure 3.5. Inhibition o f upregulation o f [,25I]-a-bgt binding sites in SH-SY5Y cultures. SH-
SY5Y cultures were exposed to chronic drug treatments for 4 days to investigate the effects of verapamil 
(verap; 5 pM) and KN-62 (5 pM) on (a) KCI- (20 mM) and (b) nicotine- (hie; 10 pM)) evoked 
upregulation o f [I25I]-a-bgt binding sites. Values are the mean ± S.E.M. from at least 4 independent 
cultures. * Significantly different from control at p<0.05; one way ANOVA.
A preliminary investigation into the dependence on protein synthesis of the process 
of upregulation elicited by nicotine or by KCI depolarisation in SH-SY5Y cells was 
undertaken using cycloheximide (Figure 3.6). Cycloheximide is a general blocker of 
protein synthesis and therefore would prevent the synthesis of new nAChR (Peng et al
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1994b). Cycloheximide (35 pM) treatment for 4 days significantly reduced the level of 
a7* nAChR detected by [I25I]-a-bgt binding by 75% and 64% (Figure 3.6a, c 
respectively) and decreased the fmol [125I]-a-bgt bound/mg protein compared to control 
cells (Figure 3.6.b, d). There were also fewer cells observed in the wells after 
cycloheximide treatment, another sign reflecting the toxic nature of this effective 
inhibitor of protein synthesis over the time-course of this drug treatment regime. The 
treatment of cycloheximide alone was not significantly different from its corresponding 
combined treatment with either chronic KCI or nicotine. This indicates that KCI or 
nicotine treatment in the presence of cycloheximide does not result in upregulation of 
[125I]-a-bgt binding sites due to the maintained reduction of protein levels. In the 
absence of cycloheximide, KCI and nicotine upregulated [125I]-a-bgt binding sites to 60 
± 23% (n=4) and 43 ±6% (n=3) respectively above control. Treatment with a 
combination of KCl/cycloheximide or nicotine/cycloheximide produced no upregulation
125of [ I]-a-bgt binding sites. Due to the general deleterious effect of cycloheximide on 
SH-SY5Y cells, and no upregulation produced by KCI or nicotine in the presence of 
cycloheximide, it may be interpreted that this effect is due to a cytotoxic action of 
cycloheximide on SH-SY5Y cells. The inhibition of protein synthesis by cycloheximide 




Figure 3.6. The effect o f cycloheximide on / 125I]-a-bgt binding sites in SH- 
SY5Y cultures. SH-SY5Y cultures were exposed to chronic drug treatments for 4 days 
to investigate the effects of cycloheximide (cyclo; 35 pM) on (a, b) KCI (20 mM) and 
(c, d) nicotine (nic; 10 pM) evoked upregulation of [,25I]-a-bgt binding sites expressed 
as a percentage o f control (a, c) and fmol [n5I]-a-bgt bound/mg protein (b, d). Values 
are the mean ± S.E.M. from at least 3 independent cultures. * Significantly different 
from control atp<0.05; one way ANOVA.
3.4.5. U pregulation o f  [3H]-epibatidine b inding sites in SH -SY 5Y  
cultures:
In addition to [12;>I]-a-bgt binding sites, SH-SY5Y cells also express a3* nAChR sites 
that can be identified with [3H]-epibatidine binding (Peng et al., 1997; Wang et al., 
1998). In the absence of drugs, cultures expressed 69 ± 4 fmoles [3H]-epibatidine
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binding sites/mg protein (Table 3.1). Chronic nicotine (10 ju.M) treatment of SH-SY5Y 
cultures for 4 days upregulated [3H]-epibatidine binding to 36 ± 6% (n=13; Figure 3.7) 
above control binding. DMAC (10 pM) produced a comparable upregulation o f [3H]- 
epibatidine binding sites to 43 ± 8% (n=13; Figure 3.7). These responses are similar in 
magnitude to the changes evoked by nicotine and DMAC with [125I]-a-bgt binding to 
SH-SY5Y cells (Table 3.1). In contrast to the response to nicotinic agonists, KCI 
depolarisation (20 mM) failed to significantly upregulate a3* nAChR (107 ± 5%, n=13; 












Figure 3.7. Upregulation o f [3H]-epibatidine binding 
sites in SH-SY5Y cultures. SH-SY5Y cultures were 
exposed to chronic drug treatment with either nicotinic 
agonists DMAC (10 pM), nicotine (nic; 10 pM) or KCI 
depolarisation (20 mM) for 4 days before binding assays 
were performed. Values are the mean ± S. E.M. from at least 
5 independent cultures. * Significantly different from control 
atp<0.05; one way ANOVA.
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3.4.6. M echanism s o f  nicotinic agonist-evoked upregulation o f  [3H]- 
epibatidine binding sites in SH -SY 5Y  cultures:
Verapamil and KN-62 (Figs. 3.8 and 3.9 respectively) in the presence of either
nicotine or DMAC did not block the upregulation elicited by these compounds.
Figure 3.8. The effect o f verapamil on 
upregulation o f f3H]-epibatidine binding 
sites in SH-SY5Y cultures. The effect of 
verapamil (verap; 5 pM) was examined on SH- 
SY5Y cultures exposed to chronic drug 
treatment with either (a) KCI depolarisation (20 
mM), or nicotinic agonists (b) nicotine (nic; 10 
pM) and (c) DMAC (10 pM) for 4 days before 
binding assays were performed. Values are the 
mean ± S.E.M. from at least 4 independent 
cultures. * Significantly different from control 
at p<0.05; one way ANOVA.
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Figure 3.9. The effect o f KN-62 and KN- 
04 on upregulation o f [3H]-epibatidine 
binding sites in SH-SY5Y cultures. The
effect of KN-62 (5 pM) and KN-04 (5 pM) 
were examined on SH-SY5 Y cultures exposed 
to chronic drug treatment with either (a) KCI 
depolarisation (20 mM), or nicotinic agonists 
(b) nicotine (nic; 10 pM) and (c) DMAC (10 
pM) for 4 days before binding assays were 
performed. Values are the mean ± S.E.M. 
from at least 4 independent cultures. * 
Significantly different from control at p<0.05; 
one way ANOVA.
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KN-62 applied alone to SH-SY5Y cultures for 4 days, in the absence of nicotinic 
agonist or KCI depolarisation, produced a marked upregulation of the [3H]-epibatidine 
binding sites to 144 ± 34%, 140 ± 48% and 176 ± 35 above control shown in Figure 
3.9a, b and c respectively. The effect of KN-04, an inactive analogue of KN-62 that 
does not inhibit CaM-kinase II, was also investigated. KN-04 alone had no effect on the 
number of [3H]-epibatidine binding sites, when compared to the control condition
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(Figure 3.9). This suggests that KN-62 elicits upregulation o f a3* nAChR through the 
inhibition of CaM-kinase II.
The effect of a PKC inhibitor was also investigated to identify if  this signalling 
protein was involved in the cellular mechanism underlying the upregulation of [3H]- 
epibatidine binding sites by nicotinic agonists. The effect of Ro 31-8220, a PKC 
inhibitor, was investigated on nicotinic agonist mediated upregulation. Figure 3.10 
shows that Ro 31-8220 (1 pM) had no effect on [3H]-epibatidine binding when applied 
alone. When co-applied with either nicotine or DMAC, RO 31-8220 did not abolish the 
nicotinic agonist-evoked upregulation of [3H]-epibatidine binding sites. Upregulation 
mediated by either nicotine or DMAC was maintained to 53 ± 3% (n=6) and 53 ± 2% 
(n=6) respectively above control binding in the presence of Ro 31-8220. This shows 
that a PKC signalling pathway is not involved in the upregulation of [3H]-epibatidine 
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Figure 3.10. The effect o f a PKC inhibitor on upregulation o f [3H]-epibatidine binding sites 
in SH-SY5Y cultures. The effect of Ro 31-8220 (1 pM) was examined on SH-SY5Y cultures that were 
exposed to chronic drug treatment with nicotinic agonists (a) nicotine (nic; 10 pM) or (b) DMAC (10 
pM) for 4 days before binding assays were performed. Values are the mean ± S.E.M. from at least 4 
independent cultures. * Significantly different from control at p<0.05; one way AN OVA.
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Section 2: Detection and quantitation o f nAChR subunit 
RNA in SH-SY5Y cells after chronic drug treatment.
3.5. Introduction.
Section 1 has established that chronic nicotine, DMAC and KCI depolarisation 
differentially upregulate a3* and a7* nAChR subtypes in the SH-SY5Y human 
neuroblastoma cell line. De Koninck and Cooper (1995) reported data on the regulation 
of nAChR genes in neonatal rat superior cervical ganglion (SCG) neurones developing 
in culture. Rat SCG neurones are known to contain a3, a5, a7, 02 and 04 nAChR 
subunits (Mandelzys et al., 1994). It was shown that in untreated cells, a7  mRNA levels 
decreased over a period of 3 days when compared to initial control levels. Exposure of 
these neurones to high K+ at the time of plating maintained the level of a l  mRNA at 
their initial plating value after 72 hours in the presence of KCI. If  SCG neurones were 
exposed to membrane depolarisation with KCI (40 mM) for 48 hours, this treatment was 
shown to evoke a specific and significant increase in surface a-bgt binding when 
compared to untreated control cultures (De Koninck and Cooper, 1995). This increase in 
a-bgt binding after KCI treatment is correlated to a significant increase in the level of 
expression of a l  subunit mRNA in SCG neurones developing in culture, with little 
effect on the other nAChR transcripts expressed in SCG neurones.
De Koninck and Cooper (1995) also investigated the effect of protein kinase activity 
on nAChR subunit expression. When activators or inhibitors of PKA, PKC or tyrosine 
kinase were applied, no change in the level of expression of nAChR subunit transcripts 
was observed. The proposed mechanism of KCl-evoked upregulation of a l  subunit
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mRNA expression through Ca2+ influx, was concluded to be via L-type VOCC and the 
result of a CaM-kinase II pathway, due to inhibition of upregulation in the presence of 
L-type VOCC blockers and CaM-kinase II inhibitors (De Koninck and Cooper, 1995). 
KCI depolarisation therefore elicits an increase in transcription resulting in an increase 
of the a l  subunit mRNA, evoking an eventual upregulation of surface a7* nAChR 
identified by [125I]-a-bgt binding. In contrast to KCI treatment, chronic nicotine (1 mM) 
failed to upregulate transcription of either a3 or a7  subunit mRNAs in the SH-SY5Y 
cell line (Peng et al, 1997).
In this section, the level of nAChR subunit RNA expression was examined after 
chronic drug treatment to determine whether the results reported by De Koninck and 
Cooper (1995) were observed in the present study after KCI treatment applied to SH- 
SY5Y cells. This is in contrast to the expected lack of change of a7  RNA expression 
after chronic nicotine treatment. This investigation aimed to attempt whether increases 
in binding of [125I]-a-bgt and [3H]-epibatidine to nAChR after chronic drug treatment 
are accompanied by increases in the level of expression o f corresponding nAChR 
subunit genes. The experiments described in this section involve chronically treating 
confluent SH-SY5Y cells for 4 days with nicotine (10 pM), DMAC (10 pM) or KCI (20 
mM) before isolating either total or poly (A)+ RNA for Northern blot and RT-PCR 
analysis.
3.5.1. Aims:
This section aims to investigate whether chronic exposure, for 4 days, with nicotine, 
DMAC or a depolarising concentration of KCI induce changes in the expression of a3 
and a l  subunit RNA isolated from SH-SY5Y cell cultures.
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3.6. Methods.
3.6.1. Drugs and reagents:
Molecular biological grade chemicals were purchased from BDH chemicals (Poole, 
Dorset, U.K.), Sigma Chemical Company Ltd. (Poole, Dorset, U.K.) or Fisons 
Scientific Equipment (Leicestershire, U.K.). Agarose was supplied by Biogene Ltd. 
(Kimbolton, Cambridgeshire, U.K.) and ethidium bromide and diethyl pyrocarbonate 
(DEPC) by Sigma. Restriction endonucleases were supplied by NEB (Hitchin, 
Hertfordshire, U.K.). T4 DNA ligase was from Gibco BRL (Renfrewshire, Scotland).
The reagents for RT-PCR and the preparation of total cellular RNA at Organon 
Laboratories were supplied by Promega. RNase treated solutions used in the Northern 
analysis protocols performed in Bath were from Helana Biosciences (Eppendorf) and 
the DIG-labelling and hybridisation biochemicals were from Roch Boehringer. The 
dynabeads used to isolate poly (A)+ RNA were from Dynal. The human a3 and a l  
nAChR cDNAs were cloned by Organon Laboratories. G3PDH was purchased from 
Clontech.
3.6.2. Preparation of probes for RT-PCR and Northern Analysis (A):
3.6.2.1. Design and synthesis of primers for PCR:
The primer sequences for a3, a l  and cyclophilin amplification were replicas of those 
used in earlier reports (Burnet et al., 1994; Gopalakrishnan et al., 1995; Gorbounova et 
al., 1998). The primer sequences (human versions), positions and the PCR product sizes 
are shown in Table 3.3.
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Table 3.3. Primer sequences used for PCR amplification of the cc3 and a7 nAChR subunits 
and cyclophilin used in the present study.
Subunit Sequence Position Size (bp)










cyclophilin 5 ’-GACAAGGTCCCAAAGACAGC-3 ’ 




3.6.2.2. Calculation o f annealing temperature for primers:
Predicted melting point temperatures (Tm) of primers were estimated using either the 
following equations (Lowe e ta l., 1990):
Tm = 4(GC) + 2(AT) or Tm = 62.3 + 0.41(G+C%)-500/amplified length
3.6.2.3. Amplification and purification o f a3 , a7  and cyclophilin PCR  
products:
The primers used for a3, a7  and cyclophilin detection were in a lyophilised form and 
were resuspended to 60 pmoles/fil for the PCR reaction (Table 3.4) performed in a 
Perkin-Elmer, Model PTC-100™ (from MJ Research, Inc) thermo-cycling machine 
with the conditions shown in Table 3.5.
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Table 3.4. Reagents used in the PCR reaction.
Reagent Volume
10 x buffer 5 pi
dNTP (10 mM of each dNTP) 1 pi
Primer 1 1 pi
Primer 2 1 pi
DNA (whole brain cDNA) 1 pi
Amplitaq gold (1 unit/pl) 0.5 pi
dH20 40.5 pi
Table 3.5. The conditions used in the PCR reaction.
Conditions
Denature; 94°C 10 min 
Denature; 94°C 30 s }
Anneal; 60/52°C 30 s }x 30 cycles 
Extend; 68°C 1 min }
Extend; 68°C 10 min
PCR products were analysed by agarose gel electrophoresis: 10 pi DNA samples 
were loaded with 0.25 vol. loading dye (15% Ficol, 0.25% bromophenol-blue, 0.25% 
xylene cyanol) onto a 1.5% agarose DNA gel made with 1 x Tris acetate buffer (TAE; 
0.04M Tris-acetate, 0.001 mM EDTA, pH 7.6) containing 0.5 pg/ml ethidium bromide. 
DNA products were viewed under UV transillumination before being photographed 
using Kodak film. The sizes of the PCR products were estimated from the migration of 
a DNA size marker run concurrently (100-bp DNA ladder; GibcoBRL Life
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Technologies, U.K.). The a3, a7  and cyclophilin DNA products were visible as single 
bands at 286, 256 and 235 bp.
The Geneclean® kit (Bio 101) spin method was used for the purification of the DNA 
bands excised from the TAE agarose gel. In brief GC spin glassmilk (400 pi) was added 
to a spin filter before adding the a3, a7  or cyclophilin bands excised from the DNA gel. 
The contents were heated to 55°C for 5 min in order to melt the gel and inverted every 
minute to prevent the matrix from settling. After incubation, the supernatant was 
collected by microcentrifugation into a clean tube. The filter was washed twice with GC 
spin new wash (500 pi) and microcentrifuged for 30 s after each wash. A final 
centrifugation of 1 min was used to dry the pellet. The spin filter was transferred to a 
fresh tube and nuclease free water (20 pi) was added to resuspend the glassmilk by 
gently vortexing for 1-2 s.
3.6.2.4. Ligation of DNA:
The purified DNA PCR product (10 pi) was incubated at 68°C for 20 min with 
amplitaq gold (0.5 pi), 10 x PCR buffer (lp l) and dNTPs to ensure that the PCR product 
had ‘A’ overhangs to ensure that ligation would be successful. The fresh PCR product 
(6 pi; approximately 10 ng) was mixed with 10 x ligation buffer (1 pi), PCR 2.1 vector 
(2 pi; 25ng/pl; Invitrogen) and T4 DNase ligase (1 pi; consisting of 50 mM Tris-HCl 
(pH 7.5), 10 mM MgCh, 10 mM dithiothreitol, 1 mM ATP, 25 pg/ml BSA) and 
incubated at 14°C overnight.
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3.6.2.5. Transformation o f competent cells:
An appropriate number of vials of One shot™ bacteria (Invitrogen) were thawed on 
ice and (3-mercaptoethanol (2 pi; 0.5 M) was added into each vial. The cells were mixed 
by stirring gently with a pipette tip and 2 pi of the prechilled ligated DNA reaction 
mixture was added into the cells and stirred with the pipette tip to mix before incubating 
on ice for 30 min. Cells were heat-shocked for exactly 30 s at 42°C and then chilled on 
ice for 2 min. Luria-Bertani (LB) medium (250 pi; 10 g bacto-tryptone, 5 g yeast 
extract, 5 g NaCl dissolved and made up to 1 litre in ddt^O) was added to each vial and 
the cells incubated at 37°C in a shaker for 30 min. The cells were then plated onto a 
prewarmed LB agar plate (LB substituted with 15 g agar) containing 50 pg/ml 
ampicillin and X-Gal. After overnight incubation at 37°C, the plates were placed at 4°C 
for 2-3 h for colour development. Individual white colonies, indicating the presence of 
the inserted DNA, were transferred, using sterile techniques, to 1.5 ml of LB medium 
containing 50 pg/ml ampicillin and incubated in a shaking incubator at 37°C overnight.
3.6.2.6. Isolation o f plasmid DNA using the Promega W izard™  Plus 
miniprep method:
After overnight growth at 37°C, an aliquot of the culture (1.5 ml) was transferred to a 
fresh microcentrifuge tube and pelleted by centrifugation (10,000 x g; 1 min). The pellet 
was resuspended by vortexing in 250 pi of cell resuspension solution (50 mM Tris-HCl 
(pH 8.0), 10 mM EDTA, 100 pM RNase A) before lysing the cells by the addition of 
250 pi cell lysis solution (0.2 M NaOH, 1% (w/v) SDS). The contents were mixed by 
inversion. After complete lysis, 350 pi neutralisation solution (3 M potassium acetate, 
11.5% (v/v) glacial acetic acid, pH 4.6) was added. Following mixing by inversion, the
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bacterial lysate was centrifuged at 14,000 x g for 10 min at room temperature. A 
Wizard™ Plus miniprep column (Promega) was prepared by attaching a vacuum 
adapter with Luer-Lok® extension fitting to one port of the manifold. Spin columns 
were attached to the vacuum adapter and the cleared bacterial lysate was transferred into 
the spin column by decanting the liquid. Vacuum pressure was applied to draw the 
liquid though the column. Wash solution (750pl; 1 M NaCl, 50 mM 3-[V- 
morpholino]propanesulfonic acid (MOPS; pH 7.0), 15% (v/v) ethanol) was added to the 
column and passed through by vacuum. The washing procedure was repeated using 250 
pi wash solution. After removal of the wash solution by vacuum, the spin column was 
removed and placed into a clean microcentrifuge tube, before centrifugation at 14,000 x 
g for 1 min to remove any remaining wash solution. The column was transferred to a 
clean microcentrifuge tube and nuclease free water (100 pi) added to the spin column to 
elute the plasmid DNA by centrifugation (14,000 x g; 1 min).
3.6.2.7. Restriction endonuclease digestion o f DNA
DNA samples (10 pi) were digested with the restriction enzyme EcoRl (1 pi) in 10 x 
reaction buffer (2 pi; consisting of 50 mM NaCl, 100 mM Tris-HCl, 10 mM MgCh, 
0.025% Triton X-100 (pH 7.5)). Sterile water was added to a volume of 20 pi and the 
reaction incubated at 37°C for 1 h. Samples (20 pi with 3 pi loading buffer) were run on 
a 1.5% agarose gel to check for the presence of the appropriate insert.
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3.6.3. SH-SY5Y cell culture:
SH-SY5Y cells were grown and maintained in 75 cm2 flasks containing 20 ml of 
supplemented medium and maintained at 37°C in 5% C02/humidified air (see section 
3.3.2 for maintenance of SH-SY5Y cell cultures). Cultures for total RNA preparation 
were subcultured in 6 well plates at a seeding density of 105 cells/ml (adapted from 
Vaughan et al., 1993). Once confluent, SH-SY5Y cultures were treated chronically for 4 
days with either nicotinic agonists (nicotine; 10 pM and DMAC; 10 pM) or KCI (20 
mM) as described in section 2.4.2. Human embryonic kidney (HEK) cells were also 
used at Organon as a comparison for the level of expression of the a7  or a7/5-HT3 
subunit RNAs compared to the expression of a l  subunit RNA isolated from SH-SY5Y 
cells. The HEK cells had been transfected and the total RNA isolated by Organon (prior 
to 1998).
3.6.4. Total RNA preparation at Organon Laboratories:
Total RNA was prepared using the SV-Total RNA kit from Promega. Total cellular 
RNA was isolated from confluent SH-SY5Y cells chronically treated with or without 
drugs for 4 days. SH-SY5Y cell cultures were washed with warm PBS before 
trypsinising the cells. The cell suspension was placed into a 50 ml tube containing SH- 
SY5Y medium and centrifuged (300 x g, 5 min). The pellet was resuspended in 25 ml 
of ice cold sterile PBS solution before re-centrifuging. The PBS was carefully removed 
before adding SV RNA lysis buffer (175 pi; 4 M GTC, 0.01 M Tris (pH 7.5), 0.97% p- 
mercaptoethanol). The samples were mixed well by vortexing before being transferred 
to a microcentrifuge tube. SV RNA dilution buffer (350 pi) was added to the samples, 
the tube capped and inverted several times to ensure that the solution was well mixed.
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Samples were incubated at 70°C for 3 min before being centrifuged (14,000 x g; 10 min 
at room temperature). The resulting clear lysate was pipetted into a fresh centrifuge, 
ethanol (200 pi; 95%) added and mixed with a pipette 3-4 times.
Samples were transferred to separate spin column assemblies. After centrifugation 
(14,000 x g, 1 min), SV RNA wash solution (600 pi; 60 mM potassium acetate, 10 mM 
Tris-HCl and 60% ethanol (95%, RNase free)) was added to the spin column assembly 
before an identical centrifugation process. Freshly prepared DNase incubation mix (50 
pi; 40 pi yellow core buffer (0.0225 M Tris (pH 7.5), 1.125 M NaCl, 0.0025% yellow 
dye (w/v)), 5 pi of 0.09 M MgCb and 5 pi of DNase) was applied to each sample, 
ensuring that the whole of the filter was covered by the mixture. After a 15 min 
incubation at 20°C DNase stop solution (200 pi; 2 M guanidine isothiocyanate, 4 mM 
Tris-HCl (pH 7.5) and 57% ethanol (95%, RNase free)) was added evenly over the 
filters before centrifugation (14,000 x g, 1 min). Two washing steps followed, the first 
was with SV RNA wash solution in ethanol (600 pi), centrifuged at 14,000 x g for 1 
min, followed by a second wash of SV RNA wash solution in ethanol (250 pi) and 
centrifuged at 14,000 x g for 2 min. The cap was removed from the spin basket by 
twisting and the spin basket was placed into an elution tube, each spin basket had its 
own elution tube. Nuclease free water (100 pi) was added to completely cover the 
surface of the membrane to elute the sample RNA. The spin basket assemblies were 
centrifuged (14,000 x g, 1 min) to spin the RNA down from the filter. At this point the 
spin basket was removed and discarded and the elution tubes capped and stored at - 
80°C until use.
Chapter 3. 149
3.6.4.1. Concentration o f RNA by ethanol precipitation:
RNA samples were thawed on ice before concentrating the RNA by precipitation 
with 0.1 volumes of RNase free sodium acetate (3 M) and 2.5 volumes of absolute 
ethanol at -20°C overnight, centrifuged at high speed (14,000 x g) for 30 min. The pellet 
was washed with 70% ethanol, centrifuged (14,000 x g; 10 min), and allowed to air dry 
after removal of most of the ethanol, before resuspending in sterile RNase free water.
3.6.4.2. Estimation o f concentration o f RNA:
Total cellular RNA samples isolated from SH-SY5Y cells were diluted 1:100 in 
DEPC-treated sterile water. Spectrophotometer (Perkin Elmer UV/VIS Lambda 11) 
readings were obtained at absorbencies A260 and A2 8 0 . The concentration of RNA was 
calculated using the equation:
RNA = A26o x 40 x dilution factor
Standards = 1 O.D. unit for RNA corresponds to 40 |ug/ml
The ratio (A2 60/A2 8 0) provides an estimation of the purity of the RNA preparation. A 
ratio of 2.0 indicates a high purity of RNA. A ratio greater than 2.0 indicates 
contamination with DNA, while a lower figure indicates protein contamination.
3.6.5. RT-PCR:
Total RNA was isolated and precipitated as described in sections 3.6.4 and 3.6.4.1 
and resuspended to give the same concentration in each tube. The reagents used for RT- 
PCR are shown in Table 3.6. All RT-PCR reagents were supplied by Promega. RT-PCR 
reactions for each of the drug and untreated control RNA samples were performed using
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specific primers for human a3, a7  nAChR subunits and cyclophilin (see section 
3.6.2.1); controls were performed in parallel with nuclease free water substituting the 
sample RNA.
Table 3.6. Reagents and their volumes used in the RT-PCR reaction.
Reagent Volume
Nuclease free water 32 pi
AMV/Tfl 5 x reaction buffer 10 pi
dNTP mixture (10 mM each of dATP, dCTP, dGTP and dTTP) 1 pi
Downstream primer 1 pi
Upstream primer 1 pi
MgSC>4, 25 mM 2 pi
AMV reverse transcriptase 1 pi
Tfl DNA polymerase 1 pi
RNA sample (or RNase free H20  for control) 1 pi
Thermocycling conditions included an initial reverse transcription step of 45 min at 
48°C followed by denaturation of cDNA for 2 min at 94°C. This was followed by 30 s 
at 94°C, primers hybridise to the template at previously calculated annealing 
temperatures (60°C for a3 and cyclophilin; 52°C for a7, see section 3.6.2.2) for 30 s 
and then the strands were elongated at 68°C for 1 min, these three steps were repeated 
for 40 cycles. Finally a 10 min step at 68°C was included to ensure the PCR fragments 
were fully elongated and that no single stranded products remained in the reaction tube. 
Following thermocycling, 10 pi of reaction product was run on a 1.5% agarose 
electrophoretic gel for analysis by UV illumination.
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3.6.6. Gel electrophoresis:
Total cellular RNA (5 pl/10 |ug) or poly (A)+RNA (5pl) samples were made up to 20 
pi with loading dye (48% formamide, 10.7% 10 x 2-[7V-morpholino]ethanesulphonic 
acid (MESA): 200 mM MOPS, 50 mM sodium acetate, 10 mM EDTA in DEPC water; 
pH 7, kept at 4°C in the dark, 17.3% formaldehyde (37% stock), 17.3% DEPC treated 
water, 6.7% glycerol (80%) and 0.01% bromophenol blue) and incubated at 65°C for 15 
min to allow for denaturation of the RNA. After incubation, the samples were 
centrifuged in a microfuge before placing on ice for 2 min. Ethidium bromide (2 pi; 1 
mg/ml) was added to each sample before loading onto a 1% agarose gel using RNAse- 
ffee filter pipette tips and running in 1 x MESA (diluted with DEPC treated water) as 
the running buffer. The samples were electrophoresed at 150 V until the bromophenol 
blue dye front migrated approximately 75% down the gel. At this point the gel was 
photographed using UV light on a transilluminator prior to sample transfer onto a nylon 
membrane.
3.6.7. Capillary transfer to the membrane blot:
RNA was transferred by a downward capillary transfer method from the gel to a 
Nytran membrane (modified from Chomczynski, 1992); the downward transfer 
apparatus was assembled as depicted in Figure 3.11. After transfer was complete 
(usually overnight), the membrane was exposed briefly to UV illumination to crosslink 











Figure 3.11. Schematic representation o f a downward capillary transfer apparatus. (Modified from 
Chomczynski, 1992).
3.6.8. Labelling the probes, hybridisation and m em brane washes:
Hybridisation (Northern Max™) was performed using 32P-dCTP-labelled human a3 
or a l  with cyclophilin purified DNA products (obtained as described in section 3.6.2). 
Human cyclophilin cDNA was used as a heterologous probe to determine the amount of 
human cyclophilin RNA expressed in the SH-SY5Y cell line, enabling normalization of 
the a3 and a l  subunit transcript signals within each lane. The following reagents were 
used to label the a3, a l  and cyclophilin DNAs: DNA (3 pi) and DEPC-treated water 
(10 pi) were initially boiled for 3 min, microfuged briefly before the addition of high 
prime (4 pi) and dCTP (32P) (3 pi; 10 pCi/pl). Samples were then placed at 37°C for 15 
min to ensure denaturation of the DNA. Either P-dCTP-labelled a3, a l  and 
cyclophilin probes were used to probe the SH-SY5Y sample RNA transferred onto the
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nylon membrane. This involves a prehybridisation step during which the membrane is 
incubated at 42°C for 2 h with the labelled DNA probes diluted in preheated ZIP-Hyb 
solution (10 ml/100 cm2) in hybridisation tubes in a roller oven. Membranes were 
washed initially with low and then high stringency wash solutions at room temperature 
and 42°C respectively to remove any unbound 32P-dCTP from the membrane. On 
removal of the high stringency wash solution the membranes were wrapped in plastic 
wrap to prevent drying out and exposed to Kodak film for autoradiography at -80°C for 
varying lengths of time.
3.6.9. Analysis of data:
Scanned images were quantified using an Arcus II scanner from AGFA and Zero- 
Dscan version 1 image software from Scanalytics, Inc to analyse band densities from 
the autoradiographs.
3.7. Preparation of probes for Northern analysis (B):
3.7.1. Subcloning DNA fragments:
Specific fragments (300-500 bp) of interest for a3 and a7 cDNAs (positions 1180 to 
1449 and 505 to 728 respectively), were cloned into the vector PCR 2.1 (Invitrogen), 
sequenced and used as putative specific nAChR subunit fragments to be labelled with 
digoxigenin (DIG). Initially the vector was linearised upstream of the a3 and a l  
sequences by restriction digest allowing the creation of run-off transcripts of uniform 
length. The DNA was purified by phenol/chloroform extraction and ethanol 
precipitation as follows. Phenol (Tris treated, pH 8), chloroform and isoamyl alcohol
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were added to the resuspended DNA in the ratio 25:24:1 in a sterile microfuge tube. The 
contents were shaken to form a milky suspension and then centrifuged for 1 min. The 
top aqueous layer was transferred to a clean microfuge tube and an equal volume of 
chloroform added before re-centrifugation. The top aqueous layer was again transferred 
to a sterile microfuge tube before adding 0.1 volumes of sodium acetate (3 M; pH 5.3) 
and 2 volumes of ethanol. The contents of the tube were left at 4°C overnight to allow 
precipitation of the DNA. The solution was then spun at 13,000 rpm for 1 h at 4 °C 
before washing the pellet in 75% ethanol for 1 h at 13,000 rpm at 4°C. The DNA pellet 
was air dried before resuspending in DEPC-treated water.
3.7.2. Labelling partial a 3 , a 7 , and G3PDH cDNA sequences with digoxigenin  
(DIG) labelled UTP mix:
The labelling reaction was set up as follows: 1 pg of the purified DNA template, 2 pi 
NTP labelling mix (10 x), 2 pi 10 x transcription buffer, 0.5 pi RNase inhibitor (40 
units/pl), DEPC-treated water to 18 pi, 2 pi T7 polymerase (20 units/ pi) (all reagents 
Roche Boehringer Mannheim; see also Table 3.7). Following mixing and brief 
centrifugation, this reaction was allowed to proceed at 37°C for 2 h before the addition 
of 2 pi RNase free, DNase I (10 units/pl) for a further incubation of 15 min at 37°C to 
remove the DNA template. EDTA (2 pi, 200 mM; pH8) was added to terminate the 
reaction. The DIG-labelled RNA probes were stored at -20°C before quantitation with a 
DIG-labelled control.
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Table 3.7. Reagents for DIG-labelling RNA.
Reagent Components
NTP labelling mix 10 mM ATP, 10 mM CTP, 10 mM GTP, 6.5 mM UTP, 3.5 
mM DIG UTP; in Tris-HCl, pH 7.5
10 x transcription buffer 400 mM Tris-HCl (pH 8), 60 mM MgCl2, 100 mM 
dithioerythritol, 20 mM spermidine, 100 mM NaCl
3.7.3. Estimation o f the yield o f DIG-labelled DNA:
The yield of DIG-labelled a3, a7  and G3PDH RNA was estimated by comparison 
with serial dilutions of an appropriate labelled standard control RNA (supplied by 
Roche Boehringer Mannheim) in a spot test on nylon membranes with a dilution series 
of the DIG-labelled sample RNA. The standard labelled control RNA (2 pi) was mixed 
with DEPC-treated water (38 pi; final concentration of 2 0  ng/pl) before performing 
serial dilutions to give concentrations from 1 ng/pl to 0.01 pg/pl. The a3, a7  and 
G3PDH DIG-labelled probes were serially diluted in an identical manner as to the 
standard DIG-labelled control.
Highly diluted solutions of RNA in water are not very stable, therefore immediately 
after the dilutions were made in RNase free water, 1 pi aliquots of each control dilution 
were spotted onto a piece of dry positively charged nylon membrane (Roche Boehringer 
Mannheim). The experimental RNA dilutions were spotted on a second row below the 
corresponding dilutions of control diluted spots (Figure 3.12). The nucleic acids were 
fixed to the membrane by UV cross-linking for 5 min. The membrane was briefly 
washed in washing buffer (maleic acid buffer with 0.3% (v/v) Tween®20; see Table 3.9) 
before incubation in blocking buffer for 30 min at room temperature. Anti-DIG-alkaline 
phosphatase antibody was diluted 1 :1 0 , 0 0 0  in blocking buffer and the membrane was
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incubated for a further 30 min in this diluted antibody solution at room temperature. The 
membrane was subsequently washed twice, 15 min per wash, in washing buffer at room 
temperature before equilibration of membrane in detection buffer for 2 min.
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Figure 3.12. Estimation o f the yield o f DIG- 
labelled DNA. Dilutions of the labelled control 
RNA with exact concentrations of 1, 0.1 and 0.01 
ng/pl are shown with the newly labelled a3, a7 and 
G3PDH DNA diluted in identical serial dilutions to 
the control were spotted on, fixed to, and directly 
detected on a nylon membrane, with 
chemiluminescent detection.
A  1:100 dilution of disodium 3-(4-methoxyspiro ( l^ -d io x e tan e ^ ^ ’- ^ ’-chloro) 
tricyclo [3.3.1.13,7] decan}-4-yl) phenyl phosphate (CSPD®; 25 mM) in detection buffer 
was carried out before applying 0.5 ml of this chemi luminescent substrate dropwise on 
top of the membrane scattering the drops over the surface of the membrane. The
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membrane at this stage has been placed between two sheets of acetate (plastic). The top 
sheet of acetate was wiped with a damp tissue to remove any air bubbles present 
between the sheet and to create a liquid seal. The filter was incubated at room 
temperature for 5 min before sealing all sides of the acetate using a heat sealer. To 
shorten exposure times the filter was incubated at 37°C for 15 min, after which the 
membrane was exposed to X-ray film for 2 h detection of the chemiluminescent signal. 
Figure 3.12 shows the estimation of yield of a3, a7  and G3PDH DIG-labelled RNA 
probes.
3.8. Preparation of total RNA isolated from SH-SY5Y cells at Bath:
SH-SY5Y cells were cultured and chronically treated with nicotine, DMAC or KC1 
in 175 cm2 flasks exactly as described for SH-SY5Y cells cultured in 75 cm2 in section
3.3.3. After 4 days in the presence of drugs, cultures were washed and total RNA was 
isolated using a TRIZOL reagent method of extraction (Life Technologies). In brief, 
cells were directly lysed in a culture flask by the addition of TRIZOL reagent (1 ml per 
1 0  cm2) and passing the cell lysate through a pipette several times. The samples were 
incubated for 5 min at room temperature to permit the complete dissociation of 
nucleoprotein complexes. Chloroform (0.2 ml per 1 ml of TRIZOL reagent) was added 
and the tubes shaken vigorously for 15 s. The samples were incubated for a further 3 
min at room temperature before centrifuging at 12,000 x g for 10 min at 4°C. The upper 
aqueous phase, containing the RNA, was transferred to a Corex tube and the RNA 
precipitated by the addition of isopropyl alcohol (5 ml per 10 ml TRIZOL used for the 
initial homogenisation). Samples were incubated at room temperature for 1 0  min and 
centrifuged at 12,000 x g for 10 min at 4°C. The RNA pellet was resuspended in ethanol
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(75%: 10 ml per 10 ml TRIZOL initially used). Samples were centrifuged at 7,500 x g 
for 5 min at 4°C. The RNA pellet was vacuum dried for 5 min and dissolved in 0.5% 
(w/v) SDS by passing through a pipette and incubating for 10 min at 55-60°C. RNA 
was quantified as described in section 3.6.4.2.
3.9. Preparation of poly (A)+ RNA:
Poly (A)+ RNA was subsequently isolated from total RNA using Dynabeads® Oligo 
(dT)25 magnetic beads (Dynal), 2.8 pm in diameter, with a 25 nucleotide long chain of 
deoxythymidylate attached covalently to the bead surface via a 5’ linker group. Beads 
were stored in PBS containing 0.02% sodium azide. An aliquot of bead suspension (0.2 
ml; 1 mg) was pipetted into a 1.5 ml microfuge tube and placed into a Dynal MPC®-E 
magnetic particle concentrator and the supernatant removed. The beads were washed by 
the addition of 100 pi 2 x binding buffer (20 mM Tris-HCl, pH 7.5, 1 M LiCl, 2 mM 
EDTA) followed by resuspension in 100 pi 2 x binding buffer. Total RNA (200 fig) 
samples were dissolved in 100 pi DEPC-treated water, incubated for 2 min at 65°C to 
disrupt the secondary structure before adding to the washed beads. The poly (A)+ RNA 
was allowed to anneal for 5 min on a rotating platform at room temperature before 
placing on the magnetic stand to allow separation and removal of the supernatant. After 
washing the beads twice with 200 pi washing buffer (10 mM Tris-HCl, pH 7.5, 0.15 M 
LiCl, 1 mM EDTA), they were resuspended in 30 pi elution buffer (10 mM Tris, pH 
7.5) before incubating at 65°C for 2 min. Eluted poly (A)+ RNA was extracted 
immediately after separation from the beads and used directly for Northern blot 
analysis.
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3.10. Denaturing formaldehyde gel electrophoresis:
Agarose (1 g) was added to 124 ml DEPC-treated water in a conical flask and heated 
in a microwave to melt the agarose. Once cooled to 55°C, 15 ml 10 x MESA and 11 ml 
37% formaldehyde were added, swirled to mix and the gel poured immediately into a 
Perspex gel rig, and left to set for approximately 45 min. All apparatus was pre-treated 
with 1% hydrogen peroxide to denature RNases. The gel rig was placed in a horizontal 
electrophoresis tank and 1 x MESA was added until the gel was submerged. Samples 
were prepared by mixing poly (A)+, or total RNA with 10 pi freshly prepared 
formaldehyde gel loading buffer and the DIG-labelled RNA molecular weight marker 
was prepared by the addition of 16 pi loading buffer to 4 pi marker. All samples were 
incubated at 65°C for 15min and chilled on ice after a brief centrifugation. Samples 
were loaded onto the gel and the gel was run at 80 V for 4 h. The cast and gel were 
transferred to a plastic box and washed with 20 x SSC to remove formaldehyde. The 
composition of solutions used for Northern blot analysis are shown in Table 3.8.
Table 3.8. Composition of Northern Blot solutions. *RNase-Jree solutions were prepared 
with 0.1% DEPC treated water.
Solution Components
10 x MESA* 200 mM MOPS, 50 mM sodium acetate, 10 mM EDTA; pH 7
Electrophoresis buffer* 1 x MESA
Formaldehyde gel loading 
buffer*
7.2 ml Deionised formamide, 1.6 ml 10 x MESA, 2.6 ml 
deionised formaldehyde, 2.6 ml water, 1 ml 80% glycerol, 
0.01% (v/v) bromophenol blue
Formaldehyde Commercially available as a 37% solution (12.3 M) in water
20 x SSC* 3 M NaCl, 300 mM sodium citrate; pH 7
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3.11. Northern transfer:
The RNA was blotted from the gel onto a piece of Boehringer positively charged 
nylon membrane by capillary transfer overnight at room temperature. RNA was then 
cross-linked to the membrane by UV illumination for 5 min.
3.12. Hybridisation and detection of Northern blot:
The composition of solutions used for hybridisation and detection are shown in Table 
3.9.
Table 3.9. Composition of solutions used for hybridisation and detection. *RNase-free 




Commercially available hybridisation buffer granules 
reconstituted in water (Boehringer Mannheim)
2 x Wash solution* 2 x SSC, containing 0.1% (w/v) SDS
0.5% x Wash solution* 0.5 x SSC, containing 0.1% (w/v) SDS
Maleic acid buffer* 100 mM maleic acid, 150 mM NaCl; pH 7.5
Washing buffer* 100 mM maleic acid, 150 mM NaCl; pH 7.5; 0.3% 
Tween 20
Blocking solution* Commercially available solution diluted 1:10 in maleic 
acid buffer
Detection Buffer* 100 mM tris-HCl, 100 mM NaCl; pH 9.5
TE buffer 10 mM Tris, 1 mM EDTA; pH8
Following removal of the marker lane from the membrane, the blot was placed in a 
hybridisation bottle and incubated with 20 ml prehybridisation solution (DIG Easy Hyb, 
Roche Boehringer Mannheim) at 68°C for 1 h. The DIG-labelled probe was meanwhile
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heat-denatured in a boiling water bath for 10 min and diluted in 5 ml prehybridisation 
solution at a concentration of 100 ng/ml (hybridisation buffer). Prehybridisation buffer 
was discarded and the blot was incubated at 68°C overnight with hybridisation buffer 
(DIG Easy Hyb) and the cDNA probe (final concentration of 100 ng/hybridisation 
buffer volume). Following hybridisation the blot was washed twice, 15 min per wash, in 
2 x wash solution at room temperature followed by 2 washes in 0.5 x wash solution at 
68°C. All further steps were carried out at room temperature unless stated otherwise. 
The marker lane was included in all further steps.
The membrane was equilibrated in washing buffer for 1 min (maleic acid buffer 
containing 0.3% (v/v) Tween 20). This was discarded and the membrane was blocked 
by gentle agitation in blocking solution for 1 h. The blot was incubated with gentle 
agitation for 30 min with anti-Digoxigenin antibody (diluted 1:10,000 in blocking 
solution). The antibody solution was discarded and the membrane gently washed twice 
in washing buffer. The membrane was equilibrated in detection buffer for 2 min. 
Meanwhile CSPD® was diluted 1:100 in detection buffer. The membrane was placed 
between 2 sheets of acetate and 0.5 ml chemiluminescent substrate was scattered 
dropwise on the surface. The top sheet was lowered and wiped with a damp tissue to 
remove air bubbles and the bag was sealed and incubated at room temperature for 5 
min. To decrease time taken for the chemiluminescent reaction to reach equilibrium, the 
membrane was incubated at 37°C for 15 min before exposure to X-ray film (Roche 
Boehringer Mannheim) for approximately 20 min. Sometimes the film had to be left 
overnight for detection of a signal.
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3.13. Results.
RT-PCR and Northern blot hybridisation analysis were used to determine whether 
the increased levels of nicotinic binding sites found after chronic nicotine, DMAC or 
KC1 treatment described in Section 1 were due to increased transcription of nAChR 
subunit genes resulting in an increase in the level of expression of a3 and a l  subunit 
RNA.
The SH-SY5Y cell line was used to investigate the expression of the a3 and a l  
nAChR subunits. Total RNA samples isolated from SH-SY5Y cells were used in an 
RT-PCR protocol to amplify both the a3 and a l  transcript signals and hence confirm 
their expression. RT-PCR analysis of a3, a l,  and the internal standard housekeeping 
gene cyclophilin, expressed in total cellular RNA samples isolated from control and 
drug treated SH-SY5Y cells with nicotine (10 pM), DMAC (10 pM) or KC1 
depolarisation (20 mM) are shown in Figure 3.13. The a3, a l  and cyclophilin RT-PCR 
products were visible as single bands at 286, 256 and 235 bp as indicated in Figure 3.13.
One of the disadvantages of RT-PCR, although sensitive, it cannot be used as a direct 
quantitative method for analysing significant differences in the level of expression of 
different transcripts. This is a major drawback of exponential amplification, in that 
small sample-to-sample differences in amplification potentially translate to huge 
differences in the product yield. Therefore the a3 and a l  subunit RNA signals 
amplified from SH-SY5Y cells chronically treated with drugs could not be directly 
quantitated to their corresponding control untreated RNA samples, or normalised to the 
internal standard housekeeping gene due to the putative exponential amplification 
process that occurs in the process of RT-PCR.
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Figure 3.13. Reverse transcriptase PCR (RT- 
PCR) analysis o f a3, a7 and cyclophilin 
expression. Total RNA was extracted from 
_̂a7 confluent SH-SY5Y cells after chronic treatment
with either DMAC (10 /jM; lanes 3 and 4), nicotine 
(10 juM; lanes 5 and 6) or KCl (20 mM; lanes 7 and 
8) for 4 days. All control untreated (lanes 1 and 2)
* -  a 3
and drug treated RNA used in the RT-PCR protocol 
also had RT-PCR performed without reverse 
transcriptase added to the reaction mix to test for 
contaminating genomic DNA template (lanes 2, 4, 6 
and 8). Water controls, with no RNA added are also 
600 bp cyclophilin  included. Samples were run on a 1.5% agarose gel
and viewed by UV illumination.
It was then decided to investigate by quantitative evaluation, the level of expression 
of the a3 and a l  nAChR subunit RNA levels expressed in control untreated and chronic 
drug treated SH-SY5Y cells. Northern blot hybridisation analysis was performed using 
total RNA isolated form control and drug treated SH-SY5Y cells. This technique 
remains the standard for detection and quantitation of RNA levels, and permits a direct 
relative comparison of message abundance between samples on a single nylon 
membrane. Initial experiments performed at Organon Laboratories using total RNA 
produced faint or no bands when probed for the a l  transcript (Figure 3.16c). Figure 
3.14 shows samples of total RNA run on a 1% agarose gel (a) before and (b) after 
transfer to a membrane, clearly showing in (b) that the samples have been successfully 
transferred.
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Figure 3.14. A representative RNA agarose gel. Total RNA (10 jug) isolated from SH- 
SY5Y cells (lanes 2 and 4), HEK cells (lanes 5 and 9) or from HEK cells containing the 
a7/5-HT_i chimera (lanes 3, 6-8 and 10) were run on 1% agarose gel and visualised by UV 
illumination. Panel (a) shows two distinct bands in each lane of the total RNA samples, this 
corresponds to rRNA. Panel (b) was viewed under UV illumination after transfer to a nylon 
membrane.
Figure 3.15 shows the corresponding autoradiographs for Figure 3.14 after the 
membranes were probed with (a) a3 and cyclophilin or (b) a l  and cyclophilin with a 6 
or 16 day exposure respectively. In panel (a) lanes 2 and 4 contain total RNA samples 
isolated from control SH-SY5Y cells and the a3 transcript can easily be observed (band 
at 3.6 kDa). The other lanes are total RNA prepared from either HEK cells (lanes 5, 9) 
or HEK cells containing either a l  (lanes 6-8) or the a7/5-HT3 chimera (lanes 3 and 10) 
and do not express the a3 nAChR subunit.
b 2 3 4 5  6 7 8 9  10
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3). HEK + a7/5-HT3 chimera
4). SH-SY5Y (27.1.98)
5). HEK 27.1.98
6). HEK + a? 1.5
7). HEK+ ct7 2.25
8). HEK+ a7 2.75
9). HEK (4.12 97)





Figure 3.15. Typical autoradiographs obtained after hybridisation. Total RNA samples extracted 
from SH-SY5Y cells and HEK cells (expressing either a7 or the a7/5-HTj chimera) were transferred to a 
nylon membrane and crosslinked before performing hybridisation. Panel (a) was probed with oc3 and 
cyclophilin for a 6 day exposure; panel (b) was probed with a7 and cyclophilin for a 16 day exposure 
using 32P labelled DNA probes. Kodak film was placed over the membrane, sealed in a cartridge box and 
placed at -80 °C being developed. (Total RNA had previously been isolated from HEK, HEK/a7 and HEK7 
a7/5-HTj cells for a different project under investigation at Organon Laboratories and were used as a 
positive control for the detection of the a7 nAChR subunit).
2.4
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Figure 3.15b shows the absence of an a l  transcript in lanes 2 and 4 that contain total 
RNA isolated and prepared from SH-SY5Y cells whereas lanes 3, 6-8 and 10, samples 
of RNA isolated from HEK cells containing either the a l  subunit or the a7/5-HT3 
chimera, show distinct bands for the a l  or a7/5-HT3 transcript respectively (at 
approximatley 2.4 kDa, serving as a positive control).
Figure 3.16a shows a representative 1% agarose gel run with total RNA samples 
isolated from control and drug treated SH-SY5Y cells with corresponding 
autoradiographs for the detection of a3 (Figure 3.16b) and a l  (Figure 3.16c) transcripts 
for 6 or 16 days exposure respectively. Cyclophilin was used as the internal standard 
gene. The scanned images shown in Figures 3.16b and c were quantified by analysing 
band optical densities obtained from the autoradiographs. Band density was normalised 
by correlating the a3 and a l  RNA bands to their corresponding cyclophilin bands for 
each sample. Quantitation of the level of a3 and a l  subunit RNA isolated from SH- 
SY5Y cells chronically treated with nicotine (10 |iM), DMAC (10 (iM) and KC1 (20 
mM) were then expressed as a percentage of the a3 and a l  bands obtained in the 
control untreated cells (expressed as 100%). The values obtained from this independent 
experiment are shown in Table 3.10. Values obtained reveal that expression of the a3 
transcript are 99%, 97% and 102% of control values for nicotine (10 fiM), DMAC 
(10pM) and KC1 (20 mM) treated SH-SY5Y cells respectively. This preliminary 
independent result indicates that chronic drug treatment with nicotinic agonists, nicotine 
or DMAC, and a depolarising concentration of KC1 do not upregulate a3 total cellular 
RNA levels in SH-SY5Y cells. The bands for the a l  transcript detected in SH-SY5Y 
cells were extremely faint and hard to analyse once scanned, thus producing no
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conclusive results on the effect of these chronic drug treatments when compared to 
control.
a













Figure 3.16. (a) A representative agarose RNA gel, with autoradiographical 
analysis o f (b) a3 and cyclophilin and (c) a7 and cyclophilin. Total RNA (10 jug) 
isolated from control (lane I and 3) or SH-SY5Y cells treated chronically with nicotine (10 
fjM; lane 2 and 4), DMAC (10 /jM; lane 5) or KCl (20 mM; lane 6) for 4 days were run on 
a 1% agarose gel and visualised by UV illumination as shown in panel a. Corresponding 
autoradiographs obtained after hybridisation with 32P labelled DNA probes for (b) a3 and 
cyclophilin or (c) a l  and cyclophilin are presented after 6 or 16 days exposure 
respectively to Kodak film.
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Table 3.10. The level o f  expression o f a3 and a l  nAChR subunit RNA expressed as a 
percentage o f  these subunits present in untreated control cells. Confluent SH-SY5Y cells were 
pretreated fo r  4 days with nicotine (10 pM), DMAC (10 pM) or KCl (20 mM) before isolating 
total RNA. RNA (10 pg) samples were run on a 1% agarose gel before being probed with 32P 
labelled cDNA probes fo r  a3, a l  and cyclophilin. The level o f  expression o f  a3 and a l  
transcripts were normalised to the level o f expression o f  their corresponding cyclophilin 
housekeeping gene before expressing these as a percentage o f  the a3 and a l  RNA obtained 
from  control untreated cells. (n.d. Denotes not detectable).
nAChR subunit transcript (as % 
of control)




The result obtained for a l  RNA levels after chronic nicotine treatment when 
compared as a percentage of control indicates that a l  RNA levels are putatively 
unaltered by this treatment for 4 days. Due to nicotine treatment upregulating [125I]-ot- 
bgt binding sites in SH-SY5Y cells, indicative of putative a l * nAChR, the unaltered a l  
RNA levels after nicotine treatment suggests that nicotine-induced upregulation of a l * 
nAChR is possibly by a post-transcriptional mechanism.
Figure 3.17 shows a Northern blot of various human brain regions probed for the a l  
subunit transcript and cyclophilin to demonstrate that the a l  nAChR subunit transcript 
can be detected by this protocol. After 24 h exposure, the cyclophilin bands are clearly 
visible, but a longer exposure of 16 days was required to identify the respective a l  
transcript bands. These data indicate that the Northern analysis procedure used at
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Organon Laboratories, for the detection of both a3 and a l  transcripts is effective. This 
procedure reliably detects a l  transcripts in HEK cells expressing a l  nAChR subunits or 
the a7/5-HT3 chimera (Figure 3.15b) and in various regions of human brain tissue 
(Figure 3.17), in contrast to the extremely low level of a l  expression in SH-SY5Y cells 
that is difficult to detect (Figs. 3.15b, 3.16c). Low level a l  subunit expression in SH- 
SY5Y cells may result in comparative but harder to detect increases of [ I]-a-bgt 
binding after chronic drug treatment compared to primary hippocampal cultures.
4 .4
2 .4
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Figure 3.17. Clontech human brain multiple tissue Northern blot (Human Brain III  
MTN). Various human brain regions were probed with a7 and cyclophilin probes and exposed at - 
8(f Cfor (a) 24 h and (b) 16 days.
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On consideration of the preliminary data generated at Organon Laboratories, it was 
decided to repeat the Northern analysis at Bath, on control and drug treated SH-SY5Y 
cells, using DIG-labelled DNA probes to detect the a3 and a l  nAChR subunit RNA. 
Total RNA and also poly (A)+ RNA was isolated from SH-SY5Y cells. Approximately 
1-4% of total RNA in the cytoplasm of a typical eukaryotic cell is mature poly (A)+ 
RNA. By using poly (A)+ RNA in the Northern analysis procedure, the a3 and a 7 
signals should give cleaner results with reduced background and therefore produce a 
signal with greater sensitivity and intensity. Total cellular RNA was used in all 
subsequent Northerns as the poly (A)+ RNA proved more susceptible to degradation. 
The data for each drug treatment was normalised to their internal standard G3PDH 
before being expressed as a percentage of the control values and are summarised in 
Figure 3.18.
The results parallel the initial preliminary data (generated at Organon Laboratories) 
in that the nicotinic agonists, nicotine and DMAC, and KCl depolarisation do not alter 
the level of expression of a3 RNA expressed in SH-SY5Y cells after 4 days of chronic 
drug treatment (n=3). On analysis of the a l  data (n=l; bands observed were still faint), 
nicotine and DMAC do not significantly change the expression of the a l  transcript, 
relative to control, when normalised to their G3PDH internal standard. This is in 
contrast to chronic KCl treatment that increases the expression of the a l  subunit RNA 
to 137% above control levels of expression. Nicotinic agonist and KCl treatment both 
upregulate [125I]-a-bgt binding in SH-SY5Y cells; the increase in a l  RNA observed 
after KCl treatment but not after nicotinic agonist treatment suggests that KCl-evokes 
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Figure 3.18. Level o f expression o f G3PDH, a3 and a l  total RNA 
extracted from SH-SY5Y cells relative to control untreated cells.
Amounts of a3 and a7 subunit total RNA were measured from SH-SY5Y 
cells that had been treated with DMAC (10 pM), nicotine (10 pM), KCl (20 
mM) or no drugs for control (not shown but are expressed as 100%), using 
Northern blot analysis. Each set of blots was used to quantify the level oj 
nAChR subunit expression by scanning the autoradiographs and 
normalisation to the expression of G3PDH as an internal standard control in 
each o f the drug treated conditions relative to control (100%). Values for 
G3PDH and a3 are the mean ±  S.E.M. from at least 3 independent sets oj 
total RNA and the a l  data are from 1 set of total RNA.
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Section 3: Visualisation o f cx3* and a.7* nAChR subunits 
in SH-SY5Y cells.
3.14. Introduction.
So far this Chapter has described data revealing that oc3* and a l*  nAChR are 
upregulated in SH-SY5Y cells by different chronic drug treatments and by different 
cellular mechanisms. This section will describe experiments that use specific antibodies 
and confocal microscopy to identify populations of a3 and a l  nAChR subunits in both 
control and drug treated SH-SY5Y cells. The aim was to elucidate whether the 
distribution of these a3 and a l  nAChR subunits is altered after chronic drug treatment 
compared with control untreated conditions. Confocal microscopy as a technique is 
briefly introduced in section 3.14.2.
3.14.1. nAChR subunit composition and monoclonal antibodies to nAChR  
subunits:
The a3 and a l  subunits are of interest to this project because they are definitive of 
a3* and a l * nAChR. nAChR containing the a3 subunit are capable of forming 
receptor complexes in various combinations with p2, P4 and a5 and are found in 
autonomic ganglia where they play a post-synaptic role (Vernallis et al., 1993; Ullian et 
al., 1997). The a3 nAChR subunit mRNA can be found in high abundance in the 
thalamus (e.g. dorsomedial and ventro-posterolateral regions), moderate to low 
abundance in most cortical regions (e.g. preffontal, motor, entorhinal, cingular and 
temporal) and in low levels of expression in the hippocampus, dentate gyrus and
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cerebellum in human brain (for review see Paterson and Nordberg, 2000). The a l  
subunits usually have an extra- or peri-synaptic location and can be found within the 
same ganglionic neurones as a3* nAChR (Vemallis et al., 1993; Horch and Sargent, 
1995). In human brain, a l  nAChR subunit mRNA can be detected in high abundance in
• 123the motor cortex and hippocampus (a7* nAChR are also detected with [ I]-a-bgt, 
with highest density of binding observed in the hippocampus), moderate abundance in 
the dentate gyrus, caudate putamen, preffontal cortex and dorsomedial thalamus, with 
lower expression in the entorhinal cortex and cerebellum (for review see Paterson and 
Nordberg, 2000). The SH-SY5Y cell line endogenously expresses both a3 and a l  
nAChR subunits and is therefore a useful model cell line to visualise these subunits that 
are upregulated after chronic drug treatment.
From the sequences of cDNAs encoding nAChR subunits it has been possible to 
design and synthesise peptides to generate subunit-selective antibodies. These 
antibodies can be used to identify and investigate various aspects of receptor structure, 
function, biosynthesis and their general pharmacological characterisation (Lindstrom, 
1986; Whiting et al., 1987). Other advantages of antibodies include their ability to 
identify novel ligand binding sites and the orientation of the subunits within the nAChR 
complex (Beroukhim and Unwin, 1995). Antibodies may not possess all o f the desired 
properties even if they are binding at the correct subunit, for example they may not 
cross-react with nAChR from the desired species of interest. There is also a problem if 
the antibody only binds to the native receptor subunit or to the denatured receptor 
subunit. More problems can still arise when the correct antibody is used in the correct 
species, if the procedure for preparing and fixing of the tissue is too harsh and leads to 
either the destruction of the epitope or creates an environment that is inaccessible for 
histological localisation. Usually when the correct antibody has been produced, is used
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in the correct species with an optimised fixation protocol, the immunoaffinity 
purification and quantitation of nAChR (Peng et al., 1994b), or other receptors of 
interest, can be identified.
The binding sites for the endogenous nAChR ligand, ACh, are thought to be at the 
interfaces of specific subunits, one always being the a  subunit (Karlin and Akabas, 
1995; see section 1 .2 ). Antibodies have been synthesised to distinguish between the two 
ACh binding sites located on the muscle nAChR (Mihovilovic and Richman, 1987). 
The different conformational transitions of a  subunits can be detected by their ability to 
bind a conformation-dependent monoclonal antibody (mAb) directed at the main 
immunogenic region (MIR), e.g. mAb 35, or the ability to bind a-bgt with moderate 
affinity. Antibodies that bind to the extracellular surface of the a  subunit usually do not 
interfere with the functional properties of the nAChR, however, function can be 
inhibited if antibodies bind to sites which are at or near to the ACh binding site 
(Lindstrom, 1986). An antibody capable of exhibiting high affinity and specificity to 
only one type of nAChR subunit is ideal as a biochemical probe as it will reliably detect 
the subunit under investigation without cross reacting with other nAChR subunits. To 
date there are still some nAChR subunits to which there are no specific antibodies 
available. However, the resulting subunit specific antibodies that have been generated 
are extremely powerful tools suitable as biochemical probes for the detection of nAChR 
located in the CNS and are able to reveal structural information about receptor 
stoichiometry, synthesis and assembly in vitro.
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3.14.2. Fluorescent immunostaining and the scanning laser confocal microscope:
The confocal microscope can accommodate light sources of different wavelengths 
and is capable of exciting a vast range of fluorophores that can be used to probe various 
cell lines or larger whole tissue specimens. The confocal microscope used in this study 
(Zeiss LSM 510) uses a laser beam as the light illumination source used to scan the 
specimen under investigation. There is a variety of commonly used sources of excitation 
for the confocal laser scanning microscope (CLSM) system including, argon (Ar; 488 
nm and 514 nm), krypton (Kr; 568 nm), argon-krypton (Ar-Kr; 488 nm, 514 nm and 
568 nm) and helium-neon (He-Ne; 633 nm) (Dailey e ta l., 1999).
This study uses the technique of fluorescent immunostaining using the specificity of 
antibodies (mAbs and polyclonal antibodies) in conjunction with the CLSM to visualise 
various nAChR subunits present in SH-SY5Y cells. Recent developments have led to 
the production of a plethora of specific probes that allow for specific nAChR subunits to 
be labelled. The fluorescent dye fluorescein isothiocyanate (FITC) (a standard green 
dye) is excited by argon laser radiation at a wavelength of 488 nm, emits green light and 
can be used as a secondary antibody in the detection process of particular nAChR 
subunits. The CLSM is a useful instrument to use for the visualisation of surface and 
cellular components in 3-D. By means of using CLSM and fluorescent probes to 
identify subcellular structures in living cells. However, prolonged exposure of the 
specimen to any form of laser radiation can result in the phenomenon of photobleaching 
of the fluorescent secondary antibody used.
The conventional light microscope is often used to visualise living cells dynamically 
in situ in culture. Problems arise with epi-fluorescence, as there is often background 
fluorescence glowing from structures present above and below the optical plane of 
interest and therefore obscures and visually impairs much relevant morphology of
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biological structures, particularly in multicellular specimens due to out-of-focus signals. 
When using the light microscope vital areas of interest can be obscured, predominantly 
when examining thick specimens, and therefore lacks the ability to generate much of the 
ultrastructural and out-of-focus information, except when working with cells which 
have a flattened appearance (White et al., 1987; Shotton, 1989). This is also a 
disadvantage when using transmission electron microscopy (EM) which is capable of 
producing 2-dimensional (2-D) images of cut sections that have been subjected to 
fixation. The preparation and fixation procedures during the production of serial 
sections can damage living cells as well as extremely laborious.
The confocal microscope is a powerful new imaging tool equipped with either a 
scanning laser or stage that has been developed to circumvate previous technical 
complications with out-of-focus blur (Shotton, 1989; Paddock, 1999). This technique 
offers several advantages and improvements over both the conventional light 
microscope and EM equivalents. It is a solution to their problems by providing high 
contrast and improved clarity when optically sectioning and viewing both living and 
fixed thick specimens (White et al., 1987). This technique has new prospects to 
elucidate morphological and spatial characteristics of cell structure, physiological 
properties occurring within cell in culture, processes occurring within various intact 
biological tissue specimens in their native tissue environment in 3-D, details that have 
previously been difficult to detect.
The confocal microscope has an exceptionally shallow depth of field. This property 
enables detailed and direct optical sections of between 0.5-1.5 pm in thickness to be 
obtained rather than an overall image of the entire specimen under investigation as is 
obtained when viewed under a conventional equivalent light microscope (Wright and 
Schatten, 1991). The confocal instrument used in this series of experiments (Zeiss LSM
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510 confocal microscope (Oberkochen, Germany) is comprised of a finely focused light 
source (a moving laser beam) capable of scanning the SH-SY5Y cells under 
investigation. The laser travels through a pin hole located in front of the photodetector 
which aids in the elimination out-of-focus blurred data with the help of a small aperture 
located to the front of the photodetector (Wright and Schattan, 1991) (Figure 3.19). The 
resulting images have greater resolution and produce improved epi-fluorescent images 
when compared to images with a high level of background non-specific staining 
produced by a conventional microscope (White et al., 1987).
This imaging technique relies on its ability to reject out-of-focus light. This property 
leads to an increase in the signal-to-noise ratio and results in the production of sharp, 
high-contrast images of cells and their subcellular components (even within relatively 
thick samples) (Brakenhoff et al., 1985; Shotton, 1989; Dailey et al., 1999). Confocal 
images have a depth discriminated fluorescence image that has high spatial resolution 
compared to using a standard epi-fluorescence microscope. The depth is created from a 
series of captured 2-D optical images obtained by scanning the specimen point-by-point 
with a laser beam from successively different levels of depth of focus, also known as a 
Z-series.
Non-invasive optical sections obtained with the confocal approach are captured from 
scanning in a series of different optical sections obtained from different focal planes 
(the X-Y plane and also vertically in the X-Z plane; this enables depth (Z-axis) and 
lateral (X-axis) scanning to be obtained) (Wright and Schatten, 1991). These series of 
optical sections can be collected, combined and used to reconstruct orthogonal images 









The arrow heads denote the direction of the light path
Out of focus light 
In focus light
Figure 3.19. Diagram to illustrate the essential components o f a confocal laser 
scanning microscope (modified from Shotton, 1989).
Recent technological advances in computer systems allow for rapid image acquisition 
times, processing, storage and manipulation of the scanned image data, which in the 
past has been difficult to obtain from biological specimens. The clarity of the images 
produced, provide an exciting and powerful insight into the topology of cellular
Chapter 3. 179
structure, tissue organisation and functional properties due to the reduction of 3-D point 
spread by the unique optical sectioning of the CLSM.
3.15. Aims:
The aim of this section is to undertake a preliminary investigation into the 
intracellular localisation of a3 and a7 nAChR subunits in control untreated SH-SY5Y 
cells and following nAChR upregulation by chronic treatment with either nicotinic 
agonists (nicotine and DMAC) or KC1 depolarisation. This will show whether 
upregulation of nAChR evoked by these drug treatments results in an increase of 
intracellular receptor subunits and whether these subunits are in diffuse or punctate 
populations.
3.16. Methods.
3.16.1. Cell culture: maintenance of SH-SY5Y cells:
SH-SY5Y cells were routinely cultured and maintained as described in section 3.3.2.
Cells for confocal microscopy were seeded at a density of 5 x 1 0 5 cells/cm2 onto sterile 
2 • •2 cm glass coverslips in 200 pi volumes. After 90 min to ensure attachment of the cells 
to the coverslips, prewarmed medium was added to a volume of 3 ml to each of the 
coverslips in well areas of a 6  well cell culture plate.
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3.16.1.1. Chronic drug treatment to SH-SY5Y cells:
After 24 h, maintenance medium was gently aspirated from the SH-SY5Y cells 
grown on coverslips and replaced by either 3 ml maintenance medium (control) or this 
medium containing either nicotine (10 pM), DMAC (10 pM) or KC1 (20 mM) for drug 
treated conditions (see section 2.4.2). Cells were maintained at 37°C in 5% 
CCVhumidified air for a further 4 days before preparation for confocal microscopy. 
After 4 days incubation, drugs were removed by washing four times with warm medium 
over a 30 min period. Medium was removed from the cells and replaced by 1 ml warm 
sterile PBS, before proceeding to the immunostaining method (see section 3.16.3). 
Control sister cultures of SH-SY5Y cells were cultured in parallel for 4 days prior to 
staining and visualisation.
3.16.2. Antibodies:
Primary antibodies were as follows: a3 nAChR subunit specific Sc-1771 goat 
polyclonal IgG, stored as a stock of 200 pg/ml at 4°C, from Santa Cruz Biotechnology, 
(Santa Cruz, CA.) and used in a 1 / 2 0 0  dilution; a l  nAChR subunit specific mAb 306 
was a generous gift donated by Dr. Jon Lindstrom (Dept, of Neuroscience, University of 
Pennsylvania Med. Sch., Philadelphia, PE, USA), it was stored at -20°C and used in a 
dilution of 1 / 1 0 0 0 .
Secondary antibodies were as follows: for a3 nAChR subunit detection, either 
biotinylated rabbit anti-goat IgG (H+L) affinity purified (1:200 dilution from stock kept 
at 4°C) then FITC-labelled streptavidin as a tertiary label was used in a dilution of 1:500 
or an anti-goat IgG FITC labelled antibody was used. The secondary antibodies used for
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a3 detection were purchased from Vectorlabs., (Peterborough, U.K.) The secondary 
antibody used in the detection of a7  nAChR subunits was a horse anti-mouse IgG 
(H+L), FITC labelled, rat absorbed affinity purified antibody (1:50 dilution), also 
purchased from Vectorlabs., (Peterborough, U.K.)
3.16.3. Immunofluorescence labelling of a3 and a7 nAChR 
subunits in SH-SY5Y cells:
The immunostaining procedure was adapted from Maimone and Merlie (1993). In 
brief, glass coverslips with adherent SH-SY5Y cells were transferred to individual wells 
of a 6  well plate and washed with 1 ml of warm PBS before incubating with 1 ml of 
fixative solution (1% paraformaldehyde, L-lysine (100 mM), sodium metaperiodate (10 
mM), and 0.1% saponin in PBS) for 20 min at room temperature. The cells were then 
rinsed with PBS and permeabilised for 10 min in 1 % Triton X-100 in PBS (La 
Rochelle et al., 1989) before being washed x 3 in PBS and immediately immunostained 
as follows.
The cells were initially blocked in 10% FCS (diluted in PBS) for 30 min prior to 
immunostaining. For staining, the coverslips were inverted (so that the cells were on the 
under surface) onto 1 0 0  pi drops of the primary antibody solution (placed on a piece of 
parafilm) for either a3 or a7  subunits (1:200 and 1:1000 dilutions respectively in 10% 
FCS in PBS for 2 h in humid conditions at room temperature (see Figure 3.20). Any 
unbound primary antibody was rinsed from the cells by placing the coverslips in fresh 6  
well culture plates and washing x 3 by 5 min washes in PBS.
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—  petri dish and lid
moist cotton wool for 
humid conditions
parafilm
inverted coverslip with 
cells on under surface
Droplet o f antibody
Figure 3.20. Schematic representation o f single fluorescence labelling o f SH-SY5Y cells.
SH-SY5Y cells were grown to confluency on glass coverslips in 6 well culture plates before 
chronically treating for 4 days with nicotine (10 juM), DMAC (10 pM) or KCl (20 mM). The cells 
were fixed and permeabilised before labelling for aS or a l  nAChR subunits. Coverslips were 
inverted onto droplets o f antibody before washing and mounting with vectashield on glass slides. 
Negative controls were incubated in parallel, on sister cultures of SH-SY5Y cells, they were incubated 
in blocking solution before proceeding to incubation with secondary antibody.
The bound antibody was detected by incubation with a relevant fluorescently labelled 
secondary antibody by inverting the coverslip onto 100 pi drops of this secondary 
antibody solution. For a3 subunit detection, incubation was with a biotinylated goat 
anti-rabbit IgG (stock diluted 1:200 in 10% FCS in PBS; 1 h at room temperature). The 
coverslips were washed x 3 by 5 min washes in PBS before inverting coverslips for a 
further hour, at room temperature in the dark on 100 pi drops of FITC-labelled 
streptavidin as a tertiary label. After incubation with the primary a3 antibody, detection 
was also performed with a secondary anti-goat IgG FITC labelled antibody (stock 
diluted 1:200 in 10% FCS in PBS; 1 h at room temperature) to try to decrease 
background staining found with FITC-labelled strepavidin. For secondary a l  subunit 
detection, incubation was with an anti-mouse IgG FITC labelled antibody (stock diluted 
1:50 in 10% FCS in PBS). The cells were incubated with the secondary antibody at 
room temperature, in dark (in the case of FITC), humid conditions. After 1 h the
Chapter 3. 183
coverslips were washed x 3 by 5 min washes in PBS to remove excess secondary 
fluorescence tag and then briefly in distilled water before being mounted in Vectashield 
on clean glass microscope slides, sealed with nail varnish and stored at 4°C in the dark 
until ready for visualisation under the CLSM. Negative controls were set up in parallel 
with cells treated chronically with drugs. On the day of labelling, the cells were 
incubated with 10% FCS (instead of primary antibody) and stained with a single 
secondary antibody. This was to make sure that the secondary antibody did not produce 
a fluorescence signal on its own.
3.16.3.1. Confocal protocol:
Prepared SH-SY5Y cells were visualised using a Zeiss LSM 510 confocal 
microscope (Oberkochen, Germany) equipped with an argon-krypton mixed gas laser 
(488 nm wavelength) for detection of FITC labelling and using a 63 x 1.4 differential 
interference contrast (DIC) oil objective lens. The images collected and recorded were 
processed using Adobe Photoshop 3.0 (Adobe Systems, Mountain View, CA, USA).
3.17. Results.
3.17.1. SH-SY5Y cell morphology:
The images obtained from confocal microscopy provide details of the SH-SY5Y cell 
line morphology: images illustrate the flattened, ovoid morphology of SH-SY5Y cells 
that have been in culture for approximately 5 days. It can be observed that the cells 
project processes that form contacts with neighbouring cells. There is considerable 
morphological homogeneity within the population of SH-SY5Y cells stained in each of
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the panels shown in Figs. 3.21, 3.23 and 3.25. All of the cells used in this preliminary 
immunofluorescence investigation into the localisation of a3 and a l  nAChR subunits 
were fixed and permeabilised, because the primary antibodies used recognised 
intracellular epitopes. This enables an analysis of total intracellular located receptor 
subunits to be visualised.
3.17.2. Immunolabelling of nAChR a3 subunits in control and 
drug treated cells:
The a3 specific goat polyclonal antibody Sc-1771 was used to label the intracellular 
distribution of a3 nAChR subunits in permeabilised SH-SY5Y cells. These experiments 
were performed to visualise the location of the a3 nAChR subunits and also to identify 
whether there was a change in expression after the nicotinic agonist-evoked 
upregulation. The negative control immunolabelling confocal pictures obtained and 
presented in Figure 3.21a and b have a filamentous background staining. These cells 
were only labelled with a secondary antibody and tertiary FITC-labelled strepavidin. 
This staining may be representative of biotin binding to an intracellular structure 
detected with the FITC-labelled strepavidin. These results should be viewed with 
caution due to the filamentous background staining with biotin making detection of the 
a3 nAChR subunit difficult.
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Figure 3.21. Detection o f a3 nAChR subunits in the SH-SY5Y cell line.
a3 nAChR subunits were visualised in SH-SY5Y cells in either (c) control, (d) 
nicotine (10 juM), (e) DMAC (10 /jM) or (f) KCl (20 mM) treated cells by 
immunofluorescent staining o f fixed cells with Sc-1771 for 2 hat room temperature 
followed by a biotinylated antibody and FITC-labelled streptavidin. Panels (a) and 
(b) are negative controls labelled only with the secondary antibodies. All cells were 
permeabilised with 1% Triton X-100 for 10 min to visualise total a3 nAChR 
subunits before labelling with Sc-1771. All scale bars represent 20 /Lon and 
representative images are shown.
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Confocal images of SH-SY5Y cells grown under standard control, untreated 
conditions are shown in Figure 3.21c. The population of SH-SY5Y cells is 
heterogeneous with respect to their expression of the a3 nAChR subunit, intracellular 
fluorescence is relatively widespread throughout the cytoplasm with some cells clearly 
expressing more a3 subunits than others. In control conditions (Figure 3.21c) the FITC- 
labelled strepavidin binding to the a3 nAChR subunit primarily has an intracellular 
location with fluorescence surrounding the nucleus. The staining pattern of the a3 
subunit is hard to recognise due to the background filamentous staining but appears 
punctate and heterogenous.
Section 1 described how nicotinic agonist treatment but not KC1 depolarisation for 4 
days upregulated a3* nAChR, detected by significant increases in [3H]-epibatidine 
binding from control. Cultured cells were exposed to chronic nicotinic agonist treatment 
with either 10 (iM nicotine (Figure 3.2Id) or 10 (xM DMAC (Figure 3.21e) for 4 days 
before fixation, permeabilisation and immunolabelling for the a3 subunit. In these 
agonist treated cultures there seems to be a slightly greater proportion of staining of the 
a3 nAChR subunit within the cytoplasm surrounding the nucleus and also extending 
into the cytoplasmic projections. Cultures chronically treated with a depolarising 
concentration of KC1 (20 mM) appear to have a3 subunit labelling similar to control 
conditions with fluorescence staining not as intense as that found in nicotinic agonist 
treated cells. In all of the panels observed in Figure 3.21 the labelling of surface a3 
nAChR subunits is difficult to distinguish, due to the a3 primary polyclonal Ab 
recognising an intracellular portion of the a3 nAChR subunit.
The non-specific filamentous background fluorescence obtained with the negative 
controls presented in Figure 3.21, led to further experiments performed with the primary
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a3 polyclonal antibody but using an anti-goat IgG FITC labelled secondary antibody to 
try to reduce background staining. Representative negative controls for control, nicotine 
(10 pM), DMAC (10 pM) and KC1 (20 mM) treated SH-SY5Y cells are shown in 
Figure 3.22a-d respectively.
Figure 3.22. Representative negative control staining for a3 nAChR 
subunit localisation in the SH-SY5Y cell line, (a) Control, (b) nicotine 
(10 juM), (c) DMAC (10 /jM) or (d) KCl (20 mM) treated SH-SY5Y cells were 
visualised after immunofluorescent staining of fixed cells with blocking 
solution for 2 h at room temperature followed by an anti-goat IgG FITC 
labelled antibody. All cells were permeabilised with 1% Triton X-100 for 10 
min before initial blocking stage. All scale bars represent 20 jum.
The images produced for negative controls using the FITC labelled secondary antibody 
alone to control or drug treated SH-SY5Y cells showed low non-specific background
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staining, facilitating the detection of the specific a3 nAChR subunit fluorescence signal 
(Figure 3.23a-d).
Figure 3.23 shows populations of SH-SY5Y cells expressing the a3 nAChR subunit 
at different levels with some cells expressing little a3 nAChR subunit. In control 
cultures (Figure 3.23a), the a3 subunit has a widespread intracellular location within the 
cytoplasm with some cells showing more intense fluorescence. The staining patterns of 
the a3 nAChR subunit appear to be punctate and the majority of a3 subunit staining is 
roughly spherical in shape. The effect of 4 day treatment with either 10 pM nicotine 
(Figure 3.23b) or 10 pM DMAC (Figure 3.23c) on a3 subunit distribution in cultured 
cells, produces a greater intensity of fluorescence. This is particularly evident in the 
nicotine treated cells where the staining of a3 nAChR subunits is punctate in small 
discrete spherical compartments scattered asymmetrically throughout the cell 
cytoplasm, in the cytoplasmic extensions as well as surrounding the nucleus of the cell 
and on the cell surface/or close to the cell surface. KC1 treated cultures (Figure 3.23d), 
show fluorescence staining of the a3 nAChR at levels of expression similar to control 
untreated SH-SY5Y cell cultures.
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Figure 3.23. a3 nAChR subunit localisation in the SH-SY5Y cell line. a3 nAChR subunits 
were visualised in SH-SY5Y cells in either (a) control, (b) nicotine (10 fjM), (c) DMAC (10 juM) or 
(d) KCl (20 mM) treated cells by immunofluorescent staining of fixed cells with Sc-1771 for 2 h at 
room temperature followed by an anti-goat IgG FITC labelled antibody. All cells were 
permeabilised with 1% Triton X-100 for 10 min to visualise total a3 nAChR subunits before 
labelling with Sc-1771. All scale bars represent 20 jum.
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3.17.3. Distribution of a l  nAChR subunits in control and drug 
treated cells:
The cellular distribution of a l  nAChR subunits in cells under control, untreated and 
upregulated conditions was investigated by immunocytochemical detection with the a l  
nAChR subunit specific primary mAb 306 and secondary labelling with a FITC-labelled 
antibody. Figure 3.24 and 3.25 represent negative controls and positive staining 
respectively. The cells visualised in Figure 3.24 were not incubated with the primary 
mAb 306, but instead were incubated with blocking solution and then with the 
secondary anti-goat IgG FITC-labelled antibody, identifying low non-specific 
fluorescence that subsequently did not interfere with specific a l  nAChR subunit 
detection (Figure 3.25).
Figure 3.24. Representative negative 
control staining for a l  nAChR 
subunit localisation in the SH-SY5Y 
cell line. SH-SY5Y cells were 
permeabilised with 1% Triton X-100 for 
10 min before incubation with blocking 
solution for 2 h at room temperature 
followed by an anti-mouse IgG FITC 
labelled antibody before visualising. All 
scale bars represent 20 /an.
Figure 3.25 shows a l  nAChR subunit staining in control, untreated cells or cells that 
had been treated chronically for 4 days with either 10 pM nicotine, 10 pM DMAC or 
(20 mM) KC1 represented in Figure 3.25a-d respectively. The population of control,
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untreated SH-SY5Y cells are homogeneous with respect to their expression of the a l  
nAChR subunit (Figure 3.25a). The distribution of fluorescence for a l  nAChR subunits 
in control cells appears to be predominantly intracellular in the cytoplasm and 
cytoplasmic projections with little surface labelling. Staining is punctate in nature and 
uniform in the nuclear region/or over the nucleus in control SH-SY5Y cell populations.
SH-SY5Y cells treated with nicotine for 4 days have predominant intracellular a l  
nAChR subunit staining, with fluorescence being uniform throughout the cytoplasm 
(Figure 3.25b). In DMAC treated cells (Figure 3.25c), there is a greater intensity of 
staining for the a l  nAChR subunit compared to control, untreated cultures. Staining is 
again predominantly intracellular with fluorescence observed in the cytoplasm and 
cytoplasmic extensions. Figure 3.25d shows cells treated with KC1 for 4 days prior to 
immunolabelling with the specific a l  nAChR subunit mAb 306. Staining of a l  nAChR 
subunits was found to be intracellular and asymmetrically located around the cell 
nucleus. The staining of KC1 treated cells appears to be less intense than that observed 
in control or nicotinic agonist treated SH-SY5Y cells. A reason for this could be 
attributed to photobleaching due to the longer time taken to locate a population of cells. 
KC1 may predominantly upregulate surface a l  nAChR subunits which are not 
distinguished by mAb 306 binding in permeabilised cells.
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Figure 3.25. a7 nAChR subunit localisation in the SH-SY5Y cell line, a l  nAChR subunits 
were visualised in SH-SY5Y cells in either (a) control, (b) nicotine (10 fjM), (c)DMAC (10 /jM) or (d) 
KCl (20 mM) treated cells by immunofluorescent staining of fixed cells with mAb 306for 2 hr at room 
temperature followed by an anti-mouse IgG FITC labelled antibody. All cells were permeabilised 
with 1% Triton X-100 for 10 min to visualise total a l  nAChR subunits before labelling with mAb 306. 
Scale bars represent 20 fjm.
If time had permitted, this preliminary investigation into the visualisation of a3 and 
a l  nAChR subunits in SH-SY5Y cells would have been followed by optimising the 
conditions used in the labelling protocol. It would be desirable to also detect surface
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labelling of a3 and a l  nAChR subunits, but this would require different antibodies that 
recognise extracellular epitopes or using non-permeabilised cells in the protocol. 
Surface versus intracellular staining could be compared in control and drug treated SH- 
S Y5 Y cells.
It must be emphasised that the findings from this confocal microscopy study are 
preliminary. This confocal study has implicated that there are changes in the cellular 
location and intensity of staining of a3 and a l  nAChR subunits after drug treatments 
that evoke upregulation of nAChR subunits. It must be emphasised that the results relate 
to the immunolabelling of a3 and a l  nAChR subunits detected in the form of both 
unassembled and assembled nAChR complexes.
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Section IV: Discussion of results.
This Chapter has investigated drug treatments that influence the expression of a3* 
and a7* nAChR in SH-SY5Y cells grown in culture. Novel findings reveal that the 
nAChR subunits under investigation were differentially regulated by different chronic 
drug treatments and that these drug treatments produced upregulation of the nAChR 
subunits by different cellular mechanisms.
Upregulation of nAChR after prolonged agonist treatment appears to contradict the 
paradigm that chronic agonist exposure results in receptor down regulation while long 
term exposure to antagonists elicit receptor upregulation (for review, see Creese and 
Sibley, 1980). Previous studies have shown that the concentration of nicotine required 
to evoke upregulation of either a3* and a7* nAChR was higher than those required to 
elicit upregulation of the a402 nAChR complex (Peng et al., 1997; Wang et al., 1998). 
Concentration-response analyses have shown that nicotine concentrations from between 
10 pM and 1 mM were required to promote significant upregulation of either [3H]- 
epibatidine (Wang et al., 1998) or [125I]-a-bgt binding sites in SH-SY5Y cells (Peng et 
al., 1997) or HEK-293 cells transfected with human a l  neuronal nAChR subunits 
(Molinari et al., 1998). The requirement for these greater concentrations of nicotine to 
evoke upregulation of a3* and a l * nAChR, compared to the a4(32 nAChR, is probably 
due to their lower affinity for nicotine. In the present study by using [3H]-epibatidine 
and [125I]-a-bgt binding to SH-SY5Y cells to label and a3* and a l * nAChR 
respectively, a comparison could be made between 1) the ability of different drug 
treatments to alter the binding sites detected by these radiolabelled compounds and 2) 
between the [125I]-a-bgt binding data obtained from primary hippocampal and SH- 
SY5Y cell cultures.
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3.18. Upregulation of [125I]-a-bgt binding sites in SH-SY5Y cells:
To demonstrate whether upregulation of [125I]-a-bgt binding sites was evoked in SH- 
SY5Y cells, different chronic drug treatments previously shown to evoke upregulation 
of [125I]-a-bgt binding sites in primary hippocampal cultures (see section 2.7.2) were 
applied to SH-SY5Y cells grown in culture. The extent of upregulation of [125I]-a-bgt 
binding sites, above control levels, in SH-SY5Y cell cultures induced by 20 mM KC1 
(51 ± 10%) and the nicotinic agonists nicotine (10 pM; 37 ± 5%) and DMAC (10 pM; 
20 ± 6%) are reminiscent of the increases observed in rat primary hippocampal neuronal 
cultures after chronic treatment with these drugs (see section 2.7.2.1). The magnitude of 
upregulation evoked by nicotine is in agreement with a recent report where the level of 
a l * nAChR expression in SH-SY5Y cells was increased by approximately 30% using a 
higher concentration of nicotine at 1 mM for 4 days (Peng et al., 1997). These data 
indicate that the SH-SY5Y neuroblastoma cell line is a valid model for the study of 
upregulation of nAChR and the cellular mechanisms underlying this phenomenon.
Previous investigations examined the effect of other activator ligands such as DMPP 
(see section 2.8.1), GTS-21 and (±)-epibatidine, to determine whether the phenomenon 
of upregulation was unique to nicotine (Molinari et al., 1998). These compounds were 
also found to produce a concentration-dependent upregulation of [125I]-a-bgt binding 
sites above control levels in a l  transfected HEK-293 cells (Molinari et al., 1998). The 
present study did not encompass the effect of antagonists, however previously 
antagonists have been reported to upregulate a l  nAChR in cultured cells. Molinari et al. 
(1998) observed that the a l  nAChR antagonist MLA promoted a concentration- 
dependent upregulation of [125I]-a-bgt binding sites in HEK-293 cells transfected with 
human a l  subunits.
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The novel a l  selective antagonist MLA, was made available to us in the tritiated 
form and it was decided to perform saturation analysis of [3H]-MLA binding to SH- 
SY5Y membrane preparations. The data revealed that nicotine-induced and KCl-evoked 
increases in a l * nAChR result from an increase in the amount of a l  binding sites rather 
than from an increase in the affinity of a l*  nAChR for nicotine (Table 3.2). This agrees 
with previous data reported for nicotine-evoked upregulation of the a l*  nAChR in SH- 
SY5Y cells and HEK-293 cells (Peng et al., 1997; Molinari et al., 1998). In the present 
study there appears to be one class of [3H]-MLA binding site in SH-SY5Y cells (Kd  = 3 
nM with a respective Bmax value of 28.0 fmol [3H]-MLA bound/mg protein) (Table 3.2). 
These values are in close accordance with respective Bmax value of 25.6 fmol [125I]-a- 
bgt bound/mg protein reported by Lukas et al. (1993) for [125I]-a-bgt binding to SH- 
SY5Y cell membrane preparations. The site labelled both on the surface and 
intracellularly in the present study by [3H]-MLA probably reflects the same site labelled 
with [125I]-a-bgt on the cell surface (Lukas et al., 1993) and identifies the putative 
homomeric a l*  nAChR.
Preliminary confocal analysis was used in the present study to label the a l  nAChR 
subunits with the a l  nAChR subunit specific mAb, mAb 306 that specifically binds to 
the intracellular portion of the loop between TM3 and TM4 of the a l  nAChR subunit. 
The fluorescence observed in control and drug treated cells was predominantly of a l  
subunits located within the cell cytoplasm where they would be non-functional and not 
detected by [125I]-a-bgt binding assays in situ. Chronic treatment with DMAC for 4 
days produced the greatest intensity of intracellular labelling of the a l  subunit, followed 
by nicotine and KC1 depolarisation. This is the opposite order compared to their ability 
to upregulate surface a l*  nAChR detected with [125I]-a-bgt binding. It would be of
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interest to compare intracellular to surface staining to identify if these chronic drug 
treatments upregulate surface a l  subunits to a similar extent as observed in binding 
studies. This could be achieved by using non-permeabilised cells and labelling them 
with rhodamine labelled a-bgt to identify surface a l  subunits. This would identify 
whether KC1 upregulates surface a l  nAChR subunits in preference to intracellular a l  
subunits and would also enable comparisons to be drawn with nicotinic agonist-evoked 
upregulation of surface versus intracellular subunit labelling.
The experiments reported in the present study so far have shown that a7* nAChR are 
upregulated by KC1 and nicotinic agonists in SH-SY5Y cells and that these treatments 
produce an increase in surface [125I]-a-bgt binding sites (Bmax) with no change in Kd. It 
was then decided to investigate the mechanisms underlying the process of upregulation 
of [125I]-a-bgt binding sites evoked by these chronic drug treatments and to elucidate 
whether Ca2+ influx and protein kinase pathways were involved.
3.18.1. Mechanisms of nicotine- and KCl-evoked upregulation of putative a l * 
nAChR in SH-SY5Y cultures:
De Koninck and Cooper (1995) previously demonstrated that an increase in surface 
[125I]-a-bgt binding sites evoked by KC1 depolarisation (40 mM) was paralleled by an 
increase in a7-gene expression in sympathetic neurones developing in culture. Further 
experiments identified an essential role for CaM-kinase II in the induction of the a l  
gene (De Koninck and Cooper, 1995). There is a well-established role of sustained Ca2+ 
entry via L-type VOCC and activation of CaM-kinase II in gene activation, via 
phosphorylation of transcription factors and regulation of immediate early gene 
transcription (Greenberg et al., 1992). CaM-kinase II is a ubiquitous multifunctional,
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cytosolic enzyme activated by signal transduction pathways that result in the elevation 
of [Ca2+]i (for review see, Schulman, 1993). This protein kinase is abundant in brain 
where it is enriched in neurones (Bennett et al., 1983; Ouimet et al., 1984) and has been 
implicated in diverse cellular functioning. CaM-kinase II has been suggested to have a 
pivotal role in the regulation of synaptic strength and growth of dendrites (Mayford et 
al., 1995; Lisman et al., 1997; Wu and Cline, 1998), in the maturation of synapses 
during development (Wu et al., 1996) and to encode ‘memory’ in neurones (Lisman, 
1985, 1994; Malinow et al., 1988; Silva e ta l,  1992).
To establish if Ca2+ influx and/or the activation of a CaM-kinase II pathway were 
essential mechanisms underlying nicotinic agonist- or KCl-evoked upregulation of 
[125I]-a-bgt binding sites in SH-SY5Y cells, experiments were performed using the L- 
type Ca2+ channel blocker, verapamil (5 pM) and the potent CaM-kinase II inhibitor 
KN-62 (5 jiM). KN-62 has previously been found to have a K\ value of 0.9 pM for 
inhibition of CaM-kinase II activity, with inhibition being competitive with respect to 
calmodulin and hence binding directly to the calmodulin binding site on the enzyme 
(Tokumisto et al., 1990). Verapamil and KN-62 were found to inhibit KCl-evoked 
upregulation but had no effect on nicotine-induced upregulation of [125I]-a-bgt binding 
sites. These binding data generated with the SH-SY5Y cell line closely parallel the 
differential sensitivity of primary hippocampal cultures to verapamil and KN-62. This 
suggests that the mechanism is common to different types of neurones. Upregulation 
evoked by nicotine was neither dependent on Ca2+ flux through L-type VOCC nor 
involved a CaM-kinase II pathway, as increases in [125I]-a-bgt were maintained in the 
presence of either verapamil or KN-62. Figure 3.26 summarises these results. These 
data compliment the data produced by De Koninck and Cooper (1995) in SCG neurones
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and provide further support that SH-SY5Y cells are a valid model system to investigate 
the mechanisms of nAChR upregulation operating in the CNS.
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Figure 3.26. A representation o f KCl- and nicotinic agonist-evoked upregulation o f [I25I]-a- 
bgt binding sites in SH-SY5Y cells. Chronic treatment o f SH-SY5Y cells for 4 days upregulates 
[I25l]-a-bgt binding sites (indicated as H receptors on the cell surface) after (a) KCl depolarisation by 
Ca2+ influx through L-type VOCC and by a CaM-kinase II-dependent pathway or (b) Nicotine by a 
pathway not involving L-type VOCC or CaM-kinase II.
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CaM-kinase II has recently been reported to act as a critical signalling element 
required to regulate changes in synaptic strength of the density of glutamatergic 
synapses within the ventral nerve cord synapses in Caenorhabditis elegans (C. elegans) 
(Rongo and Kaplan, 1999). It was found that a coupling of CaM-kinase II and VOCC 
was the mechanism for maintaining the level of AMPA-type glutamate receptors (GLR- 
1) at a constant density in C. elegans (Rongo and Kaplan, 1999). In wild-type worms 
Ca2+ influx via VOCC and CaM-kinase II activity promoted the transport of GLR-1 
from the cell body to synapses. Wild-type C. elegans have a single CaM-kinase gene, 
unc-43; in worms lacking the unc-43 gene GLR-1 accumulates in the cell body. This 
could be analogous to and be a putative mechanism occurring with KCl-evoked
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upregulation of the density of a l*  nAChR in both SH-SY5Y cells and primary 
hippocampal neurones in culture. Under KCl depolarisation, VOCC channels are 
activated and increase [Ca2+]i within the cell. CaM-kinase II is activated by Ca2+ and 
could regulate receptor trafficking perhaps by augmenting the transport of nascent 
receptors from the cell cytoplasm to increase [125I]-a-bgt binding sites located on the 
cell surface. In the presence of the CaM-kinase II inhibitor KN-62, this process could be 
disrupted and would therefore result in the inhibition of upregulation of surface a7* 
nAChR. It would be reasonable to suggest that these a l * nAChR could be accumulated 
intracellularly within the cell cytoplasm, resulting in a level of expression of surface 
[125I]-a-bgt binding sites similar to control untreated cells. The accumulated 
intracellular a l*  nAChR would not be detected with [I25I]-a-bgt binding assays due to 
the large, protinaceous cell impermeant nature of this radiolabelled snake toxin and its 
inability to penetrate the cytoplasm and label intracellular a l*  nAChR. A proposed 
scheme for this process is summarised in Figure 3.27. [3H]-MLA, an a l  antagonist that 
is capable of crossing the cell membrane, would aid in the detection of any intracellular 
a l*  nAChR accumulated in the presence of KN-62. This would help to distinguish a 
role for CaM-kinase II in receptor assembly and trafficking or gene transcription (or 
both).
The activity of CaM-kinase II has been previously reported as having dual regulation 
by membrane voltage (Xiao et al., 1994; Williams et al., 1996) and by Ca2+ influx via 
depolarisation of L-type VOCC (Jefferson et al., 1991; Ocorr and Schulman, 1991; 
MacNicol and Schulman, 1992; Xiao et al., 1994). ICK, a CaM-kinase II peptide 
inhibitor (CaM-kinase II fragment-(290-309)), abolished calcium currents elicited by 
Ca2+ influx or by membrane depolarisation in cardiac myocytes (Xiao et al., 1994). This
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modulatory effect of CaM-kinase II by depolarisation may be extrapolated to the 
increased KCl concentration applied to SH-SY5Y cells or primary hippocampal 
neurones and could establish a positive feedback loop evoked by KCl by placing the 
Ca2+ channel proteins into conformations more favourable for phosphorylation by CaM- 
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Figure 3.27. A model fo r CaM-kinase II (CaMK II) regulation o f a7* nAChR evoked by 
KCl depolarisation in SH-SY5Y cells or primary hippocampal neurones, (a) KCl
depolarisation mediates Ca2T influx through VOCC, CaM-kinase II is activated by Ca2+ to putatively 
promote transport o f intracellular a7* nAChR from the ‘stores' to synapses, and addition or stability 
at nicotinic synapses located on the cell surface, detected by [I25I]-a-bgt (indicated as H  receptors on 
the surface), (b) illustrates the inhibitory effect of KN-62 on KCl-evoked upregulation of surface [I25I]~ 
a-bgt binding sites, leading to an accumulation of al* nAChR within the cell cytoplasm due to 
inhibition of CaM-kinase II activity (indicated as H receptors intracellularly, undetected by [I25I]-a- 
bgt). Adapted from Rongo and Kaplan, (1999).
KN-62 has also been proposed to inhibit depolarisation-dependent Ca2+ influx via 
VOCC without affecting Ca2+ mobilisation from intracellular stores (Williams et al., 
1996) as well as inhibiting CaM-kinase II in small cell lung carcinoma (SCLC) SCC-9 
cells (Williams et al., 1995). VOCC in SCLC seem to be regulated in a similar manner 
to those found in neuronal cells. The ability of CaM-kinase II to phosphorylate L-type
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(Chang et al., 1991) and N-type (Hell et al., 1994) VOCC provides a possible 
mechanism by which CaM-kinase II could regulate the activity of VOCC. Li et al. 
(1992) suggested that KN-62 mediated inhibition by direct blockade of VOCC in HIT- 
T15 cells, rather than a CaM-kinase dependent pathway. This was concluded after KN- 
62 was found to inhibit VOCC in previously depolarised cells that should have been 
fully activated by CaM-kinase II and hence insensitive to subsequent addition of this 
inhibitor. In contrast, Williams et al. (1995) demonstrated that KN-62 did not 
significantly inhibit VOCC activity in SCC-9 cells previously depolarised before the 
application of KN-62 and therefore these cells have fully activated CaM-kinase II. Pre­
incubation with KN-62 was found to inhibit depolarisation-dependent 
autophosphorylation of CaM-kinase II (Williams et al., 1996). These findings are 
consistent with the hypothesis that the inhibition of VOCC by KN-62 in SCC9 cells is 
due to inactivation of CaM-kinase II, rather than a direct block of VOCC.
In the experiments described in the present study, KN-62 may inhibit KCl-evoked 
upregulation of a7* nAChR by an inhibitory action on CaM-kinase II and/or by a direct 
blockade of VOCC after co-application of KCl with KN-62. The underlying mechanism 
by which CaM-kinase II promotes upregulation of a l * nAChR trafficking and 
localisation is as yet unknown. Upregulation of a l * nAChR by KCl depolarisation 
could be a form of neuronal plasticity utilised to maintain synapses and their growth in 
developing neurones.
3.19. Upregulation of [3H]-epibatidine binding sites in SH-SY5Y cells:
After investigating the effect of chronic drug treatment on numbers of a l * nAChR, it 
was decided to examine the effect of these same chronic drug treatments on a3*
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nAChR detected with [3H]-epibatidine binding. In SH-SY5Y cells, [3H]-epibatidine 
could label a variety of different subtypes of human a3* nAChR, namely a3p2, 
a3p2a5, a3p4, a3p4a5 and a3a5P2p4 combinations. All of these receptor complexes 
respond in a concentration dependent manner to ACh and are therefore capable of 
forming functional nicotinic receptor ion channels (Wang et al., 1998). Wang et al. 
(1998) previously demonstrated that upregulation of a3* nAChR depended on the 
presence of the P2 subunit, and that approximately 56% of a3* receptors also contained 
the P2 subunit. Hence, a3p2 and a3p2a5 heterogeneous nAChR complexes were 
upregulated after chronic exposure to nicotine and carbamylcholine whereas their P4 
counterparts were not significantly altered (Wang et al., 1998). Intrinsic differences 
between the P2 and P4 subunits, including differences in their efficiency of synthesis, 
maturation or assembly of the different P subunits with a3 subunits, could determine 
the fate of a3 nAChR subunits with regard to upregulation. These differences may lead 
to alterations in the turnover of receptor numbers, with the a3p2 receptor complex 
being longer lived and more stable than the a3p4. It seems that an alteration in receptor 
synthesis, maturation or assembly is a logical explanation for nicotine-evoked 
upregulation because in the absence of protein synthesis, nicotine still upregulates the 
amount of a3p2 nAChR to 25% as compared to in the absence of cycloheximide (6-fold 
upregulation versus 24-fold upregulation) (Wang et al., 1998). In the tsA201 cell line 
stably transfected with a3 and p2 subunits, nicotine-evoked upregulation was observed 
as soon as after 15 minutes exposure (Wang et al., 1998). Due to this rapid increase in 
nAChR numbers, the upregulation is probably mediated by an enhanced assembly of a3 
and P2 subunits from subunit reserves already present in the cells, rather than from an 
increase in de novo subunit synthesis (Wang et al., 1998). This concept of enhanced
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subunit maturation or assembly of upregulated a3* nAChR evoked by nicotine is also 
proposed by Peng et al. (1997).
The binding assays performed over the course of this project to detect a3* nAChR 
used a modest concentration of [3H]-epibatidine at 500 pM. This concentration of 
radioligand will predominantly detect p2* nAChR (Wang et al., 1998). In the present 
study [3H]-epibatidine binding sites were differentially upregulated by chronic drug 
treatment. Nicotinic agonists, nicotine (10 pM) and DMAC (10 pM) were found to 
upregulate [3H]-epibatidine binding sites to 36 ± 6% and 43 ± 8% respectively above 
control levels observed in untreated SH-SY5Y cells. The upregulation of [3H]- 
epibatidine binding sites reported in this study is somewhat lower than previously 
reported for SH-SY5Y cells (Peng et al., 1997). In the present study, lower 
concentrations of nicotine (10 pM) were used to evoke upregulation, compared to 
previous reports that have generally used 1 mM nicotine to elicit upregulation of the 
a3* and also a7* nAChR in SH-SY5Y cells: therefore a lower level of upregulation 
might be expected. The recent report by Peng et al. (1997) revealed a 575% increase in 
total a3* nAChR with only a 30-40% increase of surface a3* nAChR expressed in SH- 
SY5Y cells after chronic nicotine (1 mM) exposure. This concentration of nicotine is 
400-fold higher than concentrations required for the upregulation of a4J32 nAChR 
expressed in fibroblast M10 cells (Peng et al., 1997; Warpman et al., 1998; Whiteaker 
et al., 1998) and 100-fold higher than used in the present study.
There is evidence that upregulation of the a3* nAChR is mediated at the cell surface 
as the membrane impermeable quaternary nitrogen containing ligand carbamylcholine 
also induced a concentration-dependent upregulation of intracellular ot3* nAChR in SH- 
SY5Y cells (Peng et al., 1997). The channel blocker mecamylamine was found not to
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upregulate a3* nAChR and did not inhibit upregulation evoked by nicotine. This 
implies that mecamylamine itself does not induce the conformation of a3* nAChR 
required for upregulation, and that ion flow through a3 nAChR is not a requisite signal 
to the intracellular compartment of SH-SY5Y cells to initiate the rapid upregulation of 
a3* nAChR (Peng e ta l., 1997).
Previous studies have revealed that upregulated a3* nAChR are mainly located 
intracellularly in SH-SY5Y cells after chronic exposure to nicotine (Peng et al., 1997; 
Wang et al., 1998). Confocal analysis was employed in the present study to detect a3* 
nAChR subunits by using a polyclonal antibody that labels the intracellular portion of 
the loop between TM3 and TM4 of the a3 nAChR subunit. Most of the fluorescence 
observed was of a3 nAChR subunits located within the cell cytoplasm where they 
would be non-functional. Peng et al. (1997) demonstrated the inhibition of nicotine- 
evoked upregulation of oc3* nAChR by using antigenic modulation, and that the 
receptors affected by nicotine had previously been located on the surface of SH-SY5Y 
cells. Perhaps chronic exposure to nicotinic agonists leads to receptor internalisation 
and accumulation rather than receptor degradation.
Specific antibodies that label extracellular portions of the a3 subunit were not 
available to us at the time of this study, but would be useful as a comparison for total 
versus surface a3 nAChR subunits in control and drug treated cells. Both nicotine and 
DMAC treated cells appeared to have greater intracellular staining of the a3 nAChR 
subunit than control conditions. Chronic KC1 depolarisation resulted in the staining of 
a3 nAChR subunits similar to that in control untreated SH-SY5Y cells. This is 
consistent with the finding that KC1 depolarisation does not upregulate a3* nAChR as
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detected by [3H]-epibatidine binding. This is in contrast to KCl-evoked upregulation of 
[125I]-a-bgt binding sites in both SH-SY5Y cells and in primary hippocampal cultures.
By using the technique of confocal microscopy qualitatively this method allows for 
the assessment of the presence or absence of different nAChR subunits by using a 
variety of specific mAb for different nAChR subunits. Quantitative analysis of the 
fluorescence signal recorded from different samples and treatment conditions will vary 
due to different coverslips used and if the mAb was applied slightly longer than another. 
A numerical estimate of the mean fluorescence intensity can be made, however a large 
sample population would be required to generate a reliable quantitative statistical 
analysis.
3.19.1. M echanisms o f nicotinic agonist-evoked upregulation o f [3H]-epibatidine 
binding sites in SH-SY5Y cultures:
The interesting finding that KC1 upregulated a7* but not a3* nAChR and that the 
nicotinic agonists nicotine and DMAC evoked upregulation of both a3* and a7* 
nAChR led to further analysis of the underlying mechanisms of nicotinic agonist- 
induced upregulation of [3H]-epibatidine binding sites. Experiments were conducted to 
investigate the effect of Ca2+ influx using verapamil, the inhibition of CaM-kinase II 
with KN-62 and the effect of inhibiting PKC with Ro 31-8220. None of these
• * 3  _ icompounds were able to prevent the nicotine or DMAC evoked upregulation of [ H]- 
epibatidine binding sites. This demonstrated that nicotinic agonist-evoked upregulation 
of a3 * nAChR was not mediated by Ca2+ influx through L-type VOCC, nor by CaM- 
kinase II or PKC pathways.
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A surprising yet interesting result was obtained when KN-62 was applied to SH- 
SY5Y cultures alone for 4 days. A huge 2-3 fold upregulation of [3H]-epibatidine 
binding was produced when compared to control untreated cells. To determine if this 
effect was a specific action due to the inhibition of CaM-kinase II, the effect of KN-04 
was investigated. KN-04 is an inactive structural analogue of KN-62 and therefore does 
not inhibit CaM-kinase II (Ishikawa et al., 1990). SH-SY5Y cultures in the presence of 
KN-04 for 4 days produced no change from control in the level of [3H]-epibatidine 
binding, indicating that the upregulation obtained with KN-62 must reflect a direct 
inhibitory action of CaM-kinase II. The upregulatory effect of KN-62 was maintained in 
the presence of nicotinic agonists with a particular enhancement in the presence of 
DMAC. If the Rongo and Kaplan (1999) proposal for regulation of the density of 
glutamatergic synapses by a CaM-kinase II-dependent pathway is taken into 
consideration (as described in section 3.18.1), it may help to relate to and understand the 
maintenance of ot3* nAChR in control cells and the enhanced [3H]-epibatidine binding 
detected in the presence of KN-62. A proposed scheme is shown in Figure 3.28 for the 
regulation of [3H]-epibatidine binding sites in control and KN-62 treated SH-SY5Y 
cells.
This scheme could account for the huge increase in a3* nAChR detected in the 
presence of KN-62 alone due to inhibition of CaM-kinase II and a potential alteration in 
the trafficking of a3 from the cell cytoplasm to expression on the cell surface. This 
would promote the accumulation of a3* nAChR subunits within the cytoplasm that are 
labelled together with surface a3 binding sites by [3H]-epibatidine, due to its cell 
permeant nature (which is in contrast to the membrane impermeable [125I]-a-bgt). 
Conformation of an increase in intracellular receptors detected with [3H]-epibatidine
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Figure 3.28. A model fo r  CaM-kinase II  (CaMK II) regulation o f  ct3* nAChR in SH-SY5Y  
cells, (a) In control conditions CaM-kinase II activity promotes the transport o f a3* nAChR from the 
cell cytoplasm to the cell surface, and addition or stability at nicotinic synapses located on the cell 
surface to maintain basal levels of a3* nAChR (b) Illustrates the effect of KN-62 in control cells 
leading to an accumulation of a3* nAChR within the cell cytoplasm due to inhibition of CaM-kinase II 
activity (receptors detected by [3H]-epibatidine are indicated as 00, located on the surface and 
intrace llularly in SH-SY5Y cells). Adapted from Rongo and Kaplan (1999).
If a huge upregulation of [3H]-epibatidine binding sites is maintained by KN-62 in the 
presence of ACh, it would confirm that KN-62 promotes upregulation of non-functional 
intracellular a3* nAChR perhaps by a process involving the disturbance of trafficking 
of a3* nAChR from the cell cytoplasm to cell surface (adapted from the hypothesis 
proposed by Rongo and Kaplan, 1999). Upregulation o f [3H]-epibatidine binding sites 
produced by KN-62 alone is perhaps not quite so surprising as first thought. The action 
of KN-62 is interesting with respect to a possible trafficking pathway of a3* nAChR in 
control cells involving a CaM-kinase II, analogous to the regulation of glutamatergic 
synapses in C. elegans (Rongo and Kaplan, 1999)
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3.20. Is transcription involved in the upregulation of a3 and a l  
nAChR subunits in SH-SY5Y cells?:
The mechanism by which nicotinic agonists increase a3* and a7* nAChR numbers 
remains unknown. One possible explanation is that the increase in these receptor 
subtypes is regulated by increases in transcription or stabilisation of the poly (A)+ RNA, 
producing an elevation in the quantity of RNA encoding for the receptor subunits. 
Initial studies performed in Section 2 used the technique of reverse transcription, 
coupled with the polymerase chain reaction (RT-PCR) which is an extremely sensitive 
method for detecting the expression of specific RNA transcripts. The apparent low 
expression of the a l  subunit in SH-SY5Y cells was not a problem, as the detection of 
any gene using this technique is not limited by the paucity of initial starting material. In 
the process of PT-PCR the RNA template during the procedure of reverse transcriptase 
is copied into a complementary DNA (cDNA) transcript, this is followed by a series of 
polymerase chain reactions (PCR) that exponentially amplifies the cDNA by a 
thermostable DNA polymerase. Warpman et al. (1998) performed RNase protection 
assays with SH-SY5Y cells to identify the levels of different subunit transcripts and 
found it hard to quantitate the level of a l  expression in SH-SY5Y cells, due to the a l  
mRNA content being below the level of detection compared to the other nAChR 
transcripts. RT-PCR analysis in the present study identified the presence of both a3 and 
a l  nAChR subunits in SH-SY5Y cells, but because of the amplification technique it 
was not possible to quantitate the level of expression of these subunits in drug treated 
conditions versus control untreated cells.
A recent study demonstrated that nicotine treatment (1 mM for 4 days) increased the 
density of a3* and a l * nAChR without upregulating the transcription of a3 and a l
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subunit mRNA (Peng et al., 1997). The present study also demonstrated the failure of 
nicotinic agonists to upregulate a3 and a7 nAChR RNA levels by Northern analysis. 
Northern blotting is a time-consuming method that requires RNase-free techniques and 
reagents, as this method of RNA detection is extremely vulnerable to RNA degradation. 
The result obtained with a l  is preliminary, as levels of the a l  RNA were difficult to 
detect when using either total cellular RNA or poly (A)+ RNA in Northern analysis. 
Northern analysis allows for a direct relative comparison of message abundance 
between samples on a single membrane.
KC1 depolarisation (20 mM) did not alter the level of expression of the a3 transcript, 
but it did upregulate the a l  transcript to 137% above control levels. This preliminary 
result is in agreement with the significant increase of 156 ± 15% (above control 
expression) detected for the a l  subunit transcript after 40 mM KC1 applied to 
sympathetic SCG neurones for 48 hours (De Koninck and Cooper, 1995). The induction 
of expression of the a l  nAChR subunit by membrane depolarisation can therefore be 
postulated to be due to an influx of Ca2+ through L-type VOCC and by a CaM-kinase II 
dependent pathway identified by KN-62. The effects of KN-62 are perhaps due in part 
to inhibition of Ca2+ influx via a possible inhibition at VOCC, this has been discussed 
above in section 3.18.1 and also addressed by Li et al. (1992) and Wyllie and Nicoll 
(1994). L-type VOCC have previously been reported to have a role in the regulation of 
the expression of immediate early genes within neurones (Murphy et al., 1991b; Bading 
et al., 1993; Bessho et al., 1994; Enslen and Soderling, 1994; Rosen et al., 1994; Ghosh 
and Greenberg, 1995) and to target the nucleus (Srinivasan et al., 1994).
Together, the binding data suggest that upregulation of [125I]-a-bgt and [3H]- 
epibatidine binding sites evoked by nicotinic agonists are not mediated by an increase in
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a3 or a l  nAChR subunit RNA. These data are in agreement with Peng et al. (1997) 
who observed no change in a3 or a l  mRNA levels after chronic nicotine exposure. 
Figure 3.29 summarises the proposed action of KC1 depolarisation and nicotinic 
agonists on cx3* and a l * nAChR in the SH-SY5Y cell line.
Previous in vivo and in vitro studies investigating high affinity nicotinic binding 
sites, have shown that upregulation of the 0,402 nAChR complex by nicotinic agonists 
is by an increase in the Bmax (fmoles/mg protein) with no apparent increase in affinity of 
the a402 nAChR for nicotine (Bencherif et al., 1995). Peng et al. (1994b) reported that 
nicotine increases a402 AChR in transfected M10 cells with no change in the level of 
a4  or 02 subunit mRNA expression. A process involving increased transcription has 
therefore been ruled out as a possible pathway for the resulting upregulation of mRNAs 
coding the a4  or 02 subunits. This has been also been demonstrated in vivo (Flores et 
al., 1992; Marks et al, 1992) as well as in vitro (Peng et al., 1994b, 1997; Zhang et al, 
1995; Warpman et al., 1998). Peng et al. (1994b) reported that chronic nicotine induced 
upregulation of a402 nAChR may involve post-transcriptional mechanisms. A variety 
of hypotheses have arisen to suggest post-transcriptional mechanisms including, a 
decrease in receptor turnover (Peng et al., 1994b), the recruitment of nAChR from a 
pre-existing pool of receptors (Bencherif et al., 1995), an increased efficiency of 
assembly of subunits into receptor complexes (Rothhut et a l, 1996), or indeed altered 
rates of translation (Gopalakrishnan et al., 1997). It should also be taken into 
consideration that these studies with high affinity nAChR are all from cell lines that 
have been transfected with the a4  and 02 subunits and not from a system where they are 
endogenously expressed. Using cell lines transfected with either a3 and 02 subunits or
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a l  nAChR subunits would be useful to compare data generated in SH-SY5Y cells that 
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Figure 3.29. A representation o f  KCl- and nicotinic agonist-evoked upregulation o f nAChR 
binding sites in SH-SY5Y cells. Chronic treatment o f SH-SY5Y cells for 4 days with either (a) KCl 
depolarisation upregulates [,25I]-a-bgt binding sites by Cct2 influx through L-type VOCC and by a CaM- 
kinase I I-dependent pathway that increases the transcription o f a7* nAChR subunit RNA or (b) Nicotinic 







The identification of a post-transcriptional mechanism of upregulation for a4p2 
nAChR mediated by chronic nicotine may also be extrapolated to the SH-SY5Y cell 
line for both the a3* and a l * nAChR. The failure of chronic nicotinic agonist treatment 
to upregulate transcription of a3 or a l  subunit RNA in SH-SY5Y cells is consistent 
with previous observations with the effect of nicotine in brain tissue on a4 and p2 
subunit expression (Marks et al., 1992). This study therefore leads to the proposal that 
nicotinic agonists upregulate a3* and a l * nAChR by a post-transcriptional mechanism 
that may be similar to that upregulating the a4p2 high affinity nAChR. Studies with the 
tsA2013 cell line transfected with a3 and p2 nAChR subunits conclude that chronic 
nicotine treatment evoked upregulation by an assortment of processes, including an
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increase in the rate of nAChR subunit synthesis, maturation and assembly (Wang et al., 
1998).
Bencherif et al. (1995) examined possible mechanisms underlying upregulation of 
the high affinity a4f>2 nAChR using both primary cultures of fetal rat brain cortex and 
the M10 clonal cell line. The former naturally expresses high affinity [3H]-nicotine 
binding sites whereas the latter are stably transfected with the a4  and P2 nAChR 
subunits which are under the control of a dexamethasone-inducible promoter. Removal 
of dexamethasone (1 |uM; 2 days) from M10 cultures terminates the synthesis of new 
a4p2 nAChR and enables the study of degradation of a4p2 receptors, a 50% reduction 
in [3H]-nicotine binding was observed after 24 hours (Bencherif et al., 1995). If nicotine 
(1 (iM) is applied to the cells at the time of removal of the dexamethasone an elevation 
from control values in the level of [3H]-nicotine binding results. The effect of chronic 
nicotine was interpreted to be a result of degradation of pre-existing nAChR and 
recruitment of nAChR complexes from a finite pool of receptors previously undetected 
by high affinity agonist binding. In cells where nicotine is applied at the time of 
removal o f dexamethasone, the prevention of new receptor synthesis is compensated for 
by the recruitment of receptors from the finite pool, giving the impression of a reduction 
in receptor turnover. In cells already exposed to nicotine treatment to upregulate nAChR 
before dexamethasone withdrawal, the pool containing receptor reserves is used and 
will hence not make up for subsequent receptor degradation.
Peng et al. (1997) argue against a decrease in the degradation rate of oc3* nAChR 
after chronic nicotine treatment compared to control. Cells treated with or without 
nicotine before the addition of cycloheximide to block protein synthesis of new nAChR, 
did not alter the turnover rate of a3* nAChR (Peng et al., 1997). This is in contrast to
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observations found with the action of cycloheximide on a4(32 nAChR (Peng et al., 
1994b; Rothhut et al., 1996), indicative that a decrease in nAChR turnover may be 
restricted to cell lines that have been stably transfected with subunits rather than 
endogenously expressing them. The action of cycloheximide was not investigated in the 
present study with [3H]-epibatidine binding due to its observed cytotoxicity and general 
deleterious effect when previously applied to SH-SY5Y cells either alone or with 
chronic KCl and nicotine treatment to detect changes in [125I]-a-bgt binding (see section 
3.4.4).
To conclude, from this and previous studies the underlying mechanism o f KC1- 
evoked upregulation of surface [125I]-a-bgt binding sites involves L-type VOCC and a 
CaM-kinase II pathway which in turn leads to an increase in a7  subunit RNA. In 
contrast, the mechanism underlying nicotinic agonist-induced upregulation of a3, a7
i ̂  c
and a4p2 nAChR subtypes remains unknown. From this study, upregulation of [ I]-a-
bgt and [3H]-epibatidine binding sites evoked by nicotinic agonists is not clear but does 
not seem to involve Ca2+ flux through L-type VOCC, a CaM-kinase II or PKC pathway 
or by increasing the level of either a3 or a7  subunit RNA levels. Chronic nicotinic 
agonist treatment indicates that the upregulation of a3* and a7* nAChR must be via a 
post-transcriptional mechanism and perhaps this mechanism shares pharmacological 
and cellular properties with the mechanism of upregulation of the higher affinity a4p2 
nAChR.
Chapter 4. Functional Studies in SH-SY5Y cells.
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4.1. Introduction to the calcium signal and the cell:
Ca2+ has been proposed as a key common biological regulator and trigger that gives 
rise to many diverse cellular events. Ca2+ acts as an internal signal and can be 
considered as a universal ionic messenger important in cellular signal transduction and 
has a role in a variety of neuronal processes. Examples of events involving a minute 
Ca2+ flux across the cell membrane include the secretion of hormones, the release of 
neurotransmitters from the presynaptic nerve terminal into the synaptic cleft, neuronal 
excitation and plasticity that is responsible for the processes of learning and memory 
(Miller, 1988; Berridge etal., 1998; Fossier et al., 1999). The Ca2+ signal is required as 
a signal for cell life, fertilisation, development and proliferation of cells. Ca2+ has also 
been implicated in the disintegration of cells (necrosis) and in programmed cell death 
(apoptosis) (Miller, 1988; Berridge et al., 1998; for review see, Toescu, 1998) after a 
rapid influx of Ca2+ passes into the cell and produces a prolonged Ca2+ rich 
environment, as associated with cerebral ischaemia, and other pathological disease 
states including AD, AIDS and cancer. AD and PD are of interest with respect to 
neuronal nAChR, due to these conditions having altered numbers of receptors in 
specific brain regions, as introduced in sections 1.9.2 and 1.9.3. The paradoxical action 
of Ca2+ (life and death signal) has a pivotal role in conveying different incoming signals 
received at the cell surface, to mediate an increase in [Ca2+]i and activate Ca2+- 
dependent intracellular signalling pathways within cells (Berridge, 1998; Berridge et a l, 
1998).
The resting [Ca2+]i within a cell is usually in the range 50 to 100 nM which is about 
ten thousand times lower than the extracellular [Ca2+] (Miller, 1988; Taylor and Broad, 
1998). In the past there have been difficulties associated with the measurement of such 
intracellular free ion concentrations. Recent advances in this field have made it possible
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to detect Ca2+ in many cellular scenarios. Developments include the founding of user- 
friendly fluorescent chelating agents, fura-2, fluo-3, quin-2 and indo-1, that have 
advanced the investigation of different intracellular ion concentrations within the 
cytosol of living cells (Tsien, 1988; Neher, 1995). In vitro cell biology has been 
transformed by the development of fluorescent agents that undergo a change in their 
fluorescent profile after ion binding. Fluorescent chelating agents allow the quantitative 
measurement of cytosolic free [Ca2+] and a comparison between control and drug 
stimulated conditionings. Using SH-SY5Y cells loaded with a fluorescent chelating 
agent, exact concentrations of an acute drug challenge can be applied to the cells in 
suspension and produce direct drug-concentration-response relationships.
The fluorescent probes used to identify changes in [Ca2+]i have had an enormous 
impact due to their non-destructive nature to living cells once loaded into the cellular 
cytoplasmic compartment. These probes are useful for investigating the changes in 
[Ca2+]i in living cells evoked by different external stimuli. Previously, SH-SY5Y cells 
have been used to investigate the effects of muscarinic (Lambert and Nahorski, 1990; 
Lambert et al., 1990; Murphy et al., 1991a; Forsythe et al., 1992) and nicotinic 
responses (Forsythe et al., 1992), and bovine chromaffin cells to examine increases in 
[Ca2+]i evoked by nicotine (Lopez et al., 1993). The parent SK-N-SH human 
neuroblastoma cell line has been used to identify Ca2+ influxes mediated via nAChR 
and VOCC (Noronha-Blob et al., 1989). Cell lines stably transfected with nAChR 
subunits have also been used to examine nAChR responses for example, GH4 C 1 rat 
pituitary cells (Quik et al., 1997) and HEK cells stably transfected with a7  nAChR 
subunits (Molinari et al., 1998).
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4.1.2. M echanism s that raise |C a 2+]i; C a2+ entry pathw ays and release 
from  internal stores:
At a cellular level, Ca2+ is capable of entering cells by several routes. Activation of 
either VOCC opened by voltage, or receptor-operated Ca2+ channels for example, 
glutamate receptors that respond to NMDA (Rogers and Dani, 1995), will mediate Ca2+ 
entry to the cell from extracellular sources (Figure 4.1). nAChR also represent a class of
fy » i
receptors permeable to Ca as well as Na (for review, see Sargent 1993). In
o  i ' j  i
particular, the a7* nAChR possess the greatest Ca :Na permeability when the a7 
subunit gene is expressed as homomeric receptors in Xenopus oocytes, values are 





Figure 4.1. A schematic representation o f the major cellular 
Ca2+ transport pathways showing both Ca2+ buffering and 




Ca2+ can also be released into the cell from internal stores, via store-operated Ca2+ 
channels located on the endoplasmic or sarcoplasmic reticulum (Berridge, 1993; Taylor 
and Broad, 1998). The endoplasmic reticulum is an important continuous membrane 
structural network within cells which maintains a large [Ca2+] gradient (Berridge, 1998). 
The presence of inositol 1,4,5-trisphosphate (IP3) and ryanodine receptors on the surface 
of the endoplasmic reticulum allows for the release of accumulated stored Ca2+ into the 
cytosol of the cell if Ca2+ levels are raised within the cytosol (Ca2+-induced Ca2+- 
release). In essence, the involvement of both the plasma membrane and the endoplasmic 
reticulum regulate the flux of Ca2+ into and out of the cell cytosol from extracellular and 
accumulated Ca2+ stores depending on the [Ca2+]i and can be considered as a binary 
system working synergistically to control a vast array of Ca2+-dependent processes.
4.1.3. Considerations when measuring changes in [Ca ]j with 
fluorescent ion dyes:
Indicator dyes used for ion measurements are chelating agents commonly modelled 
on EGTA, a Ca2+-selective chelating agent that is non-fluorescent and is well suited to 
buffer Ca2+ in physiological ranges (for review, see Cobbold and Rink, 1987). EGTA 
has selectivity for Ca2+ over the smaller divalent cation Mg2+ by an affinity of 
approximately five to six orders of magnitude. Chelating agents, by definition, are 
highly charged molecules and are therefore unable to penetrate the apolar cell 
membrane. This means that the active form of the chelating agent can not be used to 
initially load the cell. Cell loading is usually accomplished using uncharged membrane 
permeable acetoxymethyl (AM) esters that will not bind the ion under investigation. 
After cell entry the AM ester is acted upon by non-specific esterases leading to the 
conversion of the AM-dye into the impermeable active free-acid form of the dye which
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• ■ 2+is capable of ion binding and is trapped within the cell cytoplasm. The binding of Ca 
to the active free-acid form of the chelating dye changes the fluorescence signal 
properties in the presence of Ca2+ compared to the unbound form. Ca2+ fluorescent 
indicators are widely available, easy to use in experimental protocols and are therefore 
useful tools used to measure changes in fluorescence (which can be converted to 
changes in [Ca2+]i). These fluorescent agents have transformed and helped to further 
elucidate the mechanisms involved in mediating changes in cytosolic Ca2+. A suitable 
ion dye should incorporate the following:
1). To determine fluorescence changes and for quantitative analysis of [Ca2+]i 
evoked by different compounds, an indicator dye that exhibits a shift in its 
excitation spectrum upon Ca2+ binding is useful. This will establish a ratio of the 
dye in the Ca2+-free and Ca2+-bound form, from which the [Ca2+]i can be 
calculated by a simple equation (see section 4-.2.3.1).
2). Of central importance is the dissociation constant (Kd), this is a measure of the 
ability of a chelating agent to bind the target ion, which in the present study is 
Ca2+, and can be considered as its binding strength. By definition the Kd of a 
chelation indicator dye is the half-saturation point for that dye. The Kd should be 
compatible with the [Ca2+] range of interest and is usually expressed in units of 
concentration. The smaller the value of the Kd the more powerful and selective a 
chelating agent is, therefore a Kd of in the nanomolar range will be a better target 
ion binder than an agent with a greater Kd value, for example fiira-2 has a KD 
value o f224 nM.
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3). As mentioned above, the form of the chealting agent is important for cell loading. 
The uncharged, hydrophobic dextran or AM esters are favoured for their ease of 
loading and membrane permeable nature. Within the cell after loading, these 
agents are cleaved by cellular esterases to generate the dye in a membrane 
impermeant nature.
4.1.4. Ratiometric calcium dyes:
4.I.4 .I. Fura-2:
When ratiometric dyes are used in fluorescence studies, they allow for the generation 
of quantitative information on changes in [Ca2+]i. Fura-2 is typically the Ca2+ indicator 
dye of choice used for many functional fluorescence studies (Murphy et al., 1991a; 
Forsythe et al., 1992; Barrantes et al., 1995b; Sharpies et al., 2000) and has been widely 
used in imaging microscopy techniques performed on single cells grown on coverslips 
and also following photometric changes in cell suspensions. This indicator dye is 
excited by ultraviolet (UV) radiation at 340 nm in the Ca2+-bound form and at 380 nm 
in the Ca2+-ffee form with an emission at 510 nm. The ratio of the fluorescence 
produced at 340 nm/380 nm is directly correlated to [Ca2+]i by the Grynkiewicz 
equation (Grynkiewicz et al., 1985) (see section 4.2.3.1). Fura-2 is approximately 30 
fold brighter that quin-2 (the first practical non-ratiometric dye) due to it possessing a 
greater extinction coefficient, increased quantum efficiency and being more resistant to 
photobleaching. Complete de-esterification of the AM-ester dye is necessary after 
loading for accurate [Ca2+]i estimates. Sometimes these AM-esters are incompletely de- 
esterified, perhaps due to low levels of cytosolic esterase activity, and result in 
compartmentalisation into organelles (Tsien, 1988).
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4.1.4.2. Indo-1
Indo-1 is another ratiometric dye that possesses brighter fluorescence and a higher 
Kd at 250 nM than compared to fura-2. In contrast to fura-2, this fluorescence Ca2+ 
chelator produces a shift in its emission maximum rather than an excitation shift after 
Ca2+ binding with the Ca2+-bound and Ca2+-ffee forms emitting at 400 and 475 nm 
respectively (Grynkiewicz et al., 1985). Indo-1 is more susceptible to photobleaching 
than fura-2, but is less problematic in terms of incomplete hydrolysis and organelle 
compartmentalisation.
4.1.5. Non-ratiometric dyes:
Non-ratiometric dyes are excited at one wavelength: UV (quin-2) or visible (fluo-3, 
fluo-4) and have a higher emission wavelength, thus resulting in a change in 
fluorescence intensity without a shift in the ratio of wavelength. Quin-2 provided the 
first useful measurements of resting and activated [Ca2+]i, and binds Ca2+ with a 1:1 
stochiometry and a KD of 114 nm, which increases with increased ionic strength and 
increases approximately two fold when the temperature is increased from room 
temperature to 37°C (Cobbold and Rink, 1987). This dye also suffers from poor 
fluorescence brightness (Rink and Pozzan, 1986).
A newer dye, fluo-3 is excited by light in the visible wavelength range, providing 
advantages of reduced autofluoresence from tissue/cells loaded with this agent. Fluo-3 
does not undergo a wavelength shift after binding Ca2+, has a 40 fold fluorescence 
intensity increase and a weaker affinity for Ca2+ (Kd = 400 nM) when compared to 
quin-2 so concentrations of up to 5-10 pM are permitted. This dye has the advantages of 
causing less photodamage and possesses higher absorbency, thus allowing a lower
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concentration of dye on loading. Fluo-4 is another dye based on fluo-3 that possesses 
further improvements for fluorescence procedures and is capable if generating stronger 
fluorescence signals.
4.1.6. Aims:
The main aim of this Chapter is to establish an assay for nicotine- and KCl-evoked 
functional responses by monitoring fluorescence changes in fura-2 loaded SH-SY5Y 
cell suspensions. Changes in [Ca2+]i provide information on the source of Ca2+ entry to 
the cell after receptor activation. Chronic drug treatments that have been shown to 
upregulate nAChR in this cell line will also be applied to establish the functional status 
of upregulated nAChR in response to acute challenges with either nicotine or KCl. 
These experiments will provide an insight into the functional properties of responses to 
both acute and chronic application of nicotinic agonists and KCl depolarisation.
4.2. Methods.
4.2.1. Drugs and reagents:
Nicotine, KCl and verapamil were made up daily in distilled water before addition to 
the cuvette of SH-SY5Y cell suspensions. (±)-Anatoxin-a and mecamylamine were 
stored as stocks of 1 mM in distilled water, at -20°C. a-CTX-Iml and a-CTX-MII were 
kept as stocks of 100 pM and 11.2 pM, respectively, in distilled water at -20°C. MLA 
was kept at -20°C in absolute ethanol, as stocks of 1 pM and 100 pM. Nicotine, 
DMAC, KCl, verapamil, KN-62, KN-04 used for chronic treatment of SH-SY5Y cells
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were made up as described in sections 2.4.2 and 3.3.3 and applied to cells on day 1 of 
drug treatment.
Cadmium chloride and mecamylamine were purchased from Sigma; (±)-anatoxin-a 
fumarate was purchased from Tocris, (Cookson, U. K.); a-CTX-MII was synthesised as 
previously described (Cartier et al., 1996; Kaiser et al., 1998); fura-2, AM solution in 
dry DMSO was purchased from Molecular Probes, (Eugene, Oregon USA). MLA was 
provided by Dr. I. S. Blaghbrough, (Dept. Pharmacy and Pharmacology, University of 
Bath, U.K.).
4.2.2. Maintenance ofSH-SY5Y cells:
SH-SY5Y cells were sub-cultured and grown to confluency in 175 cm2 flasks 
containing 25 ml of supplemented medium as described in section 3.3.2. For chronic 
treatments, drugs were added 3-5 days after the cells reached confluency in the 175 cm2 
flasks. Four days later, the confluent 7-9 day old cultures were harvested for 
measurement of [Ca2+]i.
4.2.3. Measurement of [Ca2+]ii
Measurements of [Ca2+]i from SH -SY 5Y  cells in suspension were made as 
previously described (Murphy et al., 1991a; Forsythe et al., 1992; Sharpies e ta l ., 2000). 
In brief, cultures were washed twice with warm Ca2+-free PBS (150 mM NaCl, 8 mM 
K2HPO4, 2 mM KH2PO4, pH 7.4, 37°C) before removing the cells by incubating for 3 
min at 37°C in Ca2+-free PBS. The cell suspension was centrifuged (500 x g, 3 min) and 
the cell pellet resuspended in 5 ml of Ca2+-free HEPES buffer (10 mM HEPES, 145 mM
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NaCl, 5 mM KCl, 1 mM MgCl2-6 -hydrate, 0.5 mM Na2H P04 and 5.5 mM glucose 
dissolved in millipore water, pH 7.4) and recentrifuged (500 x g, 3 min). The cells were 
loaded with 5 pM fura-2 AM (similar to Lambert and Nahorski, 1990) by resuspending 
the pellet in 3 ml Ca2+-free HEPES buffer containing 0.25% (w/v) BSA, to improve the 
solubilisation of the dye. Cells were incubated for 45 min in darkness at room 
temperature; this enables the fura-2 AM to be internalised within the cytoplasm of the 
SH-SY5Y cells where it becomes hydrolysed by non-specific esterases into the cell
i
impermeant Ca -sensitive fura-2 free acid (see Figure 4.2).
VOCC




Figure 4.2. Determination o f [Ca2+Ji in SH-SY5Y cells using
fura-2 AM. SH-SY5Y cells loaded with fura-2 AM incorporate the dye 
into their cytoplasm where it undergoes hydrolysis by non-specific 
esterases to produce the cell-impermeant Ca2*-sensitive fura-2 free 
acid. Membrane depolarisation opens VOCC and nAChR activation 
increases the [Ca2*],. Ca2* binds to fura-2 causing a shift in its 
excitation wavelength (hvEx) from 2.=380 nm to 1 340 nm. 
Fluorescence emission ( h v ^  is monitored at 1=510 nm. After each 
experiment calibration was performed by the sequential addition of 
0.5% Triton X-100 followed by 20 mM EGTA to obtain Rmax and Rmn 
values respectively, which are used to calculate [Ca2*] using the 
Grynkiewicz equation.
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Excess free dye was removed by x 4 washes by centrifugation (500 x g, 3 min) with 5 
ml of Ca2+-free HEPES buffer. When investigating the effect of the a7-selective 
antagonist a-bgt on nicotinic mediated responses, a-bgt (final concentration 50 nM) 
was co-incubated with fura-2 AM for 45 min at room temperature.
(\ 4̂-The cell density was adjusted to 1-2 x 10 cells/ml and [Ca ]i was measured in 2 ml 
aliquots of cells kept in suspension using a magnetic cell stirred cuvette, maintained at 
37°C by a thermostatically controlled heat exchanger, in a PTI dual-excitation 
photofluorimeter. The excitation wavelengths were 340 nm and 380 nm, with an 
emission wavelength of 510 nm, 4 nm slit width, equipped with Pti software version 
2.060 (Photon Technology International Inc., Deerpark Drive, South Brunswick, 
NJ08852 USA). Before the addition of nicotinic agonist or KCl, 2 mM CaCh was 
introduced into the cuvette and the fura-2 fluorescence was monitored for 80 s (see 
Figure 4.3). Where used, antagonists (mecamylamine (10 pM), MLA (10 nM, 100 nM, 
1 pM), a-CTX-IMI (1 pM) or a-CTX-MII (112 nM)), or inhibitors KN-62 (5 pM), its 
inactive analogue, KN-04 (5 pM) or the L-type VOCC blocker verapamil (5 pM)) were 
added 5 min before the addition of acute nicotine or KCl.
4.2.3.I. Calibration of [Ca2+]i measured in SH-SY5Y cells suspensions:
At the end of the experiment with each cuvette of SH-SY5Y cells in suspension, 
calibration was performed. This was achieved by sequentially adding 0.5% Triton X- 
100 to lyse the cells in order to obtain Rmax (the fluorescence of Ca2+-saturated dye), 
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Figure 4.3. Respective fluorescence traces for (a) Fura-2 at 340 nm and 380 nm as traces 1A 
and 2A and as (b) the fluorescence ratio o f340 nm/380 nm. SH-SY5Y cell suspensions were loaded 
with 5 pMfura-2 before measuring the changes in fluorescence after the application of CaCUfor 80 s until 
a stable baseline has been recorded before the application of nicotine (hie; 10 juM (small response 
observed on this scale)). Calibration was determined by the addition of 0.5% Triton X-100 (T) followed by 
20 mM EGTA (E).
[Ca2+]i was determined from the fluorescence ratio of fura-2 at 340 nm/380 nm 
excitation (A340/A380; given as R below) (Figure 4.3b) as described by the Grynkiewicz 
Equation (Grynkiewicz et al., 1985):
[Ca2+]i = A:Dn(R-RnUn)/(Rmax-R)]*(Sf2/Sb2)
where Kd is the dissociation constant of fura-2 for Ca2+ binding, 224 nM (Tsien et al 
1982), Rmin is the fluorescence ratio under “zero” Ca2+ conditions, Rmax is the 
fluorescence ratio under saturating Ca2+ conditions and Sf2/Sb2 is the ratio for 
fluorescence values of Ca2+-free and Ca2+-saturated fura-2, measured at the excitation 
wavelengths 380 nm and 340 nm respectively and emission at 510 nm. The ratio of
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fluorescence at the two wavelengths, 380 nm and 340nm, is directly related to the ratio
2+
of the two forms of the dye and can be used to calculate [Ca ]i.
4.2.4. Data Analysis:
Changes in [Ca2+]i were expressed as mean ± S.E.M. and, where appropriate, as a 
percentage of the increase in [Ca2+]i recorded from control cells. For concentration- 
response curves, agonist responses were calculated as a percentage of the change in 
[Ca2+]i produced by a maximum stimulating concentration of agonist or KC1 
depolarisation, assayed in parallel SH-SY5Y cell suspensions on the same day. Data 
were expressed as means ± S.E.M. of at least five determinations and the EC50 value for 
concentration-response curves was calculated by fitting the data to the Hill equation, 
using the non-linear least squares curve fitting facility of Sigma Plot V2.0 for windows:
% maximal stimulation = 100%/(l+[L]/EC5o)”̂
where nn is the Hill number, [L] is the concentration of the nicotinic agonist or KC1 
depolarisation, and EC50 is the concentration of ligand that produces 50% maximum 
stimulation. All data were analysed statistically using an analysis of variance (ANOVA) 




4.3.1. Acute nicotine and KC1 depolarisation increase [Ca ]* in SH- 
SY5Y cells:
The resting [Ca2+]i in fura-2-loaded SH-SY5Y celis was 140 ± 4 nM (n=160). An 
acute challenge of nicotine produced an increase in fluorescence, which relates to an
I
elevation of [Ca ]i (Figure 4.4b). Acute nicotine stimulation resulted in a rapid increase 
in fluorescence reaching a maximum within 1-2 s that was sustained as a plateau 
(Figure 4.4b inset). This plateau level was taken to be the value of the nicotine-evoked 
response and used to derive the [Ca2+]i. Nicotine-evoked increases in [Ca2+]i in a 
concentration-dependent manner, with a maximum increase observed in response to 100 
pM  nicotine, which elevated [Ca2+]i by 102 + 9 nM from its resting level (n=29; Figure 
4.4a). Taking this increase in [Ca2+]i in response to 100 pM nicotine as 100%, responses 
to a range of nicotine concentrations were analysed in parallel, and used to construct a 
concentration response curve (Figure 4.4b). The half-maximum response (EC50) for 
nicotine-evoked increases in [Ca2+]i was 7 . 5+4  pM.
Acute stimulation with KC1 depolarisation also produced a concentration-dependent 
response to [Ca2+]i (Figure 4.4c) with a rapid increase in [Ca2+]i and produced a 
maximum value after 1-2 s of application. This level of [Ca2+]i was maintained as a 
steady plateau similar to the responses evoked by nicotine (see inset Figure 4.4c). The 
maximum increase in [Ca2+]i was achieved with 80 mM KC1, which increased the 
[Ca2+]i by 100 ± 12 nM (n=12). Taking the response to 80 mM KC1 as 100% a 
concentration-response curve was constructed for KC1 (Figure 4.4c). The EC50 
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Figure 4.4. The effect o f nicotinic agonists and KCI depolarisation on [Ca2+]i in SH-SY5Y cell 
suspensions, (a) Increases in [C(f*]i evoked by (±)-anatoxin-a (JO pM), nicotine (nic; JO pM, J00 pM) 
and KCI depolarisation (20 mM, 80 mM, 100 mM). (b) A concentration response curve was constructed with 
a range o f nicotine concentrations. The response to 100 pM nicotine was taken as 100% and all other 
values were expressed as a percentage of this. (Inset) A representative time course trace o f [C<f+], evoked by 
nicotine (10 pM). (c) A concentration response curve wav constructed with a range o f KCI concentrations. 
The response to 80 mM KCI was taken as 100% and all other values were expressed as a percentage o f this. 
(Inset) A representative time course trace o f [Ca2+], evoked by of KCI. Data points for both dose response 
curves were fitted to the Hill equation. All values are the mean ± S.E.M. from at least 5 independent cultures.
The increase in [Ca2+]t evoked by (±)-anatoxin-a '17 r_! ~ was measured in parallel 
with nicotine and KCI, and was found to elicit a response comparable to that of 100 pM 
nicotine (Figure 4.4a). We have previously shown that this concentration of (±)- 
anatoxin-a produces a maximum effect (Sharpies et al., 2000) and the present results 
indicate that nicotine (100 pM) and (±)-anatoxin-a (10 pM) are equally efficacious in
evoking increases in [Ca2+]j. This observation is compatible with the fact that (±)-
2 |
anatoxin-a is approximately 10 fold more potent than nicotine. The increases in [Ca ], 
induced by 100 pM nicotine and by 10 pM (±)-anatoxin-a are also similar to that 
evoked by a maximum effective concentration of KCI (Figure 4.4a).
^
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4.3.2. T he effect o f n icotinic antagonists on nA C hR  evoked increases in
[C a2+|j:
Nicotinic antagonists were examined for their effect on nicotine-evoked increases of 
[Ca2+]! in fura-2 loaded SH-SY5Y cell suspensions The increase in [Ca2+]i after acute 
nicotine was completely blocked when SH-SY5Y cells were exposed to 10 pM 
mecamylamine for 5 min before the nicotine challenge (Figs 4.5 and 4.6a). 
Mecamylamine itself had no effect on basal levels of [Ca2+], (Figure 4.5). This result 











5 0  -
Nicotine
4 0 5 0 6 0 7 0 8 0 9 0 100
Time (s)
Figure 4.5. The effect of 
mecamylamine on nicotine-evoked 
increases in [Ca2+f  in SH-SY5Y cells.
The effect of nicotine (100 jjM) was 
observed in the presence cmd absence of 
mecamylamine (10 pM). The antagonist 
was applied 5 min prior to exposure to 
nicotine and was found to completely 
abolish the nicotine-evoked increase in 
[Ccrf, without significantly affecting the 
basal intracellular [Ca ],.
To characterise pharmacologically which nAChR subtypes might be involved in 
mediating the elevation in [Ca2+]i in SH-SY5Y cells, a selection of chemically distinct, 
subtype-selective antagonists were used to address the relative contributions of different
i
nAChR subtypes to the plateau of Ca entry evoked by nicotine. This was achieved 
either by incubating the antagonist with the SH-SY5Y cells at the time of fura-2 loading
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• • • • • 2+(when using a-bgt), or for a 5 min incubation of antagonist following the initial Ca
transient and before the subsequent application of an acute nicotine challenge.
The SH-SY5Y cell line has previously been shown to possess functional a302* 
nAChR, that are upregulated after chronic nicotine treatment (Wang et al., 1998). a3* 
nAChR in SH-SY5Y cells are possible candidates for the functional response mediated 
by nicotine. The a3P2-selective antagonist a-CTX-MII (112 nM; Cartier et al., 1996) 
was found to block 50 ± 5% of the increase in [Ca2+]i evoked by 10 pM nicotine (Figure 
4.6a).
In addition to a3* nAChR, nAChR containing the a7  subunit are also present in SH- 
SY5Y cells. To explore if a7* nAChR contribute to the functional response mediated 
by nicotine, MLA was examined. Because MLA is selective for a7* nAChR when used 
at low nM concentrations, rather than having absolute specificity, it was decided to 
examine the concentration-dependency of MLA inhibition of nicotinic-evoked (10 and 
100 pM) increases in [Ca2+]i (Figure 4.6b). The increase in the [Ca2+]i in response to 10 
pM nicotine was inhibited by 38 ± 10% (n = 6), 44 ± 4% (n = 3) and 53 ± 11% (n = 3) 
by 10 nM, 100 nM and 1 pM MLA respectively, compared to control responses. These 
concentrations of MLA blocked the elevation in [Ca2+]i mediated by 100 pM nicotine 
by 30 ± 9% (n =3), 31 ± 13% (n = 4) and 49 ± 6% (n = 5) respectively (Figure 4.6b). 
The lower concentration of MLA (10 nM) significantly inhibited responses to both 10 
and 100 pM nicotine by similar amounts, and this degree of inhibition was not increased 
by a great deal after raising the concentration of MLA to 100 nM. These data suggest an 
inhibition of the [Ca2+]i evoked by nicotine is mediated in part by a7* nAChR. This was 
further verified using two other a7-selective antagonists. a-CTX-IMI (1 pM; Pereira et 
al. (1996)) and a-bgt (50 nM) were found to block 10 pM nicotine-evoked increases in
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[Ca2+]i by 39 ± 5% (n = 4) and 41 ± 8% (n = 5) respectively; these results are 
comparable to the 40 ± 6 % (n = 4) inhibition mediated by MLA (10 nM) (Figure 4.6a). 
These data show an a l  component of the [Ca2+], mediated response by 10 pM nicotine.
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Figure 4.6. The effect o f nicotinic antagonists on increases in [Ca2+]t evoked by 
nicotine in fura-2 loaded SH-SY5Y cells. SH-SY5Y cell suspensions were incubated with 
either (a) mecamylamine (mec; 10 pM), a-conotoxin-MII (a-CTX-MH; 112 nM), a-bungarotoxin 
(a-bgt; 50 nM), a-conotoxin-lMl (a-CTX-IMI; 1 pM), MLA (10 nM), or co-application of MLA 
(10 nM) and a-CTX-MH (112 nM) prior to an acute nicotine challenge, (b) The effect of various 
concentrations o f MLA were investigated on the response to acute nicotine (10 pM and 100 pM). 
The control response to nicotine (nic; 10 pM or 100 pM) was measured in parallel and expressed 
as 100%. All other responses were calculated as a percentage o f this acute nicotinic response in 
untreated control cells. Each bar represents the mean ± S.E.M. of at least 4 independent 
experiments. * Indicates significantly different from control at p<0.05; one way ANOVA.
When MLA (10 nM) and a-CTX-MII (112 nM) were applied together for 5 min to 
SH-SY5Y cells in suspension, a partially additive inhibition of the nicotine-evoked 
increase in [Ca2+], of 69 ± 9% was produced that was significantly different from the 
inhibition evoked by MLA (10 nM) or a-CTX-MII when applied alone. The a l-  and 
a3p2-insensitive portion of the functional nicotinic response could be due to a3p4*
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nAChR, but selective antagonists for this receptor subtype are not commercially 
available. These data indicate that functional responses evoked by nicotine are mediated 
by at least two receptor subtypes, a3p2* and a l * nAChR.
4.3.3. Acute nicotine and KCI increase [Ca2+]j in SH-SY5Y cells via L- 
type VOCC:
2_j_
Analysis of functional responses is perhaps made more complicated due to Ca 
entry into the cell by other mechanisms for example via Ca2+ channels. Nicotine- and 
KCl-evoked increases in [Ca2+]j were dependent on the presence of extracellular Ca2+ 
(data not shown). Section 3.4.4 has reported that KCl-evoked upregulation in contrast to 
nicotine-evoked upregulation of surface [125I]-a-bgt binding sites involves Ca2+ entry 
via L-type VOCC and a CaM-kinase II-dependent pathway, in contrast to upregulation 
of these sites evoked by nicotinic agonists. It was therefore decided to explore the effect 
of the phenylalkylamine L-type VOCC blocker, verapamil. A 5 min exposure to 
verapamil (5 pM) resulted in the inhibition of both nicotine (10 pM, 100 pM) and KCI 
(80 mM) evoked increases in [Ca2+]i when compared to control (Table 4.1). The 
responses to 10 pM and 100 pM nicotine were inhibited by 53 ± 7% (n = 4) and 82 ± 
4% (n = 3) respectively, and responses to KCI (80 mM) appeared to be slightly less 
sensitive to verapamil showing 31 ± 1% (n = 3) inhibition compared to control.
Chronic treatment of SH-SY5Y cells with verapamil (5 pM) for 1 or 4 days prior to 
harvesting was also investigated. These treatments produced similar levels of inhibition 
of the nicotinic-induced increase in [Ca2+]i by 53 ± 12% (n = 3; 1 day) and 48 ± 4% (n = 
4; 4 days), compared with responses to nicotine (10 pM) from untreated, control cells 
assayed in parallel (Table 4.1). Thus the effect of prior chronic treatment with verapamil
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is comparable to the inhibition of the [Ca2+]i evoked by nicotine observed after an acute 
5 min application of verapamil to the cuvette of cells. However, responses to 20 mM 
KCI were inhibited to 42 ± 5% (n = 3) and 50 ± 4 % (n = 4) after 1 or 4 days prior 
exposure to verapamil respectively. This contrasts with the lack of effect of an acute 
application of verapamil on [Ca2+]i evoked by 20 mM KCI (inhibition of 8 ± 2%; n = 
14). Thus chronic application of verapamil has a similar effect on responses to 10 pM 
nicotine and 20 mM KCI, whereas the acute (5 min) application of this drug has a 
greater effect on the nicotine-evoked response.
Table 4.1. The effect of acute and chronic treatment with verapamil on increases in [Ca2+]i in 
SH-SY5Y cells stimulated by acute nicotine and KCI depolarisation. Significantly different from 
control, *p<0.05, (Oneway ANOVA); n.d. not determined.
Verapamil (5pM) 
[Ca2+]i % of control
CdCl2 (200
HM) [Ca2*], 
(% o f control)
Acute drug 
challenge





Nic 10 pM 47 ± 7% (n=4)* 47 ± 12% (n=3)* 52 ± 4% (n=4)* 24 ± 3%(n=2)*
100 pM 18 ± 4% (n=3)* n.d. n.d. n.d.
KCI 20 mM 91 ± 2% (n=14) 58 ± 5% (n=3)* 50 ± 4% (n=4)* n.d.
80 mM 69 ± 1% (n=3)* n.d. n.d. n.d.
Due to the possibility of verapamil having a non-specific action on nicotinic 
receptors, the effect of CdCl2, a general blocker of VOCC which does not block 
nicotinic currents at the concentration used (200 pM) (Quik et al.y 1997), was examined 
on nicotine-evoked increases in [Ca2+]i accumulation. No significant change in the basal
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[Ca2+]j was observed after a 5 min incubation with CdCh (200 pM) compared to
• • • • 2"buntreated, control cells prior to the application of nicotine. The elevation in [Ca ]i 
evoked by acute nicotine (10 pM) was inhibited by 76 ±  3% (n = 2) in cells pretreated 
with CdCb. This indicates that a major proportion of the nicotine-evoked response 
arises from activation of VO CC. Taken together these results confirm that nicotine and 
KCI depolarisation increase [Ca2+]i in part through Ca2+ influx via V O CC, possibly of 
the L-type subclass.
4.3.4. The effect of chronic drug treatments on nicotine- or KCl-evoked 
responses:
Chronic exposure (4 days) to nicotine (10 pM ), DMAC (10 pM ) and KCI (20 mM) 
was investigated. These concentrations of drugs have previously been demonstrated to 
differentially evoke upregulation of nAChR subtypes after this chronic drug exposure 
regime (see sections 3.4.2 and 3.4.5). Cells subjected to these chronic drug treatments 
were challenged with 10 pM  and 100 pM  nicotine and 20 mM KCI and increases in 
[Ca2+]i examined (Figure 4.7). Nicotine and KCI at concentrations of 10 p M  and 20 mM 
respectively, were chosen to elicit submaximum responses whereas nicotine at the 
higher concentration of 100 pM  was chosen to evoke a maximum increase in [Ca2+]i.
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Figure 4.7. The effect o f  chronic drug 
treatment on fCa2+f  in S H S Y 5 Y  cells. SH-
SY5Y cells were treated with (a) chronic nicotine 
(nic; 10 gM), (b) chronic DMAC (10 gM) and (c) 
chronic KCI (20 mM) for 4 days. On the day of 
assay the cells were washed rigorously before 
measuring [C<f*]i. The effect of acute nicotine 
(nic; 10 gM, 100 gM) and KCI (20 mM) applied 
to untreated control cells was taken as 100% and 
the response to acute drug challenges were 
calculated as a percentage o f this control. Each 
bar represents the mean ± S.E.M. o f at least 4 
independent experiments. * Indicates significantly 
different from control at p<0.05; one way 
ANOVA.
Chronic treatment with both nicotine (10 juM) and DMAC (10 |uM) produced 
significant decreases in the [Ca2+]i measured after an acute submaximum-stimulating 
concentration of nicotine (10 juM) but no significant differences after acute maximum 
stimulating nicotine (100 juM) or KCI challenges (Figure 4.7a and b). Chronic
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pretreatment with KCI (20 mM) elicited significant decreases in function after acute 
submaximum or maximum nicotine concentrations. Although not significant, there was 
a trend towards a decrease in functional responses after an acute KCI challenge in 
chronic KCI pretreated cells when compared to untreated, control cells (Figure 4.7c). 
Responses to acute DMAC were not investigated due to its intense colour, even when 
diluted, which was found to interfere with the fluorescence recording.
4.3.5. The effect of acute MLA on nicotine-evoked responses produced 
by SH-SY5Y cells after chronic drug treatment:
SH-SY5Y cells chronically treated with nicotine or KCI caused a significant decrease 
in the [Ca2+]i, evoked by an acute nicotine challenge, by 27 + 13% (n = 3) and 26 ± 7% 
(n = 4) respectively, compared to the nicotine response elicited in untreated control 
cells. The effect of acute MLA (10 nM) on nicotine-evoked responses was examined in 
cells chronically treated with either nicotine or KCI, to identify if there were any 
changes in the proportion of [Ca2+]i mediated via a7* nAChR. Acute MLA incubation 
inhibited the increase in [Ca2+]i evoked by a challenge with nicotine applied to control 
cells by 40 ± 8% (n = 5; Figure 4.8) in agreement with our previous experiments (Figure 
4.6). Chronic nicotine pretreated cells (4 days), significantly increased the [Ca2+]i when 
challenged with acute nicotine (52 ± 22%; n = 6) after a 5 min incubation with MLA 
(compared to chronic nicotine treated cells not exposed to MLA) (Figure 4.8). This 
increase in [Ca2+]i evoked by a nicotine challenge in chronic nicotine treated cells after 
a preincubation with MLA, results in a similar increase in [Ca2+]i as observed with a 
nicotine challenge in untreated cells. However, chronic KCI pretreated cells exposed to 
MLA for 5 min prior to an acute nicotinic challenge, inhibited the nicotine-evoked
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increase in [Ca2+]i by 9 ± 9% (n = 7) when compared to the response evoked in the 
absence of MLA. MLA therefore had no significant effect on the nicotine-evoked 
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Figure 4.8. The effect o f acute MLA on [Ca2+]i evoked by 
nicotine in chronically treated cells. Fura-2 loaded SH-SY5Y 
cell suspensions were incubated for 5 min with MLA (10 nM) prior 
to an acute drug challenge with nicotine (10 pM). Increases in 
[Ca2*], (nM) were recorded from control, nicotine (10 pM) or KCI 
(20 mM) pretreated cells. The data are expressed as a percentage 
of the acute nicotine (10 pM)-evoked increase in [Ca2*], measured 
in untreated control cells. Each bar represents the mean ± S.E.M. 
of at least 4 independent experiments. * Indicates significantly 
different from the nicotine-evoked response in control untreated 
cells atp<0.05; one way ANOVA.
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4.3.6. The effect of chronic treatment with KN-62 or KN-04 on acute 
nicotine- and KCl-evoked responses in SH-SY5Y cells:
This study has previously shown that chronic treatment with KN-62 alone (5 pM; 4 
days) dramatically upregulates [3H]-epibatidine binding sites in SH-SY5Y cells (see 
section 3.4.6). It was therefore decided to investigate whether chronic exposure of SH- 
SY5Y cells to either KN-62 (5 pM) or its inactive analogue, KN-04 (5 pM) altered the 
subsequent response to acute nicotine (10 pM) or KCI (20 mM). KN-04 treatment had 
no significant effect on basal levels of Ca2+ in SH-SY5Y cells prior to stimulation with 
nicotine or KCI (basal [Ca2+]i were 112 ± 10 nM (control, n = 3) and 125 ± 4 nM (KN- 
04, n = 14). However in KN-62-treated cells, basal [Ca2+]i was 97 ± 5nM (n = 14) which 
was significantly lower when compared to control levels (p<0.05) in untreated cells. 
Acute nicotine (10 pM) or KCI (20 mM) produced similar increases in [Ca2+]i in KN-04 
pretreated cells and untreated cultures grown and assayed in parallel (Table 4.2). In 
contrast, KN-62 pretreatment significantly reduced responses of [Ca2+]i evoked by both 
acute nicotine and KCI, when compared to either control or KN-04 pretreated cells 
(Table 4.2). If the nicotine- and KCl-evoked increases in [Ca2+]i are taken into 
consideration and compared to the baseline [Ca2+]i in each condition, the comparative 
increases in [Ca2+]i are not significantly different from each other (Table 4.3). 
Therefore, although chronic KN-62 treatment decreases the basal [Ca2+]i compared to 
control, acute drug challenges evoke similar increases in [Ca2+]i when expressed as a 
percentage of the basal [Ca2+]i for each chronic condition, compared to those observed 
in control cells (Table 4.3).
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Table 4.2. Comparison o f  increases in [Ca2+]i evoked by nicotine (10 fiM) or KCI (20 mM) in 
untreated control cells and cells that were chronically treated with KN-04 (5 pM ) or KN-62 (5 
pM) fo r  4 days. Subsequent changes elicited by nicotine or KCI are expressed as a percentage of the 
increase in [C<f+]i evoked by nicotine or KCI in untreated control cells. Significantly different from 
control, *p<0.05, (One way ANOVA).
Pretreatment
Control KN-04 (5 fiM) KN-62 (5 |iM )
Nicotine (10 fiM) 
(% of control)
100 ± 5 (n=3) 106 ± 6 (n=5) 82 ± 1 (n=5)*
KCI (20 mM) 
(% of control)
100 ± 14 (n=3) 95 ± 7 (n=3) 75 ± 6 (n=3)*
Table 4.3. Comparison o f  the [Ccf^fi evoked by nicotine (10 pM ) or KCI (20 mM) as a 
percentage o f  the basal [Cc?+]  in each condition. Significantly different from control, *p<0.05, (One 
way ANOVA).
Pretreatment
Control KN-04 (5 iiM) K N-62 (5 fiM)
Basal [Ca2+] (nM) (for 
nicotine-evoked responses)
112 ± 10 (n=3) 125 ± 4 (n=14) 97 ± 5 (n=14)*
Nicotine evoked t  [Ca2+]j 
as a % of the basal [Ca2+]
19 ± 3 (n=3) 18 ± 2 (n=3) 20 ± 3 (n=3)
Basal [Ca2+] (nM) (for KCl- 
evoked responses)
100 ± 6 (n=3) 123 ± 12 (n=3) 92 ± 12 (n=3)
KCI evoked t  [Ca2+]i as a 
% of the basal [Ca2+]
14 ± 1% (n=3) 18 ± 10 (n=3) 19 ± 3 (n=3)
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4.4. Discussion.
The purpose of this Chapter was to evaluate the responses evoked by nicotine and 
KCI depolarisation in control and chronic drug treated SH-SY5Y cells loaded with fura- 
2, and to evaluate the proportion of Ca2+ influx through various nAChR subtypes and 
their functional status after chronic drug treatment. nAChR are highly permeable to 
Ca2+, therefore the influx of this ion through the activated receptor can be utilised as a 
measure of nAChR function. nAChR possess a Ca2+ permeability, which in the case of 
a7* nAChR, is comparable to NMD A glutamate receptors (Rogers and Dani, 1995) and 
upon activation a substantial Ca2+ influx into the cell is generated. The SH-SY5Y cell 
line and its parent human neuroblstoma cells, SK-N-SH have previously been shown to 
be useful cell lines in which to study reproducible fura-2/quin-2 fluorescence changes in 
response to depolarisation by KCI or activation of nicotinic and muscarinic receptors by 
nicotine and muscarine respectively (Noronha-Blob et al., 1989; Lambert and Nahorski, 
1990; Lambert et al., 1990; Murphy et al., 1991a).
Cell suspensions of fura-2 loaded SH-SY5Y cells and quin-2/fura-2 loaded SK-N-SH 
cells have previously shown the basal [Ca2+]i to range from 70 ± 8 mM (Lambert and 
Nahorski, 1990; 1.3 mM C aC y, 98 ± 4 nM (Martin et al., 1999), 129 ± 8 mM 
(Noronha-Blob etal., 1989; 1 mM C aC y to 199 ± 14 nM (Murphy et al., 1991a; 1 mM 
C aC y at rest. Ca2+ responses in neurons upon nicotinic agonist stimulation have also 
been observed in rat CNS primary hippocampal neuronal cultures (Barrantes et al., 
1995b) and in SH-SY5Y cells (Sharpies et al., 2000) with basal [Ca2+]i in the range of 
200-400 nM. In this study the basal [Ca2+]i was approximately 140 nM after 80 s in the 
presence of 2 mM CaCb before the addition of agonist, which is in the range of values 
reported in the literature. In the presence of 2 mM CaCh both KCI and nicotine evoked
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concentration-dependent increases in [Ca2+]i with maximum stimulation occurring at 80 
mM and 100 pM and half maximum stimulation occurring at 26 ± 8 mM and 7.5 ± 4 
pM, respectively. These values are similar to responses evoked by nicotine and KCI in 
the parent SK-N-SH cell line (Noronha-Blob et al., 1989) and in SH-SY5Y cells 
(Lambert e ta l ., 1990).
In the present study the accumulation of [Ca2+]i induced by the maximum effective 
concentration of nicotine is comparable to the [Ca2+]i evoked by the maximum effective 
concentration of KCI in this cell line. (±)-Anatoxin-a is a product of the freshwater alga 
Anabena flos-aquae and a potent nicotinic agonist; for comparison, the effect of (+)- 
anatoxin-a was examined as this compound was previously shown to produce maximum 
stimulation of [Ca2+]i at concentrations of 10 pM , being 10 fold more potent than 
nicotine (Sharpies et al., 2000). (±)-Anatoxin-a (10 pM ) was found to be equally 
efficacious in stimulating increases in [Ca2+]i as compared to 100 p M  nicotine and 80 
mM KCI depolarisation consistent with (±)-anatoxin-a being at least 10 fold more 
potent than nicotine, in this system. The increases in [Ca2+]i evoked by nicotine are 
small in comparison to the dramatic fluorescence increases induced by muscarinic 
agonists in the SH-SY5Y cells line (Murphy et al., 1991a; Forsythe et al., 1992; Martin 
etal., 1999).
In the absence of extracellular Ca2+, both nicotine and KCI challenges were 
completely ineffective in augmenting [Ca2+]j. A previous study examining the effect of 
fluo-3 loaded chick ciliary ganglion neurones, when challenged with nicotine ( 0 . 5 - 1  
pM) or KCI depolarisation (50 mM), were found to produce detectable fluorescence
responses that were prevented in the presence of the Ca2+ chelator, EGTA, reminiscent
2+
of the Ca -dependence observed in this study. This cell line is therefore a suitable
Chapter 4. 244
model system for studying the functional responses evoked by KCI depolarisation and 
nAChR activation after acute drug challenges and hence for examining the effect of 
chronic drug treatments on nicotine- and KCl-evoked responses.
4.4.1. Acute nicotinic antagonist treatment and [Ca ]j measured in 
response to nicotine:
4.4.1.1. M ecamylamine-sensitivity of the nicotinic response:
The nicotinic evoked increases in [Ca2+]i are mediated in a mecamylamine-sensitive 
manner. In the presence of mecamylamine there is a 100% inhibition of the increase in
/y_i
[Ca ]i induced by an acute nicotinic challenge. This result demonstrates that mcotine 
activates nAChR, resulting in the stimulation of a Ca2+-dependent accumulation of 
[Ca2+]i in SH-SY5Y cells. In addition to this non-selective nicotinic antagonist, further 
experiments were performed with nAChR subtype selective antagonists to explore the 
nAChR subtypes that may be involved in mediating the nicotinic-evoked increase in 
[Ca2+]j.
4.4.1.2. nAChR subtypes involved in mediating the nicotine-evoked  
stimulation o f [Ca2+]i in SH-SY5Y cells:
Two major classes of nAChR are abundantly expressed in SH-SY5Y cells. One class 
of nAChR contain the a3 subunit resulting in receptor combinations of a3 or a3 and a5 
with either the 02 or 04 subunits. The a302* nAChR have previously been shown to be 
upregulated after chronic nicotine treatment in vitro (Wang et al., 1998). These a3* 
nAChR desensitise relatively slowly and are insensitive to a-bgt blockade (Zhang et al., 
1994). The second class of nAChR located within SH-SY5Y cells can be recognised by
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their sensitivity to a-bgt blockade and contain the a l  gene product (Couturier et al., 
1990; Vemallis etal., 1993; Blumenthal etal., 1999).
Previous studies have demonstrated that activation of both a3* and a7* nAChR 
cause depolarisation and increase the [Ca2+]i directly by means of their permeability to 
Ca2+ and indirectly via VOCC (Vijayaraghavan et al., 1992; Rathouz et al., 1995). 
Specific inhibitors of these classes of nAChR were used to elucidate the nAChR 
subtypes mediating this response. The results demonstrate that a-CTX-MII, a selective 
antagonist that binds to the interface between a3 and P2 subunits in a3p2* nAChR 
(Cartier et al., 1996), blocked 50% of the evoked increase in [Ca2+]i elicited by 10 pM 
nicotine. This identifies a3p2* nAChR being involved in the functional nicotinic- 
evoked response in [Ca2+]i in SH-SY5Y cells.
It was also decided to investigate the action of a7-selective antagonists and their 
effect on nicotinic-induced elevations of [Ca2+]i in SH-SY5Y cells. Vijayaraghavan et 
al. (1992) established that preincubating chick ciliary ganglion neurones with a-bgt (20- 
50 nM) for 40 min prior to the nicotine challenge, abolished the effect of nicotine 
elevating [Ca2+]i above resting levels. MLA also abolished the nicotinic response of 
ciliary ganglion neurones with an I C 5 0  of 1-2 nM (Vijayaraghavan et al., 1992). This is 
consistent with the study by Seguela et al. (1993) who showed that at least a portion of 
the increase in [Ca2+]i is the result of Ca2+ flux through a l*  nAChR when this receptor 
subtype is expressed as homomeric nAChR in Xenopus oocytes. Whole-cell patch- 
clamp recording from chick ciliary ganglion neurones in situ demonstrates that 
approximately 49% of the charge entering these cells was mediated by an a-bgt-
sensitive synaptic current, further demonstrating that a l*  nAChR evoke increases in
2+
[Ca ]i in neurones.
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MLA is selective for a7* nAChR at low nanomolar concentrations; therefore the 
effect of a range of concentrations of MLA on nicotine-evoked fluorescence responses 
in SH-SY5Y cells was investigated. In the present study, the partial inhibition of 
nicotine-evoked responses by MLA (10 nM -  1 pM ) is similar to the level of inhibition 
(56 ± 7%) of nicotine-induced fluorescence responses observed after incubating ciliary 
ganglion neurones with MLA (10 nM) (Vijayaraghavan et at., 1992). The increase in 
[Ca2+]i accumulation evoked by a maximum effective concentration of nicotine (100 
pM) was also inhibited by MLA in a concentration-dependent manner; 10 nM and 100 
nM MLA diminished the 100 pM  nicotine-evoked elevation in [Ca2+]i by approximately 
30%, with 1 p M  MLA increasing this inhibition to 49 ± 6%.
The present study used a prior incubation with a variety of a7-selective nicotinic 
antagonists: MLA (10 nM), a-bgt, a-CTX-IMI, to investigate the Ca2+ release evoked 
by an acute challenge with nicotine. All of these antagonists partially blocked the 
nicotinic mediated increase in [Ca2+]i by approximately 40%. Taken together, the results 
are consistent with the specific blockade of a7* nAChR. The coincubation of an a302- 
and an a7-selective antagonist did not produce a complete block of the nicotinic 
mediated response, the block was only partially additive, producing an inhibition of 
approximately 70%, indicating that the nicotine-evoked accumulation of [Ca2+]i is 
mediated by at least two populations of nAChR; one class containing a3p2 interfaces 
and the other subtype containing a l  nAChR subunits. The remaining portion of 
fluorescence maintained in the presence of MLA and a-CTX-MII could be due to Ca2+ 
influx through a3p4* nAChR. At the time of this study selective antagonists for a3p4* 
nAChR were not available to us. The a-CTX, a-CTX-AUlB has been demonstrated to 
be selective for a3p4* nAChR and will be a useful pharmacological ligand to
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characterise the proportion of Ca2+ flux mediated through these nAChR in SH-SY5Y 
cells if it becomes available generally (Luo etal., 1998).
4.4.2. The role of VOCC in nicotine- and KCl-evoked responses:
Both a3* and a l*  nAChR function have been shown to increase [Ca2+]i indirectly, 
by producing sufficient current to depolarise the membrane and subsequently activate 
VOCC (Vijayaraghavan et al., 1992; Rathouz et al., 1995). Vijayaraghavan et al. (1992) 
demonstrated that the rise in [Ca2+]i evoked by nicotine and KCI depolarisation was 
abolished by Ca2+ channel blockers when applied to chick ciliary ganglion neurones.
Verapamil, a phenylalkylamine that inhibits L-type VOCC, was used to examine its 
effect on the fluorescence signal evoked by an acute nicotine challenge and KCI 
depolarisation. Prior incubation with verapamil indicated that approximately 50% of the 
nicotine-evoked response appeared to be dependent on activation of L-type Ca2+ 
channels. To confirm that verapamil was exerting its effect on L-type VOCC and not 
indirectly on nAChR (as is the case for the dihydropyridines, another class of L-type 
Ca2+-channel blockers (Lopez et al., 1993)), Cd2+, an ion that generally blocks several 
classes of VOCC with no affinity for nAChR was examined. Cd2+ abolished most of the 
nicotine-induced fluorescence response, inferring that much of the increase in [Ca2+]i 
resulting from nAChR activation depended on VOCC. Previous studies have also 
shown that pretreatment with the VOCC blocker Cd2+ substantially abolished nicotine- 
induced increases in [Ca2+]i in rat hippocampal neurones (Barrantes et al., 1995b) and 
nicotine- and KCl-evoked increases in [Ca2+]i in chick ciliary ganglion neurones 
(Vijayaraghavan et al., 1992). This implies that Ca2+ influx through activated nAChR 
causes membrane depolarisation, enough to open VOCC and to evoke an approximate
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75% influx of Ca2+, via L- and probably N-type VOCC in SH-SY5Y cells. The opening 
of VOCC by nAChR evoked membrane depolarisation has been implicated as a 
mechanism for the modulation of neurotransmitter release by presynaptic nAChR 
(Soliakov and Wonnacott, 1996).
Verapamil was found to partially block the KCI depolarisation response at both 
maximum and submaximum concentrations. This is in agreement with the effect of 
nifedipine, a dihydropyridine that acts preferentially on high threshold Ca2+ channels, 
which was found to block the nicotine-evoked signal while only partially blocking the 
KCl-induced response (Vijayaraghavan et al., 1992). Nifedipine was applied 3 min 
before the challenge with either nicotine or KCI, an incubation period analogous to that 
used for verapamil in the present study (Vijayaraghavan et al., 1992). KCI (25 mM) 
evoked a response that was 90 ± 8% compared to control in the presence of nifedipine, 
which parallels closely to the 91 ± 2% KCl-evoked response observed in the present 
study after verapamil. This identifies a difference in blockade evoked by L-type VOCC 
blockers on nicotine- and KCl-induced fluorescence responses in SH-SY5Y cells. This 
implies that different VOCC predominate in evoking the nicotine and KCI responses or 
that the KCl-induced response (20 mM) is not, in general, significantly inhibited by 
individual channel classes for example the L-type VOCC subtype after a short duration 
of exposure to verapamil.
The functional data generated in the present study was derived from cell suspensions 
of SH-SY5Y cells. This allows for an average fluorescence response from the whole 
population of cells in suspension to be recorded. The fluorescence response is therefore 
expressed as a percentage of basal fluorescence before the application of acute drug 
challenges rather than resolving local changes of [Ca2+]i that may be higher under the 
plasma membrane after nAChR and VOCC activation. Studies that measure single cell
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Ca2+ fluorescence may be useful to identify the influx o f Ca2+ into SH-SY5Y cells after 
nicotine and KCI drug challenges and to dissect and quantitate the proportion of Ca2+ 
entering the cell by specific subtypes of VOCC and nAChR rather than observing global 
changes in [Ca2+]i.
4.4.3. The effect of chronic drug treatments on nicotine- and KCl- 
evoked responses:
4.4.3.1. Chronic treatment with nicotinic agonists and KCI:
Chronic treatment with either nicotine, DMAC or KCI upregulates the number of 
[125I]-a-bgt binding sites on the surface of SH-SY5Y cells. In cells that have been 
chronically treated with nicotine or DMAC at the same concentrations that elicit 
upregulation, there is a decrease in the functional response evoked by a sub-maximum 
concentration of nicotine. There are no significant differences in the responses evoked 
by a maximum stimulating concentration of nicotine or KCI (20 mM) recorded from 
cells chronically treated with nicotine or DMAC. This result indicates that upregulated 
a7* nAChR display decreased functional responses, as fluorescence responses evoked 
by cells treated with nicotinic agonists are not significantly different from responses 
evoked by control cells even though there is an increase in [125I]-a-bgt binding in terms 
of Bmax. This decrease in receptor function could be viewed as a consequence of 
upregulation and a compensatory mechanism to aid in the reduction of [Ca2+]i mediated 
by activation of upregulated a l*  nAChR and would serve as an essential 
neuroprotective mechanism, given the reported high Ca2+ permeability of this LGIC and 
allow for optimal neuronal responsiveness in vivo. Chronic KCI treatment significantly 
diminishes the response evoked by nicotine at both half-maximum and maximum
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concentrations with a trend to decrease the response evoked by an acute challenge with 
KCI. This indicates that chronic treatment with KCI, upregulates a7* nAChR as 
detected with [125I]-a-bgt binding to the surface of SH-SY5Y cells, and these receptors 
also have a decrease in their functional activity compared to untreated control cells.
In terms of [3H]-epibatidine binding, the responses are complicated as the 
experiments reported here have measured total cellular [3H]-epibatidine binding sites in 
SH-SY5Y cells located both on the cell surface and also intracellularly, hence detecting 
both potentially functional and non-functional nAChR respectively. If the majority of 
sites upregulated by nicotinic agonist treatment are located intracellularly as proposed 
by Peng etal. (1997), Wang etal. (1998) and Whiteaker et al. (1998), this could explain 
the observed decrease in nicotinic agonist evoked response. Surface receptors are 
perhaps transported from the cell surface and/or accumulated intracellularly (Peng et al., 
1997; Wang et al., 1998) hence accounting for the decreased functional responses 
mediated by the existing surface nAChR. Chronic KCI treatment does not significantly 
alter [3H]-epibatidine binding sites, therefore the significant decreased fluorescence 
responses evoked by acute nicotine and the trend towards decreased responses evoked 
by a KCI challenge could be due to decreased function of the surface [3H]-epibatidine 
binding sites. However, if KCl-evokes a change in a3* nAChR distribution by 
transporting receptors from the cell surface to cytoplasm of SH-SY5Y cells this could 
also explain differences in functional activity of a3* nAChR. KCI treatment does not 
alter the total number of [3H]-epibatidine binding sites compared to control cells. 
However, if after KCI treatment a greater proportion of non-functional intracellular 
versus functional surface [3H]-epibatidine binding sites are expressed, an overall 
reduction in nAChR function will result due to the lower expression of functional 
nAChR located on the cell surface.
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In the case of chronic KCI treatment, reduced functional responses may be the result 
of a prolonged effect of KCI on VOCC in SH-SY5Y cells. De Lorme and McGee 
(1986) investigated the regulation of VOCC mediated by changes in membrane 
potential. It was shown that depolarisation of PC 12 cells, by elevating the extracellular 
K+ concentration (15 - 70 mM for up to 6 days), evoked a concentration-dependent loss 
of [3H]-nitrendipine binding (De Lorme and McGee, 1986). The decrease of [3H]- 
nitrendipine binding was due to a decrease in the maximum number of binding sites 
(Bmax) without a change in the K d , suggesting that the changes in [3H]-nitrendipine 
binding evoked by chronic depolarisation reflect changes in the number of functional 
VOCC on the cell membrane. The present study shows that there is a trend for [Ca2+]i 
evoked by acute drug challenges to be decreased after chronic KCI treatment compared 
to control, this could also be due to decreased numbers of VOCC in SH-SY5Y cells 
after KCI treatment. This could be verified by examining the verapamil-sensitive 
component of nicotine- and KCl-evoked responses in both nicotine and KCI chronically 
treated cells, to show if the L-type VOCC mediated component is decreased.
Wang et al. (1998) demonstrated that chronic nicotine treatment of tsA201 cells 
transfected with a3 and 02 nAChR subunits did not alter the functional response 
compared to control cells, as demonstrated by nicotinic application (100 pM) and whole 
cell patch clamp analysis. This higher nicotine concentration corresponds to the 
maximum stimulating concentration of nicotine used as a drug challenge in this present 
study; this concentration of nicotine had no significant effect on the function of nicotine 
and DMAC treated cells compared to control. The decreased responses evoked after 
chronic drug treatment are not due to residual ligand present due to the rigorous 
washout procedure before fiira-2 loading of the SH-SY5Y cells. Lukas (1991) 
investigated functional activation of nAChR in TE671/RD (containing muscle type
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nAChR) human clonal cell line and in PC 12 cells after chronic nicotinic ligand 
exposure. After 3-72 hours exposure of either nicotine or carbamylcholine, treatments 
that previously induced upregulation of nAChR ligand binding sites, resulted in 
complete loss of function of nAChR in the TE671 cells and near complete loss of 
nAChR function in PC12 cells (Lukas, 1991). Hsu et al. (1996) investigated the effect 
of sustained nicotine exposure on a3(32* nAChR expressed in oocytes. Peak responses 
to 7 pM nicotine were observed before and after 48 hour exposure to nicotine (1 pM). 
Responses were decreased by 50-60% after exposure to nicotine for 24-48 hours with 
half-life of recovery of 7.5 hours (Hsu et al., 1996). Functional inactivation may be 
another process occurring in the present study with SH-SY5Y cells after acute 
challenges with sub-maximum stimulating concentrations of nicotine. There is also the 
possibility that chronic nAChR activation and KCI depolarisation influence other 
aspects of the cells ability to enhance [Ca2+]i by modulating cellular pathways 
downstream of nAChR activation. Such aspects relating to altered [Ca2+]i signalling and 
chronic drug treatment have yet to be addressed in this field.
4.4.3.2. The effect o f MLA on functional responses evoked by cells after 
chronic nicotinic agonist and KCI treatment:
To identify if the a7-sensitive component of nicotine-evoked responses in SH -SY 5Y  
cells is altered after chronic treatment with either nicotine or KCI, the effect of M L A  
was investigated in both control and drug treated cells. The application of M L A  to 
control cells results in the inhibition of the nicotine-evoked elevation of [Ca2+]i; in 
nicotine pretreated cells there is a significant reduction in the response evoked by 
nicotine that is significantly increased after a 5 min incubation with M LA. In KCI 
treated cells there is a significant decrease in the fluorescence response elicited by
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nicotine with no significant difference in the presence of MLA. Additional approaches 
are needed to disentangle the nature and interplay between the effect of MLA when 
applied to chronic nicotine treated cells compared to untreated cells. Further 
experiments will help to elucidate the source of the increase in [Ca2+]i, whether it is 
from extracellular sources or from Ca2+ mobilisation from intracellular stores. MLA 
alone has no effect on basal levels of [Ca2+]i but after chronic nicotine treatment when 
nAChR are less responsive to the same dose of nicotine, the presence of MLA in this 
condition acts to enhance the nicotine-evoked [Ca2+]j. Perhaps chronic nicotine 
treatment reduces the number of functionally available nAChR due to functional 
inactivation where nicotine would act like an “antagonist”, then when the cells are 
exposed to MLA for a brief incubation this could increase the [Ca2+]i evoked by 
nicotine. This intriguing effect of MLA on nicotine treated SH-SY5Y cells will be 
investigated in the near future in Dr Wonnacott’s laboratory.
4.4.3.3. Chronic treatment with a CaM-kinase II inhibitor:
Previous data presented in this study identified that KCl-evoked upregulation of 
[125I]-a-bgt binding sites in both primary hippocampal cultures (see section 2.7.2) and 
in SH-SY5Y cells (see section 3.4.4) was mediated by a CaM-kinase II dependent 
pathway and by Ca2+ influx through L-type VOCC. In the present study when KN-62 
was applied alone for 4 days there was no change in [125I]-a-bgt binding sites but a huge 
upregulation of [3H]-epibatidine binding sites resulted and was not observed after 
chronic KN-04 treatment. This suggested that upregulation of [3H]-epibatidine binding 
sites evoked by KN-62 was by a CaM-kinase II dependent pathway. It was therefore 
decided to further investigate the effect of KN-62 and elucidate if chronic KN-62 
treatment altered [Ca2+]i within SH-SY5Y cells due to inhibition o f CaM-kinase II.
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Chronic KN-62 treatment decreased the basal [Ca2+]i compared to control and KN-04 
treated SH-SY5Y cells. This effect could be due to the ability of KN-62 to block VOCC
• 2 “hor its inhibition of a CaM-kinase II dependent mechanism, hence lowering the [Ca ]i. 
The nicotine- and KCl-evoked responses in SH-SY5Y cells chronically treated with 
KN-62 was significantly lower compared to the increase evoked by nicotine in control 
untreated cells and in KN-04 treated cells. However, if the drug-evoked increases of 
[Ca2+]i are compared to the initial basal [Ca2+]i, the fluorescence increases in each of the 
conditions (either control, KN-04 or KN-62 treated) are of the same proportion of the 
basal level of [Ca2+]i for each condition. As mentioned above, this lower basal [Ca2+]i 
could be due to inhibition of CaM-kinase II, VOCC or perhaps an effect on Ca2+ 
mobilisation within the cytoplasm to produce a decrease in [Ca2+]i after chronic KN-62 
treatment for 4 days. This indicates that KN-62 pretreatment does not reduce the 
proportion of nicotine-evoked response compared to control cells, but has a decreased 
response due to a lower initial basal [Ca2+]i level.
Together the data in this Chapter demonstrate that nicotine and KC1 evoke [Ca2+]i 
accumulation in a concentration- and Ca2+-dependent manner. The nicotine-evoked 
response has been shown to be mediated by both ot7* and a302* nAChR subtypes. 
Chronic drug treatments that differentially upregulate [125I]-a-bgt and [3H]-epibatidine 
binding sites in SH-SY5Y cells have also generated changes in the [Ca2+]i evoked by 
nicotine and KC1 challenges. This maybe related to changes in receptor numbers and 




From the present study I conclude that:
• Increasing the KC1 concentration form 5 to 20 mM upregulated [125I]-a-bgt binding 
sites in primary hippocampal neurones, and in the SH-SY5Y human neuroblastoma 
cell line. KC1 upregulates a7* nAChR by Ca2+ influx through L-type VOCC, a 
CaM-kinase II dependent pathway and by increasing the expression of a7  subunit 
RNA. In contrast, neither the level of [3H]-epibatidine binding sites nor a3 subunit 
RNA levels were affected by chronic KC1 treatment in SH-SY5Y cells. The finding 
in this study that chronic KC1 depolarisation uniquely regulates the expression of a7 
nAChR through L-type VOCC and a CaM-kinase II pathway, may reflect a 
mechanism underlying some form of neuronal plasticity and a possible role for a7  
nAChR in neuronal development, synaptic plasticity and axonal regeneration after 
neuronal injury.
• The nicotinic agonists, nicotine and DMAC, upregulated [125I]-a-bgt (by increasing 
Bmax with no change in KD) and [3H]-epibatidine binding sites in SH-SY5Y cells; 
these sites were not upregulated by a mechanism involving Ca2+ influx through L- 
type VOCC, CaM-kinase II- or PKC-dependent pathways or increased transcription 
of the a3 and a7  subunit RNA levels. These data suggest that upregulation of [3H]- 
epibatidine and [125I]-a-bgt binding sites evoked by nicotinic agonists were 
mediated by post-transcriptional mechanisms that may be similar to those 
mechanisms proposed for the upregulation of the high affinity a4p2 nAChR 
subtype.
• An interesting result was obtained with KN-62 when chronically applied to SH- 
SY5Y cells for 4 days; KN-62 did not alter [125I]-a-bgt binding, in contrast to 
evoking a huge upregulation of [3H]-epibatidine binding sites. This is attributed to
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KN-62 inhibiting CaM-kinase II as KN-04, an inactive analogue of KN-62 had no 
significant effect on the level of [3H]-epibatidine binding sites compared to control. 
This result has led to the hypothesis that KN-62 treatment could cause an 
intracellular accumulation of nAChR labelled by [3H]-epibatidine.
• Both nicotine and KC1 produced concentration- and Ca2+-dependent increases in 
[Ca2+]i in fura-2 loaded SH-SY5Y cells. Nicotinic responses were partially inhibited 
by L-type VOCC blockers, identified by blockade with verapamil, and completely 
abolished after prior exposure to mecamylamine. It was shown that a3p2* and a7* 
nAChR contribute to the nicotinic response, as indicated by the nAChR subtype 
selective antagonists a-CTX-MII and a variety of a7-selective compounds, a-bgt, 
a-CTX-IMI and MLA (10 nM). MLA was found to block nicotine-evoked 
fluorescence responses in a concentration-dependent manner.
• Chronic nicotinic agonist treatment significantly decreased the fluorescence 
response evoked by a sub-maximum concentration of nicotine indicating that, 
although these chronic drug treatments elicit upregulation of [125I]-a-bgt and [3H]- 
epibatidine binding sites, the upregulated receptors located on the surface are less 
functional than nAChR located in control untreated cells.
• Chronic KC1 treatment significantly decreased responses to nicotine and there was 
also a trend to decrease the fluorescence response evoked by an acute challenge with 
KC1 compared to responses evoked in control untreated cells. These diminished 
functional responses could also be explained by KC1 affecting the numbers of 
surface versus intracellular nAChR or by a reduction in numbers of VOCC, hence 
reducing functional responses.
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• The effect of a 5 min incubation of MLA on cells chronically treated with nicotine 
resulted in enhanced functional responses evoked by nicotine. This unexpected 
result must be due to a synergistic effect of acute MLA and chronic nicotine 
treatment as there was no significant difference between the nicotine-evoked 
increase in [Ca^+]i observed in chronic KC1 treated cells in either the presence or 
absence of MLA. Subsequent experiments will need to be performed to address the 
role of extracellular Ca2+ and intracellular Ca2+ stores in mediating or amplifying the 
increase in the fluorescence response evoked by nicotine applied to (pre-MLA 
exposed) chronic nicotine treated SH-SY5Y cells. The source of this enhanced 
increase in [Ca2+]i evoked by an acute nicotine challenge in nicotine treated cells 
after 5 min incubation with MLA will be investigated in Dr Wonnacott’s laboratory 
in the near future.
• Chronic treatment for 4 days with KN-62 elicited significant decreases in the [Ca2+]j 
evoked by both KC1 and nicotine when compared to either control cells or cells 
pretreated for 4 days with KN-04, the inactive analogue of KN-62. There were no 
significant differences observed between control and KN-04 pretreated cells. 
Comparatively the increase in [Ca2+]i evoked by acute nicotine or KC1 expressed as 
a percentage of the basal [Ca2+], in each condition was not significantly different 
from each other. The lower basal level of [Ca2+]i recorded in KN-62 treated SH- 
SY5Y cells suggests that intracellular Ca2+ may be mobilised by a CaM-kinase II 
pathway.
• Together these data demonstrate that chronic drug treatment regimes differentially 
upregulate the number of nicotinic binding sites by different cellular mechanisms 
producing changes in nAChR function as measured by changes in [Ca2+]i using fura- 
2 fluorescence.
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Previous studies investigating a3* and a l*  nAChR have been less extensive than 
those performed with the high affinity a4 f2  nAChR subtype. The experiments 
presented here produce a story consistent with previous reports with regard to 
upregulation of nAChR subunits after chronic nicotine treatment (Barrantes et al., 
1995a; Peng et al., 1997; Molinari et al., 1998) and that these receptors are located 
intracellularly. It was interesting to observe that KCl-evoked upregulation of [125I]-oc- 
bgt binding sites in both primary hippocampal cultures and SH-SY5Y cells was 
dependent on Ca2+ flux through L-type VOCC and the activation of CaM-kinase II. The 
increased expression of a l  subunit RNA in SH-SY5Y cells after chronic KC1 treatment 
was in agreement with data generated in rat SCG neurones after chronic KC1 
depolarisation (De Koninck and Cooper, 1995). The signalling events downstream of 
CaM-kinase II leading to the increase in expression of the a l  nAChR subunit transcript 
have not been determined in this study.
The high Ca2+ permeability of a l * nAChR and their ability to raise [Ca2+]i along 
with oc3* nAChR, perhaps offers a physiological role for these nAChR subtypes to 
influence subsequent intracellular Ca2+-dependent cellular events using Ca2+ as a second 
messenger within neurones. This implicates the activation of nAChR coupled with the 
activation of L-type VOCC to increase [Ca2+]i with a resulting endorsement of neuronal 
survival. Previous studies have shown that nicotine and KC1 treatment are implicated in
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the mediation of Ca -dependent processes including neurite retraction (Pugh and Berg, 
1994) and neurite growth (Chan and Quik, 1993; Solem et al., 1995). Nicotine, 
carbachol and KC1 depolarisation all promote survival of avian ciliary ganglion 
neurones and it was demonstrated that nicotinic agonist treatment enhanced survival by 
activation of a-bgt-sensitive nAChR (Hory-Lee and Frank, 1995) as well as a3* 
nAChR in these neurones (Pugh and Margiotta, 2000). Neuronal survival has also been
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demonstrated in rat brain sections (Shimohama et al., 1998), hippocampal (Semba et al., 
1996) and cerebellar neurones (Minana et al., 1998) and in PC12 cells (Egea et al., 
1999; Li et al., 1999) resulting either from activation of a-bgt nAChR or membrane 
depolarisation.
Messi et al. (1997) reported that spinal cord motoneurones undergo cell death during 
embryonic development. Survival of these motoneurones is essential to prevent 
disorders such as amyotrophic lateral sclerosis. Activation of nAChR have been 
implicated in promoting cell survival of spinal cord motoneurones by significantly 
increasing the [Ca2+]i to result in the rescue of a significant number of cultured spinal 
cord motoneurones (Messi et al., 1997) and PC 12 cells (Yamashita and Nakamura, 
1996) from programmed cell death. Activation of both a3* and a l * nAChR may be 
necessary to ensure total neuronal survival. This could be a reason why after chronic 
drug treatment a3* and a l * nAChR are upregulated, but have differential functional 
responses when exposed to acute drug challenges. It is possible that both nAChR 
activation and KC1 depolarisation elicit independent microdomains of high [Ca2+]i and 
this may be physiologically relevant as a neuroprotective mechanism in developing 
neurones, in neurite retraction and in the mediation of Ca2+-regulated events in 
neurones.
CaM-kinase II is a ubiquitous cytosolic enzyme involved in a number of cellular 
processes making it an attractive candidate in terms of regulating a l  subunit gene 
expression. CaM-kinase II has been implicated in long-term modifications of synaptic 
transmission via post-translational modifications of receptors, ion channels and altering 
neurotransmitter release (reviewed by Hanson and Schulman, 1992; Lisman, 1994) and 
in pathways involved with the storage of memory and the modulation of synaptic 
transmission. Some of these functional roles for CaM-kinase II have been suggested as
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roles for the al* nAChR. A Ca2+-calmodulin mechanism has also been implicated in 
the promotion of survival of PC 12 cells (Egea et al., 1999) and chick spinal cord 
motoneurones (Soler et al., 1998) evoked by membrane depolarisation. Depolarisation- 
induced neurite outgrowth with 45 mM KC1 applied to PC 12 cells, required CaM-kinase 
II and IV activation and was also reduced in the presence of L-type VOCC blockers 
(Solem et al., 1995). Neuronal survival was prevented in the presence of VOCC 
blockers (Chan and Quik, 1993; Pugh and Berg, 1994; McGehee et al., 1995, Role and 
Berg, 1996; Pugh and Margiotta, 2000). CaM-kinase II has also been implicated in the 
regulation of neurite outgrowth and growth cone motility in neuronal Neuro 2a and NG 
108-15 neuroblastoma cell lines (Goshima et al., 1993). These data are consistent with 
earlier reports of the developmental regulation of the a l* nAChR by depolarisation at 
the transcriptional level (Courtier et al., 1990) and being dependent on a CaM-kinase II 
pathway and Ca2+ influx through VOCC (De Koninck and Cooper, 1995) and consistent 
with the transcriptional control of a l  subunit RNA in this study by KC1 depolarisation.
Mandelzys et al. (1994) observed that there was greater than a three-fold increase in 
the level of expression for both the a3 and a l  nAChR subunit mRNA during the first 
two postnatal weeks in rat sympathetic neurones. This change in nAChR gene 
expression occurs during a period when most synapses are forming on these 
sympathetic neurones, providing yet further support that nAChR containing the a3 and 
al  subunits are important during neuronal development. a3* and a l* nAChR may 
increase [Ca ]i during synapse formation to regulate second messenger systems that 
allow for the modulation of other proteins needed to establish synapses (see Changeux, 
1991). Neurite retraction and synaptic remodelling are known to occur and be important 
during development. Presynaptic a-bgt-sensitive nAChR could provide a mechanism to 
terminate axonal growth during development and may also be extrapolated to
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pathological sprouting of neural processes and synaptic reorganisation in the brain after 
seizures or neuronal injury. Perhaps there is synergy between nAChR activation, KC1 
depolarisation on neurones and the involvement of CaM-kinase II in the upregulation of 
[125I]-a-bgt binding sites evoked by KC1 implicating these processes in mechanisms 
underlying forms of synaptic plasticity.
Low level activation of a3* and a l * nAChR may also have important effects on 
intracellular Ca2+-mediated events by creating high local concentrations of Ca2+ 
immediately beneath the plasma membrane after direct Ca2+ influx through these LGIC. 
This suggests a role for these nAChR subtypes in events related to synaptogenesis (De 
Koninck and Cooper, 1995). These effects may be neuroprotective due to the mode of 
entry of Ca2+ via nAChR and also by the activation of VOCC. Specific local changes in 
Ca2+ could be the trigger to activate other Ca2+-dependent pathways or enzymes to 
regulate cell signalling and other cellular processes in neuronal cells. Collins et al. 
(1991) demonstrated that a sustained increase in [Ca2+]i induced by raising KC1 from 5 
to 40 mM promoted neuronal survival in ciliary ganglion neurones. This effect was 
abolished in the presence of PN 200-110, a dihydropyridine VOCC blocker, thereby 
preventing KC1 to induce survival of neurones.
The decrease in nAChR function observed after some chronic drug treatments may 
be a compensatory process so that during enhanced KC1 or nAChR activated conditions 
there is not Ca2+ overload to the neurone that would induce apoptosis. One such 
function of nAChR activation would be to regulate the amount of Ca2+ entering the cell 
from extracellular sources and promote neuronal survival. By monitoring the levels of 
endogenous agonist ACh or membrane depolarisation this information could be relayed 
to trigger necessary Ca2+-dependent cascades within neurones to regulate neuronal 
survival and ensure the prevention of or reduced apoptosis.
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Continued study of a3* and a l * nAChR will help to elucidate physiological 
functional roles for these receptors. Upregulation of a3* and a l * nAChR have 
previously been shown to require higher concentrations of nicotine to evoke 
upregulation (Peng et a l,  1997; Wang et al., 1998) compared to concentrations 
necessary to elicit upregulation of the high affinity a4p2 nAChR sites. These higher 
concentrations of nicotine may be relevant in some neurological conditions especially in 
schizophrenia where patients smoke excessively and have high plasma nicotine levels 
that could be capable of upregulating these specific nAChR subtypes, and 
neuroprotective in other neurological disorders such as AD and PD. The development of 
commercially available nAChR subtype-selective nicotinic ligands allow for further 
analyses and a better understanding of nicotinic-evoked modulation of nAChR, their 
modulation of signal transduction and involvement of Ca2+-dependent cascades to 
mediate cellular functions including neuronal development, neuronal survival and their 
roles in neuromodulation and cytoprotection in pathological conditions and also as 
therapeutic applications in smoking cessation strategies.
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